Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation by Crossan, C et al.
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 19 ISSUE 9 JANUARY 2015
ISSN 1366-5278
DOI 10.3310/hta19090
Cost-effectiveness of non-invasive methods for 
assessment and monitoring of liver fibrosis and 
cirrhosis in patients with chronic liver disease: 
systematic review and economic evaluation
Catriona Crossan, Emmanuel A Tsochatzis, Louise Longworth,  
Kurinchi Gurusamy, Brian Davidson, Manuel Rodríguez-Perálvarez, 
Konstantinos Mantzoukis, Julia O’Brien, Evangelos Thalassinos,  
Vassilios Papastergiou and Andrew Burroughs

Cost-effectiveness of non-invasive
methods for assessment and monitoring
of liver fibrosis and cirrhosis in patients
with chronic liver disease: systematic
review and economic evaluation
Catriona Crossan,1 Emmanuel A Tsochatzis,2
Louise Longworth,1* Kurinchi Gurusamy,3
Brian Davidson,3 Manuel Rodríguez-Perálvarez,2
Konstantinos Mantzoukis,2 Julia O’Brien,2
Evangelos Thalassinos,2 Vassilios Papastergiou2
and Andrew Burroughs2
1Health Economics Research Group, Brunel University London, Uxbridge, UK
2Sheila Sherlock Liver Centre, Royal Free Hospital and UCL Institute for Liver and
Digestive Health, Royal Free Hospital, London, UK
3Royal Free Campus, UCL Medical School, London, UK
*Corresponding author
Declared competing interests of authors: none
Published January 2015
DOI: 10.3310/hta19090
This report should be referenced as follows:
Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, et al.
Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and
cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health
Technol Assess 2015;19(9).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA/HTA TAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 5.116
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index and is
assessed for inclusion in the Database of Abstracts of Reviews of Effects.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: nihredit@southampton.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to
minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 09/114/02. The contractual start date
was in November 2011. The draft report began editorial review in August 2013 and was accepted for publication in February 2014. The
authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and
publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on
the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the
interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA
programme or the Department of Health.
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Crossan et al. under the terms of a commissioning
contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and
study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement
is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre,
Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR  
Journals Library
Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK
NIHR Journals Library Editors
Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical 
School, UK
Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group),  
Queen’s University Management School, Queen’s University Belfast, UK
Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School,  
University of Warwick, UK
Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK
Dr Peter Davidson Director of NETSCC, HTA, UK
Ms Tara Lamont Scientific Advisor, NETSCC, UK
Professor Elaine McColl Director, Newcastle Clinical Trials Unit, Institute of Health and Society,  
Newcastle University, UK
Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK
Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK
Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Please visit the website for a list of members of the NIHR Journals Library Board: 
www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: nihredit@southampton.ac.uk
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Cost-effectiveness of non-invasive methods for assessment
and monitoring of liver fibrosis and cirrhosis in patients
with chronic liver disease: systematic review and
economic evaluation
Catriona Crossan,1 Emmanuel A Tsochatzis,2 Louise Longworth,1*
Kurinchi Gurusamy,3 Brian Davidson,3 Manuel Rodríguez-Perálvarez,2
Konstantinos Mantzoukis,2 Julia O’Brien,2 Evangelos Thalassinos,2
Vassilios Papastergiou2 and Andrew Burroughs2
1Health Economics Research Group, Brunel University London, Uxbridge, UK
2Sheila Sherlock Liver Centre, Royal Free Hospital and UCL Institute for Liver and Digestive Health,
Royal Free Hospital, London, UK
3Royal Free Campus, UCL Medical School, London, UK
*Corresponding author Louise.Longworth@brunel.ac.uk
Background: Liver biopsy is the reference standard for diagnosing the extent of fibrosis in chronic liver
disease; however, it is invasive, with the potential for serious complications. Alternatives to biopsy include
non-invasive liver tests (NILTs); however, the cost-effectiveness of these needs to be established.
Objective: To assess the diagnostic accuracy and cost-effectiveness of NILTs in patients with chronic
liver disease.
Data sources: We searched various databases from 1998 to April 2012, recent conference proceedings
and reference lists.
Methods: We included studies that assessed the diagnostic accuracy of NILTs using liver biopsy as the
reference standard. Diagnostic studies were assessed using the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) tool. Meta-analysis was conducted using the bivariate random-effects model with
correlation between sensitivity and specificity (whenever possible). Decision models were used to evaluate
the cost-effectiveness of the NILTs. Expected costs were estimated using a NHS perspective and health
outcomes were measured as quality-adjusted life-years (QALYs). Markov models were developed to
estimate long-term costs and QALYs following testing, and antiviral treatment where indicated, for chronic
hepatitis B (HBV) and chronic hepatitis C (HCV). NILTs were compared with each other, sequential testing
strategies, biopsy and strategies including no testing. For alcoholic liver disease (ALD), we assessed the
cost-effectiveness of NILTs in the context of potentially increasing abstinence from alcohol. Owing to a lack
of data and treatments specifically for fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), the
analysis was limited to an incremental cost per correct diagnosis. An analysis of NILTs to identify patients
with cirrhosis for increased monitoring was also conducted.
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Results: Given a cost-effectiveness threshold of £20,000 per QALY, treating everyone with HCV without
prior testing was cost-effective with an incremental cost-effectiveness ratio (ICER) of £9204. This was
robust in most sensitivity analyses but sensitive to the extent of treatment benefit for patients with mild
fibrosis. For HBV [hepatitis B e antigen (HBeAg)-negative)] this strategy had an ICER of £28,137, which was
cost-effective only if the upper bound of the standard UK cost-effectiveness threshold range (£30,000) is
acceptable. For HBeAg-positive disease, two NILTs applied sequentially (hyaluronic acid and magnetic
resonance elastography) were cost-effective at a £20,000 threshold (ICER: £19,612); however, the results
were highly uncertain, with several test strategies having similar expected outcomes and costs. For patients
with ALD, liver biopsy was the cost-effective strategy, with an ICER of £822.
Limitations: A substantial number of tests had only one study from which diagnostic accuracy was
derived; therefore, there is a high risk of bias. Most NILTs did not have validated cut-offs for diagnosis
of specific fibrosis stages. The findings of the ALD model were dependent on assuptions about abstinence
rates assumptions and the modelling approach for NAFLD was hindered by the lack of evidence on
clinically effective treatments.
Conclusions: Treating everyone without NILTs is cost-effective for patients with HCV, but only for
HBeAg-negative if the higher cost-effectiveness threshold is appropriate. For HBeAg-positive, two NILTs
applied sequentially were cost-effective but highly uncertain. Further evidence for treatment effectiveness
is required for ALD and NAFLD.
Study registration: This study is registered as PROSPERO CRD42011001561.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Clinical terms
Alcoholic fatty liver (hepatic steatosis) Accumulation of excess fat in the liver cells as a result of excess
alcohol consumption.
Alcoholic hepatitis An acute inflammatory condition in patients who abuse alcohol involving liver
damage, which is associated with high mortality.
Cirrhosis A consequence of chronic liver disease, most commonly alcoholism, hepatitis B and C, or fatty
liver disease. It is characterised by diffuse nodular regeneration surrounded by dense fibrotic septa with
subsequent parenchymal extinction and collapse of liver structures, together causing a marked distortion of
hepatic vascular architecture, leading to loss of liver function.
Compensated cirrhosis Cirrhosis with no associated complications.
Hepatitis B A hepatotropic virus that causes chronic infection and is associated with progressive liver
damage that can lead to cirrhosis and hepatocellular cancer.
Hepatitis C A hepatotropic virus that causes chronic infection and is associated with progressive liver
damage that can lead to cirrhosis and hepatocellular cancer.
Hepatocellular carcinoma The most common type of liver cancer, usually secondary to scarring of the
liver (cirrhosis) or hepatitide viral infection (hepatitis B or C).
Histological Related to the microscopic structure of tissue.
Liver biopsy Removal of a small sample of liver tissue using a hollow needle for examination in
the laboratory.
Liver fibrosis Formation of excessive fibrous scar tissue in the liver.
Non-alcoholic fatty liver disease Liver disease characterised by the accumulation of fat in the liver cells
of people who do not drink alcohol excessively but are obese and/or have other features of the
metabolic syndrome.
Non-alcoholic steatohepatitis The progressive form of non-alcoholic fatty liver disease involving
inflammation in and around the fatty liver cells. It may cause scarring of the liver and lead to cirrhosis.
Obese Having a body mass index ≥ 30 kg/m2.
Oesophageal varices Varicose veins in the lower end of the oesophagus which develop as a
complication of cirrhosis.
Percutaneous Performed through a needle puncture of the skin.
Steatosis A condition characterised by the accumulation of excess fat within the liver cells.
Transjugular Via the jugular vein in the neck.
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Variceal bleeding Gastrointestinal bleeding caused by rupture of the oesophageal/gastric varices.
Varices varicose Veins usually in the stomach and lower end of the oesophagus (gullet) which develop as
a complication of cirrhosis.
YKL-40 The name of a direct marker of liver fibrosis.
Diagnostic accuracy terms
Combined cut-off This refers to the use of a dual cut-off for classifying patients with a non-invasive
fibrosis test. If a patient has a value below the low or above the high cut-off, then he or she is classified
into a fibrosis stage; otherwise, he or she falls in the grey zone or indeterminate range and requires further
non-invasive testing or a liver biopsy.
False negative A test result which indicates that a person does not have the disease when that person
actually does have the disease.
False positive A test result which indicates that a person does have the disease when that person actually
does not have the disease.
High cut-off This refers to the use of a cut-off for staging of liver fibrosis by a non-invasive fibrosis
test that aims to maximise specificity. Usually the high cut-off is pre-set using the receiver operating
characteristic curve to allow for a specificity of 90–95%.
Index test The test whose performance is being evaluated.
Low cut-off This refers to the use of a cut-off for staging of liver fibrosis by a non-invasive fibrosis test
that aims to maximise sensitivity. Usually the low cut-off is pre-set using the receiver operating
characteristic curve to allow for a sensitivity of 90–95%.
METADAS The name of a macro in the SAS software.
METAVIR score A histological scoring system developed by a French working group to assess and stage
necro-inflammation and fibrosis.
QUADAS-2 A tool developed for quality assessment of diagnostic accuracy studies.
Receiver operating characteristic curve A receiver operating characteristic curve represents the
relationship between the ‘true-positive fraction’ (sensitivity) and the ‘false-positive fraction’ (specificity).
It displays the trade-offs between sensitivity and specificity as a result of varying the cut-off value for
positivity in case of a continuous test result.
Reference standard Established test(s) against which the accuracy of a new test for detecting a particular
condition can be evaluated.
Sensitivity (true-positive rate) The proportion of individuals with the target condition who are correctly
identified by the index test.
Specificity (true-negative rate) The proportion of individuals free of the target condition who are
correctly identified by the index test.
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True negative A person without the disease correctly identified as negative by the index test.
True positive A person with the disease correctly identified as positive by the index test.
Non-invasive liver tests
Computed tomography A medical imaging technique using tomography created by computer
processing to generate a three-dimensional internal image from a series of two-dimensional
radiographic images.
Contrast-enhanced ultrasound The application of a contrast agent to conventional ultrasonography.
Ultrasound contrast agents rely on the different ways that sound waves are reflected from interfaces
between substances, for example microbubbles and human tissue. The difference in echogenicity (ability to
reflect ultrasound waves) between microbubbles and surrounding tissues is very high and intravenous
contrast injection can be used to visualise blood perfusion and to distinguish between benign and
malignant tissue.
Magnetic resonance imaging A medical imaging technique that uses nuclear magnetic resonance to
image the nuclei of atoms inside the body. It provides good contrast between the different tissues of the
body and can be useful in distinguishing malignant from benign tumours.
Economic and statistical terms
Cost-effectiveness acceptability curve A graph that plots a range of possible cost-effectiveness
thresholds on the horizontal axis (x-axis) against the probability that the intervention will be cost-effective
on the vertical axis (y-axis) in order to give a representation of the decision uncertainty.
Cost-effectiveness acceptability frontier A graph that shows the probability that the technology with
the highest expected net benefit is cost-effective.
Dominance An intervention is dominated if it has higher costs and worse outcomes than an alternative
intervention. An intervention is dominant if it has lower costs and better outcomes than all
other alternatives.
EQ-5D A generic preference-based instrument for measuring health-related quality of life.
Incremental cost-effectiveness ratio The ratio of the difference in the mean costs of two interventions
divided by the difference in the mean outcomes.
Markov model An analytical method particularly suited to modelling repeated events or the progression
of a chronic disease over time.
Meta-analysis Statistical techniques used to combine the results of two or more studies and obtain a
combined estimate of effect.
Net benefit The overall benefit of the technology net of costs. Net (monetary) benefit is the difference
between the monetary value of total expected quality-adjusted life-years (expected quality-adjusted
life-years multiplied by the threshold value, e.g. £20,000) and total expected costs.
One-way sensitivity analysis An analysis that varies each parameter individually to assess the impact of
its change on the results of the study.
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Parameter A measurable or quantifiable characteristic.
Probabilistic sensitivity analysis An analysis in which probability distributions are assigned to the
uncertain parameters in order to give a representation of decision uncertainty.
Quality-adjusted life-year A measure of length of survival that takes account of the patient’s
health-related quality of life during this time.
Randomised controlled trial A comparative study in which people are randomly allocated to
intervention and control groups and followed up to examine differences in outcomes between groups.
Relative risk The number of times more or less likely an event is to happen in one group compared with
another (calculated as the risk of the event in group A divided by the risk of the event in group B).
Sensitivity analysis An analysis to give an indication of the uncertainty in, or robustness of, the results of
an analysis.
Threshold sensitivity analysis A sensitivity analysis in which the values of a parameter a systematically
changed to identify the point above or below which the conclusions of the study will change.
Utility A measure of the strength of a person’s preference for a specific health state in relation to
alternative health states measured on a scale where 0 represents a state ‘as bad as being dead’ and 1
represents ‘full health’.
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List of abbreviations
AASLD American Association for the Study
of the Liver
ACE angiotensin-converting enzyme
ALD alcoholic liver disease
ALT alanine aminotransferase
APRI AST to platelet ratio index
ARFI acoustic radiation force impulse
AST aspartate aminotransferase
AUROC area under the receiver operator
curve
BARD BMI, AST–ALT ratio, diabetes
BMI body mass index
BNF British National Formulary
CEAC cost-effectiveness acceptability
curve
CEAF cost-effectiveness acceptability
frontier
CELT Cost-Effectiveness of Liver
Transplantation
CI confidence interval
CT computed tomography
DNA deoxyribonucleic acid
EASL European Association for the Study
of the Liver
ELF enhanced liver fibrosis test
GGT gamma-glutamyl transpeptidase
GP general practitioner
GUCI Göteborg University Cirrhosis Index
HBeAg hepatitis B e antigen
HBV hepatitis B
HCC hepatocellular cancer
HCV hepatitis C
HRQoL health-related quality of life
HTA Health Technology Assessment
ICER incremental cost-effectiveness ratio
MR magnetic resonance
MRI magnetic resonance imaging
MTC mixed-treatment comparison
NAFIC ferritin, fasting insulin, type IV
collagen
NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatitis
NFS non-alcoholic fatty liver disease
fibrosis score
NICE National Institute for Health and
Care Excellence
NILT non-invasive liver test
PGAA prothrombin time, GGT,
apolipoprotein A1,
α2-macroglobulin
PIIINP amino-terminal propeptide of
type III procollagen
PSA probabilistic sensitivity analysis
PSSRU Personal Social Services Research
Unit
QALY quality-adjusted life-year
QUADAS Quality Assessment of Diagnostic
Accuracy Studies
RCT randomised controlled trial
RR relative risk
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SAFE sequential algorithm for fibrosis
evaluation
SAPI splenic artery pulsatility index
SHTAC Southampton Health Technology
Assessment Centre
SROC summary receiver operating
characteristic
SVR sustained virological response
TE transient elastography (Fibroscan)
TIMP tissue metalloproteinase
ULN upper limit of normal
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Plain English summary
L iver has various functions including elimination of drugs and toxins. However, repeated insults to theliver including alcohol and viral infections can lead to loss of its structure and function. Fibrosis (slight)
and cirrhosis (severe) are different degrees of loss of structure and function of the liver.
At present, there is no curative treatment for cirrhosis other than liver transplantation. Early diagnosis and
treatment of fibrosis will improve survival and quality of life and reduce the need for liver transplantation.
Traditionally, fibrosis is diagnosed by taking a bit of the liver using a wide-bore needle (biopsy); however,
this is invasive and can cause serious complications. This study assessed alternative tests which are not
invasive to determine whether or not they can replace liver biopsy and offer value for money.
A review of literature on how accurately the non-invasive tests are for the diagnosis of fibrosis and cirrhosis
was carried out. We used this information to conduct an economic analysis to estimate the implications
for NHS resources (including costs of testing and long-term costs of treating patients) and the health
outcomes associated with each non-invasive test.
We found that the economic benefits vary according to the cause of the liver disease. In some cases, the
non-invasive tests appeared best value for money (some types of hepatitis B); in others, biopsy was best
(alcoholic cirrhosis); and in some cases, starting treatment early, without the need for testing, produced the
highest health gain for a given cost (hepatitis C and some circumstances for hepatitis B).
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Scientific summary
Background
In 2011, it was estimated that 2.3 million people, or approximately 5% of the population of England,
had liver disease. Currently, liver biopsy is used in patients with suspected liver disease to determine the
extent of liver fibrosis and to help inform treatment decisions. However, biopsy is an invasive procedure
associated with morbidity and mortality risks. Alternatives to liver biopsy include non-invasive liver tests
(NILTs) which can be serum tests or imaging modalities and have in many cases replaced liver biopsy in
clinical practice. As liver biopsy is high risk and costly, NILTs may offer cost-effective alternatives.
Objectives
There were two related objectives for the study:
1. to determine the diagnostic accuracy of different NILTs in the diagnosis and monitoring of liver fibrosis
and cirrhosis in patients with various aetiologies for chronic liver disease; and
2. to estimate the incremental cost-effectiveness of the NILTs.
Methods
A systematic review was conducted to identify studies which reported the diagnostic accuracy of NILTs
used for the identification of liver fibrosis in patients with various causes of liver disease. The causes of liver
disease included hepatitis C (HCV), hepatitis B (HBV), alcoholic liver disease (ALD) and non-alcoholic fatty
liver disease (NAFLD).
The following databases were searched: MEDLINE (PubMed), EMBASE, Science Citation Index Expanded,
Bioscience Information Service (BIOSIS), Cochrane Central Register of Controlled Trials (CENTRAL), Latin
American and Caribbean Health Sciences Literature (LILACS) and Cumulative Index to Nursing and Allied
Health Literature (CINAHL). The search was conducted from 1998 to April 2012 for all databases.
Reference lists of identified studies and reviews, and conference proceedings from recent conferences,
were hand-searched to identify further studies.
Data from relevant studies were reviewed by two independent reviewers using the Quality Assessment of
Diagnostic Accuracy Studies (QUADAS-2) tool.
Studies were included if they reported the diagnostic accuracy of non-invasive tests using liver biopsy
as the reference standard. Studies were excluded if the time difference between the tests was greater
than 6 months.
Decision-analytic models were developed to assess the cost-effectiveness of the NILTs. Health outcomes
were measured using quality-adjusted life-years (QALYs) and took into account the long-term
consequences of test results where possible. Costs were estimated from a NHS perspective. Fully
incremental analyses were conducted. Separate models were constructed for each of the four causes of
liver disease included in the systematic review. Two models were constructed for HBV representing the
different disease progression and epidemiology for patients with hepatitis B e antigen (HBeAg)-positive and
HBeAg-negative. Additionally, an analysis of the NILTs in the diagnosis of cirrhosis (irrespective of cause)
was conducted.
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For HBV and HCV, the analysis reflected a use of the tests to determine when patients should receive
antiviral treatment. The NILTs were compared with each other as single tests; combinations of NILTs using
four alternative strategies; biopsy; a strategy of treating all with suspected fibrosis; and no testing or
treatment. Markov models were developed to estimate the long-term outcomes of each test result.
For ALD, there are no specific treatments initiated as result of the diagnosis of liver fibrosis. These
patients are advised to abstain from alcohol intake. For our cost-effectiveness analysis of the NILTs, we
hypothesised that people diagnosed with cirrhosis would be more likely to abstain from drinking and
estimated the benefit to long-term health outcomes and associated costs.
It was not possible to conduct the same analysis for NAFLD as there are currently no specific therapeutic
interventions which depend on the degree of fibrosis. Instead, we conducted a cost per correct diagnosis
which allowed us to identify the incremental cost associated with an additional correct diagnosis for each
test. The results are presented separately for correct positive and negative diagnoses. We also conducted
an exploratory analysis for NAFLD to assess the impact of using the non-invasive tests to determine
referral of patients to tertiary care for treatment and monitoring.
Results
Results of the systematic review
During the search, 114,071 studies were found and, after review, 302 of these papers were deemed
suitable. The highest number of studies identified was for HCV, and ALD had the lowest number.
Data from tests that converged using the bivariate model are more robust; however, despite the vast
amount of literature, very few tests’ results converged. In HBV, only five tests had a robust evidence base.
There were no tests in ALD where the bivariate model converged; therefore, the use of NILTs in such
patients for treatment decision is not yet proven. In patients with NAFLD, the evidence base is slightly
larger than for ALD; for the diagnosis of F3 (using Kleiner score), five tests converged. HCV has the highest
number of tests where the bivariate model converged (14 NILTs). The findings show that the evidence base
for many NILTs is not yet proven and further studies are required.
Diagnostic threshold cut-offs of NILTs to determine specific fibrosis stages were not always predetermined
or sufficiently validated; this represents a significant limitation in the interpretation of their results. Among
all NILTs, aspartate aminotransferase (AST) to platelet ratio index (APRI) (low and high cut-offs) had
established cut-offs which were almost universally used in published studies.
Fibroscan (Echosens, Paris) was the NILT assessed in most studies across diseases aetiologies (37 studies in
HCV, 13 in HBV, eight in NAFLD and six in ALD). APRI was also widely assessed in HBV and HCV but not in
NAFLD or ALD.
The methodological quality of included studies as assessed by the QUADAS-2 tool was poor; only 5 of the
302 studies (1.6%) were of high methodological quality. The most common causes were that diagnostic
threshold cut-offs were not predetermined and liver biopsy samples were not of adequate length or did
not have a sufficient number of portal tracts for reliable staging. Therefore, all reported results are
likely biased.
Results of the economic evaluation
Using a cost-effectiveness threshold of £20,000, the results from the analysis for HBV suggests that for
people with HBeAg-positive disease, using two non-invasive tests together [first NILT-hyaluronic acid, with
magnetic resonance (MR) elastography to confirm positive results] is cost-effective with an incremental
cost-effectiveness ratio (ICER) of £19,612. There was, however, a substantial amount of uncertainty around
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this result and the probability that it would have the highest expected net benefit is < 5% and several
combinations of tests had similar costs and outcomes.
The results for the HBeAg-negative analysis differed from those for HBeAg-positive disease and found that
treating all patients suspected of fibrosis without prior testing for the extent of fibrosis was the most
cost-effective option only if the upper bound of the standard UK cost-effectiveness threshold range of
£30,000 is considered acceptable (mean ICER: £28,137), with a probability having the highest expected
net benefit of 38%. The reasons for the difference in results between HBeAg-positive and HBeAg-negative
are due to the underlying characteristics for both groups; the HBeAg-negative population tend to be older
with a higher proportion of males who have a higher all-cause mortality risk than females.
Treating patients with HCV regardless of the degree of fibrosis was the most cost-effective option given a
cost-effectiveness threshold value of £20,000. The results imply that there is no necessity for a diagnostic
test in patients with HCV to determine fibrosis stage. This concurs with current National Institute for
Health and Care Excellence guidance for HCV, which recommends early treatment in all patients with mild
chronic HCV rather than waiting for disease progression to fibrosis. This finding was robust to a number of
sensitivity analyses. It was sensitive to the size of treatment effect in people with very mild disease, but
remained the cost-effective option provided that the benefit to these patients is at least approximately
75% of those with more severe fibrosis.
In patients with ALD, abstinence is usually recommended. The analysis of the tests for ALD was limited as
there are few data available on whether or not abstinence rates are influenced by the diagnosis of liver
fibrosis. It has been theorised that liver biopsy, due to its invasive nature, may encourage abstinence in
more people than non-invasive tests. We incorporated this assumption into our analysis and the base-case
results indicated that liver biopsy was the most effective test to use in patients with ALD; however, the
conclusions were sensitive to some assumptions including differential abstinence rates, which led to
non-invasive testing becoming the cost-effective option.
The analysis of the incremental cost per correct positive diagnosis for NAFLD found that most of the tests
were dominated or extendedly dominated by liver biopsy; however, hyaluronic acid had an ICER of £1.27
and NAFIC (ferritin, fasting insulin, type IV collagen) (low cut-off) had an ICER of £1.29. The analysis found
that it costs an additional £112.30 to obtain an additional correctly diagnosed positive result from biopsy,
compared with these NILTs. The analysis of the incremental cost per correct negative diagnosis found that
FIB-4 (high cut-off) and non-alcoholic fatty liver disease fibrosis score (NFS) (high cut-off) had ICERs of
below £1, the ICERs for NFS enhanced liver fibrosis test was £5.72 and for biopsy was £145.39. Whether
or not the ICERs for the biopsy represent good value for money is difficult to judge as there are no
established cost-effectiveness thresholds for this measure.
The analysis of the NILTs in people with cirrhosis found that the most cost-effective NILT to select patients
for intensive hepatocellular cancer surveillance and monitoring was Forns index. This test has an ICER of
£2032 per additional QALY gained and, if the cost-effectiveness threshold is set at £20,000, is 50% likely
to be the optimal test.
Discussion
We have comprehensively assessed the evidence on the accuracy of the non-invasive tests for liver fibrosis
and the economic implications of using them routinely within a NHS setting for a variety of aetiologies. In
some cases, such as for HCV, the results suggest that early treatment without the need for fibrosis staging
is cost-effective. In other cases, such as for HBeAg-positive disease, the NILTs (single or in combination)
may be more appropriately used to determine treatment; however, several of these tests have very similar
long-term expected mean health and cost outcomes.
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Given the robustness of the data, the results must be approached conservatively. Most studies had a high
risk of bias; therefore, reported results might be biased. Moreover, reported cut-offs for specific fibrosis
stages were seldom predetermined and in most cases insufficiently validated. In addition, a considerable
number of NILTs were tested in only one or a very few studies in specific disease aetiologies, most notably
HBV and ALD; therefore, further studies are needed to assess their diagnostic accuracy.
Furthermore, as some NILTs from the direct tests and imaging modalities categories are not yet widely
available, they cannot be universally applied. Further high-quality research is required on the diagnostic
accuracy of the tests.
As the diagnostic accuracy of most tests was based on studies conducted within tertiary care settings,
the population analysed in the studies may have had more advanced disease than the general population.
This could overestimate the prevalence of the disease, leading to an overestimation of the diagnostic
accuracy for each test.
All reported non-invasive tests were developed and compared with reference to liver biopsy, which is a
reference standard with limitations, most notably misclassifications due to sample variability and intra- and
interobserver variability. A potential solution would be to develop and validate non-invasive tests with
reference to clinical outcomes; however, this would take time.
The findings of the cost-effectiveness study imply that for HCV the best option is to treat all patients
regardless of stage of liver disease. For HBeAg-negative chronic HBV, this is also the case if the higher
bound of the standard cost-effectiveness threshold is considered acceptable. These findings would be
applicable in settings similar to the UK; however, in resource-poor settings, a treat-all strategy may not be
possible. In this case, from our findings, a non-invasive test may be a better diagnostic option than
liver biopsy.
Conclusion
The evidence suggests that, for HCV, treating all patients without prior diagnostic testing is the most
cost-effective option. This analysis has not included the recently approved, more costly, interferon-free
regimes. For HBV, the results differed for patients with HBeAg-positive and HBeAg-negative. The results
suggest that, if the upper band of the standard UK cost-effectiveness threshold is accepted
for patients with HBeAg-negative disease, the strategy of treating all patients regardless of fibrosis level
is cost-effective. For similar patients with HBeAg-positive disease, at standard UK cost-effectiveness
thresholds the results are highly uncertain, with several test strategies having similar expected outcomes
and costs.
Abstinence is recommended for patients with ALD. There was a lack of data to allow robust modelling
of the impact of testing on abstinence rates and whether or not these are affected by the degree of
invasiveness of the tests. If abstinence is likely to increase following diagnosis of fibrosis or cirrhosis,
and if it is likely to be higher following an invasive test, then biopsy will be cost-effective.
For NAFLD, most interventions are aimed at behavioural change rather than treatment and are not
specifically recommended to reduce or halt fibrosis progression (e.g. weight-loss programmes for obesity);
therefore, it is not possible to robustly determine the long-term costs and health consequences of
fibrosis testing.
Suggested research priorities
Research on treatment effectiveness for patients with NAFLD is required, such as on the impact of fibrosis
diagnosis on weight loss and other behaviour changes, and the relative effectiveness of primary care
interventions versus secondary referrals.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xlii
High-quality studies with a low risk of bias for NILTs are required to allow for sufficient validation of
specific cut-offs to stage fibrosis in different disease aetiologies. These require the use of predetermined
cut-offs for the NILTs, adequate biopsy samples, selection of consecutive patients with no inappropriate
exclusions and adequate reporting of patient flow and indeterminate results.
The potential use of NILTs to predict liver-related complications rather than to stage fibrosis should be
further explored. This would provide a hard end point and overcome the need for liver biopsy.
Currently-available NILTs cannot differentiate simple steatosis from steatohepatitis. Therefore, there is a
need to develop reliable non-invasive tests for this, as simple steatosis is usually non-progressive, whereas
steatohepatitis could potentially progress to significant fibrosis and cirrhosis.
Further research on abstinence rates following diagnosis with either a NILT or liver biopsy is required.
The applicability of the findings for HBV and HCV to different countries and settings would benefit from
future research.
The impact of new therapies on cost-effectiveness (higher costs but fewer side effects and better efficacy)
for HCV also warrant further investigation.
Study registration
This study is registered as PROSPERO CRD42011001561.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
L iver fibrosis is scarring of the liver.1 Subsequently, areas of regenerating hepatocytes surrounded byfibrosis tissue develop, resulting in the development of liver cirrhosis.1 Fibrosis and cirrhosis form chronic
liver disease. Every year, around 6000 to 7000 people in the UK die from chronic liver disease2,3 and about
600 adults have to have a liver transplant to survive.4 In 2000, cirrhosis accounted for nearly 500 deaths in
men aged 25 to 44 years and nearly 300 deaths in women of this age group, a seven- to eightfold
increase in the deaths compared with the rate in 1970.2 The age-standardised death rates from cirrhosis
tripled from 2 per 100,000 population to 6 per 100,000 population between 1970 and 2000 in England,2
and doubled from 9 per 100,000 population to 19 per 100,000 population between 1979 and 2007
in Scotland.5
Diagnostic testing for fibrosis and cirrhosis
Liver biopsy
Currently, histological examination of a tiny piece of liver tissue (liver biopsy) is considered the reference
standard for the diagnosis and monitoring of liver fibrosis and cirrhosis. This is usually performed through
the skin under the guidance of ultrasound6–8 and involves taking a small section of the lesion using a sharp
hollow needle. This can usually be performed under local anaesthesia.6–8 The main risks of percutaneous
biopsy are clinically significant bleeding (1.1–1.6%),6,7 which can be fatal.7
Histological examination provides a spectrum of information, including liver architecture, presence and
extent of steatosis, presence and grade of necroinflammation and presence and extent of liver fibrosis.
It can also provide a diagnosis in cases of unexplained liver function test abnormalities. This amount of
information is not provided by any non-invasive test, as they are mainly confined in the assessment of liver
fibrosis. Therefore, liver biopsy will remain essential in many cases, whereas non-invasive liver function tests
will be used in cases where the aetiology of liver disease is known and the clinical question is the extent
of fibrosis.
Liver fibrosis is assessed in liver histological scoring systems using various staging systems that assess liver
architecture and fibrosis. Such systems include Ishak, Knodell, Sheuer and METAVIR.9,10 The METAVIR
scoring system stages fibrosis in five categories, from 0 to 4, while the Ishak system stages fibrosis in seven
categories, 0 to 6. Cirrhosis always represents the end stage of the spectrum and is characterised by
bridging fibrosis and regenerative nodules.
It should be stressed that histological stages are descriptive semiquantitative categories that assess both
liver architecture and liver fibrosis and do not provide a quantitative assessment of liver fibrosis.10,11
The numbers that have been assigned to histological stages have no quantitative relationship between
them, i.e. METAVIR fibrosis stage 2 does not mean twice the amount of fibrosis of stage 1.12 Therefore,
non-invasive fibrosis markers, which assess fibrosis quantitatively, should be ideally developed and
validated with reference to a histological quantitative assessment of liver fibrosis.13,14 Such histological
methods have indeed been developed and quantify fibrosis by measuring liver collagen using digital
image analysis.15–17
As liver biopsy assesses only a tiny amount of the liver, sample variability could potentially misclassify the
extent of fibrosis. In addition, histological staging is also prone to intra- and interobserver variability, even
when senior liver histopathologists are involved. A French study found that, in patients with chronic
hepatitis C (HCV), 35% of biopsies 15mm in length were not categorised correctly.18 The study suggested
that a sample at least 25mm in length is necessary to evaluate fibrosis accurately with a semiquantitative
score, with the possible exception of cirrhosis. Biopsies of such length are not always feasible with one
needle pass in a percutaneous biopsy and, therefore, the patient’s discomfort and also the complication
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rate might increase. The misclassification rate (percentage of incorrect staging of fibrosis) of liver biopsy is
the source of the myth that non-invasive fibrosis tests cannot achieve a high concordance with histological
stages. This is only true for non-invasive tests for which their development was independent from liver
histology, such as transient elastography (TE), although the diagnostic test accuracies of such tests are also
evaluated using histology; it could be argued that in certain cases the false positive or false negative of
such a test compared with the result of a liver biopsy is a fault of the biopsy rather than the test itself,
i.e. the test diagnosed correctly what was missed by the biopsy. However, serum non-invasive fibrosis
markers have been developed and calibrated with direct reference to a set of liver biopsies. Therefore, the
perfect serum marker in this case would replicate the ‘golden’ histological standard and could theoretically
reach an area under the receiver operator curve (AUROC) of 1, replicating even the misclassifications of a
liver biopsy.19
Non-invasive fibrosis tests
During the last few years, there has been an explosive development and use of non-invasive fibrosis
tests.20,21 These tests in many cases have replaced liver biopsy in clinical practice in the staging of fibrosis
and follow-up of patients with established chronic liver disease, especially in patients with chronic HCV.
The non-invasive liver tests (NILTs) can be broadly divided into three categories: simple or indirect serum
markers, direct serum markers and imaging modalities.
Indirect serum markers or class II biomarkers consist of the combination of routine biochemical or
haematological tests, such as transaminases, platelet count and albumin, and patient demographics that
are associated with fibrosis, such as age or the presence of diabetes.20 These tests usually have dual
cut-offs: a high cut-off with high specificity and a low cut-off with high sensitivity. Depending on the
clinical scenario and the disease prevalence, the low or high cut-off is used at the expense of increased
false positives and false negatives, respectively. If these cut-offs are combined, then the number of false
positive and false negatives are minimised; however, a number of patients will fall in the indeterminate
range of fibrosis (i.e. their score will be between the low and the high cut-off) and will need either further
non-invasive testing or a liver biopsy. Commonly used indirect serum markers are FIB-4, aspartate
aminotransferase (AST)-to-alanine aminotransferase (ALT) ratio and APRI (AST to platelet ratio index).
Direct serum non-invasive tests or class I biomarkers are intended to detect extracellular matrix turnover
and/or fibrogenic cell changes. The most common markers used in current assays involve measuring
products of extracellular matrix synthesis or degradation, and the enzymes that regulate their production
or modification, such as hyaluronic acid, serum collagenases and their inhibitors and profibrogenic
cytokines. It should be noted that these markers are not exclusively found in liver tissue; therefore, they
reflect fibrogenic processes in various other organs. For instance, the enhanced liver fibrosis (ELF)
biomarker is influenced by age and sex.22 Moreover, their sensitivity is low in the initial stages of fibrosis.
Various direct and indirect tests have been combined in patented commercial algorithms that improve
the diagnostic accuracy of tests when used singly. These are ELF, Fibrotest, Fibrospect, Fibroindex and
Fibrometer. Of the tests, Fibrotest (Fibrosure in the USA) is the most widely validated panel; it consists of
five parameters, namely total bilirubin, haptoglobin, gamma-glutamyl-transpeptidase, α2-macroglobulin
and apolipoprotein A1, and has been studied in viral hepatitis, non-alcoholic fatty liver disease (NAFLD) and
alcoholic liver disease (ALD).23 The Fibroindex was developed for patients with chronic HCV and uses platelet
count, AST and g-globulin levels.24 Fibrospect includes hyaluronate, tissue metalloproteinase (TIMP)-1 and
α2-macroglobulin, and is validated in chronic HCV.25 Fibrometers are a family of six blood tests: one for
staging and one for quantifying liver fibrosis in each of the three main causes of liver disease (chronic viral
hepatitis, ALD and NAFLD).26 The ELF biomarker is a panel of direct noninvasive markers that includes
hyaluronic acid, type III collagen and TIMP-1.27 It has been used in patients with chronic HCV and NAFLD.
New imaging modalities offer better sensitivity and specificity than conventional techniques, such as
ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI). The last of these can
only identify cirrhosis, based on imaging findings of coarse echo-texture, collaterals suggestive of portal
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hypertension and nodularity. These new modalities measure liver elasticity or liver stiffness based on
ultrasound or magnetic resonance (MR) techniques. The most widely used imaging modality is TE or
Fibroscan (Echosens, Paris).28 Briefly, vibrations of mild amplitude and low frequency are transmitted by
an ultrasound transducer, inducing an elastic shear wave that propagates within the liver. Pulse-echo
ultrasonic acquisitions are performed to follow the shear wave and measure its speed, which is directly
related to the tissue stiffness (the harder the tissue, the faster the shear propagates). Results are expressed
in kilopascals (kPa) and correspond to the median value of 10 validated measurements ranging from
2.5 to 75 kPa, with 5.5 kPa reported to define normality. The volume of liver tissue evaluated by TE
approximates a cylinder 4 × 1 cm which is at least 100 times bigger than a liver biopsy. Moreover,
TE is painless and rapid (< 5 minutes) and thus highly acceptable for patients.
Other modalities include acoustic radiation force impulse (ARFI)29 and MR elastography.30 ARFI allows the
evaluation of liver stiffness in a region of interest (ROI) involving mechanical excitation of tissue by the use
of short-duration (≈262 μs) acoustic pulses while performing a real-time B-mode conventional hepatic
ultrasound. Results are expressed in m/s. Although the volume of liver explored is smaller than that for
TE (10mm long × 6mm wide), a critical advantage is the possibility to choose the representative area
of interest, thereby avoiding large vessels and ribs. An advantage over TE is that it can be easily
incorporated into a modified ultrasound machine. MR elastography uses a modified phase-contrast
method to evaluate the propagation of the shear waves within the liver. It is a very promising technique
but is not yet widely available and cost might be an important limiting factor.
Finally, algorithms of sequential or contemporary use of NILTs have been used mainly in chronic HCV,
to improve the diagnostic accuracy of single tests.31 These are typically based on an agree–disagree
scenario or the sequential use of a second test if the result of the first test falls in the grey zone of an
indeterminate result.
A major limitation of all the above NILTs is the absence of uniformly established and validated cut-offs for
specific aetiologies of liver disease and fibrosis stages and the poor methodological quality of many of the
published studies. In a recent meta-analysis on TE, only 6 of 41 included studies had both histological
evaluation and Fibroscan measurements optimally performed, while all studies had a high risk of bias
based on quality assessment by the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool.32
Aetiologies assessed
The study population comprised all patients with chronic liver disease (irrespective of the aetiology for
chronic liver disease, age and clinical presentation). The aetiologies modelled and assessed were hepatitis B
(HBV), HCV, ALD and NAFLD. We modelled and analysed these four aetiologies of liver disease, as the
staging of fibrosis is pertinent in their prognosis and management. In all other causes of chronic liver
disease, only the diagnosis of cirrhosis is important and liver biopsy is seldom performed for staging of
fibrosis. Therefore, patients with primary biliary cirrhosis, autoimmune hepatitis, haemochromatosis and
Wilson’s disease are treated irrespective of fibrosis stage, whereas fibrosis evaluation is not pertinent in
primary sclerosing cholangitis.33–35 We also modelled liver cirrhosis irrespective of aetiology, as this
diagnosis is important for every patient with chronic liver disease and heralds screening for oesophageal
varices and hepatocellular carcinoma.36
Chronic HCV is a major cause of liver-related morbidity and mortality worldwide, and it is estimated that
around 200 million people are infected worldwide.37 The diagnosis of chronic HCV is based on serological
testing and does not require a liver biopsy. The natural history of chronic HCV is variable; it is estimated
that one-third of the infected patients will progress to cirrhosis.38 Factors that are associated with fibrosis
progression are age at infection > 40 years, male sex, obesity, alcohol abuse, presence of diabetes and
coinfection with human immunodeficiency virus (HIV).37,38 Current therapeutic options include dual therapy
with pegylated interferon and ribavirin in patients with genotypes 2, 3 and 4, and triple therapy with the
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addition of boceprevir or telaprevir in patients with genotype 1. The sustained virological response (SVR)
rate in previously untreated patients is approximately 70% in genotype 4 and 80% in genotypes 1, 2 and
3.37,39,40 Treatment is less successful in patients who were previously unsuccessfully treated, in obesity and
in more advanced fibrosis.37 Currently, antiviral treatment is recommended for all patients with chronic
HCV irrespective of stage of fibrosis.
However, the decision to treat or not to treat is not always straightforward.41,42 Many patients cannot
tolerate the side effects of antiviral treatment, have unfavourable treatment response factors and in fact
might never progress to severe fibrosis. Moreover, new treatment options with better efficacy and fewer
side effects are rapidly emerging.43,44 Non-invasive fibrosis tests offer the option not only of baseline
fibrosis staging but also of follow-up measurements to determine the rate of fibrosis progression.
Therefore, an alternative option would be to use an effective non-invasive fibrosis test for staging and treat
only those patients with F2 and above, which represents clinically significant fibrosis. The test could be
repeated in order to capture the false negatives and also potential fibrosis progression.
Chronic HBV is highly prevalent worldwide and it estimated that 350–400 million people are HBsAg
carriers.45 The natural history of the disease is variable; the virus itself is hepatotropic but not hepatotoxic,
and liver damage is caused when the immune system attacks the hepatocytes that are infected by the virus.
The natural history of the disease can be divided in four distinct phases.46
(1) The ‘immune tolerant’ phase is characterised by hepatitis B e antigen (HBeAg) positivity and high levels
of virus replication but normal transaminases and no or minimal necroinflammation and progression of
fibrosis. The virus, although in high concentrations, is not recognised by the immune system at that
phase. This phase usually occurs in patients with perinatal infection in the first years of their lives.
(2) The ‘immune reactive HBeAg(+)’ phase is characterised by immune reaction, which leads to decreased
HBV replication but also to destruction of hepatocyte, elevated transaminases, necroinflammation and
fibrosis. This phase may last for several years and leads to HBeAg seroconversion to anti-HBe.
(3) The ‘inactive HBC carrier state’ phase is characterised by low or undetectable HBV deoxyribonucleic acid
(DNA) and normal transaminases. This phase is characterised by immunological control of the infection
and is associated with low risk of cirrhosis.
(4) The ‘HBeAg(–) chronic hepatitis B’ phase may follow immediately after the HBeAg sero-conversion or
after years in the inactive carrier state. It is characterised by periodic virus reactivation with a pattern of
fluctuating levels of HBV DNA and aminotransferases, active necroinflammation and progression
of fibrosis.
Patients in the ‘immune tolerant’ and the ‘inactive carrier’ phase do not need antiviral treatment as they
are not at imminent risk of fibrosis progression, but require regular follow-up with determination of
viral load and transaminases.45 Available treatment options include nucleoside or nucleotides analogues
indefinitely or pegylated interferon alfa-2b for a finite period of 12 months. Treatment indications are
based on the combination of criteria that take into account the HBV DNA levels, ALT levels and severity
of liver disease based on histology. Current treatment guidelines advocate liver biopsy before initiating
treatment in the majority of cases. The only exception is patients with obviously active chronic HBV,
i.e. those with ALT > 2 upper limit of normal (ULN) and HBV DNA > 20,000 IU/ml, who may start
treatment without a biopsy.45 Patients with abnormal transaminases, HBV DNA > 2000 IU/ml and a
biopsy showing moderate to severe active necroinflammation and/or at least moderate fibrosis using
a standardised scoring system should be started on antiviral treatment.45 Non-invasive fibrosis tests could
potentially substitute liver biopsy in such patients, i.e. those with a non-invasive diagnosis of ≥ F2.
A minority of patients with moderate necroinflammation but < F2 fibrosis, who would need treatment
according to guidelines, would not be captured with a non-invasive fibrosis test, and would only be
treated once they progressed to F2.
Non-alcoholic fatty liver disease affects approximately 20% of the general population and encompasses
a wide range of liver disease, from simple steatosis to necroinflammation, fibrosis and cirrhosis.47
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It is associated with obesity and is considered the hepatic manifestation of metabolic syndrome.48
Non-alcoholic steatohepatitis (NASH) is the progressive form of NAFLD and affects 15–20% of
patients with NAFLD.49 Only patients with steatohepatitis have increased liver-related mortality.47
Data on natural history of NAFLD are still scarce; in a meta-analysis of 10 studies comprising 221 patients,
37.6% had progressive fibrosis, 41.6% had no change and 20.8% had improvement in fibrosis over a
mean follow-up of 5.3 years.50 Age and initial necroinflammation grade were the only factors associated
with progression of fibrosis.50 Even in patients with NASH, the primary cause of death was cardiovascular
disease, with liver disease being only the third cause.51 Compensated cirrhosis due to NASH is associated
with a lower mortality rate than that due to HCV, and also with lower rates of development of ascites,
hyperbilirubinemia and hepatocellular carcinoma.52
Treatment strategies for NAFLD/NASH are mainly based on lifestyle changes, including weight loss and
exercise, and treatment of the individual components of the metabolic syndrome, such as diabetes,
hypertension and hyperlipidaemia.47 Vitamin E in non-diabetic patients and pioglitazone may improve
steatosis and necroinflammation but not fibrosis, as shown in randomised controlled trials (RCTs).47
Currently, no validated non-invasive tests are available to differentiate NAFLD from NASH.47 Diagnosis
of patients with advanced fibrosis (≥ F3) is of significance, as such patients could benefit from
multidisciplinary treatment of metabolic syndrome components, targeted intervention for weight loss
and specific treatment (vitamin E or pioglitazone) in selected cases.
Alcoholic liver disease encompasses a spectrum of injury that ranges from simple steatosis to cirrhosis.53
The amount of ingested alcohol is the most important risk factor for the development of ALD.54 Suggested
safe limits are 21 units per week in men and 14 units per week in women.53 Development of ALD
is not dose dependent, as ALD is found in only a subset of patients. Women are more susceptible to
alcohol-mediated liver injury than men.55 Binge drinking and consumption of alcohol outside meal times
are both associated with a higher risk of ALD.55 The risk of developing cirrhosis is increased with ingestion
of > 60–80 g/day of alcohol for > 10 years in men and > 20 g/day in women.53
The only effective treatment in patients with ALD is abstinence.53 Prognosis is determined both by the
degree of liver fibrosis and by the subsequent drinking behaviour. Interestingly, 5-year mortality in
patients with well-compensated ALD cirrhosis was 10% in those who abstained and 30% in those who
continued drinking.56 Abstinence improves the histological features of ALD and may reverse fibrosis or
decompensated cirrhosis to compensated cirrhosis. Diagnosis of patients with advanced fibrosis (≥ F3) is of
significance, as it will allow the timely provision of interventions to induce and maintain abstinence before
cirrhosis occurs.
Decision problem to be addressed
As liver biopsy is an invasive procedure and is associated with morbidity and mortality risk, it is important
(1) to assess the diagnostic accuracy of the different non-invasive fibrosis tests available and (2) to
determine the most cost-effective approach in the clinical management of patients with chronic liver
disease using either biopsy or non-invasive fibrosis tests for clinical decisions.
A range of non-invasive tests have become available and offer potential alternatives to liver biopsy.
In order to assess the most appropriate use of the tests within a NHS setting, the relative accuracy and
cost-effectiveness of the tests need to be evaluated. Furthermore, as liver biopsy is costly, and associated
with morbidity and a small risk of mortality, the non-invasive tests may offer cost-effective alternatives.
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Our analysis aims to assess the diagnostic accuracy and cost-effectiveness of the non-invasive tests in
people with suspected liver fibrosis or cirrhosis. The tests are compared with each other, liver biopsy and
strategies without testing. Fully incremental analyses are conducted wherever possible.
When assessing the cost-effectiveness of a test, it is important to consisder the consequences of the test
result. A positive test result is likely to lead to a different course of treatment or action than a negative
result; therefore, the consequences of an incorrect positive diagnosis are likely to differ from the
consequences of an incorrect negative diagnosis. In order to reflect this, and a range of mobidity outcomes
and mortality, our analyses are conducted using the quality-adjusted life-year (QALY) as the measure of
outcome where possible. Where this has not been possible, analyses have been conducted to reflect
potential differences between positive and negative diagnoses.
Structure of report
The rest of this report is structured as follows. The methods of the systematic review and overall
methodological approach to the cost-effectiveness analysis are described in Chapter 3. Chapter 4 presents
results of the systematic review and meta-analysis. Chapters 5–9 present the aetiology-specific methods
and results of the cost-effectiveness analyses for HBV, HCV, ALD, NAFLD and cirrhosis, respectively.
Chapter 10 is a discussion of the findings from the study is provided and Chapter 11 presents
our conclusions.
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Chapter 2 Objectives
There were two related objectives for the study:
1. To compare the diagnostic accuracy of different non-invasive tests in the diagnosis and monitoring of
liver fibrosis and cirrhosis in patients with various aetiologies for chronic liver disease.
2. To estimate the incremental cost-effectiveness of the non-invasive tests in patients with various
aetiologies for chronic liver disease.
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Chapter 3 Methods of systematic review and
economic evaluation modelling
Section 1 outlines the systematic review and meta-analysis methodology used in the study. Section 2outlines the modelling methodology employed for the five aetiologies; HBV, HCV, NAFLD, ALD
and cirrhosis.
Section 1: overview of systematic review methodology
Criteria for considering studies for review
The aim of the systematic review was to identify papers comparing the diagnostic accuracy of different
non-invasive tests in the diagnosis and monitoring of liver fibrosis and cirrhosis with liver biopsy, and to
synthesise the outcomes where possible. We included studies providing cross-sectional information of the
index test(s) and reference test. In other words, we included all studies that reported staging of fibrosis by
index test(s) and reference standard so that it is possible to know how many patients had a certain stage
of fibrosis by index test and reference test (true positive), how many had that stage by index test but
not on the reference test (false positive), how many did not have that particular stage by index test
but were found to have that stage by reference test (false negative), and how many patients did not have
a certain stage of fibrosis by index test or reference test (true negative) in the appropriate patient
population, irrespective of language or publication status, or whether data were collected prospectively
or retrospectively.
We also included comparative studies in which the different index tests were performed in the same study
population, or studies in which different individuals in the study population received different index tests,
and the choice of tests that the different individuals received were determined in a random manner or if all
the patients underwent both the index tests that were assessed. We excluded diagnostic case–control
studies from the analysis if there were at least four cross-sectional or comparative studies for that test.
We also excluded studies where the maximum interval between the reference standard (liver biopsy) and
the non-invasive fibrosis test (index test) was > 6 months.
Participants
Adult patients with chronic liver disease (irrespective of the aetiology and clinical presentation). Studies
reporting on paediatric patients were excluded.
Index tests
Ultrasound, CT scan, MRI, elastography (TE by ultrasound or MR elastography), and direct and indirect
serum markers (such as AST–ALT ratio, APRI, ELF test, Fibrotest, etc.).
Target condition
Liver fibrosis and cirrhosis.
Reference standards
Histopathological examination of liver tissue (percutaneous or transjugular or laparoscopic biopsy). The
staging and grading of liver biopsy can be performed by various histological scoring systems such as Ishak,
METAVIR, Knodell and others.57 We included studies irrespective of the histological scoring system used.
For data synthesis and analysis we transformed the histological scores used in individual studies to
METAVIR for HBV, HCV and alcohol and to Kleiner for NAFLD/NASH as these are the most commonly used
histological scores. Conversion of various histological stages to METAVIR is shown in Table 1.
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Search methods for identification of studies
Electronic searches
The following databases were searched from 1988 until April 2012: MEDLINE (PubMed), EMBASE, Science
Citation Index Expanded, Bioscience Information Service (BIOSIS), Cochrane Central Register of Controlled
Trials (CENTRAL), Latin American and Caribbean Health Sciences Literature (LILACS) and Cumulative Index
to Nursing and Allied Health Literature (CINAHL).58,59
The search strategies for the different databases are provided in Appendix 1.
Initially, we did not use any filter; however, this yielded 200,000 references and a compromise had to be
arranged, as it would not be possible to complete the analysis within the time scale allowed for this
study. Therefore, a methodological filter is included but does not act as a filter for all search results
(see Appendix 1). This represents a potential limitation in our search strategy.
Searching other sources
Reference lists of identified studies and reviews, and conference proceedings from the recent hepatobiliary
conferences (last 2 years), were hand-searched to identify further studies.
Data collection and analysis
Selection of studies
The references were searched by two researchers independently for identification of relevant studies.
No restrictions were placed on the language or the publication status (full text vs. abstract from conference
proceedings). However, studies which reported on a total of fewer than 10 patients with fibrosis or
cirrhosis were excluded. Full texts were obtained for the references that at least one of the reviewers
considered relevant. Full-text articles were then used to include or exclude studies for the review.
Data extraction and management
Data were extracted by two reviewers independently. Any differences in the data extraction were resolved
by the lead applicant, Professor Burroughs, and Dr Gurusamy. Data necessary to calculate the true positive,
false positive, true negative and false negative diagnostic test results were extracted using the reference
standard of liver biopsy. If the information on true positive, false positive, false negative and true negative
diagnostic test results were not available directly, these were calculated from information available in the
study. Data were entered into a Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) file created
for the purpose.
TABLE 1 Conversion of various histological systems to METAVIR
Ishak Knodell Scheuer METAVIR
0 0 0 0
1 1 1 1
2, 3 1 2 2
4, 5 3 3 3
6 4 4 4
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The following data were extracted:
1. year of publication
2. country/ethnicity of included patients
3. inclusion criteria
4. exclusion criteria
5. total number of patients
6. patients included in the analysis
7. mean age
8. mean body mass index (BMI)
9. sex
10. mean ALT
11. aetiology of liver disease
12. technical failure in undertaking liver biopsy or non-invasive tests
13. non-invasive test used
14. fibrosis histological scoring system used
15. non-invasive test cut-off for diagnosing specific fibrosis stages
16. distribution of patients across histological stages
17. sensitivity, specificity, true positive, false positive, false negative, true negative of non-invasive test for
diagnosing different histological stages
18. number of patients with uninterpretable liver biopsies or index tests
19. number of patients with indeterminate non-invasive test for a specific fibrosis stage
20. methodological quality using the QUADAS-2 assessment tool.
Assessment of methodological quality
The quality of the studies was assessed independently by two reviewers using the QUADAS-2 assessment
tool.60–62 This tool comprises four domains: patient selection, index test, reference standard, and flow and
timing. Each domain is assessed in terms of risk of bias, and the first three domains are also assessed in
terms of concerns regarding applicability. Signalling questions are included to help judge the risk of bias.
The quality criteria that were derived from the QUADAS-2 tool and were assessed are shown in Table 2.
Statistical analysis and data synthesis
The data obtained from the various studies are presented in the form of summary sensitivity and specificity
with their corresponding 95% confidence intervals (CIs). The data were combined using the bivariate
random-effects model with correlation between sensitivity and specificity63 using the METADAS macro
developed by the Systematic Review Diagnostic Test Accuracy Group64 in the SAS 9.2 statistical software
(SAS Institute Inc., Cary, NC, USA). We calculated the summary sensitivity and specificity at specific
thresholds for tests with explicit thresholds such as serum markers and calculated the overall summary
sensitivity and specificity for tests that do not have an explicit threshold (such as ultrasound).
The bivariate model allows for meta-analysis of diagnostic test accuracy studies to be conducted in which both
the index test under study and the reference test (gold standard) are dichotomous. Bivariate analysis involves
statistical distributions at two levels. At the lower level, it models the cell counts in the 2 × 2 tables extracted
from each study using binomial distributions and logistic (log-odds) transformations of proportions. At the
higher level, random study effects are assumed to account for heterogeneity in diagnostic test accuracy
between studies beyond that accounted for by sampling variability at the lower level.65
If the results did not converge using the above random-effects model with correlation between sensitivity
and specificity, we performed the meta-analysis with variations of bivariate analysis. The variations
included different assumptions such as no correlation between the sensitivity and specificity in the studies;
random-effects model for sensitivity but fixed-effect model for specificity; fixed-effect model for sensitivity
but random-effects model for specificity; and fixed-effect models for both sensitivity and specificity
(Takwoingi, University of Birmingham, March 2013, personal communication).
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TABLE 2 Assessment of methodological quality using the QUADAS-2 tool
Quality assessed Description Choice Comment
Domain 1:
patient sampling
Was a consecutive or random sample of
patients enrolled?
Yes/no/unclear
Was a case–control design avoided? Yes/no/unclear
Did the study avoid inappropriate
exclusions?
Yes/no/unclear For example exclusion of patients
with severe or low fibrosis,
obese, etc.
Risk of bias Could the selection of patients have
introduced bias?
Low risk/high
risk/unclear
Summarises previous questions: if
any has no as answer then high risk,
if any has unclear then unclear
Concerns about
applicability
Are there concerns that the included
patients and setting do not match the
review question?
High/low
concern/
unclear
Tertiary centres, selected difficult
cases
Domain 2:
index test
Were the index test results interpreted
without knowledge of the results of the
reference standard?
Yes/no/unclear Relevant only in US, CT, MRI
If a threshold was used, was it
prespecified?
Yes/no/unclear
Risk of bias Could the conduct or interpretation of
the index test have introduced bias?
Low risk/high
risk/unclear
Summarises previous questions: if
any has no as answer then high risk,
if any has unclear then unclear
Concerns about
applicability
Are there concerns that the index test,
its conduct, or interpretation differs
from the review question?
High/low
concern/
unclear
Index test not conducted according
to manufacturer recommendations
Domain 3: reference
standard
Is the reference standard likely to
correctly classify the target condition?
Yes/no/unclear Yes if biopsy length > 15mm and/or
> 6 portal tracts
Was the reference standard results
interpreted without knowledge of the
results of the index tests?
Yes/no/unclear
Risk of bias Could the reference standard, its
conduct, or its interpretation have
introduced bias?
Low risk/high
risk/unclear
Summarises previous questions: if
any has no as answer then high risk,
if any has unclear then unclear
Concerns about
applicability
Are there concerns that the target
condition as defined by the reference
standard does not match the question?
High/low
concern/unclear
Always low concern
Domain 4: flow and
timing
Was there an appropriate interval
between index test and reference
standard?
Yes/no/unclear Yes if interval between biopsy and
index test < 3 months, no if interval
> 3 but < 6 months, excluded study
if interval > 6 months
Did all patients receive the same
reference standard?
Yes/no/unclear
Were all patients included in the
analysis?
Yes/no/unclear No if patients with uninterpretable
results were not included in the
analysis or if there were patients
with indeterminate results
Risk of bias Could the patient flow have
introduced bias?
Low risk/high
risk/unclear
Summarises previous questions: if
any has no as answer then high risk,
if any has unclear then unclear
US, ultrasound.
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It must, however, be pointed out that the assumptions used to perform the above analysis (e.g. if one
assumes that there is no correlation between the sensitivity and specificity, one has to ensure this from a
scatterplot and correlation coefficient, and when one assumes a fixed-effect model, the values should be
relatively close to each other) were not always met and the summary values of a model that converged
was used. This could have resulted in a biased effect estimate. The alternative was not to conduct a
meta-analysis for those tests which would have meant that the information could not be used in the
cost-effectiveness analysis.
We also calculated the median, the lowest and the highest prevalence for the specific stages of fibrosis in
the studies included.
Investigations of heterogeneity
The following sources of heterogeneity were explored.
1. Studies of high methodological quality versus low methodological quality.
2. Different stages of fibrosis (different scoring systems were converted to comparable stages in METAVIR
in viral diseases and alcohol, and to Kleiner scoring system in NAFLD).
3. Different reference histological scoring systems (e.g. Ishak scoring, METAVIR, Knodell score, etc.).57
4. Different aetiological diagnosis (e.g. ALD, HCV infection, etc.).
5. Different threshold levels for classification of positive and negative results. We performed a
meta-analysis for every possible cut-off in each fibrosis stage of the reference standard.
6. Studies not published in full text were compared with studies published in full text.
7. Different ranges of transaminases (normal, between normal and up to three times the normal level,
and more than three times the normal level).
Section 2: overview of economic modelling methodology
The population of interest is patients who are suspected of having liver fibrosis or cirrhosis (patients who a
hepatologist would wish to biopsy to inform treatment decisions). Owing to differences in treatment
and natural history of disease, the analysis is conducted separately for subgroups defined according to
aetiology. Five subgroups are defined for the analysis: patients with HBV, HCV, ALD, NAFLD and cirrhosis.
More details are given in the dedicated chapters according to disease aetiology (see Chapter 5 for HBV,
Chapter 6 for HCV, Chapter 7 for ALD and Chapter 8 for NAFLD).
The overall aim of the health economic analysis was to assess the incremental cost-effectiveness of the
NILTs. Wherever possible, the analyses take a lifetime perspective. Health outcomes were measured using
QALYs. A NHS perspective was taken for the estimation of costs. Both costs and QALYs were discounted
at 3.5% in accordance with current National Institute for Health and Care Excellence (NICE) guidelines.66
The consequences following diagnosis are estimated and included in the analyses. In most cases the test
diagnoses are expected to potentially affect decisions about future treatments (HBV, HCV and cirrhosis)
or behaviour change (ALD). The long-term costs and health outcomes as a result of these treatments/
behaviour changes are taken into account in the analysis (including the potential impacts of correct and
incorrect diagnoses). Where this has not been possible, due to insufficient evidence or lack of treatments
specifically aimed at fibrosis, the analysis has been restricted to an incremental cost per correct diagnoses,
supplemented by exploratory analyses (NAFLD). In the cost per correct diagnoses, correct positive
diagnoses have been presented separately from correct negative diagnoses as the consequences of each
are likely to be very different.
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Comparators
Where a large number of applicable NILTs were located by the systematic literature review (HBV and HCV),
a two-stage approach to the analysis was conducted. The first stage compared each NILT identified from the
systematic review (per aetiology) with each other and with liver biopsy. Where analyses involved treatment
(HBV, HCV and cirrhosis), two additional testing approaches were included: a ‘treat all’ approach, where
everyone is treated, and a ‘no treatment’ approach, where no diagnostic tests or treatments are administered.
The second stage of the analysis evaluated comparisons of sequential testing strategies, again compared
with each other, biopsy and the treat-all and treat-no-one strategy. For this, combinations of the two
most cost-effective tests within each category were chosen based on an incremental analysis using a
cost-effectiveness threshold value of £20,000.66 We assumed a decision rule whereby the two most
cost-effective tests from each category were combined with tests from the other categories (reflecting
combinations which would happen in actual current practice or potential future practice). Some of the
NILTs evaluated have defined ‘low’ or ‘high’ cut-off thresholds and were analysed as separate test options.
Combinations of tests considered to be clinically implausible were excluded; for example, a NILT with
a low cut-off diagnostic threshold would not be followed by a second NILT with a low cut-off diagnostic
threshold in practice but could be followed by a test with a high cut-off threshold. The following
assumptions were made when combining the tests:
l If the first NILT used was an indirect serum marker, a patented or direct serum marker or an imaging
modality or liver biopsy could be administered as a second test.
l If the first NILT used was a direct or patented serum marker, an imaging modality or liver biopsy could
be administered as a second test.
l If the first test used was an imaging modality, a liver biopsy could be administered as a second test.
The analysis also assumed that the sensitivity and specificity of each test were independent of each other,
i.e. there was no correlation of sensitivities and specificities of the tests used in the first stage and the
second stage. The combinations were assumed to take four possible sequential testing strategies (Table 3).
The probabilities of having each of the four possible diagnoses (true negative, true positive, false negative,
false positive) for the four sequential testing strategies were determined by multiplying the probabilities
(i.e. using decision tree calculation methodology: multiplying probabilities along pathways from left to right
to estimate the probability of each pathway).
Each of the sequential tests were compared with each other; liver biopsy alone; ‘treat all’ and ‘no
treatment’ approaches; each cost-effective test singly; reported tests which used a combined cut-off; and
any reported tests whose efficacy was estimated using a published algorithm derived from two or more
tests used sequentially.
TABLE 3 Sequential testing strategies
Strategy number
First NILT result Second NILT result
Positive Negative Positive Negative
Strategy 1 Treat patients Liver biopsy
Strategy 2 Do second test Watchful waiting Treat patients Liver biopsy
Strategy 3 Do second test Liver biopsy Treat patients Liver biopsy
Perform two NILTs regardless of test outcome
Strategy 4 Agree (+): treat Disagree: liver biopsy
Agree (–): watchful waiting Positive: treatment
Negative: watchful waiting
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Synthesis of economic evidence
A decision tree model was constructed to estimate the cost-effectiveness of all comparators. Sensitivity and
specificity data included in the decision tree were extracted from the meta-analysis (see Chapter 4).
Long-term costs and QALYs were taken from the literature if estimates specifically matching the decision
tree pathways were available. Where this was not possible, long-term costs and outcomes were estimated
using a series of Markov models. Figure 1 depicts the flow of data between the different modelling
elements for the models estimating incremental cost per QALY.
The watchful waiting strategy incorporated a retest every 2 years. We assumed that the retest would have
perfect sensitivity and specificity in the base case for modelling practicality due to the large number of
applicable NILTs identified.
Literature review
Literature searches were undertaken to identify incremental-cost-per-QALY analyses of the non-invasive
tests for each aetiology. Titles and abstracts were reviewed and full papers were retrieved if deemed
relevant. If existing systematic reviews were available, these were reviewed and the searches updated
and/or amended as required.
Studies were excluded if not in the English language due to resource limitations. We gave preference to
UK-based studies for cost data as there may be transferability issues using data from other populations due
to underlying differences between the populations.
Literature searching was undertaken to populate input parameters for the models (for natural history,
costs and QALY inputs). Titles and abstracts were reviewed and full papers were retrieved if deemed
relevant. We started by identifying existing recent reviews. The papers identified in these were reviewed.
The searches were updated, amended if needed, and rerun.
For data on natural history, inclusion criteria related to the population of interest. Judgements about the
relevance of studies also took into account the country of origin (preference for UK data), high-quality and
recent studies. For cost studies, those reporting data from a NHS perspective were preferred. For studies
reporting health-related utility inclusion criteria requiring data from the population of interest (depending
on aetiology), information on health had to be collected directly from patients and the method of
preference elicitation had to be a choice-based method (e.g. time trade-off) in a UK population. As per
standard NICE methods guidance,66 data obtained through the EQ-5D measure were preferred.
Meta-analysis
Prevalence data
Meta-analysis
Sensitivity data
Meta-analysis
Specificity data
Long-term costs and QALY of
test diagnoses (TP, FP, TN, FN)
Cost and QALY each
comparator
Decision
tree
Test costs and liver
biopsy utility
decrement
FIGURE 1 Illustration of data flow (input into decision tree from other modelling elements). FN, false negative;
FP, false positive; TN, true negative; TP, true positive.
DOI: 10.3310/hta19090 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 9
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Crossan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
15
Further details of the search results are described in the cost-effectiveness chapters (see Chapters 5–9) and
the individual search strategies are listed in Appendix 2.
Costs
All unit costs reported in the analysis for health states and liver biopsy are priced for the year 2012.
Where required, costs were inflated to 2012 prices using NHS inflation indices.67 Test costs for the NILTs
are costed for the year 2012–13 as costs for some of the components for the NILTs were sourced in
early January 2013.
Incremental-cost-per-quality-adjusted-life-year analyses
All analyses were fully incremental. In the incremental analyses, test strategies were ordered according to
the least effective and test strategies which were found to be more costly and less effective (‘dominated’)
than another strategy were ruled out of the analysis. Incremental cost-effectiveness ratios (ICERs) were
calculated for the tests that were not dominated and test strategies with an ICER greater than that of a
more effective intervention (‘extendedly dominated’) were also ruled out; the ICER was calculated using
the formula
ICER= ½(C1−C0)=(E1−E0) (1)
where C1 equals the cost of strategy 1, C0 equals the cost of (the next best) strategy 0, E1 equals QALYs
from strategy 1 and E0 equals QALYs from (the next best) strategy.
The cost-effectiveness results for the remaining strategies which were not ruled out (not ‘dominated’ or
‘extendedly dominated’) were presented as ICERs.68
Probabilistic sensitivity analysis (PSA) was conducted. With a PSA, rather than using the average values
for each parameter input, the value is instead drawn from a distribution. The probability distribution for
each input variable (natural history data, mortality rates, costs, QALYs, treatment effectiveness and
test effectiveness) was constructed using estimates of the mean value and standard error (if required for
probability distribution) and Monte Carlo simulation was used to randomly sample from each input
distribution simultaneously for 1000 runs of the models. For each of the decision tree model outputs
(1000 simulation runs), an average total lifetime cost and QALY was calculated for each testing strategy.
To summarise the uncertainty around the cost-effectiveness result, we constructed cost-effectiveness
acceptability curves (CEACs) which are derived from a joint distribution of the costs and effects (QALYs) to
represent the probability that a testing option is cost-effective (had the highest net monetary benefit) at
different levels of a cost-effectiveness threshold (varied from £0 to £60,000 in analysis). Net benefit is
calculated using the formula
Net benefit= ECR−C (2)
where E is equivalent to the health outcome for a testing strategy, CR equals the ceiling ratio which is the
cost-effectiveness threshold (range between £0 to £60,000) and C equals the cost of the testing strategy.69
The CEAC represents the probability that a testing option has the highest probability of being
cost-effective over a range of threshold values. However, as Fenwick et al.69 have shown, the testing
option with the highest probability of being cost-effective may not necessarily have the highest expected
net benefit. In this case, the CEAC should not be used to identify the optimal option; instead, the
cost-effectiveness acceptability frontier (CEAF) which plots the uncertainty associated with the optimal
testing option (option with highest expected net benefit) for different cost-effectiveness threshold values
may be more applicable.
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We also present the CEAFs to illustrate the probability of any testing strategy being optimal (has the
highest expected net benefit) compared with each other over a range of different cost-effectiveness
thresholds (threshold value range varied from £0 to £60,000).69,70
Cost per correct diagnosis (alcoholic liver diseases and non-alcoholic fatty
liver disease)
The cost-per-correct-diagnoses analyses are presented incrementally. We carried out a probabilistic analysis
where we estimated the number of correct true responses for each tests (positive and negative responses).
We then compared the results of each test incrementally using the cost for each test to rule out tests
which were more costly and provided less correct results. Liver biopsy was included as a comparator in the
cost-per-correct-diagnosis analyses.
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Chapter 4 Results of systematic review and
meta-analysis
Systematic review results
Description of studies
The search strategy initially retrieved 114,071 studies, or after duplicate exclusion, 91,097 studies. The
flow chart is shown in Figure 2. Finally, data from 302 studies were analysed (HCV n= 162, HBV n= 52,
NAFLD n= 48, radiology n= 60, ALD n= 12).23–31,71–363 All but five of the included studies were captured by
the search strategy79,256,276,332,334 These five studies were retrieved by manually searching the reference lists
of included studies and published meta-analyses.
Meta-analysis results
Data analysis was performed separately according to disease aetiology (HCV, HBV, NAFLD and ALD)
as there are distinct patterns of fibrosis development in different aetiologies of chronic liver disease.
For example, fibrosis in chronic viral hepatitis is characterised by portal-central septa and interface hepatitis,
whereas capillarisation of sinusoids and intercellular fibrosis (chicken-wire fibrosis) are typical of alcoholic
and non-alcoholic steatohepatitis.364 This results in a statistically different amount of fibrosis as measured
by liver collagen in patients with different aetiologies of liver disease but the same histological stage.365
This is reflected in disease-specific cut-offs of non-invasive markers for the same histological stage,
for example the cut-offs using Fibroscan for F2 fibrosis differ in HBV and HCV,32 but also in differences
in diagnostic accuracy depending on the aetiology of liver disease.20
114,071 studies identified
22,974 duplicates
88,774 excluded by title and/or abstract
2323 references retrieved for
more detailed evaluation
No data on sensitivity, specificity, n = 386
Not distinct aetiologies, n = 85
Time interval > 6 months, n = 51
No pertinent aetiologies, n = 90
Not eligible, n = 1409
302 studies for analysis
FIGURE 2 Flow chart of literature review search.
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Data from radiological methods of fibrosis assessment were pooled and analysed together irrespective
of aetiology, as these methods are based on size and contour of the liver, echotexture and signs of portal
hypertension rather than on disease-specific fibrotic patterns. Data on Fibroscan, ARFI and real-time
elastography were analysed according to the aetiology of liver disease.
Non-invasive test cut-offs for the diagnosis of specific histological stages were not always predetermined,
and consequently, varied in the included studies. This probably resulted in higher diagnostic accuracies of
the non-invasive tests assessed when the cut-off was not predetermined, as such cut-offs were statistically
determined to correlate in the best way with the biopsy results. We opted not to perform a separate
meta-analysis for each stage-specific cut-off of a non-invasive test, but to group together cut-offs if the
range was reasonable. Therefore, all reported sensitivities and specificities of a non-invasive test, when a
range of cut-offs is mentioned in the results tables, are probably overestimated.
A number of NILTs, mainly indirect non-invasive fibrosis tests, report sensitivities and specificities at dual
cut-offs, a high cut-off with high specificity and a low cut-off with high sensitivity. The low and high
cut-off is usually set at 90–95% of sensitivity and specificity, respectively. Depending on the clinical scenario
and the disease prevalence, the low or high cut-off is used at the expense of increased false positives and
false negatives respectively. We performed separate meta-analyses for low and high cut-offs whenever such
cut-offs were reported and were similar across studies. Patients who have test results greater than the
higher cut-off are considered to be test positive and those with test results lower than the lower cut-off are
considered to be test negative. If these cut-offs are combined, then false positives and false negatives are
minimised but a number of patients will fall in the indeterminate range of fibrosis (i.e. their score will be
between the low and the high cut-off) and will need either further non-invasive testing or a liver biopsy.
Such patients with intermediate results were considered to have undergone a second test.
Table 4 provides a list of NILTs found, applicable aetiologies and a list of the components.
Results: hepatitis C virus
Data on patients with HCV were extracted from 162 studies.23–29,31,71–224 Meta-analysis was performed
separately for each non-invasive test which had been assessed at each METAVIR stage (F1–F4). Summary
sensitivity and specificity for F2 and F4 are shown in Tables 5 and 6, while the sensitivity and specificity
estimates for F1 and F3 are reported in Appendix 3. Individual study characteristics are shown in
Appendix 4. The median prevalence (minimum–maximum) of fibrosis stages F1–F4 in included studies was
for F1 0.875 (0.157–0.968), F2 0.522 (0.063–0.893), F3 0.291 (0.051–0.778) and F4 0.17 (0.026–0.681).
Forest plots and summary receiver operating characteristic (SROC) plots of different NILTs across fibrosis
stages are presented in Appendices 5 and 6, respectively.
For the diagnosis of fibrosis stage ≥ F2, which was the one mainly used in economic modelling,
19 non-invasive tests were evaluated in single studies. Of 47 different evaluated tests, only 18 converged
with the bivariate random-effects model [APRI low and high cut-offs, AST–ALT ratio, FIB-4 low and high
cut offs, Forns index low and high cut-off, Göteborg University Cirrhosis Index (GUCI), Lok’s index,
platelet count, hyaluronic acid, Hepascore, Fibrometer, Fibrotest standard, low and high cut-offs,
platelet-to-spleen-diameter ratio and Fibroscan]. The most commonly evaluated non-invasive tests were
APRI (low cut-off), which was evaluated in 47 studies,24,31,73,74,79,81,84,85,89,90,91,94,97,98,103,107,109,121,126,127,130,131,134,137,
140,143,144,146,150,152–154,156–158,163,164,168,182,185,187,189,194,195,210,218,220,223 followed by TE in 37 studies28,29,75,76,86–88,91,95,
98–100,102,105,106,110,116,119,130,137,141,147,153,155,159,161,164,170,172,173,194,199–201,211,223,224 and APRI (high cut-off) in
37 studies.24,31,72–74,79,81,89,90,91,94,97,100,103,121,123,126,131,134,140,143,146,150,152–154,156–158,182,187,195,209,210,218,220,223
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TABLE 4 Components of NILTs and applicable aetiology
Test Components Comments
Indirect serum non-invasive fibrosis tests
APGA AST, platelet count, GGT, α-fetoprotein HBV
APRI AST, platelet count HBV, HCV, NAFLD, ALD
Age–Platelet Index Age, platelet count HBV, HCV, NAFLD
AST–ALT ratio AST, ALT HBV, HCV, NAFLD
BARD BMI, AST, ALT, presence of diabetes
CDS AST, ALT, platelet count, INR HBV, HCV, NAFLD
FIB-4 Age, AST, ALT, platelet count HBV, HCV, NAFLD
Forns index Age, γ-GT, cholesterol, platelet count HBV, HCV, ALD
FibroQ Age, AST, ALT, INR, platelet count HCV
Fibrosis probability index Age, past alcohol intake, AST, cholesterol, HOMA-IR HCV
GUCI AST, ALT, platelet count HBV, HCV
Hui index BMI, total bilirubin, platelet count, albumin HBV
King’s Age, AST, INR, platelet count HCV
Lok’s index AST, ALT, platelet count, INR HBV, HCV, NAFLD
NAFLD fibrosis score Age, BMI, presence of diabetes or IFG, AST, ALT,
platelet count, albumin
NAFLD
NIHCED Age, prothrombin time, platelet count, AST, ALT,
splenomegaly, caudate lobe hypertrophy, right liver
lobe atrophy
HCV
PAPAS Platelet count, age, ALP, α-fetoprotein, AST HBV
PGAA Prothrombin time, GGT, apolipoprotein A1,
α2-macroglobulin
ALD
Platelet count Platelets count HCV, NAFLD
Pohl index AST, ALT, platelets HCV
Direct non-invasive fibrosis tests
13C-caffeine breath test HBV, HCV, NAFLD
Amino-breath test Aminopyrine breath test HCV
CTGF Connective tissue growth factor HBV
Fontana Hyaluronic acid, TIMP-1, platelet count HCV
Hyaluronic acid Hyaluronic acid HBV, HCV, NAFLD
Hepascore Age, sex, α2-macroglobulin, hyaluronate, bilirubin, γ-GT HBV, HCV, NAFLD
NAFIC Ferritin, fasting insulin, type IV collagen NAFLD
NAFLD diagnostic
panel – advanced fibrosis
Presence of diabetes, AST, triglycerides, TIMP-1 NAFLD
NAFLD diagnostic
panel – any fibrosis
Presence of diabetes, sex, BMI, triglycerides, M30,
M65-M30
NAFLD
PIIINP Amino-terminal propeptide of type III procollagen HCV
PIIINP/MMP1 index PIIINP, MMP1 HCV
continued
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TABLE 4 Components of NILTs and applicable aetiology (continued )
Test Components Comments
Type IV collagen Type IV collagen HBV, HCV, NAFLD
YKL-40 YKL-40 HCV, ALD
Commercial non-invasive serum fibrosis tests
ELF PIIINP, hyaluronate, TIMP-1 HCV, NAFLD
Fibroindex Platelet count, AST, γ-globulin HCV
Fibrometer Platelets, prothrombin time, macroglobulin, AST,
hyaluronate, age, urea
HCV
FibrospectII α2-macroglobulin, hyaluronate and TIMP-1 HCV
Fibrotest γ-GT, haptoglobin, bilirubin, A1 apolipopotein,
α2-macroglobulin
HBV, HCV, NAFLD, ALD
Imaging modalities
ARFI Acoustic radiation force impulse imaging HBV, HCV, NAFLD
Platelet–spleen ratio Platelet count, spleen diameter HCV
Real-time elastography Real-time elastography HBV, HCV, NAFLD
Fibroscan Transient elastography HBV, HCV, NAFLD, ALD
CT Computed tomography scan All aetiologies
MRI Magnetic resonance imaging All aetiologies
DW-MRI Diffusion-weighted magnetic resonance imaging All aetiologies
MR elastography Liver stiffness measured with MRI All aetiologies
US Conventional ultrasound All aetiologies
Contrast-enhanced ultrasound Ultrasound after the intravenous injection of specific
contrast material
All aetiologies
US SAPI Splenic artery pulsatile index measured
with ultrasound
All aetiologies
Algorithms of non-invasive fibrosis assessment
Bordeaux Synchronous Fibrotest and Fibroscan HCV
Fibropaca Synchronous Fibrotest, APRI and Forns index HCV
Leroy Synchronous Fibrotest and APRI HCV
SAFE APRI and Fibrotest sequentially HCV
ALP, alkaline phosphatase; APGA, AST, platelet count, gamma-glutamyl transpeptidase (GGT), α-fetoprotein;
BARD, BMI, AST–ALT ratio, diabetes; CDS, Cirrhosis Discriminant Score; CTFG, connective tissue growth factor;
DW-MRI, diffusion-weighted magnetic resonance imaging; GGT, gamma-glutamyl transpeptidase; GUCI, Göteborg
University Cirrhosis Index; HOMA-IR, homeostatic model assessment-insulin resistance; IFG, impaired fasting glucose;
INR, International Normalized Ratio; MMP1, matrix metalloproteinase-1; NIHCED, non-invasive hepatitis C-related early
detection; PAPAS, Age, ALP, α-fetoprotein, AST; PGAA, prothrombin time, GGT, apolipoprotein A1, α2-macroglobulin;
PIIINP, amino-terminal propeptide of type III procollagen; SAFE, sequential algorithm for fibrosis evaluation;
SAPI, splenic artery pulsatile index; YKL-40, a direct marker of liver fibrosis; US, ultrasound.
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TABLE 5 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage ≥ F2 in patients with chronic HCV
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Indirect non-invasive serum tests
APRI
(low cut-off)
47 0.4–0.7 0.82 (0.77 to 0.86) 0.57 (0.49 to 0.65) Bivariate random-effects
model with correlation
between sensitivity
and specificity
APRI
(high cut-off)
36 1.5 0.39 (0.32 to 0.47) 0.92 (0.89 to 0.95) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Age–Platelet
Index
1 3 0.58 (0.46 to 0.70) 0.70 (0.64 to 0.84) Single study
AST–ALT
ratio
7 0.6–1 0.44 (0.27 to 0.63) 0.71 (0.62 to 0.78) Bivariate random-effects
model with correlation
between sensitivity
and specificity
CDS 1 6 0.66 (0.59 to 0.73) 0.49 (0.34 to 0.64) Single study
FIB-4
(low cut-off)
11 0.6–1.45 0.89 (0.79 to 0.95) 0.42 (0.25 to 0.61) Random-effects model for
sensitivity and specificity
without correlation
FIB-4
(high cut-off)
9 1–3.25 0.59 (0.43 to 0.73) 0.74 (0.56 to 0.87) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Forns index
(low cut-off)
18 4.2–4.5 0.88 (0.83 to 0.91) 0.40 (0.33 to 0.48) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Forns index
(high cut-off)
15 6.9–8.7 0.35 (0.29 to 0.41) 0.96 (0.92 to 0.98) Bivariate random-effects
model with correlation
between sensitivity
and specificity
FibroQ 1 1.6 0.78 (0.71 to 0.83) 0.66 (0.51 to 0.78) Single study
Fibrosis
probability
index
(low cut-off)
2 0.2 0.91 (0.83 to 0.96) 0.45 (0.34 to 0.57) Fixed-effects model for
sensitivity and specificity
without correlation
Fibrosis
probability
index
(high cut-off)
2 0.8 0.42 (0.32 to 0.54) 0.95 (0.87 to 0.98) Fixed-effects model for
sensitivity and specificity
without correlation
GUCI 3 0.33–1.1 0.65 (0.1 to 1.00) 0.79 (0.03 to 1.00) Bivariate random-effects
model with correlation
between sensitivity
and specificity
King’s 1 9.87 0.84 (0.75 to 0.9) 0.70 (0.61 to 0.79) Single study
King’s
(low cut-off)
1 4.46 0.62 (0.55 to 0.69) 0.81 (0.76 to 0.86) Single study
King’s
(high cut-off)
1 12.3 0.58 (0.51 to 0.65) 0.79 (0.73 to 0.83) Single study
continued
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TABLE 5 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage ≥ F2 in patients with
chronic HCV (continued )
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Lok’s index 4 0.2–1.67 0.67 (0.55 to 0.77) 0.55 (0.29 to 0.78) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Platelets 10 48–182 0.50 (0.41 to 0.59) 0.89 (0.83 to 0.93) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Pohl index 2 Positive 0.06 (0.04 to 0.1) 0.99 (0.93 to 1.00) Fixed-effects model for
sensitivity and specificity
without correlation
Direct serum non-invasive serum tests
Aminopyrine
breath test
1 8.1 0.73 (0.57 to 0.85) 0.74 (0.58 to 0.85) Single study
Hyaluronic
acid
8 34–110 ng/
ml
0.75 (0.64 to 0.83) 0.75 (0.68 to 0.82) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Hepascore 10 0.31–0.5 0.73 (0.66 to 0.79) 0.73 (0.65 to 0.79) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Hepascore
(high cut-off)
1 0.84 0.33 (0.24 to 0.43) 0.92 (0.85 to 0.96) Single study
MP3 1 0.3 0.82 (0.73 to 0.89) 0.73 (0.63 to 0.81) Single study
PIIINP 2 8.3–9.1 0.78 (0.63 to 0.87) 0.76 (0.54 to 0.90) Fixed-effects model for
sensitivity and specificity
without correlation
PIIINP/MMP1
index
1 0.3 0.65 (0.55 to 0.75) 0.85 (0.77 to 0.90) Single study
Type IV
collagen
5 110–298 0.88 (0.71 to 0.96) 0.73 (0.63 to 0.82) Random-effects model for
sensitivity and specificity
without correlation
YKL-40
(low cut-off)
1 290 0.80 (0.66 to 0.89) 0.33 (0.26 to 0.41) Single study
YKL-40
(high cut-off)
1 540 0.33 (0.21 to 0.48) 0.80 (0.73 to 0.86) Single study
Commercial non-invasive serum tests
ELF 1 8.75 0.84 (0.69 to 0.92) 0.70 (0.52 to 0.83) Single study
ELF
(low cut-off)
1 9.55 0.90 (0.85 to 0.93) 0.52 (0.43 to 0.61) Single study
ELF
(high cut-off)
1 11.07 0.47 (0.41 to 0.54) 0.90 (0.83 to 0.94) Single study
Fibroindex
(low cut-off)
4 1.25 0.83 (0.15 to 0.99) 0.57 (0.22 to 0.86) Random-effects model for
sensitivity and specificity
without correlation
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TABLE 5 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage ≥ F2 in patients with
chronic HCV (continued )
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Fibroindex
(high cut-off)
4 2.25 0.24 (0.11 to 0.43) 0.98 (0.93 to 1.00) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
Fibrometer 4 0.42–0.57 0.79 (0.69 to 0.86) 0.73 (0.63 to 0.81) Bivariate random-effects
model with correlation
between sensitivity
and specificity
FibrospectII 5 42–72 0.78 (0.49 to 0.93) 0.71 (0.59 to 0.80) Random-effects model for
sensitivity and specificity
without correlation
Fibrotest 17 0.32–0.53 0.68 (0.58 to 0.77) 0.72 (0.70 to 0.77) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Fibrotest
(low cut-off)
7 0.1–0.3 0.91 (0.86 to 0.94) 0.41 (0.37 to 0.46) Random-effects model for
sensitivity and specificity
without correlation
Fibrotest
(high cut-off)
10 0.6–0.7 0.57 (0.46 to 0.67) 0.85 (0.74 to 0.92) Bivariate random-effects
model with correlation
between sensitivity
and specificity
ARFI 3 1.21–1.34 0.79 (0.75 to 0.83) 0.89 (0.84 to 0.93) Fixed-effects model for
sensitivity and specificity
without correlation
PLT–Spleen
ratio
3 1750–2200 0.88 (0.62 to 0.99) 0.73 (0.41 to 0.99) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Real-time
elastography
1 2.73 0.83 (0.73 to 0.90) 0.92 (0.65 to 0.99) Single study
Fibroscan 37 5.2–10.1 0.79 (0.74 to 0.84) 0.83 (0.77 to 0.88) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Combination of fibrosis non-invasive tests algorithms
Bordeaux 1 – 0.88 (0.85 to 0.91) 0.89 (0.85 to 0.92) Single study
Fibropaca 1 – 0.85 (0.81 to 0.89) 0.90 (0.86 to 0.93) Single study
Leroy 1 – 0.90 (0.79 to 0.96) 0.98 (0.95 to 0.99) Single study
SAFE 4 – 1.00 (1.00 to 1.00) 0.81 (0.80 to 0.83) Fixed-effects model for
sensitivity and specificity
without correlation
CDS, Cirrhosis Discriminant Score; MMP1, matrix metalloproteinase-1; MP3, metalloproteinase-3; PIIINP, amino-terminal
propeptide of type III procollagen; PLT, platelet; SAFE, sequential algoritm for fibrosis evaluation; YKL-40, a direct marker of
liver fibrosis.
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TABLE 6 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage ≥ F4 in patients with chronic HCV
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Indirect non-invasive serum tests
APRI
(low cut-off)
24 0.75–1 0.77 (0.73 to 0.81) 0.78 (0.74 to 0.81) Bivariate random-effects
model with correlation
between sensitivity
and specificity
APRI
(high cut-off)
19 2 0.48 (0.41 to 0.56) 0.94 (0.91 to 0.95) Bivariate random-effects
model with correlation
between sensitivity
and specificity
AST–ALT
ratio
13 1 0.49 (0.39 to 0.59) 0.87 (0.75 to 0.94) Bivariate random-effects
model with correlation
between sensitivity
and specificity
CDS 1 8 0.88 (0.66 to 0.97) 0.67 (0.57 to 0.77) Single study
FIB-4
(low cut-off)
2 1.45 0.87 (0.74 to 0.94) 0.61 (0.53 to 0.69) Fixed-effects model for
sensitivity and specificity
without correlation
FIB-4
(high cut-off)
3 3.25–4.44 0.51 (0.39 to 0.63) 0.86 (0.81 to 0.90) Fixed-effects model for
sensitivity and specificity
without correlation
Forns index
(low cut-off)
2 3.9–4.2 0.88 (0.60 to 1.00) 0.43 (0.1 to 1.00) Fixed-effect model for
sensitivity and random-
effects model for specificity
without correlation
Forns index
(high cut-off)
1 6.9 0.67 (0.53 to 0.78) 0.91 (0.84 to 0.95) Single study
GUCI 3 Positive 0.76 (0.07 to 0.99) 0.85 (0.78 to 0.90) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
Lok’s index
(low cut-off)
2 0.2–0.26 0.84 (0.88 to 1.00) 0.66 (0.01 to 100) Fixed-effect model for
sensitivity and random-
effects model for specificity
without correlation
Lok’s index
(high cut-off)
1 0.5 0.40 (0.29 to 0.52) 0.95 (0.91 to 0.97) Single study
Platelets 10 130–196 0.68 (0.59 to 0.76) 0.86 (0.72 to 0.94) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Direct serum non-invasive serum tests
13C-caffeine
breath test
2 0.01–1.7 0.88 (0.22 to 0.99) 0.73 (0.18 to 0.97) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
Fontana 1 0.3 0.79 (0.72 to 0.84) 0.66 (0.61 to 0.71) Single study
Hyaluronic
acid
7 78–237 ng/ml 0.80 (0.61 to 0.91) 0.88 (0.78 to 0.94) Bivariate random-effects
model with correlation
between sensitivity
and specificity
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TABLE 6 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage ≥ F4 in patients with
chronic HCV (continued )
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Hepascore 7 0.84 0.80 (0.68 to 0.88) 0.83 (0.76 to 0.89) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Hepascore
(low cut-off)
1 0.58 0.80 (0.72 to 0.86) 0.83 (0.80 to 0.85) Single study
Hepascore
(high cut-off)
1 1.159 0.39 (0.31 to 0.48) 0.99 (0.98 to 0.99) Single study
PIIINP 3 0.8–1 0.70 (0.42 to 0.89) 0.84 (0.74 to 0.90) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
Type IV
collagen
1 190 0.78 (0.65 to 0.86) 0.72 (0.61 to 0.81) Single study
Commercial non-invasive serum tests
ELF 1 9.4 0.93 (0.69 to 0.99) 0.79 (0.67 to 0.88) Single study
ELF
(low cut-off)
1 10.06 0.90 (0.84 to 0.94) 0.53 (0.46 to 0.59) Single study
ELF
(high cut-off)
1 11.73 0.52 (0.43 to 0.60) 0.90 (0.85 to 0.93) Single study
Fibroindex 1 1.82 0.70 (0.52 to 0.84) 0.91 (0.82 to 0.96) Single study
Fibrometer 2 0.88 0.72 (0.36 to 0.92) 0.88 (0.60 to 0.97) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
Fibrometer
(low cut-off)
1 0.63 0.96 (0.90 to 0.98) 0.71 (0.68 to 0.74) Single study
Fibrometer
(high cut-off)
1 0.98 0.36 (0.28 to 0.45) 0.98 (0.97 to 0.99) Single study
Fibrotest 8 0.56–0.74 0.60 (0.43 to 0.76) 0.86 (0.81 to 0.91) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Fibrotest
(low cut-off)
1 0.66 0.82 (0.74 to 0.88) 0.77 (0.74 to 0.80) Single study
Fibrotest
(high cut-off)
1 0.86 0.42 (0.34 to 0.51) 0.96 (0.94 to 0.97) Single study
Imaging modalities
ARFI 4 1.6–2.3 0.84 (0.72 to 0.91) 0.77 (0.50 to 0.92) Random-effects model for
sensitivity and specificity
without correlation
PLT–Spleen
ratio
1 Spleen> 120,
PLT< 140
0.85 (0.76 to 0.91) 0.82 (0.80 to 0.84) Single study
Real-time
elastography
1 3.93 0.91 (0.73 to 0.98) 0.91 (0.80 to 0.97) Single study
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For the diagnosis of cirrhosis, there were 37 different evaluated tests; however, only nine converged with
the bivariate random-effects model (APRI low and high cut-offs, AST–ALT ratio, platelet count, hyaluronic
acid, Hepascore, Fibrotest and Fibroscan).
For the diagnosis of fibrosis stage ≥ F1, there were only five tests that reported diagnostic accuracy;
however, none converged with the bivariate random-effects model.
For the diagnosis of fibrosis stage ≥ F3, there were 37 different evaluated tests, of which six converged
with the bivariate random-effects model (APRI high cut-off, FIB-4 low and high cut-offs, Hepascore,
Fibrotest and Fibroscan).
Uninterpretable NILT results were very rare in serum markers (< 1%) and were more frequently
encountered in patients who were undergoing Fibroscan examination. The rate of uninterpretable results
with Fibroscan (due to < 10 valid measurements, success rate < 60% and interquartile range > 30%) was
8.5%; however, this could be underestimated due to under-reporting.
Cut-offs of non-invasive tests for specific disease stages varied among studies and were predetermined in
only 51 studies (31.4%).25,31,72–74,83,85–87,90–92,94,95,97,99,100,106,109,117,119,127,132–134,143,144,146,150,154,156,157,167,169,171,172,175,186,
187,192–194,203,213–216,220,222,223,366 We did not include data on APRI for cirrhosis from some studies in the
meta-analysis because some cut-offs differed significantly from what is used in the literature.82,137,168,194
Liver biopsy was of acceptable quality (≥ 15 cm in length with ≥ 6 portal tracks) in only 20 studies
(12.3%),75,86,110,112,115–117,119,124,127,129,137,141,143,153,186,188,194,222,223 while minimum sample requirements were not
reported in 84 (51.8%) studies.26,27,72–74,77–80,84,85,88,91–93,96,100,101,103,104,106,107,111,114,118,121–123,125,126,130,131,133,135,138,140,
147,148,151,152,159–163,165,167–169,172–175,177,178,180,181,183–185,190–192,196–204,208–215,218,221 Overall, only three studies86,143,222 had
a low risk of bias in all of the domains of the QUADAS-2 tool; therefore, all our estimates may be biased.
Quality assessment of included studies based on QUADAS-262 is shown in Table 7. Studies that were
judged as low risk of bias or unknown in the three most important QUADAS domains, namely patient
selection, index test and reference standard, were still a modest fraction of the total number of studies
(29 out of 152; 19%).72,73,79,80,86,91,92,106,110,133,135,143,148,165,167,173,197–199,201,203,206–208,211,214,215,221,222
We explored potential sources of heterogeneity as outlined in the methods section. As all but five studies
were of low methodological quality,86,127,143,186,222 this potential source of heterogeneity could not be
assessed. Significant heterogeneity was found mainly in relation to the transaminases level, without,
TABLE 6 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage ≥ F4 in patients with
chronic HCV (continued )
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Fibroscan 36 9.2–17.3 0.89 (0.84 to 0.92) 0.91 (0.89 to 0.93) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Combination of fibrosis non-invasive tests algorithms
Bordeaux 1 – 0.87 (0.80 to 0.92) 0.95 (0.93 to 0.96) Single study
Fibropaca 1 – 0.73 (0.62 to 0.81) 0.97 (0.95 to 0.98) Single study
SAFE 4 – 0.74 (0.42 to 0.92) 0.93 (0.91 to 0.94) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
CDS, Cirrhosis Discriminant Score; GUCI, Göteborg University Cirrhosis Index; PIIINP, amino-terminal propeptide of type III
procollagen; PLT, platelet; SAFE, sequential algoritm for fibrosis evaluation.
RESULTS OF SYSTEMATIC REVIEW AND META-ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
TABLE 7 Quality assessment of studies included in the meta-analysis for chronic HCV. Quality assessment was done
using the QUADAS-2 tool
Study ID
Domain 1: patient
sampling Domain 2: index test
Domain 3: reference
standard
Domain 4: flow
and timing
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability Risk of bias
Adams 200571 ✓ ✓ ✗ ✓ ✗ ✓ ✓
Ahmad 201172 ? ✓ ✓ ✓ ? ✓ ✓
Al Mohri73 ? ? ✓ ✓ ? ✓ ✓
Anaparthy 200974 ✗ ✗ ✓ ✓ ? ✓ ?
Arena 200875 ✓ ✗ ✗ ✓ ✓ ✓ ✓
Beckebaum 201076 ✗ ✗ ✗ ✓ ✗ ✓ ✓
Bejarano 200977 ✓ ✓ ✗ ✓ ? ✓ ✓
Berg 200479 ? ? ? ? ? ✓ ?
Borroni 200280 ? ? ? ? ? ✓ ?
Bourliere 200681 ✓ ✗ ✗ ✓ ✗ ✓ ✗
Boursier 200982 ✓ ✓ ✗ ✓ ✗ ✓ ✗
Boursier 201283 ✓ ✓ ✓ ✗ ✗ ✓ ✓
Burton 201084 ✗ ✗ ✓ ✓ ? ✓ ?
Cales 201085 ✗ ✗ ✓ ✓ ? ✓ ✗
Cales 201026 ? ? ✗ ✓ ? ✓ ✓
Calvaruso 201086 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Cardoso 201287 ✓ ✓ ✓ ✓ ✗ ✓ ✗
Carrion 200688 ✓ ✓ ✗ ✗ ? ✓ ✓
Carvalho 200889 ✗ ✗ ✗ ✓ ✗ ✓ ✓
Castera 200528 ✓ ✓ ✗ ✓ ✗ ✓ ✓
Castera 200791 ? ? ✓ ✓ ? ✓ ?
Castera 200990 ✓ ✓ ✓ ✓ ✗ ✓ ✓
Ceriani 200192 ? ? ✓ ? ? ✓ ?
Chen 200893 ? ? ✗ ✓ ? ✓ ?
Cheung 200894 ✗ ✗ ✓ ✗ ✗ ✓ ✓
Cho 201195 ✓ ✓ ✓ ✓ ✗ ✓ ✓
Christensen 200696 ? ✗ ✗ ✓ ? ✓ ✗
Chrysanthos 200697 ✓ ✓ ✓ ✓ ✗ ✓ ✓
Cobbold 201098 ✓ ✓ ✗ ✓ ✗ ✓ ✗
Colletta 200599 ✗ ✗ ✓ ? ✗ ✓ ✗
Corradi 2009100 ✗ ✗ ✓ ✓ ? ✓ ✓
Crespo 2010101 ? ? ✗ ✓ ? ✓ ✓
Cross 2010102 ✓ ✓ ✗ ✗ ✗ ✓ ✗
da Silva 2008103 ? ✗ ✗ ✓ ? ✓ ✓
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TABLE 7 Quality assessment of studies included in the meta-analysis for chronic HCV. Quality assessment was done
using the QUADAS-2 tool (continued )
Study ID
Domain 1: patient
sampling Domain 2: index test
Domain 3: reference
standard
Domain 4: flow
and timing
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability Risk of bias
Danila 2011104 ? ? ✗ ? ? ✓ ✓
De Ledinghen
2006105
✓ ✓ ✗ ✗ ✗ ✓ ✓
Degos 2010106 ✓ ✓ ✓ ✓ ? ✓ ✓
Dinesen 2008107 ✗ ✗ ✗ ✓ ? ✓ ?
Esmat 2007108 ✓ ✓ ✗ ✓ ✗ ✓ ✗
Fabris 2006109 ✗ ✗ ✓ ✓ ✗ ✓ ✓
Fahmy 2011110 ✓ ✓ ? ✓ ✓ ✓ ✓
Fontaine 2009111 ✗ ✗ ✗ ✓ ? ✓ ?
Fontana 2008112 ✗ ✗ ✗ ✗ ✓ ✓ ?
Fontanges 2008113 ✗ ✗ ✗ ✗ ✗ ✓ ✓
Forestier 2010114 ✗ ✗ ✗ ✗ ? ? ✗
Forns 2002115 ✗ ✗ ✗ ✗ ✓ ✓ ✓
Fraquelli 2011116 ✗ ✗ ✗ ✓ ✓ ✓ ✗
Fujii 2009117 ✗ ✗ ✓ ✓ ✓ ✓ ✓
Fujimoto 2011118 ✗ ✓ ✗ ✓ ? ✓ ✓
Gaia 2011119 ✗ ✓ ✓ ✓ ✓ ✓ ✗
Ganne-Carrie
2006120
✓ ✓ ✗ ✗ ✗ ✓ ✓
Gara 2011121 ✗ ✗ ✗ ✓ ? ✓ ✗
Giannini 2006122 ✓ ✓ ✗ ✓ ? ✓ ✓
Gobel 2006123 ✗ ✗ ✗ ✓ ? ✓ ✓
Guechot 2010124 ✓ ✓ ✗ ✓ ✓ ✓ ✓
Guechot 1996125 ✓ ✓ ✗ ✗ ? ✓ ✓
Guzelbulut 2011126 ✓ ✓ ✗ ✓ ? ✓ ✓
Halfon 2006128 ✓ ✓ ✗ ✓ ✗ ✓ ✓
Halfon 2005129 ✓ ✓ ✗ ✓ ✓ ✓ ✗
Halfon 2007127 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Harada 2008130 ✗ ✗ ✗ ✓ ? ✓ ✗
Hsieh 2012131 ✗ ✗ ✗ ✓ ? ✓ ✓
Iacobellis 2005132 ✓ ✓ ✓ ✓ ✗ ✓ ✓
Imbert-Bismut
200123
✗ ✓ ✗ ✓ ✗ ✓ ✗
Imperiale 2000133 ✓ ✓ ✓ ✓ ? ✓ ✗
Islam 2005134 ✗ ✗ ✓ ✓ ✗ ✓ ✗
Iushchuk 2005135 ? ? ? ? ? ? ?
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TABLE 7 Quality assessment of studies included in the meta-analysis for chronic HCV. Quality assessment was done
using the QUADAS-2 tool (continued )
Study ID
Domain 1: patient
sampling Domain 2: index test
Domain 3: reference
standard
Domain 4: flow
and timing
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability Risk of bias
Jazia 200978 ✗ ✗ ✗ ✓ ? ✓ ✓
Kalantari 2011136 ✓ ✓ ✗ ✓ ✗ ✓ ✓
Kamphues 2010137 ✗ ✗ ✗ ✓ ✓ ✓ ✗
Kandemir 2009138 ✗ ✗ ✗ ✓ ? ✓ ✓
Kelleher 2005139 ✗ ✓ ✗ ✓ ✗ ✓ ✓
Khan 2008140 ? ✓ ✗ ✓ ? ✓ ✓
Kim 2011141 ✓ ✓ ✗ ✓ ✓ ✓ ✓
Koda 200724 ✓ ✓ ✗ ✓ ✗ ✓ ✓
Koizumi 2011142 ✓ ✓ ✗ ✓ ✗ ✓ ✓
Lackner 2005143 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Ladero 2010144 ✓ ✓ ✓ ✓ ✗ ✓ ✓
Lee 2011145 ✓ ✗ ✗ ✓ ✗ ✓ ✓
Leroy 2004147 ✓ ✓ ✗ ✓ ? ✓ ✓
Leroy 2007146 ✓ ✓ ✓ ✓ ✗ ✓ ✓
Leroy 2011148 ? ? ? ✓ ? ✓ ✓
Lewin 2007149 ✓ ✓ ✗ ✓ ✗ ✓ ✓
Lieber 2006150 ✗ ✗ ✓ ✓ ✗ ✓ ✗
Liu 2006151 ✓ ✓ ✗ ✓ ? ✓ ✓
Liu 2011153 ✓ ✓ ✗ ✓ ✓ ✓ ✓
Liu 2007152 ✓ ✓ ✗ ✓ ? ✓ ✓
Loko 2008154 ✓ ✓ ✓ ✓ ✗ ✓ ✓
Lupsor 2008155 ✓ ✓ ✗ ✓ ✗ ✓ ✓
Lupsor 200929 ✓ ✓ ✗ ✓ ✗ ✓ ✓
Macias 2006156 ✓ ✓ ✓ ✓ ✗ ✓ ✓
Macias 2011157 ? ? ✓ ✓ ✗ ✓ ?
Martinez 2011158 ✓ ✓ ✗ ✓ ✗ ✓ ?
Morikawa 2011159 ? ✓ ✗ ✓ ? ✓ ✓
Murawaki 2001160 ✗ ✗ ✗ ✓ ? ✓ ?
Myers 2002366 ? ✓ ✓ ✓ ✗ ✓ ✓
Nitta 2009161 ✓ ✓ ✗ ✓ ? ✓ ✓
Nojiri 2010162 ? ✓ ✗ ✓ ? ✓ ?
Nunes 2005163 ✓ ✓ ✗ ✓ ? ✓ ✗
Obara 2008164 ✗ ✓ ✗ ✓ ✗ ✓ ✗
Oliveira 2005165 ? ? ? ✓ ? ✓ ?
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TABLE 7 Quality assessment of studies included in the meta-analysis for chronic HCV. Quality assessment was done
using the QUADAS-2 tool (continued )
Study ID
Domain 1: patient
sampling Domain 2: index test
Domain 3: reference
standard
Domain 4: flow
and timing
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability Risk of bias
Orrlachio 2011166 ✗ ? ✗ ✓ ✗ ✓ ✗
Paggi 2008167 ✓ ✓ ✓ ✓ ? ✓ ✗
Parise 2006168 ✓ ✓ ✗ ✓ ? ✓ ✓
Park 2000169 ✗ ✓ ✓ ✓ ? ✓ ✗
Parkes 201127 ✗ ✓ ✗ ✓ ? ✓ ✗
Patel 200925 ? ✓ ✓ ✓ ✗ ✓ ?
Patel 2011170 ? ✓ ✗ ✓ ✗ ✓ ?
Pohl 2001171 ✗ ✓ ✓ ✓ ✗ ✓ ?
Poynard 2012172 ✗ ✓ ✓ ✓ ? ✓ ✗
Prati 2011173 ? ✓ ? ✓ ? ✓ ✗
Qiu 2004174 ✓ ✓ ✗ ✓ ? ✓ ✓
Reedy 1998175 ✗ ✓ ✓ ✓ ? ✓
Ronot 2010176 ✓ ✓ ✗ ✓ ✗ ✓
Rossi 2003177 ✓ ✓ ✗ ✓ ? ?
Rossini 2010178 ? ? ✗ ✓ ✓ ?
Said 2010179 ✓ ✓ ✗ ✓ ✓ ?
Saitou 2005180 ? ✗ ✗ ✓ ✓ ?
Sanvisens 2009181 ✓ ✓ ✗ ✓ ✓ ✗
Schiavon 2007182 ✗ ✓ ✗ ✓ ✓ ✓ ✗
Schiavon 2008183 ✗ ✓ ✗ ✓ ✓ ✓ ✗
Schneider 2006185 ? ? ✗ ✓ ✓ ✓ ?
Scneider 2005184 ✓ ✓ ✗ ✓ ? ✓ ✓
Sebastiani 201231 ✓ ✓ ✓ ✓ ✗ ✓ ✓
Sebastiani 2009187 ✗ ✓ ✓ ✓ ✗ ✓ ✓
Sebastiani 2006188 ✓ ✓ ✗ ✓ ✓ ✓ ✓
Sebastiani 2008186 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Sene 2006189 ✗ ✗ ✗ ✓ ✗ ✓ ?
Sharabash 2009190 ✗ ✓ ? ✓ ? ✓ ?
Shastry 2007191 ? ? ✗ ✓ ? ✓ ✓
Sheth 1997192 ✗ ✓ ✓ ✓ ? ✓ ✗
Singal 2011193 ✓ ✓ ✓ ✓ ✗ ✓ ✗
Sirli 2010194 ✗ ✓ ✓ ✓ ✓ ✓ ✓
Snyder 2007196 ✓ ✓ ✗ ✓ ? ✓ ✓
Snyder 2006195 ✗ ✓ ✗ ✓ ✗ ✓ ✗
Sohn 2010197 ? ✓ ? ✓ ? ✓ ?
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TABLE 7 Quality assessment of studies included in the meta-analysis for chronic HCV. Quality assessment was done
using the QUADAS-2 tool (continued )
Study ID
Domain 1: patient
sampling Domain 2: index test
Domain 3: reference
standard
Domain 4: flow
and timing
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability Risk of bias
Sporea 2008199 ✓ ✓ ? ✓ ? ✓ ✗
Sporea 2010200 ✓ ✓ ✗ ✓ ? ✓ ✓
Sporea 2011201 ? ✓ ? ✓ ? ✓ ✓
Sporea 2011198 ? ✓ ? ✓ ? ✓ ?
Sterling 2006202 ✓ ✗ ✗ ✓ ? ✓ ✗
Stibbe 2011203 ? ✓ ✓ ✓ ? ✓ ✗
Sud 2009204 ✓ ✓ ✗ ✓ ? ✓ ✓
Testa 2006205 ? ✓ ✗ ✓ ✗ ✓ ✗
Thompson 2009208 ? ✓ ? ✓ ? ✓ ?
Thompson 2009206 ? ✓ ? ✓ ? ✓ ?
Thompson 2010207 ? ✓ ? ✓ ? ✓ ?
Toniutto 2007209 ✗ ✗ ✗ ✓ ? ✓ ✓
Trang 2008210 ? ✓ ✗ ✓ ? ✓ ✗
Trifan 2009211 ✓ ✓ ? ✓ ? ✓ ✓
Trocme 2006212 ? ✓ ✗ ✓ ? ✓ ✗
Vallet-Pichard
2007214
✓ ✓ ✓ ✓ ? ✓ ✓
Tural 2007213 ✓ ✗ ✓ ✓ ? ✓ ✓
Valva 2011215 ? ✓ ✓ ✓ ? ✓ ✓
Varaut 2005216 ✗ ✗ ✓ ✓ ✗ ✓ ✗
Wai 2003218 ✓ ✗ ✗ ✓ ? ✓ ✗
Westin 2008219 ✓ ✓ ? ✓ ✗ ✓ ?
Wilson 2006220 ✗ ✗ ✓ ✓ ✗ ✓ ?
Wong 1998221 ✓ ✓ ? ✓ ? ✓ ?
Zaman 2004222 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Zarski 2012223 ✓ ✗ ✓ ✓ ✓ ✓ ✗
Ziol 2005224 ✗ ✓ ✗ ✓ ✗ ✓ ✗
✗, high risk of bias; ✓, low risk of bias; ?, unclear risk of bias.
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however, a particular pattern in relation to the transaminase elevation. More specifically and according to
source of heterogeneity, details of significant associations are:
l Full text versus abstract publication: Fibrotest for ≥ F2 (significantly higher specificity if published in full
text) and borderline for ≥ F3 (likelihood ratio test, p= 0.059) and platelet count for F4 (significantly
lower specificity if published in full text).
l Transaminases levels (comparator is normal transaminases): for ≥ F2 Fibrotest, hyaluronic acid,
Hepascore, Lok’s index, Fibroscan; for ≥ F3 FIB-4 low and high cut-off, TE; and for F4 AST–ALT ratio.
There was no specific pattern of influence; therefore, the test could have improved or worse diagnostic
accuracy if the transaminases levels were high.
l Histological score used (comparator is the METAVIR system): for Hepascore in ≥ F3, use of Ludwig
scoring system in one study76 resulted in significantly lower sensitivity. This might reflect the particular
study rather than the histological score used; for AST–ALT ratio in F4, use of Ludwig scoring system
resulted in significantly higher sensitivity; and for platelet count in F4, use of Scheuer or Knodell
resulted in significantly higher sensitivity and specificity, respectively.
Results: hepatitis B virus
Data on patients with HBV were extracted from 52 studies.116,119,120,200,225–272 Meta-analyses were performed
separately for each non-invasive test assessed at each METAVIR stage (F1–F4). Summary sensitivity and
specificity for fibrosis stages F2 and F4 are shown in Tables 8 and 9, whereas summary sensitivity and specificity
for fibrosis stages F1 and F3 are reported in Appendix 3. The median prevalence (minimum–maximum) of
fibrosis stages F1–F4 in included studies was for F1 0.617 (0.416–0.884), F2 0.528 (0.269–0.915), F3 0.370
(0.171–0.780) and F4 0.209 (0–0.604). Individual study characteristics, and forest plots and SROC plots of the
different NILTs across fibrosis stages, are presented in Appendices 4, 5 and 6, respectively.
Overall, there were 18 different non-invasive tests reported for the diagnosis of ≥ F2, of which 13 (72%)
were reported in single studies. Of 18 different evaluated tests, only five converged with the bivariate
random-effects model (APRI low and high cut-off, FIB-4 low cut-off, Fibrotest and Fibroscan). The most
commonly evaluated non-invasive tests were Fibroscan (13 studies),116,200,225,230,241,242,246,247,250,251,263,264,272
APRI (low cut-off, eight studies),225,233,256–259,269,272 APRI (high cut-off, six studies)225,256–259,270 and Fibrotest
(six studies).225,247,249,255–257
For the diagnosis of cirrhosis, there were 14 different evaluated tests; however, only Fibroscan converged
with the bivariate random-effects model.
For the diagnosis of fibrosis stage ≥ F1, there were eight tests that reported on diagnostic accuracy;
however, none converged with the bivariate random-effects model.
For the diagnosis of fibrosis stage ≥ F3, there were 10 different evaluated tests, of which only Fibroscan
converged with the bivariate random-effects model.
We explored potential sources of heterogeneity as outlined in the methods section. As all but one study200
were of low methodological quality, this potential source of heterogeneity could not be assessed. Significant
heterogeneity was only found in relation to the transaminases level (comparator is normal transaminases):
lower specificity for FIB-4 low cut-off in F2, and borderline lower specificity for Fibrotest in F2 (p= 0.055).
Cut-offs for specific histological stages were predetermined in 11 studies (21%).119,200,225,230,232,252,253,255,258,264,271
Liver biopsy was of acceptable quality in 12 studies (23%).116,119,200,225,227,230,234,251,263,266,271,272 We did not include
data from some studies on APRI for F2 and F3,242 on Forns index for F2269 and on AST–ALT ratio for cirrhosis254
in the meta-analysis because of cut-offs that differed significantly from what is used in the literature. Only one
study257 had low risk of bias in all of the domains of the QUADAS-2 tool; therefore, all our estimates may be
biased and should be assessed with caution. Studies that were judged as low risk of bias or unknown in the
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TABLE 8 Diagnostic accuracy of non-invasive tests for detection of fibrosis states ≥ F2 in patients with chronic HBV
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Indirect non-invasive serum tests
APGA 1 6.7 0.17 (0.10 to 0.27) 0.98 (0.95 to 0.99) Single study
APRI
(low cut-off)
8 0.4–0.6 0.80 (0.68 to 0.88) 0.65 (0.52 to 0.77) Bivariate random-effects
model with correlation
between sensitivity
and specificity
APRI
(high cut-off)
6 1.5 0.37 (0.22 to 0.55) 0.93 (0.85 to 0.97) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Age–Platelet
Index
1 3 0.68 (0.61 to 0.74) 0.62 (0.57 to 0.67) Single study
AST–ALT ratio 1 0.67 0.57 (0.51 to 0.64) 0.59 (0.54 to 0.63) Single study
FIB-4
(low cut-off)
4 1.1–1.7 0.68 (0.60 to 0.75) 0.73 (0.67 to 0.79) Bivariate random-effects
model with correlation
between sensitivity
and specificity
FIB-4
(high cut-off)
1 3.25 0.58 (0.04 to 0.17) 0.99 (0.96 to 1.00) Single study
Forns index
(low cut-off)
1 4.2 0.58 (0.47 to 0.68) 0.77 (0.61 to 0.88) Single study
Forns index
(high cut-off)
1 6.9 0.15 (0.08 to 0.24) 1.00 (0.90 to 1.00) Single study
GUCI 1 0.2 0.67 (0.55 to 0.76) 0.97 (0.85 to 0.99) Single study
Hui index 1 0.15 0.50 (0.39 to 0.61) 0.91 (0.78 to 0.97) Single study
PAPAS 1 1.67 0.73 (0.62 to 0.81) 0.78 (0.71 to 0.84) Single study
Direct serum non-invasive serum tests
Hyaluronic acid 1 185.3 0.84 (0.73 to 0.91) 0.83 (0.66 to 0.93) Single study
Hepascore 1 0.5 0.79 (0.68 to 0.86) 0.74 (0.65 to 0.81) Single study
Commercial non-invasive serum tests
Fibrotest 6 0.40–0.48 0.66 (0.57 to 0.75) 0.80 (0.72 to 0.86) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Imaging modalities
ARFI 1 1.33 0.71 (0.59 to 0.80) 0.67 (0.30 to 0.90) Single study
Real-time
elastography
1 55.3 0.82 (0.67 to 0.91) 0.65 (0.49 to 0.78) Single study
Fibroscan 13 6.3–8.9 0.71 (0.62 to 0.78) 0.84 (0.74 to 0.91) Bivariate random-effects
model with correlation
between sensitivity
and specificity
APGA, AST, platelet count, gamma-glutamyl transpeptidase (GGT), α-fetoprotein; PAPAS, Age, ALP, α-fetoprotein, AST.
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TABLE 9 Diagnostic accuracy of non-invasive tests for detection of ≥ F4 in patients with chronic HBV
Test
Number
of studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Indirect non-invasive serum tests
APRI
(low cut-off)
4 1 0.58 (0.49 to 0.66) 0.76 (0.70 to 0.81) Fixed-effect model for
sensitivity and random-
effects model for specificity
without correlation
APRI
(high cut-off)
3 2 0.24 (0.08 to 0.52) 0.91 (0.83 to 0.96) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
Age–Platelet
Index
2 4–4.5 0.83 (0.72 to 0.90) 0.74 (0.66 to 0.80) Fixed-effects model for
sensitivity and specificity
without correlation
AST–ALT ratio 3 1 0.33 (0.04 to 0.83) 0.77 (0.69 to 0.84) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
FIB-4
(low cut-off)
2 1.6–1.9 0.86 (0.79 to 0.91) 0.82 (0.77 to 0.86) Fixed-effects model for
sensitivity and specificity
without correlation
FIB-4
(high cut-off)
1 3.6 0.30 (0.24 to 0.36) 0.98 (0.97 to 0.99) Single study
GUCI 1 1 0.23 (0.10 to 0.43) 0.91 (0.83 to 0.95) Single study
Direct serum non-invasive serum tests
Hyaluronic acid 1 77 0.82 (0.52 to 0.95) 0.88 (0.79 to 0.93) Single study
Hepascore 1 0.87 0.87 (0.62 to 0.96) 0.85 (0.78 to 0.89) Single study
Type IV collagen 1 6.3 0.64 (0.35 to 0.85) 0.89 (0.81 to 0.94) Single study
Commercial non-invasive serum tests
Fibrotest 4 0.58–0.74 0.74 (0.25 to 0.96) 0.90 (0.83 to 0.94) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
Imaging modalities
Platelet–spleen
ratio
2 6 0.83 (0.74 to 0.90) 0.77 (0.70 to 0.83) Random-effects model for
sensitivity and specificity
without correlation
Real-time
elastography
1 90.3 0.71 (0.50 to 0.86) 0.80 (0.69 to 0.88) Single study
Fibroscan 19 9.4–16.0 0.86 (0.79 to 0.91) 0.85 (0.78 to 0.89) Bivariate random-effects
model with correlation
between sensitivity
and specificity
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three most important QUADAS domains, namely patient selection, index test and reference standard,
were still a fraction of the total number of studies (11 out of 52; 23%).225,235,236,241,242,244,246,257,263,265,271
Quality assessment of included studies based on QUADAS-262 is shown in Table 10.
Results: non-alcoholic fatty liver disease
Data on patients with NAFLD were extracted from 48 studies.117,119,165,229,284–327 Meta-analysis was
performed separately for each non-invasive test assessed at each Kleiner stage (F1–F4). Summary sensitivity
and specificity for F3 and F4 are shown in Tables 11 and 12, while summary sensitivity and specificity
for F1 and F2 are reported in Appendix 3. The median prevalence (minimum–maximum) of fibrosis
stages F1–F4 in included studies was for F1 0.588 (0.367–0.814), F2 0.319 (0.119–0.526), F3 0.186
(0.050–0.440) and F4 0.128 (0.039–0.907). Individual study characteristics are presented in Appendix 4.
The prevalence of F1–F4 in NAFLD is lower than the prevalence of such stages in the other evaluated
aetiologies of liver disease; this is probably due to the relatively low prevalence of the progressive
steatohepatitis among patients with NAFLD.47 Forest plots and SROC plots of different NILTs across fibrosis
stages are presented in Appendices 5 and 6, respectively.
Overall, there were 24 different non-invasive tests reported for the diagnosis of ≥ F3, of which 11 (46%)
were reported in single studies.117,229,284,286,287,289,290,299,304,306,327 Of 24 different evaluated tests, 10 converged
with the bivariate random-effects model [BARD (BMI, AST-ALT ratio, diabetes), AST–ALT ratio low cut-off,
NAFLD fibrosis score low and high cut-offs, FIB-4 low and high cut-off, hyaluronic acid, type IV
collagen, Fibrotest and Fibroscan]. The most commonly evaluated non-invasive tests were NAFLD fibrosis
score (low cut-off, 10 studies), 290,300,301,309,311,315,320,322 NAFLD fibrosis score (high cut-off, nine
studies),285,290,300,301,309,311,315,320,322 Fibroscan (eight studies)119,236,288,296,298,308,323,324 and BARD
(seven studies).284,291,300,301,312,315,319
For the diagnosis of cirrhosis, there were 14 different evaluated tests; however, only platelet count and
Fibroscan converged with the bivariate random-effects model.
For the diagnosis of fibrosis stage ≥ F1, there were 12 tests that reported on diagnostic accuracy, and
three of them converged with the bivariate random-effects model (NAFLD fibrosis score low and high
cut-offs, TE).
For the diagnosis of fibrosis stage ≥ F2, there were 20 different evaluated tests, of which three converged
with the bivariate random-effects model (NAFLD fibrosis score low and high cut-offs, Fibrotest).
Uninterpretable NILT results were very rare in serum markers (< 1%) and were more frequently
encountered in patients who were undergoing Fibroscan examination. The rate of uninterpretable results
with Fibroscan (due to < 10 valid measurements, success rate < 60% and interquartile range> 30%) was
9.6%; however, this could be underestimated due to under-reporting.
Cut-offs for specific histological stages were predetermined in 10 studies (21%).117,119,284,291,309,311,312,315,321,322
Liver biopsy was of acceptable quality in 10 studies (21%).117,119,229,284,286,293,308,319,321,326 We did not include
data on APRI and NAFLD fibrosis scores from one study327 in the meta-analysis because of cut-offs
that differed significantly from what is used in the literature. Only one study119 had low risk of bias
in all of the domains of the QUADAS-2 tool; therefore, all our estimates may be biased. Studies that were
judged as low risk of bias or unknown in the three most important QUADAS domains, namely patient
selection, index test and reference standard, were 21% of the total number of studies (10 out of
48).119,165,284,294,298,301,303,319,323 Quality assessment of included studies based on QUADAS-262 is shown
in Table 13.
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TABLE 10 Quality assessment of studies included in the meta-analysis for chronic HBV. Quality assessment was
done using the QUADAS-2 tool
Study ID
Domain 1: patient
sampling Domain 2: index test
Domain 3: reference
standard
Domain 4: flow
and timing
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability Risk of bias
Castera 2011225 ? ✓ ✓ ✓ ✓ ✓ ✗
Chan 2009226 ✗ ✗ ✗ ✓ ? ✓ ✓
Chen 2008227 ✗ ✗ ✗ ✓ ✓ ✓ ?
Chen 2012228 ✗ ✗ ? ✓ ? ✓ ✗
Fraquelli 2011116 ✓ ✓ ✗ ✓ ✓ ✓ ?
Fung 2011230 ✗ ✗ ✓ ✓ ✓ ✓ ✓
Gaia 2011119 ✓ ✓ ✓ ✓ ✓ ✓ ✗
Ganne-Carrie
2006120
✓ ✗ ? ✓ ? ✓ ✓
Gui 2010231 ✗ ✗ ✗ ✓ ? ✓ ✓
Guo-Qiu 2010232 ✗ ✗ ✓ ✓ ? ✓ ?
Hongbo 2007233 ✓ ✓ ✗ ✓ ? ✓ ✓
Hu 2010234 ? ✓ ✗ ✓ ✓ ✓ ?
Hui 2005235 ? ? ? ? ? ? ?
Kim 2009238 ✓ ✓ ✗ ✓ ? ✓ ✓
Kim 2010236 ? ? ✗ ? ? ✓ ✗
Kim 2009239 ✓ ✓ ✗ ✓ ✗ ✓ ✓
Kim 2007237 ✓ ✓ ✗ ✓ ? ✓ ?
Kim 2010236 ? ? ? ? ? ? ?
Kwok 2009240 ✓ ✓ ✗ ✓ ? ✓ ✗
Lee 2011241 ✓ ✓ ? ✓ ? ✓ ✓
Lesmana242 ? ? ? ? ? ? ?
Li 2012243 ✗ ✓ ✗ ✓ ✗ ✓ ✗
Liu 2011244 ? ? ? ✓ ? ✓ ?
Mallet 2009245 ✗ ✓ ✗ ✓ ✗ ✓ ?
Marcellin 2009246 ? ✓ ? ? ? ✓ ✗
Miailhes 2011247 ✗ ✓ ✗ ✓ ? ✓ ✗
Mohamadnejad
2006248
? ? ✗ ? ✗ ✓ ?
Myers 2003249 ✓ ✓ ✗ ✓ ✗ ✓ ✓
Ogawa 2011250 ? ? ✗ ✓ ? ✓ ?
Osakabe 2011251 ✓ ✓ ✗ ✓ ✓ ✓ ✓
Park 2003253 ✗ ✓ ✓ ✓ ✗ ✓ ✓
Park 2004254 ✓ ✓ ✗ ✓ ? ✓ ✓
Park 2005252 ✗ ✓ ✓ ✓ ✗ ✓ ✓
Poynard 2009255 ✗ ✓ ✓ ✓ ? ✓ ?
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TABLE 10 Quality assessment of studies included in the meta-analysis for chronic HBV. Quality assessment was
done using the QUADAS-2 tool (continued )
Study ID
Domain 1: patient
sampling Domain 2: index test
Domain 3: reference
standard
Domain 4: flow
and timing
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability Risk of bias
Raftopoulos
2012256
? ✓ ✗ ✓ ✗ ✓ ?
Sebastiani 2007257 ✓ ✓ ✗ ✓ ? ✓ ✓
Seto 2011258 ✗ ✓ ✓ ✓ ? ✓ ✓
Shin 2008259 ? ✓ ✗ ✓ ? ✓ ?
Sinakos 2011260 ? ✓ ✗ ✓ ? ✓ ?
Sohn 2011261 ? ✓ ✗ ✓ ? ✓ ?
Sokucu 2010262 ✓ ✓ ✗ ✓ ? ✓ ?
Sporea 2010263 ? ✓ ? ✓ ✓ ✓ ?
Sporea 2010200 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Vigano 2011264 ? ✓ ✓ ✓ ✗ ✓ ✓
Wang 2012265 ✓ ✓ ? ✓ ? ✓ ✓
Wong 2008267 ✓ ✓ ✗ ✓ ? ✓ ✗
Wong 2010266 ? ✓ ✗ ✓ ✓ ✓ ✗
Wong 2011268 ? ✓ ✗ ✓ ? ✓ ?
Wu 2012269 ? ✓ ✗ ✓ ✗ ✓ ✓
Zhang 2008271 ? ✓ ✓ ✓ ✓ ✓ ✗
Zhang 2011270 ✗ ✗ ✗ ✓ ? ✓ ✓
Zhu 2011272 ✗ ✗ ✗ ✓ ✓ ✓ ?
✗, high risk of bias; ✓, low risk of bias; ?, unclear risk of bias.
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TABLE 11 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage of ≥ F3 in patients with
non-alcoholic steatohepatitis
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Indirect non-invasive serum tests
APRI 4 0.5–1.0 0.40 (0.07 to 0.86) 0.82 (0.78 to 0.6) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
Age–Platelet
Index
1 6 0.66 (0.53 to 0.76) 0.78 (0.74 to 0.81) Single study
AST–ALT ratio
(low cut-off)
4 0.8 0.79 (0.51 to 0.91) 0.70 (0.55 to 0.82) Bivariate random-effects
model with correlation
between sensitivity
and specificity
AST–ALT ratio
(high cut-off)
3 1.0 0.46 (0.29 to 0.65) 0.91 (0.85 to 0.95) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
BARD 7 2 0.84 (0.69 to 0.93) 0.61 (0.47 to 0.73) Bivariate random-effects
model with correlation
between sensitivity
and specificity
FIB-4
(low cut-off)
4 1.3–1.92 0.84 (0.75 to 0.90) 0.74 (0.64 to 0.83) Bivariate random-effects
model with correlation
between sensitivity
and specificity
FIB-4
(high cut-off)
2 3.25 0.38 (0.22 to 0.57) 0.97 (0.92 to 0.99) Bivariate random-effects
model with correlation
between sensitivity
and specificity
NAFLD
fibrosis score
(low cut-off)
10 –1.455 0.80 (0.67 to 0.89) 0.66 (0.57 to 0.74) Bivariate random-effects
model with correlation
between sensitivity
and specificity
NAFLD
fibrosis score
(high cut-off)
9 0.676 0.40 (0.20 to 0.64) 0.97 (0.94 to 0.98) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Platelets 1 0.63 (0.57 to 0.69) 0.76 (0.74 to 0.78) Single study
Direct serum non-invasive serum tests
Hyaluronic
acid
4 46–50 0.88 (0.58 to 0.97) 0.82 (0.75 to 0.87) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Hepascore 1 0.37 0.75 (0.62 to 0.85) 0.84 (0.78 to 0.89) Single study
NAFIC
(low cut-off)
1 1 0.96 (0.88 to 0.98) 0.67 (0.63 to 0.71) Single study
NAFIC
(high cut-off)
1 3 0.84 (0.73 to 0.91) 0.82 (0.79 to 0.85) Single study
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TABLE 11 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage of ≥ F3 in patients with
non-alcoholic steatohepatitis (continued )
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
NDP:
advanced
fibrosis
1 0.24 0.88 (0.64 to 0.96) 0.70 (0.58 to 0.80) Single study
Type IV
collagen
2 5 0.79 (0.69 to 0.87) 0.80 (0.66 to 0.89) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Commercial non-invasive serum tests
ELF 1 10.35 0.80 (0.65 to 0.89) 0.90 (0.84 to 0.94) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Fibrotest
(low cut-off)
3 0.3 0.88 (0.68 to 0.99) 0.73 (0.56 to 0.85) Random-effects model for
sensitivity and specificity
without correlation
Fibrotest
(high cut-off)
4 0.57–0.70 0.40 (0.24 to 0.58) 0.96 (0.91 to 0.98) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Imaging modalities
ARFI 1 4.2 0.90 (0.77 to 0.96) 0.90 (0.82 to 0.94) Single study
Fibroscan 8 7.5–10.4 0.82 (0.74 to 0.88) 0.84 (0.78 to 0.89) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Combination of non-invasive test algorithms
NAFLD
fibrosis score
and ELF
(low cut-off)
1 0.91 (0.79 to 0.96) 0.96 (0.91 to 0.98) Single study
NAFLD
fibrosis score
and ELF
(high cut-off)
1 0.86 (0.73 to 0.94) 0.99 (0.96 to 1.00) Single study
Fibroscan
and Fibrotest
1 0.39 (0.27 to 0.53) 0.96 (0.92 to 0.98) Single study
BARD, BMI, AST–ALT ratio, diabetes; NAFIC, ferritin, fasting insulin, type IV collagen; NDP, NAFLD diagnostic panel.
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TABLE 12 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage of ≥ F4 in patients with
non-alcoholic steatohepatitis
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Indirect non-invasive serum tests
APRI 2 0.54
and NA
0.78 (0.71 to 0.99) 0.71 (0.30 to 0.93) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
Age–Platelet
Index
1 NA 0.89 (0.56 to 0.98) 0.83 (0.69 to 0.91) Single study
AST–ALT ratio 1 1 0.89 (0.56 to 0.98) 0.73 (0.58 to 0.84) Single study
BARD 1 2 0.52 (0.33 to 0.71) 0.84 (0.79 to 0.88) Single study
CDS
(low cut-off)
1 3 0.89 (0.56 to 0.98) 0.90 (0.87 to 0.96) Single study
CDS
(high cut-off)
1 5 0.33 (0.12 to 0.65) 1.00 (0.91 to 1.00) Single study
FIB-4
(low cut-off)
1 1.92 0.74 (0.54 to 0.87) 0.71 (0.64 to 0.76) Single study
Lok’s index
(low cut-off)
1 0.6 0.89 (0.56 to 0.98) 0.68 (0.53 to 0.80) Single study
Lok’s index
(high cut-off)
1 0.97 0.22 (0.06 to 0.55) 1.00 (0.91 to 1.00) Single study
Platelets 2 160,000 0.96 (0.30 to 0.99) 0.92 (0.85 to 0.96) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Direct serum non-invasive serum tests
13C-caffeine
breath test
1 1.27 0.90 (0.60 to 0.98) 0.76 (0.61 to 0.87) Single study
Hepascore 1 0.7 0.87 (0.68 to 0.95) 0.89 (0.84 to 0.93) Single study
Commercial non-invasive serum tests
Fibrotest 1 0.57 0.74 (0.54 to 0.87) 0.92 (0.88 to 0.95) Single study
Imaging modalities
Fibroscan 4 10.3–17.5 0.96 (0.83 to 0.99) 0.89 (0.85 to 0.92) Bivariate random-effects
model with correlation
between sensitivity
and specificity
BARD, BMI, AST–ALT ratio, diabetes; CDS, Cirrhosis Discriminant Score; NA, not applicable.
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TABLE 13 Quality assessment of studies included in the meta-analysis for NAFLD. Quality assessment was done
using the QUADAS-2 tool
Study ID
Domain 1: patient
sampling Domain 2: index test
Domain 3: reference
standard
Domain 4: flow
and timing
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability Risk of bias
Adams 2011284 ? ✓ ✓ ✓ ✓ ✓ ✗
Angulo 2007285 ✗ ✗ ✗ ✓ ? ✓ ✓
Blomme 2012286 ✗ ✗ ✗ ✓ ✓ ✓ ?
Cales 2009287 ✗ ✗ ? ✓ ? ✓ ✗
Dixon 2001229 ✓ ✓ ✗ ✓ ✓ ✓ ?
Fujii 2009117 ✗ ✗ ✓ ✓ ✓ ✓ ✓
Gaia 2011119 ✓ ✓ ✓ ✓ ✓ ✓ ✗
Guajardo-Salinas
2010289
✓ ✗ ? ✓ ? ✓ ✓
Guha 2008290 ✗ ✗ ✗ ✓ ? ✓ ✓
Harrison 2008291 ✗ ✗ ✓ ✓ ? ✓ ?
Kaneda 2006292 ✓ ✓ ✗ ✓ ? ✓ ✓
Kayadibi 2009293 ? ✓ ✗ ✓ ✓ ✓ ?
Kelleher 2006294 ? ? ? ? ? ? ?
Khosravi 2011295 ✓ ✓ ✗ ✓ ? ✓ ✓
de Ledinghen
2009288
? ? ✗ ? ? ✓ ✗
Lupsor 2010296 ✓ ✓ ✗ ✓ ✗ ✓ ✓
Lydatakis 2006297 ✓ ✓ ✗ ✓ ? ✓ ?
Mahadeva 2010298 ? ? ? ? ? ? ?
Manousou 2011299 ✓ ✓ ✗ ✓ ? ✓ ✗
McPherson 2010301 ✓ ✓ ? ✓ ? ✓ ✓
McPherson 2011300 ? ? ? ? ? ? ?
Obara 2008164 ✗ ✓ ✗ ✓ ✗ ✓ ✗
Oliveira 2005165 ? ? ? ✓ ? ✓ ?
Orlacchio 2012302 ✗ ✓ ✗ ✓ ✗ ✓ ?
Pais 2011303 ? ✓ ? ? ? ✓ ✗
Palmeri 2011304 ✗ ✓ ✗ ✓ ? ✓ ✗
Papalavrentios 2011305 ? ? ✗ ? ✗ ✓ ?
Park 2011306 ✓ ✓ ✗ ✓ ✗ ✓ ✓
Pawitpok 2006307 ? ? ✗ ✓ ? ✓ ?
Petta 2011308 ✓ ✓ ✗ ✓ ✓ ✓ ✓
Pimentel 2010309 ✗ ✓ ✓ ✓ ✗ ✓ ✓
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TABLE 13 Quality assessment of studies included in the meta-analysis for NAFLD. Quality assessment was done
using the QUADAS-2 tool (continued )
Study ID
Domain 1: patient
sampling Domain 2: index test
Domain 3: reference
standard
Domain 4: flow
and timing
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability Risk of bias
Poynard 2006310 ✓ ✓ ✗ ✓ ? ✓ ✓
Qureshi 2008311 ✗ ✓ ✓ ✓ ✗ ✓ ✓
Raszeja-Wyscomirska
2010312
✗ ✓ ✓ ✓ ? ✓ ?
Ratziu 2004313 ? ✓ ✗ ✓ ✗ ✓ ?
Ratziu 2006314 ✓ ✓ ✗ ✓ ? ✓ ✓
Ruffilo 2011315 ✗ ✓ ✓ ✓ ? ✓ ✓
Sakugawa 2005316 ? ✓ ✗ ✓ ? ✓ ?
Santos 2005317 ? ✓ ✗ ✓ ? ✓ ?
Shimada 2007318 ? ✓ ✗ ✓ ? ✓ ?
Sumida 2011320 ✓ ✓ ✗ ✓ ? ✓ ?
Sumida 2012319 ? ✓ ? ✓ ✓ ✓ ?
Suzuki 2005321 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Wong 2008322 ? ✓ ✓ ✓ ✗ ✓ ✓
Wong 2008323 ✓ ✓ ? ✓ ? ✓ ✓
Wong 2009324 ✓ ✓ ✗ ✓ ? ✓ ✗
Yoneda 2008326 ? ✓ ✗ ✓ ✓ ✓ ✗
Yoneda 2011325 ? ✓ ✗ ✓ ? ✓ ?
Younossi 2011327 ? ✓ ✗ ✓ ✗ ✓ ✓
✗, high risk of bias; ✓, low risk of bias; ?, unclear risk of bias.
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We explored potential sources of heterogeneity as outlined in the methods section. As all but one study
were of low methodological quality, this potential source of heterogeneity could not be assessed.
More specifically and according to source of heterogeneity, details of significant associations are:
l Histological score used (comparator is the Kleiner system): for NAFLD fibrosis score low cut-off in F2
and low and high cut-offs in F3, use of the Brunt scoring system resulted in significantly lower
sensitivity and higher specificity.
l Full text versus abstract publication: for BARD score in F3, full-text publication was associated with
significantly higher specificity.
l There was no heterogeneity identified in relation to transaminases levels.
Results: alcoholic liver disease
Data on patients with ALD were extracted from 12 studies.114,273–283 Meta-analysis was performed
separately for each non-invasive test assessed at each METAVIR stage (F1–F4). Summary sensitivity and
specificity of non-invasive tests for each fibrosis stage are shown in Table 14. The median prevalence
(minimum–maximum) of fibrosis stages F1–F4 in included studies was for F1 0.923 (single study), F2 0.633
(0.500–0.837), F3 0.509 (0.404–0.748) and F4 0.448 (0.145–0.971). Individual study characteristics, and
forest plots and SROC plots of the different NILTs across fibrosis stages, are presented in Appendices 4, 5
and 6, respectively.
Overall, there were four different non-invasive tests reported for the diagnosis of ≥ F3, of which three
(75%) were reported in single studies.273,275,282 The most commonly evaluated non-invasive test was
Fibroscan (four studies);273,277,278,281 however, the results did not converge with the bivariate random-effects
model. There were one, five and five NILTs evaluated for F1, F2 and F4 fibrosis stages, respectively, none
of which converged with the bivariate random-effects model. APRI (high and low cut-offs) in F2 were
evaluated in two studies273,283 and Fibroscan in F4 was evaluated in six studies;114,273,274,276,278,281 all other
tests were evaluated in single studies.
There were four different non-invasive tests reported for the diagnosis of F4, of which three (75%)
were reported in single studies.273,279,280 The most commonly evaluated non-invasive test was Fibroscan
(six studies),114,273,274,276,278,281 however, with cut-offs that widely ranged from 11.4 to 25.8 kPa. The rest of
the tests for F4 were PGAA [prothrombin time, gamma-glutamyl transpeptidase (GGT), apolipoprotein A1,
α2-macroglobulin], Fibrotest (at a low and high cut-off) and APRI (results only reported at a high cut-off;
no reason provided for not including a low cut-off).
Cut-offs for specific histological stages were predetermined in three studies (25%),276,277,282 whereas liver
biopsy was of acceptable quality in one study (8%).273 There was no study with low risk of bias in all the
domains of the QUADAS-2 tool; therefore, all of our estimates may be biased. Studies that were judged as
low risk of bias or unknown in the three most important QUADAS domains, namely patient selection,
index test and reference standard, were 25% of the total number of studies (3 out of 12).276,279,282
Quality assessment of included studies based on QUADAS-262 is shown in Table 15.
Although investigation of potential sources of heterogeneity was planned, it could not be performed due
to the small number of studies.
Results: liver cirrhosis
Diagnostic accuracy of NILTs for cirrhosis was also analysed irrespective of aetiology of liver disease and
used for the cirrhosis economic model. Summary sensitivity and specificity for cirrhosis are shown in
Table 16. Median prevalence of cirrhosis in the evaluated studies was 0.18 (range 0–0.97). Fibroscan was
by far the most commonly evaluated non-invasive test (65 studies).28,29,75,76,86–88,91,95,98–100,102,105,106,110,114,116,119,
130,137,141,147,153,155,159,161,164,170,172,173,194,199–201,211,223,224,225,230,241,242,246,247,250,251,263,264,272–274,276,278,281,288,296,298,308,323,324,236
We do not include a table on quality assessment of included studies to avoid repetition, as this was given
separately according to disease aetiology.
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TABLE 14 Diagnostic accuracy of non-invasive tests for detection of various stages of fibrosis in patients with ALD
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Non-invasive tests for diagnosis of F ≥ 1
Fibroscan 1 5.9 0.83 (0.74 to 0.89) 0.88 (0.53 to 0.98) Single study
Non-invasive tests for diagnosis of F ≥ 2
Fibroscan 1 7.8 0.81 (0.7 to 0.88) 0.92 (0.76 to 0.98) Single study
Fibrotest
(high cut-off)
1 0.7 0.55 (0.47 to 0.63) 0.93 (0.85 to 0.97) Single study
Fibrotest
(low cut-off)
1 0.3 0.84 (0.77 to 0.89) 0.65 (0.55 to 0.75) Single study
APRI
(high cut-off)
2 1.5 0.54 (0.42 to 0.66) 0.78 (0.64 to 0.88) Fixed-effects model for
sensitivity and specificity
without correlation
APRI
(low cut-off)
2 0.5 0.72 (0.6 to 0.82) 0.46 (0.33 to 0.6) Fixed-effects model for
sensitivity and specificity
without correlation
Non-invasive tests for diagnosis of F ≥ 3
CK18 1 0.84 (0.73 to 0.92) 0.71 (0.6 to 0.79) Single study
Forns index
(high cut-off)
1 6.9 0.41 (0.23 to 0.61) 0.88 (0.66 to 0.97) Single study
YKL-40 1 330 0.51 (0.38 to 0.63) 0.89 (0.8 to 0.94) Single study
Fibroscan 4 11.0–12.5 0.87 (0.64 to 0.96) 0.82 (0.67 to 0.91) Random-effects model for
sensitivity and specificity
without correlation
Non-invasive tests for diagnosis of F ≥ 4
APRI
(high cut-off)
1 2 0.40 (0.22 to 0.61) 0.62 (0.41 to 0.79) Single study
Fibrotest
(high cut-off)
1 0.7 0.91 (0.82 to 0.96) 0.87 (0.81 to 0.91) Single study
Fibrotest
(low cut-off)
1 0.3 1.00 (0.95 to 1.00) 0.50 (0.42 to 0.58) Single study
PGAA 1 7 0.78 (0.64 to 0.88) 0.89 (0.85 to 0.92) Single study
Fibroscan 6 11.4–25.8 0.86 (0.76 to 0.92) 0.83 (0.74 to 0.89) Random-effects model for
sensitivity and specificity
without correlation
CK18, cytokeratin-18; PGAA, prothrombin time, gamma-glutamyl transpeptidase (GGT), apolipoprotein A1,
α2-macroglobulin; YKL-40, a direct marker of liver fibrosis.
RESULTS OF SYSTEMATIC REVIEW AND META-ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
TABLE 15 Quality assessment of studies included in the meta-analysis for ALD. Quality assessment was done using
the QUADAS-2 tool
Study ID
Domain 1: patient
sampling Domain 2: index test
Domain 3: reference
standard
Domain 4: flow
and timing
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability
Risk of
bias
Concerns about
applicability Risk of bias
Forestier 2010114 ✗ ✗ ✗ ✗ ? ✓ ✗
Janssens 2010273 ✗ ✗ ✗ ✗ ✓ ✓ ✗
Kim 2009274 ? ? ✗ ✓ ✗ ✓ ?
Lavallard 2011275 ✓ ✓ ✗ ✓ ✗ ✓ ?
Melin 2005276 ✓ ✓ ✓ ? ? ✓ ✗
Mueller 2010277 ✗ ✗ ✓ ✓ ✗ ✓ ?
Nahon 2008278 ✓ ✓ ✗ ✗ ✗ ✓ ✗
Naveau 1994279 ? ✓ ? ✓ ? ✓ ✓
Naveau 2005280 ✓ ✓ ✗ ✓ ? ✓ ✓
Nguyen-Khac
2008281
✗ ✓ ✗ ✓ ✗ ✓ ✗
Tran 2000282 ✓ ✓ ✓ ✓ ? ✓ ?
Vanbiervliet
2005283
✗ ✗ ✗ ✗ ? ✓ ✗
✗, high risk of bias; ✓, low risk of bias; ?, unclear risk of bias.
TABLE 16 Diagnostic accuracy of non-invasive tests for detection of cirrhosis irrespective of aetiology of
liver disease
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Indirect non-invasive serum tests
APRI
(low cut-off)
27 0.75–1 0.75 (0.71 to 0.8) 0.78 (0.75 to 0.81) Bivariate random-effects
model with correlation
between sensitivity
and specificity
APRI
(high cut-off)
23 2 0.45 (0.37 to 0.52) 0.93 (0.9 to 0.95) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Age–Platelet
Index
3 0.88 (0.08 to 1.00) 0.73 (0.43 to 0.91) Random-effects model for
sensitivity and specificity
without correlation
AST–ALT ratio 13 1 0.49 (0.39 to 0.59) 0.87 (0.75 to 0.94) Bivariate random-effects
model with correlation
between sensitivity
and specificity
CDS 1 0.88 (0.66 to 0.97) 0.67 (0.57 to 0.77) Single study
FIB-4
(low cut-off)
5 1.45–1.92 0.84 (0.76 to 0.89) 0.71 (0.62 to 0.79) Bivariate random-effects
model with correlation
between sensitivity
and specificity
continued
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TABLE 16 Diagnostic accuracy of non-invasive tests for detection of cirrhosis irrespective of aetiology of
liver disease (continued )
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
FIB-4
(high cut-off)
4 3.25–4.44 0.42 (0.2 to 0.69) 0.92 (0.58 to 0.99) Random-effects model for
sensitivity and specificity
without correlation
Forns index
(low cut-off)
2 4.2 0.88 (0.73 to 0.96) 0.37 (0.26 to 0.49) Fixed-effects model for
sensitivity and specificity
without correlation
Forns index
(high cut-off)
1 6.9 0.67 (0.53 to 0.78) 0.91 (0.84 to 0.95) Single study
GUCI 4 0.33–1.11 0.64 (0.11 to 0.96) 0.86 (0.81 to 0.9) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
King’s 1 24.3 0.74 (0.59 to 0.85) 0.90 (0.84 to 0.94) Single study
Lok’s index (low
cut-off)
2 0.2–0.26 0.84 (0.09 to 1) 0.66 (0.00 to 1.00) Fixed-effect model for
sensitivity and random-
effects model for specificity
without correlation
Lok’s index
(high cut-off)
1 0.5 0.40 (0.29 to 0.52) 0.95 (0.91 to 0.97) Single study
Platelets 12 134–196 0.72 (0.62 to 0.81) 0.88 (0.77 to 0.94) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Direct serum non-invasive serum tests
13C-caffeine
breath test
1 1.27 0.93 (0.77 to 0.98) 0.84 (0.74 to 0.91) Single study
Fontana 1 0.2 0.79 (0.72 to 0.84) 0.66 (0.61 to 0.71) Single study
Hyaluronic acid 8 78–237 0.81 (0.65 to 0.9) 0.88 (0.8 to 0.94) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Hepascore 9 0.7–0.87 0.82 (0.72 to 0.88) 0.84 (0.79 to 0.88) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Hepascore
(low cut-off)
1 0.58 0.80 (0.72 to 0.86) 0.83 (0.8 to 0.85) Single study
Hepascore
(high cut-off)
1 1.16 0.39 (0.31 to 0.48) 0.99 (0.98 to 0.99) Single study
PIIINP 3 0.8–1 0.70 (0.48 to 0.86) 0.79 (0.34 to 0.96) Fixed-effect model for
sensitivity and random-
effects model for specificity
without correlation
Type IV
collagen
3 65–190 0.71 (0.57 to 0.82) 0.76 (0.59 to 0.87) Bivariate random-effects
model with correlation
between sensitivity
and specificity
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TABLE 16 Diagnostic accuracy of non-invasive tests for detection of cirrhosis irrespective of aetiology of
liver disease (continued )
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Commercial non-invasive serum tests
ELF 1 9.4 0.93 (0.69 to 0.99) 0.79 (0.67 to 0.88) Single study
ELF (low cut-off) 1 0.90 (0.84 to 0.94) 0.53 (0.46 to 0.59) Single study
ELF (high cut-off) 1 0.52 (0.43 to 0.6) 0.90 (0.85 to 0.93) Single study
Fibroindex 1 1.82 0.70 (0.52 to 0.84) 0.91 (0.82 to 0.96) Single study
Fibrometer 2 0.88 0.72 (0.36 to 0.92) 0.88 (0.6 to 0.97) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
Fibrometer
(low cut-off)
1 0.63 0.96 (0.9 to 0.98) 0.71 (0.68 to 0.74) Single study
Fibrometer
(high cut-off)
1 0.98 0.36 (0.28 to 0.45) 0.98 (0.97 to 0.99) Single study
Fibrotest 13 0.75 0.61 (0.47 to 0.74) 0.87 (0.83 to 0.9) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Fibrotest
(low cut-off)
2 0.3 0.89 (0.29 to 0.99) 0.65 (0.01 to 1.00) Fixed-effect model for
sensitivity and random-
effects model for specificity
without correlation
Fibrotest
(high cut-off)
3 0.86 0.73 (0.14 to 0.98) 0.94 (0.91 to 0.96) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
Imaging modalities
ARFI 4 1.59–2 0.84 (0.72 to 0.91) 0.77 (0.5 to 0.92) Random-effects model for
sensitivity and specificity
without correlation
Platelet–Spleen
Index
2 0.83 (0.28 to 0.98) 0.85 (0.00 to 1.00) Fixed-effect model for
sensitivity and random-
effects model for specificity
without correlation
Real-time
elastography
1 3.93 0.71 (0.5 to 0.86) 0.80 (0.67 to 0.88) Single study
Fibroscan 65 9.2–26.5 0.89 (0.86 to 0.91) 0.89 (0.87 to 0.91) Bivariate random-effects
model with correlation
between sensitivity
and specificity
Combination of fibrosis non-invasive tests algorithms
Bordeaux 1 0.87 (0.8 to 0.92) 0.95 (0.93 to 0.96) Single study
Fibropaca 1 0.79 (0.72 to 0.84) 0.66 (0.61 to 0.71) Single study
SAFE 4 0.74 (0.42 to 0.92) 0.93 (0.91 to 0.94) Random-effects model for
sensitivity and fixed-effect
model for specificity
without correlation
CDS, Cirrhosis Discriminant Score; PIIINP, amino-terminal propeptide of type III procollagen; SAFE, sequential algoritm for
fibrosis evaluation.
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Results: imaging modalities results that were used irrespective of liver
disease aetiology
Data on diagnostic accuracy of imaging modalities for the non-invasive assessment of liver fibrosis were
analysed irrespective of the aetiology of liver disease, with the exception of Fibroscan and ARFI. These two
tests measure liver stiffness that is associated with the amount of fibrosis and there is evidence of different
cut-offs according to disease aetiology. The summary sensitivity and specificity of these imaging modalities
for METAVIR stages F1–F4 are shown in Table 17.30,93,98,100,101,110,118,132,145,149,152,166,167,176,184,185,227,270,305,328–363
Certain diagnostic modalities that are not routinely used, such as MR spectroscopy,367 double-contrast
material-enhanced MRI,368 maximal accumulative respiratory strain using ultrasound,234 liver enhancement
ratio of gadoxetic acid enhanced MRI369 and single-photon emission CT parameters370 and real-time
elastography,142 are not presented and were not used in the economic analysis, as they are not widely
available and require further validation.
Data on ultrasound techniques using injection of contrast material (contrast-enhanced ultrasound)344 or
measuring the splenic artery pulsatility index (ultrasound SAPI)152 were included in the analysis and in the
economic modelling for HBV and HCV. These are based on ultrasound; however, they require well-trained
and experienced operators and use signs that are not well validated. Moreover, all data come from
specialised centres. Therefore, reported diagnostic accuracies are most probably overestimated and not
reproducible in most centres. In most centres, ultrasound, CT and MRI can only diagnose cirrhosis with
acceptable specificity but lower sensitivity, as early cirrhosis and lesser fibrosis stages are often missed.
MR elastography is a promising tool, but is of limited use at the moment due to cost and availability.
Discussion of overall results
In total, 302 studies were selected for the meta-analysis.23–29,31,71–327 For the fibrosis stages of interest
in our models (F2 for HBV and HCV, F3 for NAFLD and F4 for ALD), there were 33 NILTs assessed in
HCV,23–29,31,71–224 18 in HBV,116,119,120,200,225–272 24 in NAFLD117,119,165,229,284–327 and four in ALD.114,273–283
However, 19 out of 33 NILTs in HCV,31,83,131,142,146,147,183,189,204,205,210 13 out of 18 in HBV,243,244,256–258,263,265
11 out of 24 in NAFLD117,229,284,286,287,289,290,299,304,306,327 and three out of four in ALD273,275,282 were assessed in
single studies. HCV was the disease aetiology with most studies identified, while ALD had the fewest
studies assessed.
There were no data available for tests that converged using the bivariate model for ALD; therefore, the use
of NILTs in such patients for treatment decisions is uncertain and requires further study. Very few tests
converged using the bivariate model for HBV: only APRI (high and low cut-offs), FIB-4 (low cut-off),
Fibrotest and Fibroscan converged for F2 and Fibroscan alone for F3 and F4. In patients with NAFLD
there is a wider choice, as NAFLD fibrosis score, FIB-4, BARD, AST–ALT ratio, Fibrotest and Fibroscan
all converged. HCV is the liver disease with the highest number of available data and, subsequently,
choices on NILTs. For the diagnosis of F2, APRI low and high cut-off, AST–ALT ratio, FIB-4 low and high
cut-offs, Forns index low and high cut-offs, GUCI, Lok’s index, platelet count, hyaluronic acid, Hepascore,
Fibrometer, Fibrotest standard, low and high cut-offs, platelet-to-spleen-diameter ratio and Fibroscan
all converged.
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TABLE 17 Diagnostic accuracy of imaging modalities for detection of various stages of fibrosis in patients with
chronic liver disease
Test
Number of
studies
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Imaging modalities for diagnosis of F ≥ 1
MR
elastography
5 0.83 (0.72 to 0.9) 0.83 (0.67 to 0.92) Random-effects model for
sensitivity and specificity
without correlation
CEMRE 1 0.95 (0.75 to 0.99) 1.00 (0.57 to 1.00) Single study
CEMRI 1 0.87 (0.78 to 0.93) 0.75 (0.51 to 0.9) Single study
CEUS 1 0.80 (0.7 to 0.88) 0.90 (0.6 to 0.98) Single study
CT 1 0.70 (0.52 to 0.83) 0.64 (0.43 to 0.8) Single study
DW-MRI 1 0.79 (0.65 to 0.89) 0.83 (0.55 to 0.95) Single study
US 1 0.77 (0.6 to 0.89) 0.89 (0.69 to 0.97) Single study
US MARS 1 0.82 (0.64 to 0.92) 0.75 (0.41 to 0.93) Single study
Imaging modalities for diagnosis of F ≥ 2
CEMRI 2 0.80 (0.15 to 0.99) 0.60 (0.03 to 0.99) Fixed-effect model for sensitivity
and random-effects model for
specificity without correlation
CEUS 3 0.88 (0.07 to 1.00) 0.73 (0.11 to 0.98) Random-effects model for
sensitivity and specificity
without correlation
DW-MRI 5 0.78 (0.63 to 0.88) 0.78 (0.51 to 0.93) Random-effects model for
sensitivity and specificity
without correlation
MR
elastography
3 0.94 (0.13 to 1.00) 0.92 (0.72 to 0.98) Random-effects model for
sensitivity and fixed-effect model
for specificity without correlation
US 3 0.35 (0.14 to 0.63) 0.86 (0.59 to 0.96) Bivariate random-effects model
with correlation between
sensitivity and specificity
US SAPI 3 0.74 (0.69 to 0.79) 0.79 (0.72 to 0.85) Fixed-effects model for sensitivity
and specificity without correlation
US SAPI
(high cut-off)
2 0.61 (0.54 to 0.68) 0.96 (0.9 to 0.98) Fixed-effects model for sensitivity
and specificity without correlation
US SAPI F2
(low cut-off)
2 0.94 (0.9 to 0.97) 0.39 (0.31 to 0.49) Fixed-effects model for sensitivity
and specificity without correlation
nDW-MRI 1 0.90 (0.74 to 0.97) 0.75 (0.3 to 0.95) Single study
SPECT 1 0.86 (0.67 to 0.95) 0.83 (0.64 to 0.93) Single study
US MARS 1 0.85 (0.64 to 0.95) 0.56 (0.33 to 0.77) Single study
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TABLE 17 Diagnostic accuracy of imaging modalities for detection of various stages of fibrosis in patients with
chronic liver disease (continued )
Test
Number of
studies
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Imaging modalities for diagnosis of F ≥ 3
CEUS 3 0.78 (0.14 to 0.99) 0.87 (0.24 to 0.99) Random-effects model for
sensitivity and specificity
without correlation
DEMRI 1 0.93 (0.85 to 0.97) 0.86 (0.69 to 0.95) Single study
DW-MRI 3 0.88 (0.00 to 1.00) 0.73 (0.07 to 0.99) Random-effects model for
sensitivity and specificity
without correlation
MR
elastography
6 0.91 (0.85 to 0.95) 0.88 (0.80 to 0.93) Bivariate random-effects model
with correlation between
sensitivity and specificity
US 4 0.57 (0.31 to 0.79) 0.80 (0.67 to 0.88) Bivariate random-effects model
with correlation between
sensitivity and specificity
CEMRI 1 0.75 (0.63 to 0.85) 0.50 (0.36 to 0.64) Single study
MRI 1 0.78 (0.61 to 0.89) 0.75 (0.60 to 0.86) Single study
nDW-MRI 1 0.96 (0.80 to 0.99) 0.67 (0.35 to 0.88) Single study
Imaging modalities for diagnosis of F ≥ 4
CEUS 3 0.84 (0.01 to 1.00) 0.88 (0.27 to 0.99) Random-effects model for
sensitivity and specificity
without correlation
DW-MRI 2 0.88 (0.01 to 1.00) 0.73 (0.09 to 0.99) Fixed-effect model for sensitivity
and random-effects model for
specificity without correlation
LSPI 4 0.91 (0.41 to 0.99) 0.88 (0.3 to 0.99) Random-effects model for
sensitivity and specificity
without correlation
MR
elastography
3 1.00 (0.03 to 1.00) 0.93 (0.20 to 1.00) Random-effects model for
sensitivity and specificity
without correlation
MRI 2 0.75 (0.64 to 0.83) 0.80 (0.69 to 0.88) Fixed-effects model for sensitivity
and specificity without correlation
US 25 0.73 (0.66 to 0.79) 0.88 (0.83 to 0.92) Bivariate random-effects model
with correlation between
sensitivity and specificity
US SAPI 2 0.73 (0.25 to 0.95) 0.67 (0.43 to 0.84) Fixed-effects model for sensitivity
and specificity without correlation
CEMRI 1 0.81 (0.65 to 0.90) 0.48 (0.37 to 0.60) Single study
HVRI US 1 0.90 (0.74 to 0.97) 0.86 (0.78 to 0.92) Single study
nDW-MRI 1 0.95 (0.77 to 0.99) 0.69 (0.42 to 0.87) Single study
US MARS 1 1.00 (0.68 to 1.00) 0.50 (0.33 to 0.67) Single study
CEMRE, contrast-enhanced magnetic resonance elastography; CEMRI, contrast-enhanced magnetic resonance imaging;
CEUS, contrast-enhanced ultrasound; DEMRI, double-enhanced magnetic resonance imaging; DW-MRI, diffusion-weighted
magnetic resonance imaging; HVRI, hepatic vein resistance index; LSPI, laser speckle perfusion imaging; MARS, metal
artefact reduction sequence; nDW, diffusion weighted; SAPI, splenic artery pulsatility index; SPECT, single-photon emission
computed tomography; US, ultrasound.
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Summary sensitivity and specificity of tests that converged were as follows in HCV and HBV (≥ F2 and F4)
and NAFLD (≥ F3):
l For HCV in ≥ F2: APRI low cut-off 82% and 57%, high cut-off 39% and 92%; AST–ALT ratio 44%
and 71%; FIB-4 high cut-off 59% and 74%; Forns index low cut-off 88% and 40%, high cut-off 35%
and 96%; GUCI 65% and 79%; Lok’s index 67% and 55%; platelet count 50% and 89%; hyaluronic
acid 75% and 75%; Hepascore 73% and 73%; Fibrometer 79% and 73%; Fibrotest 68% and 72%;
Fibroscan 79% and 83%.
l For HCV in F4: APRI low cut-off 77% and 78%, high cut-off 48% and 94%; AST–ALT ratio 49% and
87%; platelet count 68% and 86%; hyaluronic acid 80% and 88%; Hepascore 80% and 83%;
Fibrotest 60% and 86%; Fibroscan 89% and 91%.
l For HBV in ≥ F2: APRI low cut-off 80% and 65%, high cut-off 37% and 93%; FIB-4 low cut-off 68%
and 73%; Fibrotest 66% and 80%; Fibroscan 71% and 84%.
l For HBV in F4: Fibroscan 86% and 85%.
l For NAFLD in ≥ F3: AST–ALT ratio 79% and 70%, BARD 84% and 61%, FIB-4 low cut-off 84% and
74%, high cut-off 38% and 97%, NAFLD fibrosis score low cut-off 80% and 66%, high cut-off
40% and 97%, hyaluronic acid 88% and 82%, Fibrotest high cut-off 40% and 96%, Fibroscan 82%
and 84%.
Regarding the choice of tests, these should be based on disease aetiology, local resources and availability,
cost-effectiveness and disease prevalence or pretest probability. Indirect NILTs can be applied at the point
of care and can differentiate patients in low risk, high risk and indeterminate for significant fibrosis or
cirrhosis. Particularly in NAFLD, they could be used to rule out patients with low risk of fibrosis, thanks to
their high negative predictive value given the low prevalence of advance fibrosis in the general population
of patients with steatosis/NAFLD. Direct serum tests or Fibroscan can be used either as second tier test
following an indeterminate result with an indirect marker, or as a one-off test to inform further decisions
on treatment or as a rule-in/rule-out test for liver biopsy. Patients who test ‘negative’ (true negative or false
negative) with a non-invasive test should be subsequently retested in order to capture disease progression.
The optimal time interval for such retesting is unknown; however, a period of 1–2 years would be safe and
reasonable. There are no data on the monitoring of liver fibrosis using sequential testing with NILTs.
Cut-offs of NILTs for specific fibrosis stages were not always predetermined or sufficiently validated and
this happened more often in direct serum biomarkers and Fibroscan; this represents a significant limitation
in the interpretation of their results. Among all NILTs, APRI (low and high cut-offs) was the one where the
established cut-offs were almost universally used in published studies. Although there are established
cut-offs for Forns index, FIB-4, AST–ALT ratio and Fibrotest, these were not consistently used in all studies.
NAFLD fibrosis score and BARD in NAFLD (10285,290,300,301,309,311,315,320,322 and seven studies,284,291,300,301,312,315,319
respectively) had consistent cut-offs used across all studies.
Fibroscan was the NILT assessed in most studies across diseases aetiologies (37 studies in HCV, 13 in HBV,
eight in NAFLD and six in ALD).28,29,75,76,86–88,91,95,98–100,102,105,106,110,116,119,130,131,141,147,153,155,159,161,164,170,172,173,194,
199–201,211,223–225,230,236,241,242,246,247,250,251,263,264,272,288,296,298,308,323,324,273,277,278,281 However, there are no established
and validated cut-offs for specific fibrosis stages across disease aetiologies. This represents a limitation
in the use of Fibroscan; therefore, all reported sensitivities and specificities are probably overestimated.
APRI was also widely assessed in HCV and HBV (47 and eight studies, respectively) but not in NAFLD
or ALD.24,31,72–74,79,81,84,85,89–91,94,97,98,100,103,107,109,121,123,126,127,130,131,134,137,140,143,144,146,150,152–154,156–158,163,164,168,182,
185,187,189,194,195,209,210,218,220,223
All non-commercial direct serum non-invasive tests assessed [hyaluronic acid, YKL-40, PIIINP
(amino-terminal propeptide of type III procollagen), type IV collagen] did not have predetermined
cut-offs; moreover, different enzyme-linked immunosorbent assay (ELISA) kits were used across studies.
Hepascore, which is a non-commercial test that consists, among other indices, of hyaluronic acid, has
predetermined cut-offs, which were not consistently used in all included studies.
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Of the commercial NILTs, Fibrotest was the most widely assessed (23 studies in
HCV,23,25,31,81,85,99,111,113,127,129,146,172,177,179,186,189,206,208,211,216,220,223,366 six in HBV,231,247,249,255–257 four in
NAFLD284,303,313,314 and one in ALD280); however, the predetermined cut-offs used were not always
used in included studies. Fibroindex,24,107,186 Fibrometer82,127,223 and FibrospectII25,96,145,170,190,196 were only
evaluated in HCV for the stages of interest in our models. ELF was evaluated in three studies in HCV27,98,158
and in a single study in NAFLD.290
Failures of the index test (e.g. due to high BMI for Fibroscan or haemolysis for serum tests) are not
incorporated in the reported sensitivities and specificities of the NILTs. Moreover, instances where the
reference standard was not adequate for analysis (insufficient sampling) is also not captured in the analysis
(applicability of index test and reference standard).
Investigations of heterogeneity revealed an influence of the level of transaminases on diagnostic accuracy
in some tests; however, the direction of this effect was not consistent. There was no significant
heterogeneity with regard to type of publication (abstract or full text) and histological scoring systems in
most tests and diseases.
Of the imaging modalities, MR elastography was assessed in three studies, with summary sensitivity and
specificity of 0.94 and 0.92, respectively. Although these are very promising results, further validation of
the technique and determination of disease and stage specific cut-offs is needed. Moreover, this technique
is not yet widely available.
The methodological quality of included studies as assessed by the QUADAS-2 tool was poor; only 6 of the
302 studies (1.6%) were of high methodological quality.86,127,143,186,200,222 Most common areas of high risk of
bias was the conduct of the index test (cut-offs were not predetermined) and of the reference standard
(liver biopsy samples were not of adequate length or did not have sufficient number of portal tracts for
reliable staging). Therefore, all reported results are likely biased.
As will become apparent in the cost-effectiveness analysis, NILTs with the most robust data were not the
most cost-effective. As mentioned, there is the risk of overestimating sensitivity and specificity in tests with
few available data.
RESULTS OF SYSTEMATIC REVIEW AND META-ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
54
Chapter 5 Cost-effectiveness analysis: hepatitis B
This chapter describes the assessment of cost-effectiveness of non-invasive tests of fibrosis and cirrhosisin patients with HBV. The population of interest were HBeAg-positive and HBeAg-negative patients
with suspected fibrosis or cirrhosis who would normally have a liver biopsy in order to assess eligibility for
antiviral treatment, i.e. patients with increased viral load and/or elevated transaminases.
Evaluation approach for hepatitis B
Twenty-five relevant NILTs were evaluated in the first stage of the analysis, which compared the NILTs with
liver biopsy alone and a ‘treat all’ and ‘no treatment’ approach. The NILTs evaluated are listed in Table 18
and are grouped according to test categories: indirect serum makers, direct and patented serum markers
and imaging modalities.
The second stage of the analysis compared a selection of tests using alternative sequential testing
strategies. The criteria for selecting these tests and the assumptions used regarding combinations of tests
and sequential testing strategies are detailed in Chapter 3.
Three of the tests evaluated in the second stage of the analysis used a combined diagnostic cut-off
threshold for staging fibrosis; the test outcomes reported a number of indeterminate responses which are
listed in Table 19. The percentage of indeterminate results was estimated using the meta-analysis data and
is an aggregated value estimated from the studies for each combined test. We allowed for patients who
had an indeterminate response to receive a retest with a commonly used imaging modality Fibroscan (TE).
We did not choose an indirect test as the combined tests were from the indirect test category and a
subsequent indirect test would not enhance the diagnostic accuracy. Of the direct tests and imaging
modalities, we chose Fibroscan based on availability and current clinical practice. Overall, 56 testing
strategies were compared in the second stage of the analysis.
TABLE 18 List of NILTs evaluated (HBV)
Indirect Direct and patented Imaging
AAR Fibrotest ARFI
APGA Hyaluronic acid CEUS
Age–Platelet Index Hepascore DW-MRI
APRI (high cut-off) MR elastography
APRI (low cut-off) CT
FIB-4 (high cut-off) Fibroscan
FIB-4 (low cut-off) US
Forns index (high cut-off) US SAPI
Forns index (low cut-off) US SAPI (high cut-off)
GUCI US SAPI (low cut-off)
Hui index
PAPAS
AAR, AST–ALT ratio; APGA, AST, platelet count, GGT, α-fetoprotein; CEUS, contrast-enhanced ultrasound;
DW-MRI, diffusion-weighted magnetic resonance imaging; PAPAS, age, ALP, α-fetoprotein, AST; US, ultrasound.
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Model structure and parameters
Decision tree structure
A decision-tree model was constructed to evaluate the cost-effectiveness of the NILTs, liver biopsy, and
the ‘treat all’ and ‘no treatment’ strategies. As per the schematic diagram depicting the flow of data
in Chapter 3 (see Figure 1), the decision tree was populated with test sensitivity, specificity and average
disease prevalence from the meta-analysis (see Chapter 4 for details), long-term costs and health outcomes
from a series of Markov models, individual test costs sourced from published literature and hospital finance
departments, and a measure of adverse effects associated with liver biopsy.
As discussed in Chapter 3, there are two stages to the decision tree analysis: the first stage where all
tests are compared singly and the second stage where combinations of tests are compared using four
different testing strategies. Schematic illustrations and descriptions of the sequential testing pathways are
provided in Chapter 3. To estimate a cost and QALY for each testing strategy the long-term costs (and test
costs) and QALY estimates (including disutility from liver biopsy if applicable) associated with each potential
test outcome (true positive, false positive, true negative, false negative) were multiplied by the probability
of each NILT returning a true positive, false positive, true negative or false negative result to give a cost
and QALY estimate for each testing option.
Markov model structure
A series of Markov models were constructed to estimate the long-term costs and health outcomes
associated with a correct (true positive and true negative) and incorrect (false positive and false negative)
diagnosis for a hypothetical cohort of 1000 patients with HBV and suspected liver fibrosis or cirrhosis.
An additional two Markov models were constructed to estimate the costs and outcomes associated with
the ‘treat all’ and ‘no treatment’ approaches. Separate models were constructed for the HBeAg-positive
and HBeAg-negative patient cohorts, as their natural history differs and, therefore, starting age, transition
probabilities and relative risks (RRs) from treatment differed for both groups. The structural assumptions
underlying the state transition models applied to both groups of patients. The models were evaluated over
a lifetime period with a cycle length of 1 year. All costs were considered from the perspective of the NHS
and health outcomes were measured in terms of QALYs. Costs and utilities were discounted using a rate
of 3.5%. A threshold value for incremental cost-effectiveness was assumed to be £20,000–30,000 per
additional QALY gained, based on UK guidelines.66
Figure 3 shows a schematic representation of the patient pathway, which is a modified version of
previously published models of liver fibrosis and cirrhosis in patients with HBV.371,372 Fibrosis and cirrhosis
health states were defined in the Markov model according to METAVIR score: mild fibrosis (F0–1),
moderate fibrosis (F2–3) and compensated cirrhosis (F4). There were five other potential health states in
the Markov model: decompensated cirrhosis, hepatocellular cancer (HCC), liver transplant, post liver
transplant and a health state representing ‘death’, which the cohort could enter from all other health
states at any time. The cohort progressed through the model as per the arrows in the illustration; the
circular arrows leading back into the same health state indicate that patients could remain within that
health state for longer than one cycle (cycle length set at 1 year) except for the liver transplant state,
where patients could only progress to a post liver transplant health state or to death. The liver transplant
state comprised two events (1 month’s duration for liver transplant and 11 months’ duration for post-liver
TABLE 19 Percentage of indeterminate results of tests with a combined cut-off applicable for HBV
Tests with a combined cut-off % of persons with inconclusive result
APRI 41
FIB-4 31
Forns index 36
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transplantation care). Patients could progress to the HCC health state from the moderate, compensated
cirrhosis and decompensated cirrhosis health states. Patients could not regress to an earlier health state.
We note that although some recent studies show that fibrosis and even cirrhosis can regress with antiviral
therapy,373 we did not allow for this in our model.
We assumed that a METAVIR test score of ≥ F2 equated to a positive test outcome (true positive and false
positive) and treatment with antiviral agents would commence at this stage. Conversely, a METAVIR test
score of < F2 indicated a negative test outcome. We incorporated treatment with peginterferon alfa-2a
for 1 year for 10% of those who tested negative to reflect that a proportion of patients would receive
treatment for necroinflammation.45 The remaining 90% would undergo a policy of watchful waiting
without immediate treatment.
The watchful waiting policy in the model incorporated a retest with a NILT every 2 years; the retest NILT
was the same as the previous test used for the initial assessment. To allow for modelling, we assumed
that the retest had perfect sensitivity and specificity and correctly diagnosed all patients. If a patient was
diagnosed as positive, immediate treatment with antiviral agents would commence. We tested the
robustness of this assumption in a sensitivity analysis by varying the retest sensitivity and specificity to
mirror that of three commonly used NILTs: an indirect serum marker, APRI; a patented serum marker,
Fibrotest; and an imaging modality, Fibroscan.
The initial starting health state for the population cohort in the models depended on the test outcome
being modelled (true positive, false positive, true negative and false negative). For example, given a false
positive or true negative test result, the population cohort entered the model in a F0–1 health state
(no fibrosis), whereas for a true positive or false negative test result, the population cohort had an initial
starting health state of F2–4, where the cohort (with fibrosis or cirrhosis) was then distributed among
the health states F2–3 and F4 based on the prevalence data from the systematic review (56% and
44%, respectively).
Death
None/mild
fibrosis
F0−F1
Compensated
cirrhosis
F4
Hepatocellular
cancer
Decompensated
cirrhosis
Post liver
transplant Liver transplant
Moderate/
significant
fibrosis
F2−3
FIGURE 3 Illustration of Markov model.
DOI: 10.3310/hta19090 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 9
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Crossan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
Input parameters
The average disease prevalence used in the model (54%) was estimated as the proportion of patients
with a METAVIR score ≥ F2, calculated from the meta-analysis results reported in Chapter 4. We used
the sensitivity and specificity estimates for each NILT and the average prevalence estimate to calculate the
probability of each test returning a true positive, false positive, true negative and false negative result.
The probability of each NILT reporting a particular diagnostic test outcome is reported in Appendix 7.
Cohort data
We identified cohort characteristics (age and sex ratio) for use in the model from published NICE guidance
on treatments for HBV: adefovir dipivoxil and pegylated interferon. After reviewing the sources of evidence
for this guidance,374,375 we identified a Health Technology Assessment report for both treatments published
in 2006 by Shepherd et al.371 This report included an economic analysis. Shepherd et al.371 sourced cohort
data from a published study undertaken by Fattovich et al.,376 which reported a median age and a
male-to-female ratio based on 10 published studies for HBeAg-positive chronic HBV377–387 and four
published studies for HBeAg-negative chronic HBV.388–391 We employed the same assumptions as those
used by Shepherd et al.:
l HBeAg-positive: starting age of 31 years and percentage of males set at 70%.
l HBeAg-negative: starting age of 40 years and percentage of males set at 90%.
Natural history: baseline transition probabilities used in model
The rate of disease progression in the models is regulated by transition probabilities. The systematic review
and economic evaluation by Shepherd et al.392 included a systematic review of epidemiological data for
HBV.371 We also reviewed a submission to NICE by Bristol Myers Squibb (BMS) for a single technology
appraisal of entecavir treatment for HBV. Upon review, the Southampton Health Technology Assessment
Centre (SHTAC) epidemiological search strategy was considered to be appropriate for our analysis.
The papers used by the authors were reviewed and the search was rerun to carry out an updated search
for natural history data. The submission report by BMS sourced data from the same literature sources
as the SHTAC study.
Our updated epidemiological search strategy was undertaken to search from the year 2004 to 2012
(as SHTAC search was undertaken to 2004). The search was carried out in the MEDLINE database using
the Ovid platform, and the search strategy is outlined in Appendix 2 (searched on 11 May 2012). The
updated search located 597 papers, whose titles were reviewed to determine if they were relevant;
24 were retrieved for abstract review. None was relevant for our study.
As none of the papers located from the updated literature search was relevant, we reviewed the studies
which informed the transition probabilities in the model constructed by Shepherd et al.372,376,392–401
Some of the papers referenced by Shepherd et al.371 were older published papers.393,394 Others were
published for other aetiologies of liver disease395 and other models did not provide separate transition
probabilities for the mild and moderate health states.399 The study by Wong et al.393 was identified
as relevant as the authors had reported separate transition probabilities for HBeAg-positive and
HBeAg-negative. As the paper by Wong et al.393 was published in 1995, we conducted a search for
recently published studies which had cited this paper. This search located a 2010 paper by Dakin et al.,372
which assessed the cost-effectiveness of various drug treatments for HBV.
The 2010 paper by Dakin et al.372 sourced transition probability data from natural history studies, economic
evaluations or the placebo arms of meta-analyses or RCTs.393,395,396,398–400,402–410 The authors used a similar
set of studies to those identified by Shepherd et al.371 and many of the transition probabilities elicited
were either identical or similar. The progression from compensated cirrhosis to decompensated cirrhosis
was the same for both studies, as Dakin et al.372 used a synthesis of the same papers396,398,399 used by
Shepherd et al.371
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Dakin et al.372 sourced aetiology-specific data for the probability of undergoing a liver transplant while in a
decompensated cirrhosis or HCC health state, using data from the UK transplant registry, specifically for
chronic HBV. This was felt to be a more relevant estimate to use in our model than the value used by
Shepherd et al.,371 who had used a value based on data from a 1997 study by Bennett et al.395 This study
had sourced a value from a paper on HCV411 and papers published in 1993412 and 1996.413
We used the transition probabilities estimated by Dakin et al.372 as the main source of transition probability
data for the cirrhotic and post-cirrhotic health states (HCC, liver transplant and post liver transplant).
However, none of the studies reviewed elicited separate transition probability data for the precirrhotic
health states (mild and moderate fibrosis). In the absence of transition probability data for these health
states, we used data from a study in patients with mild chronic HCV.414 This paper was identified in our
review of data for our analysis of HCV but was also referenced as a source of cost data in the paper by
Dakin et al.372 We adopted this approach with regard to early transition probabilities and this was
confirmed as appropriate with clinical colleagues.
Wright et al.414 were unable to locate separate estimates of probabilities of progression from mild to
moderate fibrosis disease stages health state from existing studies as they found that most data were
based on retrospective natural history studies which do not use liver biopsy to stage fibrosis and
progression. As the disease progression may not be linear, it may not be realistic to assume a constant rate
of progression from mild fibrosis to cirrhosis, and so they estimated transition probabilities for mild and
moderate health states using data from a trial of treatments for mild HCV undertaken in a number of
London hospitals,415 during which the liver fibrosis stage was determined by liver biopsy. Transition
probabilities are listed in Table 20.
TABLE 20 Annual transition probabilities and sources employed within Markov model
Health state–health state Transition probability PSA distribution Source
Mild–moderate 0.025 Dirichlet Wright et al.414
Moderate–cirrhosis (HBeAg-positive) 0.037
Moderate–cirrhosis (HBeAg-negative) 0.09 Dakin et al.372
Moderate–HCC 0.048
Excess mortality–moderate fibrosis 0.0035
Compensated cirrhosis–decompensated cirrhosis 0.05
Compensated cirrhosis–HCC 0.024
Excess mortality–compensated cirrhosis 0.051
Decompensated cirrhosis–HCC 0.024
Decompensated cirrhosis–liver transplant 0.016
Decompensated cirrhosis–death 0.30
HCC–liver transplant 0.0155
Excess mortality–HCC 0.56
Liver transplant–death 0.21
Post liver transplant–death 0.057
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Mortality data
An all-cause mortality rate was calculated using the Interim Life tables for England and Wales 2008–10.416
The risk of death increased each year according to age and the rate was weighted to allow for sex mix.
The all-cause mortality rate was added to an excess mortality value (identified from study by Dakin et al.372)
associated with the moderate fibrosis, compensated cirrhosis and HCC health states to provide a total risk
of death per year. The all-cause mortality rate was not applied to the decompensated cirrhosis, liver
transplant and post-liver-transplant health states; instead, a total mortality rate identified from the study by
Dakin et al.372 was applied. Mortality rates in the HBeAg-positive model ranged from 0.0007 to 0.337, and
from 0.002 to 0.34 in the HBeAg-negative model. Excess mortality rates and total mortality rates employed
within the models are listed in Table 20.
Antiviral treatment for hepatitis B: type and duration
The NICE website was reviewed to source national guidance on drug treatment for HBV.
We located guidelines for licensed drugs which included peginterferon alfa-2a (Pegasys®, Roche), entecavir
(Baraclude®, BMS) and tenofovir disoproxil (Viread®, Gilead). Entecavir and tenofovir have marketing
authorisation within the UK for the treatment of chronic HBV infection in adults with compensated liver
disease and evidence of active viral replication, persistently elevated serum ALT levels and histological
evidence of active inflammation and/or fibrosis. Peginterferon alfa-2a has UK marketing authorisation for
the treatment of HBeAg-positive and HBeAg-negative chronic HBV infection in adults with compensated
liver disease and evidence of viral replication, increased ALT and histologically verified liver inflammation
and/or fibrosis. Interferon antiviral agents are contraindicated in chronic hepatitis patients with
decompensated cirrhosis.375,417,418
The following treatment assumptions were employed in the model: only patients in the moderate fibrosis
(F2–3), compensated cirrhosis (F4) and decompensated cirrhosis health states received treatment with
antiviral agents; patients in the HCC, liver transplant and post liver transplant health states received usual
standard of care.
Treatment with either entecavir or tenofovir (lifetime duration) was administered if patients tested positive
(true positive or false positive); half of the eligible patients received entecavir and the other half
received tenofovir.
Ten per cent of the patients who tested negative (true negative or false negative) received peginterferon
alfa-2a for 1 year only, and if treatment was unsuccessful (we assumed that 30% of treated true negative
patients would successfully respond to treatment and would no longer progress to any further health
states except the death health state due to all-cause mortality), they would receive subsequent treatment
with either entecavir or tenofovir for lifetime duration if diagnosed as positive (≥ F2) at retest. The
remaining 90% of true negative and false negative patients would undergo ‘watchful waiting’, where they
would then receive treatment with either entecavir or tenofovir for lifetime duration (if diagnosed as
positive during a retest).
The dosage of treatment was based on national recommendations sourced from the British National
Formulary (BNF) 64419 (see Table 24).
Treatment effectiveness
A meta-analysis by Woo et al.420 which evaluated the relative efficacies of the first 12 months of treatment
for chronic HBV was identified from a general search carried out using Google Scholar (http://scholar.
google.com) and the search terms ‘treatment effectiveness’, and ‘tenofovir and entecavir’ (search date
12 May 2012). The paper evaluated a number of drugs – lamivudine, pegylated interferon, adefovir
dipivoxil, entecavir, telbivudine and tenofovir – for use as monotherapy or in combination therapy in
treatment-naive individuals.
COST-EFFECTIVENESS ANALYSIS: HEPATITIS B
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
Woo et al.420 conducted a systematic literature review to locate studies of published RCTs of drugs used to
treat chronic HBV as either monotherapies or combination therapies. They included studies that examined
the impact of treatment in both HBeAg-positive and HBeAg-negative patients. The studies included in the
review were required have examined the use of the drug using randomised, phase 3, controlled trials
comparing new drug treatments with either a placebo or a licensed drug. The methodological quality of
each paper was assessed independently by two reviewers using the Cochrane risk of bias tool.
The data were analysed using a Bayesian mixed-treatment comparison (MTC) analysis which allowed the
authors to combine direct and indirect comparisons of the treatments. Our model used the treatment
efficacy elicited from the Bayesian MTC for pegylated interferon, entecavir and tenofovir. The study did not
provide separate efficacy data for peginterferon for HBeAg-negative chronic HBV, and we assumed the
same RR as for HBeAg-positive. Treatment effectiveness represented by RRs and their associated CIs are
displayed in Table 21.
We assumed that patients who tested false positive and who were in a mild state would receive the same
treatment benefit from antiviral treatment as those in a moderate or cirrhotic health state. We also
assumed that patients who test false negative and receive peginterferon alfa-2a for 1 year would not
receive treatment benefit but would incur the costs and disutility associated with peginterferon
alfa-2a treatment.
Cost data
To populate our model, we undertook a search for other relevant cost-effectiveness literature that would
provide data on the costs associated with treating the different levels of fibrosis and cirrhosis in patients
with HBV. To do this, we employed the search strategy devised by Shepherd et al.371 and undertook an
updated search using the MEDLINE database (Ovid platform, search date 10 May 2012, searched
2004–12). The search strategy is listed in Appendix 2. Additional search terms were added to locate papers
related to other relevant treatment (entecavir, tenofovir disoproxil, and their brand names, baraclude and
viread). Nine hundred and seventy-one papers were located and their titles were reviewed to determine if
they were eligible. Twenty-three were retrieved for abstract review. Of these, 17 were excluded and six
were retrieved for full review (Table 22). Chapter 3 contains further details of the literature review inclusion
criteria used when reviewing and assessing the applicability of cost data literature.
Of the six papers reviewed, four papers included cost data from a study on mild HCV by Wright et al.414
This study collected resource use and cost data alongside a RCT for mild HCV.414,415 Detailed cost data
were collected from three centres based in London, Newcastle and Southampton. Resource use
information collected covered inpatient and outpatient care, investigations, procedures, drug use and
other services including psychiatric services.
TABLE 21 Relative risks associated with treatment
Drug RR 95% CI
HBeAg (+ve)
Entecavir 0.56 0.12 to 0.94
Tenofovir 0.53 0.06 to 0.95
Peginterferon alfa-2a 0.52 0.06 to 0.95
HBeAg (–ve)
Entecavir 0.64 0.01 to 1.00
Tenofovir 0.65 0.01 to 1.00
Peginterferon alfa-2a 0.52 0.06 to 0.95
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One of the studies, by Veenstra et al.,426 sourced additional costs from a study by Bennett et al.;395
however, this study collected costs for the health states using a US population which, due to the difference
in the health-care systems, would not be transferable to a UK population.
The study by Brown et al.421 collected data on resource use from specialists based in four countries
including the UK. The authors used the data collected to identify resource use and associated costs for the
management of fibrosis and cirrhosis.
The study by Takeda et al.425 also used the 1995 Wong paper393 as a source; as this paper is an older
published paper, we felt there would be more up-to-date costs available.
Three of the studies used data from the Cost-Effectiveness of Liver Transplantation (CELT) study424 to elicit
a cost for the liver transplant health states. The CELT study collected costs on adult patients listed for
an isolated liver transplant (aged 16 years and over) between December 1995 and December 1996.
The costs were collected and split into phases, which were determined according to when the resource
use took place and according to disease aetiology (HBV, HCV, alcoholic cirrhosis). Data were split into an
assessment phase, candidacy phase, transplant phase and post-transplant phases. The assessment phase
started at the date of admission for assessment of suitability for liver transplantation to the date of listing
for transplantation (for patients who were not listed for transplantation, the discharge date was used as
the end date). The candidacy phase started at the date of listing to the date the patient was admitted
for the transplant operation. The transplant phase started at the date of admission for the transplant
operation to the date of discharge following the operation and the post-transplant phase started at the
date of discharge following the operation onwards for a period of 2 years. Resource use data on blood
products used, number of dietitian sessions, drugs used, inpatient stay, nutritional support received,
outpatient visits, physiotherapy sessions, tests, length of transplant operation and key treatments and
investigations were collected.
TABLE 22 Papers reviewed for cost data
Authors Title Journal
Source cost data used
in study
Brown et al.421
2004
Hepatitis B management costs in France,
Italy, Spain, and the United Kingdom
Journal of Clinical
Gastroenterology
Questionnaire used to collect
data from specialist clinicians in
UK, Spain, Italy and France
Dakin et al.372
2010
Cost–utility analysis of tenofovir
disoproxil fumarate in the treatment of
chronic hepatitis B
Value in Health Published literature: Wright
et al. 2006414
Jones et al.422
2010
Tenofovir disoproxil fumarate for the
treatment of chronic hepatitis B
SHTAC Published literature: Wright
et al. 2006414
Jones et al.423
2009
Adefovir dipivoxil and pegylated
interferon alfa for the treatment of
chronic hepatitis B: an updated
systematic review and
economic evaluation
Health Technology
Assessment
Published literature: Wright et al.
2006,414 Longworth 2003424
Takeda et al.425
2007
A systematic review and economic
evaluation of adefovir dipivoxil and
pegylated interferon-alfa-2a for the
treatment of chronic hepatitis B
Journal of
Viral Hepatitis
Expert opinion and published
literature: Wong 1995,393
Longworth 2003424
Veenstra et al.426
2007
Cost-effectiveness of peginterferon
alfa-2a compared with lamivudine
treatment in patients with HBe-antigen-
positive chronic hepatitis B in the
United Kingdom
European Journal of
Gastroenterology
and Hepatology
Expert opinion and published
literature: Wright et al. 2006,414
Longworth 2003,424 Bennett
et al. 1997395
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Based on the review, we concluded that the data on costs for treating HCV from the study by Wright
et al.414 for the mild, moderate and cirrhotic health states would be comparable with the costs for treating
patients with HBV in these health states, as the resource use identified and collected (inpatient, outpatient
care, procedures) should be similar. The health state costs sourced from this study did not contain the
cost of antiviral treatment; therefore, they were suitable to use and we added the cost of treatment
separately in the model.
From the review, we decided to source information for the decompensated cirrhosis, HCC, liver transplant
and post-liver-transplant health states from the CELT study.424 Using the raw data collected in this study,
we calculated the cost for all patients with HBV who had received a transplant (sample size 24).
The average length of admission for the liver transplant operation was 28 days. We approximated
this to 1 month and calculated the yearly cost of a liver transplant as 11 months of post-transplant care
(estimated from the average monthly cost in the first year following transplantation) plus the month
the transplant operation took place. We also calculated a cost for the post-transplant health state,
estimated as the average monthly cost of the second year of post-transplant care (sample size 24).
To calculate a cost for the decompensated cirrhosis and HCC health states, we used the average cost for
patients with HBV awaiting liver transplant (patients in the ‘assessment’ and ‘candidacy’ disease stages
were used; sample size 25).
Costs were inflated to 2012 levels using NHS inflation indices.67 Health state costs did not include the costs
associated with antiviral treatment; these were included separately. Costs are shown in Table 23.
As we employed two different sources of data to populate our model, there is a sizable difference
between the cost for the compensated and decompensated cirrhosis health states. We conducted a
sensitivity analysis where we populated our model with the cost for the decompensated cirrhosis health
state (£9121) and HCC health state (£8127) from the study by Wright et al.414 The main component of the
costs for these two health states in the Wright et al.414 model was inpatient-days. We inflated the costs to
2012 prices using NHS inflation indices.67
Test costs
Non-invasive liver tests using imaging modalities were sourced from published Department of Health
reference costs.427 Costs of direct and indirect serum markers were obtained from communication with
finance departments based at the Royal Free Hospital. Costs for patented serum markers were sourced
directly from manufacturers and via communication with finance departments based at the Royal Free
Hospital (see Appendix 5, Table 68).
TABLE 23 Annual health state costs (£ 2012)
Health state Cost per year, £ Standard error PSA distribution Source
Mild fibrosis 185 36.39 Gamma Wright et al. 2006414
Moderate fibrosis 986 101.69 Gamma
Compensated cirrhosis 1521 309.05 Gamma
Decompensated cirrhosis 36,194 9967.19 Gamma Longworth et al.424
HCC 36,194 9967.19 Gamma
Liver transplant 64,122 5584.70 Gamma
Post liver transplant 16,321 7932.51 Gamma
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The two most commonly performed liver biopsy tests are percutaneous and transjugular liver biopsy.
We assumed that, for our purposes, patients received a percutaneous liver biopsy, as this tends to be
associated with less severe adverse effects. We estimated that a diagnostic liver biopsy would cost
£956.61.428 Where required, costs were inflated to 2012 prices using NHS inflation indices.67 Tests costs
and sources are listed in Appendix 9. All NILT tests costs are based on incremental costs and exclude the
capital costs of the equipment.
Medication costs
Treatment costs and recommended dosages were sourced from the BNF 64419 and are listed in Table 24.
Utility data
An initial literature search for existing published utility data for HBV was undertaken using the MEDLINE
database (Ovid platform, searched 11 May 2012, coverage 2004 to 2012). We supplemented this search
using both the cost-effectiness analysis (CEA) Registry (searched 11 May 2012, all dates) and EuroQol
website (searched 11 May 2012, all dates).
We searched the MEDLINE database using the search strategy for quality of life devised by Shepherd
et al.371 We updated this search to include papers from 2004 onwards. The full search strategy is outlined
in Appendix 2. This search returned 121 papers.
We searched the EuroQol using the general search term ‘hepatitis B’. This search returned 16 papers.
We also searched the CEA Registry using the search term ‘hepatitis B’, which returned 39 studies.
The title and abstract of each paper was reviewed and full papers were retrieved for review if they met our
inclusion criteria. Chapter 3 outlines the inclusion criteria that applied when reviewing studies for quality of
life data. After excluding three duplicate papers, eight were retrieved for full review.372,414,425,429–432
Four of the studies retrieved372,423,425,429 used the same study by Levy et al.430 as a source for utility values.
Levy et al.430 employed the standard gamble technique to collect health-related utility data for six
HBV-related health states (from both infected and uninfected respondents). Hypothetical health states
were developed using expert opinion and the Liver Disease Quality of Life Instrument. Data were elicited
from respondents from the USA, Canada, the UK, Spain, Hong Kong and China. The study analysed
1134 respondents, of whom 100 were from the uninfected population and 93 from the infected
population were from the UK.
One study used clinical judgement to elicit health-related quality of life (HRQoL) values.431 The authors
noted that the weights were arbitrary and better sources could be used.
A 2008 study by McLernon et al.432 conducted a systematic review of published literature.414,433–436 They
obtained values for the compensated cirrhosis, decompensated cirrhosis and HCC health states using these
data; however, the studies had mainly been carried out in HCV and the search conducted looked for
quality of life data for all aetiologies, not specifically for HBV.
TABLE 24 Annual cost and dosage of medication applied in model (£ 2012)
Drug Brand name Dosage Cost per year Source
Peginterferon alfa-2a Pegasys® 180mg per week £6469 BNF 64419
Entecavir Baraclude® 500mg daily £4420 BNF 64419
Tenofovir Viread® 245mg daily £2926 BNF 64419
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The search also identified the 2006 study on treatment in mild HCV by Wright et al.414 As none of the
other studies reviewed identified separate utility values for mild and moderate health states, we adopted
the same approach to sourcing data as that used for costs. We employed the same utility values used by
Wright et al.414 for the HCV mild, moderate and compensated cirrhosis health states. As both HBV and
HCV lead to cirrhosis and related complications, it is assumed that cirrhosis would impact on the quality of
life similarly for patients with HBV and HCV.
We decided to source utility values for the decompensated cirrhosis, decompensated cirrhosis, HCC, liver
transplant and post liver transplant health states from the CELT study for HBV patients.424 We used this
source rather than one of the studies reviewed, as the only study reviewed which collected data directly
used a standard gamble technique430 rather than a generic preference-based measure such as the EQ-5D.
As we had data available for patients with HBV (sourced from CELT study), it was felt this would be a
more accurate source of data to use rather than the data elicited from the study by Levy et al.430 or the
systematic review by McLernon et al.,432 which were applicable to all liver disease aetiologies.
Additionally, we concluded that both the Wright et al.414 and the CELT study424 would be suitable sources
of data as they had both used the EQ-5D preference measure to elicit utility values within a UK population
(see Chapter 3 for inclusion criteria for quality of life data).
During the mild HCV RCT,414 questionnaires were self-administered at baseline and treatment weeks 12,
24 and 48, and at follow-up weeks 12, 24 and 48. For the moderate and cirrhotic health states,
302 patients were sent an EQ-5D (of whom 60% of those with diagnosed as being in a moderate health
state responded, and 54% of those diagnosed as having cirrhosis responded).
The CELT study424 collected HRQoL data using the EQ-5D questionnaire. We analysed the data collected
for HBV patients at the time patients were placed on the waiting list for a transplant, and at 3 months,
6 months, 12 months and 24 months post transplant.
It was assumed that utility values for the decompensated cirrhosis and HCC health states would be the
same (sample size 25). This was assumed to be equivalent to the average utility value at ‘listing’ stage.
A utility value for the liver transplant health state was estimated using an area under the curve approach
and the average utility values collected at 3, 6 and 12 months post transplant (sample size 24). A utility
value for the post liver transplant disease stage was estimated from the average utility for HBV patients
collected at 24 months post transplant (sample size 24). A PSA was carried out using a utility decrement
approach. A beta distribution is often employed for utility values; however, this may not be appropriate for
states close to death, where values of less than one are possible. For the HBV model, we performed a
simple transformation of the data (D= 1 –U, where D is the utility decrement and U is the utility value).
The decrement was constrained on the interval ‘0 to positive infinity’ and a gamma distribution was then
applied.437 Table 25 lists the utility data used in the model.
As we sourced utility value data from two different studies, the utility values used in the study for the
decompensated cirrhosis and HCC health states were slightly higher than those used for the compensated
cirrhosis health state. We undertook a sensitivity analysis where we set the utility values for the decompensated
cirrhosis and HCC health states to those used in the HCV model (see Chapter 6) – as these were lower values
than those used in the HBV model – to test if this had any effect on the robustness of the results.
Adverse effects associated with antiviral treatment
As peginterferon alfa-2a has associated side effects (such as influenza-like symptoms, depression and
anxiety), we allowed for the disutility associated with antiviral treatment to be reflected in the model.
We modelled a disutility decrement that was applicable during treatment, using data identified from
the Wright et al.414 study. This study reported HRQoL data using the EQ-5D instrument for 144 patients.
They used the data from weeks 12 and 24 from the baseline date to estimate utility decrement values of
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0.11. The decrement was applied to all patients in the mild and moderate fibrosis and compensated
cirrhosis health states as a multiplicative disutility for the duration of treatment with peginterferon alfa-2a.
It was conservatively assumed that any side effects associated with treatment with entecavir or tenofovir
would have no impact on quality of life.
Disutility from non-invasive liver treatment and liver biopsy
We have assumed that any adverse events associated with the NILTs would not have a significant impact
on health-related utility. However, as liver biopsy is associated with morbidity and mortality risks and
patient discomfort, we incorporated a utility decrement to represent expected adverse events. In the
absence of identified data, this was modelled by applying a utility decrement of 0.2 based on data
employed in a previous study,428 where the authors had conducted a literature review for data on liver
biopsy associated adverse events and mortality. We undertook a number of sensitivity analyses to test the
robustness of the results to changes in the utility decrement.
Estimated long-term costs and quality-adjusted life-years
The estimated long-term costs and QALYs for HBeAg-positive and HBeAg-negative chronic HBV (output
from Markov models) are shown in Table 26.
Analysis
As discussed previously in Chapter 3, a PSA was conducted, and an incremental analysis was carried out to
estimate the most cost-effective testing option. A CEAC and CEAF were constructed to summarise the
uncertainty around the results. Several one-way sensitivity analyses were also undertaken.
Treatment benefit
Our base-case analysis assumed that patients who are in a mild health state (F0–1) receive the same
treatment benefit (same effectiveness) as patients in a moderate or cirrhotic health state, despite being
incorrectly diagnosed and treated.373 We tested the robustness of this assumption in a sensitivity analysis
by setting the treatment benefit for patients who incorrectly receive treatment while in a mild health
state to zero.
TABLE 25 Utility data
Health state Utility value SE PSA distribution Source
Mild fibrosis 0.77 0.035 Gamma Wright et al.414
Moderate fibrosis 0.66 0.018
Compensated cirrhosis 0.55 0.032
Decompensated cirrhosis 0.57 0.076 Longworth et al.424
HCC 0.57 0.076
Liver transplant 0.73 0.016
Post liver transplant 0.78 0.064
Mild: during treatment 0.65 0.035
Moderate: during treatment 0.55 0.018
Compensated cirrhosis: during treatment 0.44 0.040
Death 0 0 Assumption
SE, systemic embolism.
COST-EFFECTIVENESS ANALYSIS: HEPATITIS B
NIHR Journals Library www.journalslibrary.nihr.ac.uk
66
Robust test accuracy data
In the base-case analysis, all tests were included despite there being limited data available for some tests.
A sensitivity analysis including only tests where the standard bivariate random-effects model used for the
meta-analysis63 converged was conducted. We conducted an analysis with the five tests where the
bivariate model had converged – APRI high cut-off, Fibroscan, Fibrotest, FIB-4 low cut-off and APRI low
cut-off – and compared with liver biopsy, ‘treat all’ and ‘treat no one’ strategies.
Utility value amendment
We carried out an analysis where we amended the utility values within the model for the decompensated
cirrhosis, HCC, liver transplant and post liver transplant. The sensitivity analysis used the lower values from
the HCV model (see Chapter 6 for values).
Change in liver biopsy decrement
We also carried out analyses using different utility decrement values to measure the adverse effects from
liver biopsy. The base-case analysis set the utility decrement value to 0.2 based on a previous analysis
which had conducted a literature search for data relating to adverse events and mortality associated with
liver biopsy.428 In the sensitivity analysis we set the utility decrement at 0 and 0.3 to test the impact on the
robustness of the results.
Change to health state costs
We carried out an analysis where we changed the costs for the decompensated cirrhosis and HCC health
states to the costs used in the Wright et al.414 study.
Average disease prevalence
Prevalence within the model is based on studies that may have been carried out largely in tertiary care
centres, and the prevalence of liver fibrosis in this population may be an overestimate. To test the impact
of this we undertook a sensitivity analyses using the minimum prevalence (disease prevalence modelled as
≥ F2 at 27%), maximum prevalence (92%) and the 25th and 75th quartile values (43% and 65%,
TABLE 26 Estimated long-term costs and QALYs for HBeAg-positive and HBeAg-negative chronic HBV infection
Diagnostic test outcome Cost (£ 2012 per person) QALY (per person)
HBeAg-positive
TP 105,126 7.99
TN 39,201 15.61
FP 97,859 17.06
FN 99,997 7.46
Treat all persons 101,794 12.15
Treat no one 37,966 9.64
HBeAg-negative
TP 98,145 6.65
TN 32,772 13.12
FP 90,877 15.31
FN 92,571 6.18
Treat all persons 94,815 10.62
Treat no one 37,518 8.82
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
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respectively), estimated from the meta-analysis of the systematic review data. In this sensitivity analysis, it is
assumed that the sensitivity and specificity of the tests would be the same in populations with high and
low prevalence as observed in the studies included in the review.
Sensitivity and specificity of retest
Our base-case analysis assumes that the retest (from the meta-analysis of the systematic review data in the
watchful waiting strategy for patients with a negative test result) has perfect sensitivity and specificity.
This is likely to overestimate the accuracy of the retest procedure. We tested the impact of this assumption
by applying the sensitivity and specificity of three commonly used tests: APRI low cut-off (estimated
sensitivity of 80% and specificity of 65%), Fibrotest (estimated sensitivity of 66% and specificity of 80%)
and Fibroscan (estimated sensitivity of 71% and specificity of 84%).
Choice of tests for second stage of analysis
For the second stage of the analysis, the two most cost-effective tests when assessed within each specific
test category singly (with and without a defined threshold) were used in the analysis of sequential testing.
To test if changing the method used to choose tests for the second stage of the analysis had an effect on
the overall result, we carried out an analysis where the most effective NILT from within each NILT category
and the least costly NILT from each category were included in the analysis of sequential testing.
Change to hepatitis B e antigen-negative model (age and sex ratio)
We also undertook a sensitivity analysis, where we set the age-and-sex-mix data in the HBeAg-negative
model equivalent to the age and sex mix in the HBeAg-positive model (base age set to 31 years and the
proportion of cohort who were male set at 70%) to check if the results from both models would be
similar. The only remaining differences between the HBeAg-positive and HBeAg-negative models related to
the different efficacy of treatment and the increased probability of moving to a cirrhotic state from a
moderate health state.
Reduction in length of time of successful response rate to peginterferon
alfa-2a treatment
Our base-case analysis for true-negative patients assumes that 30% of those who receive treatment with
peginterferon alfa-2a have a successful response and no longer progress to further health states in the
model retaining a risk of all-cause mortality only. We tested this assumption in the model by assuming that
the successful response lasts for 15 years only.
Change to non-invasive liver test costs
We carried out a sensitivity analysis where we changed the cost of the NILTs [we set the watchful waiting
retest cost and all NILT costs within the model to the same cost; for comparison, we assumed an indirect
serum marker test cost (we chose a commonly used test, APRI, as our comparator)]. By changing the
cost of a NILT, we aimed to determine if changing the test cost (marginal cost) had an impact on the
robustness of the results.
Results
Hepatitis B e antigen-positive chronic hepatitis B
At a cost-effectiveness threshold of £20,000, the cost-effective strategy is to employ a sequential testing
strategy where a direct serum marker, hyaluronic acid, is combined with an imaging modality, MR
elastography, with an ICER of £19,612. With this testing strategy, positive test diagnoses are confirmed
with a second NILT and if the results disagree, a liver biopsy is administered to confirm the result; negative
test responses undergo a process of watchful waiting.
Using a higher cost-effectiveness threshold value of £30,000, an imaging modality, MR elastography, used
singly, becomes the most cost-effective option, with an ICER of £28,585. When we assessed all tests singly
COST-EFFECTIVENESS ANALYSIS: HEPATITIS B
NIHR Journals Library www.journalslibrary.nihr.ac.uk
68
in the first stage of the analysis, the most cost-effective test given a threshold value of £20,000 was GUCI,
with an ICER of £19,716.
As the CEAF is more representative of the uncertainty around the optimal testing option, we present the
CEAF (Figure 4) in the main analysis and the CEAC in Appendix 6.
The CEAF shows that the probability of hyaluronic acid combined with MR elastography (strategy 2)
being the optimal testing option, given a cost-effectiveness threshold value of £20,000, is 4%.
The CEAF also shows that MR elastography, used singly, has a 13% probability of being cost-effective
for cost-effectiveness thresholds starting at £28,585, which reduces to a 3.5% probability when the
cost-effectiveness threshold increases to £43,946. For cost-effectiveness threshold values greater than
£43,946, the ‘treat all’ strategy has a 35% probability of being cost-effective.
What is noticeable about the CEAF is that two of the strategies (testing with MR elastography alone or a
combination of hyaluronic acid and MR elastography) have a very low probability of being the optimal
testing option, compared with a testing strategy of treating everyone.
For reasons of clarity, the CEAC presented in Appendix 10 displays only those testing options which had a
≥ 4% probability of being cost-effective. The CEAC also displays some tests that are not picked up by the
CEAF, including the Forns (high cut-off) serum marker. The reasons for this include a skew in cost data and
also the fact that those tests which have the highest probability of being cost-effective may not be the
optimal testing option.
Liver biopsy was a comparator for both stages of the analysis; however, this testing option is dominated by
other less costly but more effective options. Table 27 presents incremental results for the first stage of the
analysis and Table 28 incremental results for the second stage where a number of combined tests are
compared using a number of different sequential testing strategies (see Chapter 3 for details of
testing strategies).
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 10 20 30 40 50 60 70
Ceiling ratio: cost-effectiveness threshold value (£000)
%
 o
f 
si
m
u
la
ti
o
n
 f
o
r 
w
h
ic
h
 s
tr
at
eg
y 
is
 m
o
st
 c
o
st
-e
ff
ec
ti
ve
No treat
Treat all
MRE
(S2) HA
and MRE
FIGURE 4 Cost-effectiveness acceptability frontier for HBeAg-positive second stage of the analysis. HA, hyaluronic
acid; MRE, MR elastography.
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TABLE 27 Hepatitis B e antigen-positive base-case analysis (first stage where all tests are compared singly)
Test strategy Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Treat no one 37,831 9.64 – – –
FIB-4 (high cut-off) 73,028 11.33 – – Extendedly dominated
Forns index (high cut-off) 73,115 11.35 – – Extendedly dominated
APGA 73,373 11.36 – – Extendedly dominated
Liver biopsy 75,957 11.41 – – Dominated
APRI (high cut-off) 75,139 11.45 – – Dominated
US 77,657 11.48 – – Dominated
Hui index 76,047 11.50 – – Dominated
US SAPI (high cut-off) 75,610 11.51 – – Extendedly dominated
GUCI 74,921 11.52 37,090 1.88 19,716
Fibroscan 79,004 11.61 – – Dominated
Forns index (low cut-off) 80,008 11.61 – – Dominated
Fibrotest 79,519 11.62 – – Dominated
MR elastography 77,657 11.64 2,737 0.12 23,468
US SAPI 80,442 11.66 Extendedly dominated
PAPAS 80,223 11.65 – – Dominated
Hyaluronic acid 79,084 11.66 – – Extendedly dominated
DW-MRI 80,751 11.67 – – Extendedly dominated
FIB-4 (low cut-off) 81,347 11.66 – – Extendedly dominated
Hepascore 81,399 11.69 – – Extendedly dominated
ARFI 83,487 11.71 – – Dominated
AAR 84,951 11.72 – – Dominated
CEUS 82,377 11.74 – – Extendedly dominated
CT 84,097 11.73 – – Dominated
Age–Platelet Index 84,289 11.73 – – Dominated
APRI (low cut-off) 83,770 11.75 – – Extendedly dominated
US SAPI (low cut-off) 91,287 11.95 – – Extendedly dominated
Treat all 101,484 12.18 23,827 0.54 44,256
AAR, AST–ALT ratio; APGA, AST, platelet count, GGT, α-fetoprotein; CEUS, contrast-enhanced ultrasound;
DW-MRI, diffusion-weighted magnetic resonance imaging; PAPAS, age, ALP, α-fetoprotein, AST; US, ultrasound.
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TABLE 28 Hepatits B e antigen-positive base-case analysis (second stage of the analysis where tests are combined
sequentially and compared with liver biopsy, ‘treat all’ and ‘treat no one’
Test Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Treat no one 37,831 9.64 – – –
(S1) Forns index (high cut-off) 73,960 11.16 – – Dominated
Forns index (high cut-off) 73,084 11.35 – – Dominated
(S2) Forns index (high cut-off) and
MR elastography
73,062 11.35 – – Dominated
(S2) Forns index (high cut-off)
and Fibrotest
73,037 11.35 – – Dominated
(S2) Forns index (high cut-off) and
hyaluronic acid
73,011 11.35 – – Extendedly dominated
(S1) US SAPI (high cut-off) 76,238 11.38 – – Dominated
(S1) GUCI 75,539 11.40 – – Dominated
Liver biopsy 75,957 11.41 – – Dominated
(S3) Forns index (high cut-off)
and Fibrotest
75,965 11.42 – – Dominated
(S3) Forns index (high cut-off) and
hyaluronic acid
75,939 11.43 – – Dominated
(S3) Forns index (high cut-off) and
MR elastography
75,927 11.43 – – Dominated
FIB-4 (combined cut-off) and Fibroscan 74,911 11.43 – – Dominated
(S4) Forns index (high cut-off)
and Fibrotest
74,953 11.45 – – Dominated
(S3) GUCI and US SAPI (high cut-off) 75,805 11.46 – – Dominated
(S3) Fibrotest and US SAPI (high cut-off) 76,025 11.46 – – Dominated
(S3) GUCI and Fibrotest 75,904 11.46 – – Dominated
Forns index (combined cut-off)
and Fibroscan
75,253 11.47 – – Dominated
(S2) Fibrotest and US SAPI (high cut-off) 74,851 11.47 – – Dominated
(S3) Hyaluronic acid and US SAPI
(high cut-off)
75,908 11.47 – – Dominated
(S3) GUCI and hyaluronic acid 75,803 11.48 – – Dominated
(S2) GUCI and US SAPI (high cut-off) 74,431 11.48 – – Dominated
(S4) Forns index (high cut-off) and
hyaluronic acid
75,342 11.48 – – Dominated
(S3) GUCI and MR elastography 75,778 11.48 – – Dominated
(S2) GUCI and Fibrotest 74,517 11.49 – – Dominated
(S3) Fibrotest and MR elastography 76,198 11.49 – – Dominated
(S4) Forns index (high cut-off) and
MR elastography
75,937 11.50 – – Dominated
(S2) Fibrotest and MR elastography 75,023 11.50 – – Dominated
(S2) GUCI and hyaluronic acid 74,416 11.50 – – Dominated
continued
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TABLE 28 Hepatits B e antigen-positive base-case analysis (second stage of the analysis where tests are combined
sequentially and compared with liver biopsy, ‘treat all’ and ‘treat no one’ (continued )
Test Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
(S4) Fibrotest and US SAPI (high cut-off) 75,667 11.50 – – Dominated
(S2) GUCI and MR elastography 74,404 11.50 – – Extendedly dominated
(S3) Hyaluronic acid and MR elastography 76,028 11.51 – – Dominated
US SAPI (high cut-off) 75,618 11.51 – – Dominated
(S4) GUCI and US SAPI (high cut-off) 75,450 11.51 – – Dominated
(S4) GUCI and Fibrotest 75,400 11.52 – – Dominated
(S1) Fibrotest 80,207 11.52 – – Dominated
(S2) Hyaluronic acid and US SAPI
(high cut-off)
75,265 11.52 – – Dominated
GUCI 74,942 11.52 – – Extendedly dominated
(S4) Hyaluronic acid and US SAPI
(high cut-off)
75,751 11.53 – – Dominated
(S4) GUCI and hyaluronic acid 75,440 11.54 – – Dominated
(S1) MR elastography 78,061 11.55 – – Dominated
(S4) Fibrotest and MR elastography 76,226 11.55 – – Dominated
(S4) GUCI and MR elastography 75,814 11.56 – – Extendedly dominated
(S2) Hyaluronic acid and MR elastography 75,386 11.56 37,555 1.9 19,612
(S4) Hyaluronic acid and MR elastography 76,069 11.57 – – Extendedly dominated
(S1) Hyaluronic acid 79,752 11.58 – – Dominated
APRI (combined cut-off) and Fibroscan 77,596 11.59 – – Extendedly dominated
Fibrotest 79,495 11.62 – – Dominated
MR elastography 77,627 11.64 2241 0.1 28,585
Hyaluronic acid 79,148 11.67 – – Extendedly dominated
Treat all 101,484 12.18 23,857 0.5 43,946
US, ultrasound.
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A scatterplot illustrating the position of each testing strategy on the CEAC compared with the testing
strategy ‘treat no one’ can be found in Appendix 12.
Hepatits B e antigen-negative chronic hepatitis B
The base-case analysis result indicates that given a cost-effectiveness threshold of £30,000, the
cost-effective strategy is to adopt a strategy of ‘treat all’ with an ICER of £28,137. All other testing
strategies are dominated by the ‘treat all’ strategy. As all other tests were dominated, the ICER presented
represents the ‘treat all’ strategy versus a ‘treat no one’ strategy. Given a UK threshold range of £20,000,
the ‘treat no one’ strategy was the most cost-effective option to adopt.
The CEAF (Figure 5) for the HBeAg-negative model shows that the probability of ‘treat all’ being the
optimal testing option (highest expected net benefit), given a cost-effectiveness threshold value of
£30,000, is 38%. The CEAF also shows that ‘treat all’ has a 35% probability of being cost-effective for
cost-effectiveness thresholds starting at £28,137.
Appendix 10 displays the CEAC for the overall base-case analysis for HBeAg-negative model. For reasons
of clarity, only those strategies that have on average a ≥ 4% probability of being the most cost-effective
option have been included. The CEAC demonstrates that, given the data, there is a 38% chance that the
additional cost of the ‘treat all’ strategy, compared with all other test strategies, is at or below £30,000 per
life-year gained.
Liver biopsy was a comparator for both stages of the analysis; however, this testing option is dominated by
other less costly but more effective options.
Table 29 presents incremental results for the first stage of the analysis and Table 30 presents the
incremental results for the second stage where a number of combined tests are compared using a number
of different sequential testing strategies (see Chapter 3 for details of the four testing strategies presented
in the tables as S1, S2, S3 and S4).
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FIGURE 5 Cost-effectiveness acceptability frontier for HBeAg-negative: second stage of the analysis.
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TABLE 29 Hepatitis B e antigen-negative base-case analysis (first stage where all tests are compared singly)
Test strategy Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Treat no one 37,579 8.83 – – –
FIB-4 (high cut-off) 67,267 9.56 – – Extendedly dominated
Forns index (high cut-off) 67,348 9.58 – – Extendedly dominated
APGA 67,653 9.60 – – Extendedly dominated
Liver biopsy 70,274 9.64 – – Dominated
APRI (high cut-off) 69,428 9.70 – – Dominated
GUCI 69,196 9.76 – – Extendedly dominated
Hui index 70,308 9.77 – – Dominated
US SAPI (high cut-off) 69,635 9.78 – – Extendedly dominated
US 71,710 9.81 – – Extendedly dominated
MR elastography 71,791 9.93 – – Extendedly dominated
Fibroscan 73,007 9.93 – – Extendedly dominated
Fibrotest 73,739 9.93 – – Dominated
Forns index (low cut-off) 74,317 9.94 – – Dominated
Hyaluronic acid 73,448 9.96 – – Extendedly dominated
PAPAS 74,493 9.98 – – Extendedly dominated
US SAPI 74,508 9.99 – – Extendedly dominated
DW-MRI 74,774 10.01 – – Extendedly dominated
FIB-4 (low cut-off) 75,648 10.01 – – Dominated
Hepascore 75,624 10.03 – – Extendedly dominated
CEUS 76,577 10.09 – – Extendedly dominated
ARFI 77,512 10.10 – – Extendedly dominated
Age–Platelet Index 78,647 10.13 – – Dominated
CT 78,129 10.13 – – Dominated
AAR 79,321 10.13 – – Dominated
APRI (low cut-off) 78,083 10.13 – – Extendedly dominated
US SAPI (low cut-off) 85,587 10.45 – – Extendedly dominated
Treat all 96,525 10.92 58,947 2.09 28,137
AAR, AST–ALT ratio; APGA, AST, platelet count, GGT, α-fetoprotein; CEUS, contrast-enhanced ultrasound;
DW-MRI, diffusion-weighted magnetic resonance imaging; PAPAS, age, ALP, α-fetoprotein, AST; US, ultrasound.
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TABLE 30 Hepatitis B e antigen-negative base-case analysis (second stage of the analysis where tests are combined
sequentially and compared with liver biopsy, ‘treat all’ and ‘treat no one’)
Strategies Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Treat no one 37,579 8.83 – – –
(S1) Forns index
(high cut-off)
68,237 9.40 – – Dominated
(S2) Forns index (high cut-off)
and Fibrotest
66,908 9.58 – – Dominated
(S2) Forns index (high cut-off)
and MR elastography
66,892 9.58 – – Dominated
(S2) Forns index (high cut-off)
and hyaluronic acid
66,885 9.58 – – Extendedly dominated
Forns index (high cut-off) 67,361 9.58 – – Extendedly dominated
(S1) GUCI 69,766 9.64 – – Dominated
Liver biopsy 70,274 9.64 – – Dominated
(S3) Forns index (high cut-off)
and Fibrotest
70,285 9.65 – – Dominated
(S3) Forns index (high cut-off)
and hyaluronic acid
70,261 9.65 – – Dominated
(S1) US SAPI (high cut-off) 70,230 9.65 – – Dominated
(S3) Forns index (high cut-off)
and MR elastography
70,242 9.65 – – Dominated
(S4) Forns index (high cut-off)
and Fibrotest
69,015 9.68 – – Dominated
(S3) GUCI and US SAPI
(high cut-off)
70,122 9.68 – – Dominated
FIB-4 (combined cut-off)
and Fibroscan
69,189 9.69 – – Dominated
(S3) Fibrotest and US SAPI
(high cut-off)
70,345 9.69 – – Dominated
(S3) GUCI and Fibrotest 70,212 9.69 – – Dominated
(S3) Hyaluronic acid and US SAPI
(high cut-off)
70,226 9.70 – – Dominated
(S3) GUCI and hyaluronic acid 70,115 9.70 – – Dominated
(S3) GUCI and MR elastography 70,090 9.71 – – Dominated
(S2) GUCI and US SAPI
(high cut-off)
68,562 9.71 – – Dominated
(S2) Fibrotest and US SAPI
(high cut-off)
68,870 9.71 – – Dominated
(S4) Forns index (high cut-off)
and hyaluronic acid
69,463 9.72 – – Dominated
(S2) GUCI and Fibrotest 68,637 9.72 – – Dominated
Forns index (combined cut-off)
and Fibroscan
69,559 9.72 – – Dominated
(S3) Fibrotest and MR
elastography
70,497 9.72 – – Dominated
continued
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TABLE 30 Hepatitis B e antigen-negative base-case analysis (second stage of the analysis where tests are combined
sequentially and compared with liver biopsy, ‘treat all’ and ‘treat no one’) (continued )
Strategies Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
(S2) GUCI and hyaluronic acid 68,541 9.73 – – Dominated
(S2) GUCI and MR elastography 68,529 9.73 – – Extendedly dominated
(S3) Hyaluronic acid and
MR elastography
70,332 9.74 – – Dominated
(S2) Fibrotest and MR
elastography
69,023 9.74 – – Extendedly dominated
(S4) GUCI and Fibrotest 69,537 9.75 – – Dominated
(S4) Fibrotest and US SAPI
(high cut-off)
69,827 9.76 – – Dominated
(S4) Forns index (high cut-off)
and MR elastography
70,115 9.76 – – Dominated
(S2) Hyaluronic acid and US SAPI
(high cut-off)
69,332 9.76 – – Dominated
GUCI 69,167 9.76 – – Extendedly dominated
(S4) GUCI and US SAPI
(high cut-off)
69,590 9.77 – – Dominated
(S4) GUCI and hyaluronic acid 69,610 9.78 – – Dominated
(S4) Hyaluronic acid and US SAPI
(high cut-off)
69,928 9.78 – – Dominated
US SAPI (high cut-off) 69,609 9.78 – – Dominated
(S2) Hyaluronic acid and MR
elastography
69,438 9.80 – – Extendedly dominated
(S4) Fibrotest and MR
elastography
70,429 9.81 – – Dominated
(S4) GUCI and MR elastography 70,011 9.81 – – Extendedly dominated
(S4) Hyaluronic acid and MR
elastography
70,277 9.83 – – Extendedly dominated
(S1) MR elastography 72,171 9.84 – – Dominated
(S1) Fibrotest 74,242 9.84 – – Dominated
APRI (combined cut-off)
and Fibroscan
71,769 9.87 – – Dominated
(S1) Hyaluronic acid 73,861 9.88 – – Dominated
MR elastography 71,737 9.93 – – Extendedly dominated
Fibrotest 73,812 9.94 – – Dominated
Hyaluronic acid 73,426 9.96 – – Extendedly dominated
Treat all 96,525 10.92 58,947 2.09 28,137
US, ultrasound.
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A scatterplot illustrating the position of each testing strategy on the cost-effectiveness acceptability curve
compared with the testing strategy ‘treat no one’ can be found in Appendix 12.
Sensitivity analysis results
Hepatits B e antigen-positive
The base results remained robust to the majority of the sensitivity analyses, including changes to utility
values, health state costs, liver biopsy disutility decrement and changes to NILT test costs; however,
they were sensitive to some of the analyses. These are detailed as follows.
Removing tests from the analysis (where the studies did not converge using the bivariate model) changed
the result so that the most cost-effective option, when all tests were compared singly, was to use APRI
with a high cut-off; however, with an ICER of £20,673, if using a strict cost-effectiveness threshold of
£20,000 this would not be adopted. If the cost-effectiveness threshold was set at £30,000, Fibroscan
would be the most cost-effective test with an ICER of £23,345. The ‘treat all’ approach had the highest
effectiveness (similar to base case) but with an ICER of £39,747 was not cost-effective at the standard UK
threshold range of £20,000–30,000.
Setting treatment benefit to zero for patients who were incorrectly treated (patients in a mild health
state who were diagnosed as false positive) significantly increased the ICER for ‘treat all’ to £550,668.
The ICER for MR elastography increased to £32,220, which given a strict cost-effectiveness threshold of
£20,000–30,000, would not be cost-effective. The most cost-effective option to adopt, assuming that the
cost-effectiveness threshold is £20,000, is to use an indirect serum marker, GUCI, which has an ICER value
of £19,934.
Changing the prevalence to the maximum prevalence estimated from the meta-analysis changed the result
when all tests were compared singly; FIB-4 with a high cut-off became the most cost-effective test, with an
ICER of £17,871. When the 75th quartile was used, the results changed so that treating everyone with a
prior diagnostic test was the most cost-effective strategy if the cost-effectiveness threshold was at the
upper bound of the recommended range (threshold £30,000, ICER £26,718).
Hepatits B e antigen-negative
The base results remained robust to the majority of sensitivity analyses; however, they were sensitive to
some of the analyses which are detailed below.
Amending the sex ratio and starting age to reflect the HBeAg-negative model affected the results.
Assuming a cost-effectiveness threshold of £30,000, the most cost-effective option would be to use MR
elastography singly with an ICER of £25,546. However, if a strict cost-effectiveness threshold of £20,000
was employed, none of the options would be cost-effective.
Amending the average disease prevalence value used within the model changes the result; using a
maximum prevalence returns a result where, given a cost-effectiveness threshold of £30,000, using MR
elastography singly becomes cost-effective, with an ICER of £21,489. When the minimum disease
prevalence is used, ‘treat all’ remains the most cost-effective given a threshold value of £30,000, but the
ICER value decreases to £22,871.
Allowing for zero treatment benefit for patients who are treated incorrectly while in a mild health
state (false-positive patients) changes the overall result, where MR elastography becomes the most
cost-effective; however, the ICER of £32,194 is above the standard cost-effectiveness threshold value
of £20,000–30,000. ‘Treat all’ also becomes cost-ineffective as a strategy, with an ICER of £53,660.
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The base-case analysis assumes that the retest has perfect sensitivity and specificity (for modelling feasibility
due to large number of tests and to ensure comparability across tests). When we amended this and set
the retest sensitivity to that of three NILTs, APRI, Fibrotest and Fibroscan, the results did change for
HBeAg-negative. Overall, the costs and QALYs for some of the NILTs increased, as the retest meant that
some persons in mild health state (F0–1) started to receive treatment incorrectly (false-positive diagnosis),
thereby incurring the associated costs and benefit (increased QALY outcome). ‘Treat all’ remains the most
effective strategy, but is no longer the most cost-effective at standard cost-effectiveness threshold ranges.
The most cost-effective test is now MR elastography, with an ICER in the upper band of the threshold
range (£). MR elastography has a sensitivity of 94% of and specificity of 92%, implying that it will identify
most patient correctly. This test is promising; however, as mentioned in Chapter 1, it is of limited use at
present due to its cost and availability. Further studies to assess its diagnostic accuracy are required, as this
was not one of the studies where the bivariate model converged and so the results may not be robust.
Short tables of results for the sensitivity analyses for the HBeAg-positive and HBeAg-negative models
(excluded are ‘dominated’ and ‘extendedly dominated’ test strategies) are located in Appendix 11
(full tables are available on request).
Discussion
We have estimated the cost-effectiveness of 56 testing strategies of sequential testing using 25 NILTs in
patients with chronic HBV. The results differed for the HBeAg-positive and HBeAg-negative populations.
The analysis found that for HBeAg-positive patients, adopting a sequential testing strategy where patients
who tested positive using hyaluronic acid were retested with a second NILT, MR elastography, to confirm
results was the most cost-effective approach given a cost-effectiveness threshold of £20,000. However,
though hyaluronic acid combined with MR elastography is the most cost-effective test strategy, there is
considerable uncertainty around this result and the probability of it being the optimal choice (having the
highest expected net benefit) is very low (4%). If the upper bound of the standard cost-effectiveness
range, £30,000, was considered to be appropriate, the most cost-effective strategy would be with MR
elastography singly, but again this result was associated with substantial uncertainty (13% probability of
being the optimal choice). Within the £20,000–30,000 threshold range, the difference between the
expected QALYs and costs was similar for many of the test combinations, and taking into account the
uncertainty around the input parameters results in high levels of uncertainty.
When NILTs were assessed singly, testing with an indirect serum marker, GUCI, was the most cost-effective
option at a cost-effectiveness threshold of £20,000 with a mean ICER of £19,716, but again associated
with considerable uncertainty. For a threshold of £30,000, MR elastography was most cost-effective, with
an ICER of £23,486.
For patients with HBeAg-negative disease, the strategy of treating all patients without testing and
regardless of the degree of fibrosis offered the largest QALY gain. This is, however, at a substantial
additional cost and would be cost-effective only if considered towards the upper bound of the NICE
cost-effectiveness threshold range,66 as it had an ICER of £28,317. All of the NILTs, either alone or
sequentially followed by treatment, provided a QALY gain compared with a strategy of no testing and no
treatment, but the gain was less than for the ‘treat all’ strategy, and they were dominated or extendedly
dominated by the ‘treat all (no prior test)’ treatment strategy as their costs or ICERs were higher. There
was less uncertainty in these results at the £30,000 threshold value where the probability of the ‘treat all’
strategy being optimum was 38%.
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Similar findings for treatment in HBeAg-negative patients have been reported in assessments of the
treatments conducted to inform national guidelines; the evidence review group which looked at
the evidence for entecavir conducted an analysis where they analysed lifetime treatment duration for
HBeAg-negative patients. This returned an ICER of £27,124 per QALY gained, similar to our base-case
analysis result.417
This difference in results between both models highlights that treatment is more cost-effective in patients
with positive disease as the HBeAg-negative population tend to be older with a higher risk of progressing
from a moderate health state to a cirrhotic health state than the HBeAg-positive cohort. The impact of
treatment is also more modest in this group than for the HBeAg-negative population modelled.
We conducted a sensitivity analysis to confirm that age and sex ratio drive the difference. The sensitivity
analysis results showed that when all tests were compared singly, using the indirect serum marker, GUCI,
had an ICER of £23,065, similar to the base-case result for the HBeAg-positive model. As the age and
sex ratio had been changed, this implies that the RRs (treatment effect) drives the remaining difference
between both cohorts and, indeed, is the driver behind a NILT not being cost-effective for the
HBeAg-negative cohort given a strict cost-effectiveness threshold of £20,000.
Another thing to note about the results for both models is that the differences between test outcomes are
very small, especially in relation to the health outcomes (QALYs), which implies that the long-term costs
resulting from a particular test diagnosis (true positive, false positive, false negative or true negative)
are the driving factor behind the analysis for HBeAg-positive and -negative chronic HBV.
An issue also arises regarding using the systematic literature review data to calculate the disease
prevalence of liver fibrosis within a population, as most studies may have been set within a tertiary
care centre rather than within a screening programme for the general population, and so disease
prevalence may be overestimated. When we used the minimum prevalence for the HBeAg-positive model,
this did affect the results; GUCI remained the most cost-effective test when all NILTs were compared
singly, but the ICER for MR elastography increased significantly to £37,348.
Data on diagnostic accuracy of NILTs in patients with chronic HBV were limited and of low quality;
therefore, our results should be interpreted with caution. Data on hyaluronic acid came from a single
study, while MR elastography is not widely available and needs further validation as a diagnostic test.
Although Fibroscan is widely used in most centres, it was not the most cost-effective option, even in the
sensitivity analysis when only studies that converged using the bivariate model were considered (given a
strict £20,000 cost-effectiveness threshold). Our results are, therefore, indicative that sufficiently validated
non-invasive testing strategies are more cost-effective in patients with HBeAg-positive chronic HBV than
liver biopsy or treatment decisions based on viral load and transaminases alone, but no robust specific
recommendations on the use of specific non-invasive tests can be made. Future research should further
explore these possibilities.
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Chapter 6 Cost-effectiveness analysis: hepatitis C
This chapter details the analysis of the cost-effectiveness of the diagnostic tests for staging fibrosis inpatients with HCV. The NILTs considered for evaluation in this chapter were those considered applicable
for use in people with HCV, for which data on sensitivity and specificity were available.
Evaluation approach for hepatitis C
Fifty-seven relevant NILTs were evaluated in the first stage of the analysis, which compared the NILTs with
liver biopsy, ‘treat all’ and ‘no treatment’ strategies. The NILTs evaluated are listed in Table 31, and are
grouped according to defined test categories: indirect serum makers, direct and patented serum markers
and imaging modalities.
TABLE 31 List of NILTs evaluated (HCV)
Indirect Direct and patented Imaging
APRI ELF ARFI
Age-Platelet Index ELF (high cut-off) CT
APRI (high cut-off) ELF (low cut-off) EOB-MRI
APRI (low cut-off) Fibroindex (high cut-off) MRI
AST–ALT ratio Fibroindex (low cut-off) PLT–Spleen ratio
CDS Fibrometer Fibroscan (TE)
Fibrosis Index Fibrospect US
FIB-4 Fibrotest US SAPI
FIB-4 (high cut-off) Fibrotest (high cut-off) US SAPI (high cut-off)
FIB-4 (low cut-off) Fibrotest (low cut-off) US SAPI (low cut-off)
FibroQ Hyaluronic acid CEUS
Forns index Hyaluronic acid (high cut-off) DW-MRI
Forns index (high cut-off) Hyaluronic acid (low cut-off) MR elastography
Forns index (low cut-off) Hepascore
FPI (high cut-off) Hepascore (high cut-off)
FPI (low cut-off) MP3
GUCI PIINP/MMP-1 index
King’s PIINP
King’s (high cut-off) PLT
King’s (low cut-off) Type IV collagen
Lok’s index YKL-40 (high cut-off)
Pohl index YKL-40 (low cut-off)
CDS, Cirrhosis Discriminant Score; CEUS, contrast-enhanced ultrasound; DW-MRI, diffusion-weighted magnetic resonance
imaging; EOB-MRI, (gadolinium-ethoxybenzyl-diethylenetriamine-penta-acetic-acid) enhanced magnetic resonance imaging;
FPI, Fibrosis Probability Index; MMP-1, matrix metalloproteinase-1; MP3, metalloproteinase-3; PLT, platelet; US, ultrasound.
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The second stage of the analysis compared a selection of tests using alternative sequential testing
strategies. The criteria for selecting these tests and the assumptions used regarding combinations of
tests and sequential testing strategies are detailed in Chapter 3. The systematic review and subsequent
meta-analysis of the data provided test outcome results for a number of published algorithms used for
staging fibrosis [sequential algoritm for fibrosis evaluation (SAFE), Leroy, Fibropaca and Bordeaux], which
were evaluated in the second stage of the analysis.
Ten tests evaluated in the second stage of the analysis used a combined diagnostic cut-off threshold for
staging fibrosis; the test outcomes reported a number of indeterminate responses, which are listed in
Table 32. We allowed for patients who had an indeterminate response to receive a retest with a
commonly used imaging modality Fibroscan (TE). We did not choose an indirect test as the majority of
the 10 tests with a combined diagnostic cut-off were from the indirect test category and a subsequent
indirect test would not enhance the diagnostic accuracy. Of the direct tests and imaging modalities,
we chose Fibroscan based on availability and current clinical practice. Overall, 56 testing strategies were
compared in the second stage of the analysis.
Model structure and parameters
Decision tree structure
A decision tree model was constructed to evaluate the cost-effectiveness of the NILTs, liver biopsy,
the ‘treat all’ and ‘no treatment’ strategies. As per the schematic diagram depicting the flow of data in
Chapter 3 (see Figure 1), the decision tree was populated with sensitivity, specificity and prevalence data
from the meta-analysis of the systematic review data, cost and QALY outputs from a series of Markov
models, individual test costs sourced from published literature and hospital finance departments and a
measure of adverse effects associated with liver biopsy.
As discussed previously, there are two stages to the decision tree analysis: the first stage where all tests are
compared singly and the second stage where combinations of tests are compared using four different
strategies. Schematic illustrations and descriptions of the sequential testing pathways are provided in
Chapter 3. To estimate costs and QALYs for each testing option, the long-term costs (and test costs) and
QALY estimates (including disutility from liver biopsy if applicable) associated with each potential test
outcome (true positive, false positive, true negative and false negative) were multiplied by the probability
of each NILT returning a true positive, false positive, true negative or false negative result.
TABLE 32 List of tests with a combined cut-off applicable for use in HCV
Combined diagnostic threshold test Persons with indeterminate result, %
APRI 43
ELF 41
FIB-4 29
Fibroindex 35
Fibrospect 53
Forns index 45
Fibrotest 38
Hyaluronic acid 44
Hepascore 33
YKL-40 47
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Markov model structure
A series of Markov models were constructed to estimate the long-term costs and outcomes associated
with a correct (true positive and true negative) and an incorrect (false positive and false negative) diagnosis
for a hypothetical cohort of 1000 HCV patients with suspected liver fibrosis or cirrhosis. An additional two
Markov models were constructed to estimate the costs and outcomes associated with the ‘treat all and
‘treat no one’ approaches.
Figure 6 shows a schematic representation of the patient pathway. The structure is a modified version of
previously published models of liver fibrosis in HCV.414,438 The starting health states in the Markov models
were representative of the METAVIR categorisations for staging fibrosis. There were eight potential health
states in the model: mild fibrosis (F0–1), moderate/significant fibrosis (F2–3), compensated cirrhosis (F4),
decompensated cirrhosis, HCC, liver transplant, post liver transplant and death. The patient cohort
progressed through the model as per the arrows in the illustration; the circular arrows leading back into
the same health state indicate that patients could remain within health states for longer than one cycle,
except in the liver transplant state where patients could only progress to a post liver transplant health state
or death. Patients could not regress back to an earlier health state. Patients could progress from all health
states to the ‘death’ health state at any time.
On the basis of clinical advice, we assumed that a METAVIR test score of ≥ F2 equated to a positive test
outcome (true positive and false positive) and treatment with antiviral agents would commence at this
stage; conversely, a METAVIR test score of < F2 indicated a negative test outcome and a policy of watchful
waiting without immediate antiviral treatment would commence (see Chapter 5 for description of the
watchful waiting policy assumed in the model).
As for the HBV Markov models, the initial starting health state for the population cohort in the models
depended on the test outcome being modelled [e.g. for a false positive test result, the population cohort
entered the model in a mild health state (F0–1), and for a test result of true positive the population
cohort entered the model in a F2–4 health state, where the patient cohort was then distributed according
to the estimated disease prevalence (F2–3 62%; F4 38%)].
Death
None/mild
fibrosis
F0−F1
Compensated
cirrhosis
F4
Hepatocellular
cancer
Decompensated
cirrhosis
Post liver
transplant Liver transplant
Moderate/
significant
fibrosis F2−3
FIGURE 6 Illustration of Markov model.
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Input parameters
Average disease prevalence was based on the systematic review of test accuracy (53%) using the same
methods used for the HBV model (see Chapter 5). We used the sensitivity and specificity estimates for each
NILT and the average prevalence estimate to calculate the probability of each test returning a true positive,
false positive, true negative and false negative result (see Appendix 7).
Cohort characteristics
The characteristics of the cohort (age, sex and weight) were sourced from published literature.414,439 Various
studies have determined that treatment will have different effects according to patient genotype;37,439
therefore, our model cohort is split to mirror the distribution of chronic HCV genotype 1, 2 and 3, and
4 infections,439 allowing us to model the effectiveness of treatment per genotype. These are listed in Table 33.
Natural history: baseline transition probabilities used in model
The recent systematic review by Shepherd et al.371 was reviewed and the epidemiological search strategy
(see Chapter 5 and Appendix 2 for details) updated for HCV and rerun using the MEDLINE database
(Ovid platform, searched 1 December 2012) for relevant papers related to disease progression in HCV.
The search located 2343 papers, none of which was deemed relevant for our purposes. The rate of disease
progression assumed in the models was based on transition probabilities sourced from a published
cost-effectiveness study by Wright et al.,414 which was identified in the literature search for quality of life and
cost data. This study estimated transition probabilities for the mild and moderate HCV health states from
a trial of treatments for mild HCV undertaken in a number of London hospitals,414 during which the liver
fibrosis stage was determined by liver biopsy. We deemed this a suitable study to use as it was a UK-based
study, and noted that it does not assume that the progression between early health stages is linear.414
Transition probabilities for the compensated cirrhosis, decompensated cirrhosis, HCC, liver transplant and
post liver transplant health states were also sourced from this study. For these health states, the authors
sourced the probabilities from published literature. Data from a study by Fattovich et al.409 were used for
the compensated cirrhosis, decompensated cirrhosis and HCC health states, and for mortality-specific data
relating to each health state. The study by Fattovich et al.409 was conducted in seven European centres,
including a UK tertiary centre. The study was a retrospective study looking at a cohort of 384 compensated
cirrhotic patients who were assessed annually for a mean of 5 years.
Wright et al.414 sourced transition probabilities relating to the liver transplant and post liver transplant
health state from a study by Siebert et al.,435 where the rate of liver transplants was estimated for HCV
patients in the USA and revised downwards by 2% based on European transplant registry data and
estimated the probability of death following a liver transplant from a survival analysis of the UK liver
transplant registry data conducted by the Royal College of Surgeons.440 Transition probabilities used in the
model are listed in Table 34.
TABLE 33 Cohort characteristics input parameters
Cohort characteristics Parameter value Source
Age (years) 40 Wright et al.414
Fried et al.439
Average weight 79.8 kg
Sex
Male, % 61 Wright et al.414
Female, % 39
Genotype, %
Genotype 1 66 Fried et al.439
Genotypes 2 and 3 31
Genotype 4 3
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Mortality data
An all-cause mortality rate applied to all patients within the model; this was calculated using the Interim
Life Tables for England and Wales, 2008–10.416 The risk of death increased each year according to age and
the rate was weighted to allow for sex mix.
Antiviral treatment: type, dosage, duration and effectiveness
In the model, patients received treatment with antiviral agents if they tested positive (true positive or false
positive with a test score of ≥ F2).
If patients had a successful response to treatment (modelled using a SVR rate), they no longer progressed
through the health states pathway in the model and retained a risk of all-cause mortality only. This is
similar to the assumption employed by Wright et al.414
Antiviral treatment for the management of liver fibrosis and cirrhosis in patients with HCV was based
on NICE guidance.441–443 Treatment type, duration and dosage in the model varied according to HCV
genotype. In accordance with NICE guidelines, our model assumed that HCV genotype 1 patients received
treatment with a combination of peginterferon alfa-2a or alfa-2b, ribavirin, and either telaprevir or
boceprevir.441,442 Patients with HCV genotype 2, 3 and 4 were assumed to receive dual therapy with
a combination of peginterferon alfa-2a or alfa-2b and ribavirin.443
Different branded products are marketed and available in the UK for ribavirin (BNF 64419); the summary
of product characteristics for one of the brands [Rebetol®, Merck Sharpe & Dohme (MSD)] advises that it
should only be used in combination with peginterferon alfa-2b (ViraferonPeg®, MSD).444 To allow for this,
we modelled two different combinations of antiviral agents in the model (combined as per their summary
of product characteristics) with half of eligible patients receiving one combination and the other half of
eligible patients receiving the other.
l HCV genotype 1: peginterferon alfa-2a (Pegasys®, Roche) combined with ribavirin (Copegus®, Roche)
and telaprevir (Incivo®, Janssen) or peginterferon alfa-2b (ViraferonPeg®, MSD) combined with ribavirin
(Rebetol®, MSD) and boceprevir (Victrelis®, MSD)
l HCV genotype 2, 3 and 4: peginterferon alfa-2a (Pegasys®, Roche) combined with ribavirin (Copegus®,
Roche) or peginterferon alfa-2b (ViraferonPeg®, MSD) combined with ribavirin (Rebetol®, MSD).
TABLE 34 Annual transition probabilities: HCV
Health state–health state Transition probability PSA distribution Source
Mild–moderate 0.025 Dirichlet Wright et al.414
Moderate–cirrhosis 0.037
Cirrhosis–decompensated cirrhosis 0.04
Cirrhosis/decompensated cirrhosis–HCC 0.14
Decompensated cirrhosis/HCC–liver transplant 0.02
Decompensated cirrhosis–death 0.13
HCC–death 0.43
Liver transplant–death (year 1) 0.15
Post liver transplant–death 0.03
All-cause mortality 0.0014–0.335 Interim Life Tables,
2008–10416
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Patients in the mild, moderate and compensated cirrhosis health states would receive treatment with
antiviral agents if they tested positive (true positive or false positive). Patients in the decompensated
cirrhosis, HCC, liver transplant and post liver transplant health states were assumed to receive no antiviral
treatment, but instead received usual standard of care.37
Treatment dosage and treatment duration was based on those recommended in the summary of product
characteristics for each drug (www.medicines.org.uk/emc); drug dosage depended on the weight of the
patient; for modelling purposes we assumed that the drug dosage would be administered as per the
assumed average weight in the model (79.8 kg).439 Treatment effectiveness, represented in the model by
the SVR rate, was sourced from published literature.445 Patients within the model were assumed to be
treatment naive (had not received previous treatment with antiviral agents). Different SVR rates were
employed in the model and varied according to genotype and drug therapy administered. We assumed
that treatment benefit would occur during the treatment year.
Different SVR rates for the mild, moderate and cirrhotic health states were not employed within the model
as separate rates were not reported within the source literature,441,445 except for HCV genotype 1 patients
treated with peginterferon alfa-2b, ribavirin and boceprevir,442 where a different SVR rate was reported for
HCV patients in a cirrhotic health state. As it has been noted that the SVR rates with pegylated IFN-α and
ribavirin are lower in patients with advanced fibrosis and cirrhosis than in patients with mild or moderate
fibrosis,37 we carried out a sensitivity analysis where we reduced the SVR rate for the patient cohort
receiving treatment in a cirrhotic health state. The SVR rates, recommended dosage and specific duration
employed in the model as part of dual or triple therapy are listed in Table 35.
TABLE 35 Medication used in Markov models
Drug combination Dosagea Treatment duration
SVR rate
applied Source of SVR rate
Genotype 1: treatment-naive patients
Peginterferon alfa-2a,
ribavirin, telaprevir
180mg, 1200mg
and 2250mg
PR and Telaprevir TW 12,
PR TW 48
75% NICE technology
appraisal TA252441
Peginterferon alfa-2b,
ribavirin, boceprevir
120mg, 1000mg
and 2400mg
PR for 4 weeks, PR and
boceprevir TW 36, PR TW 48
66.1% NICE technology
appraisal TA253442
Genotype 1: cirrhotic patients (treatment naive)
Peginterferon alfa-2b,
ribavirin and boceprevir
120mg, 1000mg
and 2400mg
PR for 4 weeks, PR and
boceprevir TW 48
41.7% NICE technology
appraisal TA253442
Genotype 2 and 3: treatment-naive patients
Peginterferon
alfa-2a, ribavirin
180mg, 1200mg PR for 24 weeks 76% Fried et al.439
Peginterferon
alfa-2b, ribavirin
1200mg, 1000mg PR for 24 weeks 82% Manns et al.445
Genotype 4: treatment-naive patients
Peginterferon
alfa-2a, ribavirin
180mg, 1200mg PR for 48 weeks 77% Fried et al.439
Peginterferon
alfa-2b, ribavirin
120mg, 1000mg PR for 48 weeks 69% Kamal et al.446
PR, peginterferon alfa-2a or alfa-2b and ribavirin; TW, till week.
a Recommended dosage listed: weekly for peginterferon alfa-2a and alfa-2b; daily for ribavirin, telaprevir and boceprevir.
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Costs
Health states
We updated the search strategy for costs devised by Shepherd et al.371 for HCV (see Appendix 2 for search
strategy). Using the MEDLINE database (via Ovid platform, searched 1 December 2012), the search located
21 papers, eight of which were retrieved for full review;447–454 however, six of these papers were based
outside the UK,447–449,453,454 one contained no costs451 and two were guidelines papers.450,452 As none of the
papers found was applicable, the costs of treating patients with mild, moderate and compensated cirrhosis
were sourced from a published cost-effectiveness study by Wright et al.414 identified from the literature
review for quality-of-life data for HCV. This study looked at the effectiveness of antiviral agents for mild
HCV, costs for which were collected during a RCT. The cost data from this study have been widely used in
other recently published papers.455–457
The authors collected resource use and cost data alongside a mild HCV RCT. Detailed cost data were
collected from three centres based in London, Newcastle and Southampton. Resource use information
collected covered inpatient and outpatient care, investigations, procedures, drug use and other services
including psychiatric services.
The costs associated with treating the decompensated cirrhosis, HCC, liver transplant and post liver
transplant health states were sourced from a UK cost-effectiveness study of liver transplantation424 (CELT
study) which collected costs on adult patients listed for an isolated liver transplant (aged 16 years and over)
between December 1995 and December 1996. Data collection was conducted between 1995 and 1999
and split into four phases: assessment, candidacy, transplant and post-transplant phases (see Chapter 5 for
description) and collected according to disease aetiology (HBV, HCV, ALD). Resource-use data on blood
products used, number of dietitian sessions, drugs used, inpatient stay, nutritional support received,
outpatient visits, physiotherapy sessions, tests, length of transplant operation and key treatments and
investigations were collected.
We calculated the cost for HCV patients who had received a transplant (sample size 67).
The average length of time for a liver transplant procedure (from admission to discharge) was 28 days.
We approximated this to 1 month and calculated the yearly cost of a liver transplant as 11 months of
post-transplant care (estimated from the average monthly cost in the first year following transplantation)
plus the month in which the transplant operation took place. We also calculated a cost for the post liver
transplant health state, estimated from the average monthly cost for the last 12 months of post-transplant
care (sample size 40).
The data were also used to estimate a cost for the decompensated cirrhosis and HCC health states.
For this, the average costs of treating patients with decompensated cirrhosis were assumed to be
equivalent to patients considered for a transplant. Resource-use data of patients with HCV during the
‘assessment’ and ‘candidacy’ stages of transplantation were calculated (sample size 56).
Costs were inflated to 2011–12 levels using standard NHS inflation indices.67 Health state costs did not
include the costs associated with antiviral treatment; these were included separately in the model.
Health state costs are listed in Table 36.
Test costs
Costs of imaging modalities were sourced from published Department of Health reference costs.427
Costs of direct and indirect serum markers were obtained from communication with finance departments
based at the Royal Free Hospital. Costs for patented serum markers were sourced directly from
manufacturers and via communication with finance departments based at the Royal Free Hospital.
The cost of a percutaneous liver biopsy (see Chapter 5 for further details on choice of liver biopsy) was
sourced from published literature428 (see Chapter 5). Test costs including sources are listed in Appendix 9.
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Medication costs
For HCV genotype 1 and 4 infection, a cost of 48 weeks of treatment was applied. For HCV genotype 2
and 3 infection, a cost approximate to 24 weeks of treatment was applied (Table 37). Treatment costs
were sourced using the BNF 64419 and a total cost of treatment was calculated according to the
recommended dosage and duration detailed in Table 35.
Utility values
A search was carried out using the MEDLINE database (via Ovid platform, searched 1 December 2012) for
quality of life data for use in the HCV model (see Appendix 2 for search strategy). The search returned 459
papers; seven were retrieved for full review.371,414,432,455,457–459 From these, the most relevant data identified
were found in the published study on the Mild Hepatitis C trial414 as it was from a UK population using the
EQ-5D. As this study was also used to identify data for the mild, moderate and cirrhotic health states in the
HBV model, details regarding the elicitation of utility values for the mild, moderate and compensated cirrhosis
health states are reported in the chapter for HBV (see Chapter 5) and will not be duplicated here.
As for the HBV model, we sourced health-related utility data for the decompensated cirrhosis, HCC, liver
transplant and post liver transplant health states from the CELT study.424 The transplantation study included
patients with a range of conditions that warranted liver transplantation including HCV. HRQoL data were
collected using the EQ-5D.
It was assumed that utility values for the decompensated cirrhosis and HCC health states would be the
same (sample size 56). This was assumed to be equivalent to the average utility value at the time patients
were placed on the waiting list for a transplant.
TABLE 36 Health state costs used in the model (£ 2012)
Health state Annual cost, £ Standard error PSA distribution Source
Mild fibrosis 185 36.39 Gamma Wright et al.414
Moderate fibrosis 959 101.69
Compensated cirrhosis 1521 309.05
Decompensated cirrhosis 38,871 9410.46 Longworth et al.424
Hepatocellular cancer 38,871 9410.46
Liver transplant 69,174 7054.86
Post liver transplant 4356 861.57
Death 0 0 Assumed
TABLE 37 Total annual cost of combination and triple therapy used in model (£ 2012)
Treatment Genotype 1 Genotype 2 and 3 Genotype 4
Combination therapy
Peginterferon alfa-2a and ribavirin 4446 10,411
Peginterferon alfa-2b and ribavirin 5435 10,870
Triple therapy
Peginterferon alfa-2a and ribavirin and telaprevir 32,809
Peginterferon alfa-2b and ribavirin and boceprevir
(treatment naive)
33,270
Peginterferon alfa-2b and ribavirin and boceprevir
(compensated cirrhosis)
41,670
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A utility value for the liver transplant health state was estimated using an area under the curve approach
and the utility values collected at 3, 6 and 12 months post transplantation (sample size 67). A utility
value for the post-transplant health state was estimated using the average utility for patients with HCV
patients collected at 24 months post transplant (sample size 40).
Utility values during treatment and after sustained virological response
Treatment with peginterferon alfa-2a or -2b and ribavirin is associated with a number of adverse effects
such as severe fatigue, depression, irritability, sleeping disorders, skin reactions, dyspnoea, neutropenia,
anaemia, thrombocytopenia and ALT flares and more severe side effects such as seizures, bacterial
infections, autoimmune reactions, interstitial lung disease, a neuroentinitis, bone marrow aplasia or
idiopathic thrombocytopenia.37 To reflect this in the model, we assumed a disutility value that was
applicable during treatment using data identified from the Wright et al.414 study. The authors collected
HRQoL data using the EQ-5D (sample number: 144 patients), using the data from weeks 12 and 24 when
most people were still taking treatment.
It was conservatively assumed that any adverse events associated with boceprevir or telaprevir treatment
(skin rash and exacerbation of anaemia) would have no effect on HRQoL in the base-case analysis.
We tested this assumption in a sensitivity analysis by applying a utility decrement value of 0.05 applicable
during treatment with boceprevir and telaprevir for HCV genotype 1 patients.
This study identified a number of previously published studies460–462 which reported that the HRQoL score
for patients significantly improved after successful treatment with interferon and, therefore, assumed that
therapy for mild HCV may benefit patients for non-hepatological reasons. They measured the improvement
in HRQoL after a successful response to treatment by collecting data using the EQ-5D from 21 patients
with mild fibrosis who had a SVR. As there were insufficient data to estimate an EQ-5D value for patients
in a post-SVR moderate health state, the authors estimated a post-SVR EQ-5D value by substituting the
mean estimated HRQoL for moderate disease as the baseline value into the analysis of covariance
(ANCOVA) model which had been used to estimate the treatment effect for patients with mild disease.
We used the same assumption as Wright et al.414 and allowed for an increased EQ-5D value post SVR.
The study by Wright et al.414 did not report a separate HRQoL value for patients in a cirrhotic health state
receiving treatment and post SVR. For this, we used the same assumption as that used in a study by
Grishchenko et al.,455 who assumed that patients with cirrhosis had the same absolute gain in HRQoL as
patients with mild disease.
Using the identified data, we applied a 0.11 utility decrement from baseline during treatment and a 0.05
utility increment from baseline if they had a SVR after treatment.
We tested the use of differing HRQoL values applicable during antiviral treatment and post SVR by carrying
out a sensitivity analysis where we assumed that HRQoL values did not change from baseline during or
after treatment. Utility values are listed in Table 38.
Disutility from non-invasive liver test and liver biopsy
We have assumed that no NILT has associated adverse events that would impact on HRQoL. However, as
liver biopsy is associated with morbidity and mortality risks and patient discomfort, a measure of adverse
effects resulting from liver biopsy was modelled by applying a utility decrement of 0.2 where applicable.428
As the decrement value was arbitrary, we undertook a number of sensitivity analyses to test the robustness
of the results to changes in the utility decrement.
Estimated long-term costs and quality-adjusted life-years
Table 39 presents the costs and QALYs from the Markov models for each potential diagnostic
testing outcome.
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Analysis
Probabilistic and one-way sensitivity analyses were undertaken. We also conducted threshold analyses
around the assumptions of treatment benefit and the impact of changes to the costs and effectiveness
of treatment.
Robust test accuracy data
In the base-case analysis, all tests were included despite there being limited data available for some
tests. A sensitivity analysis was conducted including only tests where the bivariate model used for the
meta-analysis converged (for 14 NILTs).
Changes to utility values
As mentioned previously, we carried out an analysis where we set utility values constant at baseline utility
values before, during and after treatment.
TABLE 38 Utility values used in analysis of HCV
Health stage Utility value SE PSA distribution Source
Mild fibrosis 0.77 0.035 Beta Wright et al.414
Moderate fibrosis 0.66 0.018
Compensated cirrhosis 0.55 0.032
Decompensated cirrhosis 0.49 0.056 Longworth et al.421
HCC 0.49 0.056
Liver transplant 0.51 0.053
Post liver transplant 0.52 0.061
Death 0 0 Assumed
Mild fibrosis (during treatment) 0.65 0.035 Wright et al.414
Moderate fibrosis (during treatment) 0.55 0.018
Compensated cirrhosis (during treatment) 0.44 0.04 Grishchenko et al.455
Mild fibrosis (SVR, after treatment) 0.82 0.04 Wright et al.414
Moderate fibrosis (SVR, after treatment) 0.71 0.05
Compensated cirrhosis (SVR, after treatment) 0.60 0.04 Grishchenko et al.455
TABLE 39 Estimated long-term costs (£) and QALYs
Diagnostic test outcome Cost (£ 2012 per person) QALY (per person)
True positive 68,667 12.89
True negative 21,812 15.84
False positive 32,318 16.86
False negative 71,818 12.48
Treat all persons 51,374 14.77
Treat no one 55,173 12.47
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We also carried out two other analyses regarding the utility values used; we set the utility values equivalent
to those used in a study by Shepherd et al.392 We also carried out an analysis where we increased the
utility value of all health states by 0.1 to determine if this had any effect on the robustness of the results.
Average disease prevalence
Prevalence within the model is based on studies that may have been carried out largely in tertiary care
centres, and the prevalence of liver fibrosis in this population may be an overestimate. To test the impact
of this, we undertook sensitivity analyses using the minimum prevalence (17%) and the maximum
prevalence (83%) estimated from the meta-analysis of the systematic review data.
Change to progression rates after sustained virological response while in
cirrhotic health state
The base-case analysis assumes that the risk of death of patients who respond successfully to treatment
(experience a SVR) is equivalent to that for the general population. We tested this assumption for patients
in a compensated cirrhosis health state as it has been noted that they may retain a small risk for progressing
to these health states.37,463 We modelled this by allowing patients in the compensated cirrhosis health state
to retain a small risk of decompensated cirrhosis (0.004) and HCC (0.002) after a successful response to
treatment (SVR).464
Lower sustained virological response rate
As mentioned previously, it may be the case that patients in a cirrhotic health state have a lower SVR rate;
to test this assumption, we carried out an analysis where we reduced the SVR rate by 20% (assuming the
same estimate used in the study by Liu et al.438) for patients who received treatment in a cirrhotic
health state.
Change in cost of non-invasive liver tests
We carried out a sensitivity analysis where we changed the cost of the NILTs (we set the watchful waiting
retest cost and all NILT costs within the model to the same cost); for comparison, we assumed an indirect
serum marker test cost (we chose a commonly used test, APRI, as our comparator). By changing the
cost of a NILT (in some cases reducing the test cost significantly, e.g. reducing cost of ELF from £108 to
£4.50) we aimed to determine if changing the test cost (marginal cost) had an impact on the robustness
of the results.
Sensitivity and specificity of retest
Our base-case analysis assumes that the retest (from the meta-analysis of the systematic review data in
the watchful waiting strategy for patients with a negative test result) has perfect sensitivity and specificity.
We tested this assumption by applying the sensitivity and specificity of three commonly used tests: APRI
(estimated sensitivity of 77% and specificity of 81%), Fibrotest (estimated sensitivity of 68% and specificity
of 75%) and Fibroscan (estimated sensitivity of 79% and specificity of 83%).
Choice of tests for second stage of the analysis
For the second stage of the analysis, the two most cost-effective tests when assessed within each specific
test category singly (with and without a defined threshold) were used in the analysis of sequential testing.
To test if changing the method used to choose tests for the second stage of the analysis had an effect
on the overall result, we carried out an analysis where we chose the most effective NILT from within each
NILT category and the least costly NILT from each category.
Change in genotype distribution
We carried out an analysis where we amended the distribution of the population cohort per genotype in
the model to determine if this had an impact on the results (HCV genotype 1 set at 50%, HCV genotype 2
and 3 set at 41% and HCV genotype 4 set at 9%).
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Change to utility values
We also carried out analyses using different utility decrement values to represent the adverse effects from
liver biopsy. The base-case analysis set the utility decrement value to 0.2; in the analyses we set the
utility decrement at 0 and 0.3 to test the impact on the robustness of the results.
Adverse events
Both telaprevir and boceprevir carry a risk of adverse events. We tested the assumption that this would not
have a significant impact on health-related utility by assuming a disutility decrement value of 0.05, which
was applicable to all patients who received triple therapy with peginterferon alfa-2a or -2b, ribavirin and
either telaprevir or boceprevir.
Threshold sensitivity analyses
Treatment benefit for patients who are incorrectly diagnosed
The base-case analysis reflects that HCV patients who are diagnosed incorrectly (‘false positive’) receive
benefit from treatment despite only having mild disease. Treatment benefit in the model is reflected by the
probability of a SVR and patients in a mild health state receive the same treatment benefit (same successful
response rate measured using SVR rate) as patients who are in a moderate or cirrhotic health state.
We tested the robustness of this assumption in a sensitivity analysis by undertaking a threshold sensitivity
analysis where we reduced the SVR rate for patients in a mild health state (F0–1) by decrements of 10%.
Sensitivity analysis on drug costs and sustained virological response rates
We are aware that new drugs are in development for the treatment in people with HCV; for example,
a new protease inhibitor has recently been investigated in phase 3 trials.43,44 With this in mind, we
conducted sensitivity analyses exploring the impact of the costs and effectiveness of treatments of fibrosis
in HCV on the conclusions regarding the cost-effectiveness of the test strategies.
We increased the SVR rate for genotype 1 and 4 HCV infections to reflect the potential efficacy of new
drugs suitable for treatment in HCV. Based on early results from two phase 3 studies,43 we assumed an
increased SVR rate of 90% for genotype 1 HCV infection and genotype 4 patients. No amendments were
made to the SVR rates for genotypes 2 and 3 HCV infections from those in the base-case analysis based
on the results of a published non-inferiority study of the same new treatment.43 We then also increased
the cost of drug treatment assuming an additional £20,000 and £40,000 cost per patient for 12 weeks of
treatment with the new drug (this was added to the existing cost for peginterferon alfa-2a and alfa-2b and
ribavirin used in the base-case analysis). We did not allow for different SVR rates per health state.
Results
Base case
At a standard UK threshold range, the cost-effective strategy is to adopt a ‘treat all’ approach with an
ICER of £9204. For values below this, a patented serum maker, Fibrospect (combined cut-off), where
indeterminate responses are retested with an imaging modality, Fibroscan, is the most cost-effective option.
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The CEAF (Figure 7) shows that the probability of ‘treat all’ having the highest expected net benefit,
given a cost-effectiveness threshold value of £20,000, is 45%. For lower threshold ranges, the CEAF also
shows that there is considerable uncertainty around which test has the highest expected net benefit.
For cost-effectiveness thresholds lower than £9200 [using Fibrospect (with a combined cut-off) where the
inconclusive responses are retested with Fibroscan] is most likely to have the highest expected net benefit;
however, there is considerable uncertainty around this result and the probability of it being optimal is
< 4%. Liver biopsy was a comparator for both stages of the analysis; however, this testing option
is dominated by other less costly but more effective options.
Appendix 10 displays the CEAC for the overall base-case analysis. For reasons of clarity, only those
strategies that have a ≥ 5% or greater probability of being optimal have been included. The CEAC
demonstrates that, given a cost-effectiveness threshold value of £20,000, the probability that the ‘treat all’
strategy is cost-effective compared with the other testing strategies is 0.449. This indicates that, given the
data, there is a 45% chance that the additional cost of the ‘treat all’ strategy, compared with all other test
strategies, is at or below £20,000 per life-year gained. The CEAC also displays that liver biopsy has a high
probability of being cost-effective for thresholds values below approximately £3500. This does not translate
into the CEAF due to skewed data on the costs of the tests and a high level of uncertainty on differences
in costs between the alternative test strategies. Often, the testing option with a high probability of being
cost-effective may not be the optimal choice, which is what the CEAF represents (Fenwick et al.).69
Table 40 presents incremental results for the first stage of the analysis and Table 41 presents incremental
results for the second stage where a number of combined tests are compared using a number of different
sequential testing strategies (see Chapter 3 for details of testing strategies, S1, S2, S3 and S4). A
scatterplot illustrating the position of each testing strategy on the cost-effectiveness acceptability curve
compared with the testing strategy ‘treat no one’ can be found in Appendix 12.
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TABLE 40 Base-case analysis (first stage where all tests are compared singly)
Test strategy Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Treat none 54,878 12.45 – – Dominated
Liver biopsy 48,710 14.03 – – Dominated
Pohl 47,727 14.04 – – Dominated
Fibroindex (high cut-off) 47,769 14.08 – – Dominated
Forns Index (high cut-off) 47,426 14.12 – – Dominated
Hepascore (high cut-off) 47,897 14.13 – – Dominated
FPI (high cut-off) 47,335 14.14 – – Dominated
APRI (high cut-off) 47,525 14.14 – – Dominated
FIB-4 47,900 14.15 – – Dominated
US 48,090 14.17 – – Dominated
ELF (high cut-off) 47,846 14.17 – – Dominated
Hyaluronic acid (high cut-off) 48,969 14.18 – – Dominated
PLT 47,742 14.18 – – Dominated
US SAPI (high cut-off) 47,073 14.18 – – Dominated
YKL-40 (high cut-off) 48,536 14.19 – – Dominated
Fibrotest (high cut-off) 47,896 14.22 – – Dominated
PIIINP/MMP-1 index 47,724 14.24 – – Dominated
King’s (low cut-off) 47,743 14.24 – – Dominated
King’s (high cut-off) 47,963 14.25 – – Dominated
Fibrosis Index 47,423 14.25 – – Dominated
ARFI 47,126 14.25 – – Dominated
GUCI 47,791 14.25 – – Dominated
AST–ALT 48,629 14.26 – – Dominated
Age–Platelet Index 47,847 14.26 – – Dominated
MR 47,101 14.26 – – Dominated
EOB-MRI 48,054 14.26 – – Dominated
MR elastography 46,896 14.27 – – –
FIB-4 (high cut-off) 48,158 14.27 – – Dominated
CEUS 47,215 14.28 – – Extendedly dominated
APRI 47,522 14.28 – – Extendedly dominated
Fibroscan 47,449 14.28 – – Extendedly dominated
US SAPI 47,763 14.29 – – Extendedly dominated
DW-MRI 47,890 14.30 – – Dominated
Fibrotest 48,327 14.30 – – Dominated
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TABLE 40 Base-case analysis (first stage where all tests are compared singly) (continued )
Test strategy Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Hyaluronic acid 48,013 14.30 – – Dominated
PIINP 47,921 14.30 – – Dominated
Hepascore 48,189 14.31 – – Dominated
Fibrometer 48,104 14.32 – – Dominated
MP3 48,008 14.33 – – Dominated
Fibrospect 48,210 14.33 – – Dominated
Type IV collagen 47,888 14.34 – – Dominated
Hyaluronic acid low 48,824 14.34 – – Dominated
King’s 47,990 14.34 – – Dominated
ELF 48,232 14.34 – – Dominated
CT 48,727 14.35 – – Dominated
FibroQ 48,372 14.35 – – Dominated
PLT–Spleen 47,803 14.35 – – Extendedly dominated
Forns index 50,555 14.37 – – Dominated
Lok’s index 49,077 14.38 – – Dominated
APRI (low cut-off) 48,713 14.40 – – Extendedly dominated
CDS 49,429 14.40 – – Dominated
Fibroindex (low cut-off) 48,872 14.40 – – Extendedly dominated
ELF (low cut-off) 49,041 14.44 – – Extendedly dominated
FPI (low cut-off) 49,232 14.47 – – Extendedly dominated
FIB-4 (low cut-off) 49,407 14.48 – – Extendedly dominated
Forns index (low cut-off) 49,571 14.49 – – Dominated
Fibrotest (low cut-off) 49,534 14.49 – – Extendedly dominated
YKL-40 (low cut-off) 50,156 14.50 – – Dominated
US SAPI (low cut-off) 49,561 14.51 – – Extendedly dominated
Treat all 51,241 14.73 4,345 0.46 9,351
CDS, Cirrhosis Discriminant Score; CEUS, contrast-enhanced ultrasound; DW-MRI, diffusion-weighted magnetic resonance
imaging; EOB-MRI, (gadolinium-ethoxybenzyl-diethylenetriamine-penta-acetic-acid) enhanced magnetic resonance imaging;
FPI, Fibrosis Probability Index; MMP-1, matrix metalloproteinase-1; MP3, metalloproteinase-3; PLT, platelet; US, ultrasound.
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TABLE 41 Base-case analysis (second stage of analysis)
Test strategy Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Treat none 54,878 12.45 – – Dominated
Liver biopsy 48,710 14.03 – – Dominated
(S3) Type IV collagen and PLT–Spleen 47,099 14.16 – – Dominated
(S3) King’s and PLT–Spleen 47,139 14.16 – – Dominated
(S3) King’s and type IV collagen 47,113 14.16 – – Dominated
Hepascore (combined cut-off)
and Fibroscan
47,675 14.19 – – Dominated
(S3) FPI (low cut-off) and type
IV collagen
47,417 14.21 – – Dominated
(S3) FPI (low cut-off) and PLT–Spleen 47,461 14.21 – – Dominated
(S2) King’s and type IV collagen 47,001 14.21 – – Dominated
(S2) King’s and PLT–Spleen 46,999 14.21 – – Dominated
Fibroindex (combined cut-off)
and Fibroscan
47,368 14.21 – – Dominated
(S3) Fibrotest (low cut-off)
and PLT–Spleen
47,548 14.21 – – Dominated
(S4) King’s and type IV collagen 46,978 14.21 – – Dominated
(S4) King’s and PLT–Spleen 46,965 14.22 – – Dominated
(S3) King’s and Fibrotest (low cut-off) 47,579 14.22 – – Dominated
(S3) Type IV collagen and US SAPI
(low cut-off)
47,516 14.22 – – Dominated
(S4) Type IV collagen and PLT–Spleen 46,911 14.22 – – –
(S2) Type IV collagen and PLT–Spleen 46,994 14.22 – – Dominated
(S3) King’s and US SAPI (low cut-off) 47,606 14.22 – – Dominated
Leroy 47,248 14.23 – – Dominated
(S4) FPI (low cut-off) and type
IV collagen
47,328 14.24 – – Dominated
(S2) FPI (low cut-off) and type
IV collagen
47,328 14.24 – – Dominated
(S2) FPI (low cut-off) and PLT–Spleen 47,359 14.24 – – Dominated
(S4) FPI (low cut-off) and PLT–Spleen 47,347 14.24 – – Dominated
(S2) Fibrotest (low cut-off)
and PLT–Spleen
47,519 14.24 – – Dominated
(S4) Fibrotest (low cut-off)
and PLT–Spleen
47,446 14.24 – – Dominated
(S4) King’s and Fibrotest (low cut-off) 47,521 14.25 – – Dominated
(S4) Type IV collagen and US SAPI
(low cut-off)
47,427 14.25 – – Dominated
Forns index (combined cut-off)
and Fibroscan
47,233 14.25 – – Dominated
(S4) King’s and US SAPI (low cut-off) 47,525 14.25 – – Dominated
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TABLE 41 Base-case analysis (second stage of analysis) (continued )
Test strategy Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
(S1) Type IV collagen 48,155 14.25 – – Dominated
(S1) PLT–Spleen 48,233 14.26 – – Dominated
(S1) King’s 48,375 14.26 – – Dominated
Fibropaca 47,545 14.26 – – Dominated
APRI (combined cut-off) and Fibroscan 47,355 14.26 – – Dominated
(S2) King’s and Fibrotest (low cut-off) 47,467 14.26 – – Dominated
Fibrospect (combined cut-off)
and Fibroscan
46,954 14.27 43.55 0.05 928
(S2) King’s and US SAPI (low cut-off) 47,466 14.27 – – Dominated
Bordeaux 47,026 14.27 – – Extendedly dominated
ELF (combined cut-off) and Fibroscan 47,533 14.28 – – Dominated
(S2) Type IV collagen and US SAPI
(low cut-off)
47,411 14.28 – – Extendedly dominated
Hyaluronic acid and Fibroscan 47,770 14.29 – – Dominated
YKL-40 (combined cut-off)
and Fibroscan
48,251 14.31 – – Dominated
FIB-4 (combined cut-off) and Fibroscan 47,739 14.31 – – Dominated
Fibrotest (combined cut-off)
and Fibroscan
47,748 14.31 – – Extendedly dominated
SAFE 47,985 14.33 – – Dominated
Type IV collagen 47,882 14.34 – – Dominated
King’s 47,976 14.34 – – Dominated
PLT–Spleen 47,874 14.35 – – Extendedly dominated
(S1) FPI (low cut-off) 49,467 14.42 – – Dominated
(S1) Fibrotest (low cut-off) 49,699 14.44 – – Dominated
(S1) US SAPI (low cut-off) 49,746 14.46 – – Dominated
FPI (low cut-off) 49,218 14.47 – – Extendedly dominated
Fibrotest (low cut-off) 49,536 14.49 – – Dominated
US SAPI (low cut-off) 49,549 14.51 – – Extendedly dominated
Treat all 51,241 14.73 4,287 0.47 9204
FPI, Fibrosis Probability Index; PLT, platelet; S1, strategy 1; S2, strategy 2; S3, strategy 3; S4, strategy 4; US, ultrasound.
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Sensitivity analyses
The base-case analysis result remained robust to the majority of the sensitivity analyses. One of the
analyses, where we held the utility values constant at baseline values (values did not differ before, during
or post treatment), did increase the ICER for the ‘treat all’ scenario to £16,727; however, assuming a
cost-effectiveness threshold of £20,000, this would still be an acceptable ICER. All other results returned
a similar ICER value to the base-case analysis.
Appendix 11 contains the short tables of incremental analysis results for all sensitivity analyses (excluding
‘dominated’ and ‘extendedly dominated’ test strategies; full tables are available on request).
Threshold sensitivity analysis
Treatment benefit varied for incorrectly diagnosed patients in mild health state.
Varying the effectiveness of treatment in patients with mild fibrosis (F0–1) affects the results of the
analysis. Assuming that no patients in a mild health state (F0–1) receive benefit from treatment returns a
result where the ‘treat all’ strategy is dominated (i.e. it is more costly and less effective than other
strategies). We then reduced the effectiveness of the treatment in patients with mild fibrosis (modelled
using the SVR rate) by decrements of 10%.
Reducing the SVR rates in the model by 90%, 80% and 70% returned a result where ‘treat all’ remained
dominated by other strategies. When we reduced the SVR rate by 60%, the ‘treat all’ strategy was the
most effective strategy but with an ICER of £723,503. The most cost-effective testing strategy to use for
these stages was to test with an imaging modality (MR elastography).
When we reduced the SVR rate by 50%, ‘treat all’ became the most effective strategy but not the most
cost-effective with an ICER of £92,995; testing with MR elastography was the most cost-effective strategy.
Given a cost-effectiveness threshold of £20,000, the ‘treat all’ strategy is no longer cost-effective when the
SVR rate is reduced by approximately 23% or more. Figure 8 plots the decreasing ICER value for the ‘treat
all’ strategy relative to the probability of an increased successful response rate to treatment (SVR rate) for
patients in a mild health state.
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FIGURE 8 Illustration of the reduction in the ‘treat all’ ICER when the SVR rate for F0–1 patients is varied.
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Increased effectiveness of cost and antiviral treatment
Changing both the SVR rate and increasing the cost by £20,000 (to reflect the new drug treatment) does
not change the base-case results, with ‘treat all’ remaining the most cost-effective strategy with an ICER
of £10,009.
Increasing the additional cost by £40,000 (with increased SVR rates) does change the results where the
ICER for treat all is now £21,174, which would be not cost-effective given a £20,000 threshold. The most
cost-effective option to adopt would be MR elastography, with an ICER of £9189.
Illustration of the reduction in the ‘treat all’ ICER when the SVR rate for F0–1 patients is varied.
Discussion
The analysis found that the most cost-effective option to adopt is one where all patients are treated
irrespective of fibrosis stage. This result held when compared with individual tests and strategies
incorporating combinations of multiple tests, and for all cost-effectiveness threshold ranges above
approximately £10,000. It was also robust to most of the amendments in the sensitivity analysis. When we
compared all tests singly, all other tests were either dominated or extendedly dominated, except for MR
elastography which, for these very low cost-effective threshold values, was the most cost-effective strategy.
National Institute for Health and Care Excellence guidance for peginterferon alfa and ribavirin treatment
in patients with HCV recommends two options for treatment in patients with mild chronic HCV: treat
immediately or adopt a watchful waiting approach. The guidelines noted that initiating treatment at an
earlier stage bypasses the need for an invasive liver biopsy tests. However, with the introduction of NILTs
such as MR elastography and Fibroscan, less invasive testing to stage fibrosis is possible.443
A key driver in the cost-effectiveness results is that patients with milder degrees of fibrosis (e.g. F0–1) gain
benefit from treatment, albeit at an increased cost. Therefore, the ‘treat all’ strategy and the tests with
highest sensitivity tend to have better results. The assumption that the efficacy of antiviral therapy is similar
for patients with mild HCV compared with those with histologically more advanced HCV457,465 was tested in
a threshold sensitivity analysis which found that for the ‘treat all’ strategy to cease to be cost-effective, the
SVR rate following treatment for patients with mild fibrosis would need to be reduced by 23%. Once we
reduced the SVR rate by 23%, MR elastography became the most cost-effective strategy; this was the NILT
with the highest sensitivity and specificity (94% and 92%, respectively).
A 2006 study by Grieve et al.457 analysed if it was cost-effective to treat patients at a mild stage compared
with waiting till patients progressed to a moderate disease stage; they found that it was generally more
effective to provide antiviral treatment at a mild rather than a moderate disease stage and this strategy
would gain improved outcomes (QALYs) rather than treating at a later stage.
However, treating patients with mild chronic HCV (who may not necessarily require treatment) exposes this
patient cohort to the risk of side effects associated with peginterferon alfa and the direct antiviral agents,
boceprevir and telaprevir. Newer drugs may provide more effective treatment with fewer side effects,
so waiting to treat this patient cohort may be a better option.466 If we were to adopt this strategy,
then testing all patients with MR elastography would be the most cost-effective option (when using a
NILT singly).
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New antiviral treatments for HCV are currently undergoing trials which indicate that these drugs may
be more effective in genotype 1 and 4 HCV infections than current triple therapy.43 However, the
cost-effectiveness of such drugs will depend on the price of the new drug and robust data on
effectiveness. Currently evidence is promising but limited to uncontrolled studies and a non-inferiority
study demonstrating equivalence. If the SVR rates observed in the studies are borne out in practice,
then the ‘treat all’ strategy could still be cost-effective if the overall impact on treatment costs is an
increase of £20,000, but not for an increase of £40,000.
When all tests were compared singly, the tests with low threshold values for classification of fibrosis
tended to have relatively higher health outcomes than tests without threshold or with high cut-off
thresholds. These tests tended to have high sensitivity values and low specificity values; when we
conducted the threshold sensitivity analysis around treatment benefit, NILTs with lower cut-off thresholds
no longer yielded the highest health outcomes. Rather, tests with both a high sensitivity and specificity
such as MR elastography had the higher QALY gain, indicating that when patients in a mild health state
are treated, tests which are more likely to identify more persons as positive (i.e. treat more persons) will be
more effective.
As some of the tests analysed have few studies on which their diagnostic accuracy is based, this means
that some tests may have results which overestimate their effectiveness. Reducing the number of tests to
those where only the bivariate model converged did not change the overall result; however, only 14 NILTs
were compared at this stage, illustrating that for the majority of tests the results of the meta-analysis may
not be very robust. When we removed ‘treat all’ from this analysis, Fibroscan was the most cost-effective
testing option to use.
We have considered the SVR a good surrogate marker of treatment efficacy. This is similar to current NICE
guidance for boceprevir and telaprevir; however, our results are applicable only if the SVR rate is a good
surrogate marker and may change if other methods of determining treatment efficacy are developed.
The results indicate that treating all patients is cost-effective; however, this result is sensitive to changes in
treatment response rates for those with mild fibrosis.
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Chapter 7 Cost-effectiveness analysis: alcoholic
liver disease
This chapter details the analysis approach for ALD and includes details of the model structure, inputs andresults. The population considered for analysis were people with ALD who were suspected of having
developed alcoholic steatohepatitis (ASH) with cirrhosis.
Background
Five NILTs were identified in the systematic review for staging liver fibrosis and cirrhosis in ALD: APRI with a
(high cut-off) diagnostic threshold, Fibrotest (high cut-off), Fibrotest (low cut-off), PGAA and Fibroscan.
Current clinical management of alcoholic cirrhosis focuses on alcohol abstinence, aggressive nutritional
therapy rich in calories and proteins, and primary and secondary prophylaxis of cirrhosis complications.35
If required and available, addiction specialists, motivational therapy and anticraving drugs are
also recommended.35
The European Association for the Study of the Liver (EASL) guidelines note that patients with ASH and
cirrhosis are at risk of developing clinical decompensation, liver failure and HCC. However, prolonged
abstinence can reverse previously decompensated cirrhosis to a compensated state. As the incidence of
HCC among patients with alcoholic cirrhosis ranges from 7% to 16% after 5 years, the guidelines
recommend that screening for HCC should be performed with ultrasound every 6 months, as
recommended for any patient with cirrhosis. Screening for alcohol-induced damage in other organs
(heart, kidneys) should also take place.
The guidelines do note that specific therapies have been tested in patients with alcoholic cirrhosis
(including S-adenosyl-l-methionine, anabolic-androgenic steroids); however, none has any consistent
beneficial effects.35
Liver transplantation is recommended for patients who remain abstinent for a 6-month period before
being added to the waiting list for liver transplantation.35 The 6-month period is recommended to capture
those patients who may recover from their liver disease and also to identify the subset of patients who
may remain abstinent after a liver transplant. NICE guidance recommends that patients who still have
decompensated liver disease after 3 months of best management and abstinence from alcohol and who
are suitable candidates for liver transplantation should be referred to assessment for liver transplantation
and considered this to be a cost-effective treatment option.467
The EASL and NICE guidelines do not recommend a specific treatment applicable after diagnosis with
fibrosis or cirrhosis; rather, they recommend that, regardless of the severity, abstinence and early
management of alcohol abuse or dependence is warranted in all patients with ASH. Therefore, we were
unable to use the same approach for a cost-effectiveness analysis as for HBV and HCV. Instead, we focus
on the health economic impact of diagnosis as a result of abstinence, assuming that abstinence may
increase as a result of diagnosis of fibrosis.
Literature review results
We identified a recent systematic review and economic analysis of non-invasive diagnostic assessment tools
for the detection of liver fibrosis in patients with suspected alcohol-related liver disease;428 the non-invasive
tests analysed in this report were ELF, Fibrotest, Fibroscan (TE) and Fibromax.
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The tests considered in the analysis by Stevenson et al.428 differed from the tests found during our
literature review. However, this study did not find any data on diagnostic accuracy for one of the NILTs,
Fibromax. With regard to the diagnostic accuracy of the ELF test, the authors located one study that
looked at the European liver fibrosis test (ELF and age)468 which had reported findings for diagnosis of
moderate to severe fibrosis; however, the diagnostic accuracy for identifying cirrhosis was not reported.
The authors concluded that the data with regard to the diagnostic accuracy of the ELF test in relation to
cirrhosis are not robust.
The review was considered highly relevant to our decision problem and population of interest. We carried
out a literature search for cost-effectiveness studies of non-invasive tests in patients with ALD using the
search strategy detailed in the Health Technology Asessment (HTA) report by Stevenson et al.428 We
updated the search to include the five NILTs analysed for ALD. We conducted the search using the
MEDLINE database (via Ovid platform, searched 25 June 2013, all years searched). The search strategy is
detailed in Appendix 2.
The search located 264 papers; titles were reviewed and the only relevant study found was the economic
analysis detailed in the HTA report by Stevenson et al.428
The report by Stevenson et al.428 estimated the incremental costs and incremental QALYs for 10 strategies
which were based on using a NILT alone to confirm cirrhosis or a combination of a NILT and liver biopsy.
The authors assumed that all patients in the model would receive lifestyle and abstinence advice. If the test
outcome was positive, the treatment strategy would be expanded to include monitoring for HCC, hepatic
encephalopathy and oesophageal varices.
Cost-effectiveness analysis
The analysis conducted by Stevenson et al.428 was considered relevant, as they also considered the use of
non-invasive diagnostic testing in patients with ALD. They conducted their analysis from a UK perspective
and their considered population was deemed to be similar (patients with ALD suspected of having
cirrhosis). The model structure employed in this study seemed appropriate given current clinical practice
and the data inputs for costs and QALYs were disease specific (based on data for ALD).
We replicated the model to include the tests relevant to our decision problem and also conducted some
sensitivity analyses where we assessed the impact of alternative inputs and adjustments to the model
structure. To replicate the model, we constructed a decision tree model to assess the cost-effectiveness of
the non-invasive tests in patients with ALD.
Decision tree model
The following section (section 1) provides a brief description of the Stevenson et al.428 model, which we
replicated. This includes a summary of the inputs which we also employed in our model. We then detail
(see section 2) the changes we made to the model for our analysis (updated inputs, different non-invasive
tests and diagnostic accuracy).
Section 1: model structure
The relevant patient population to be assessed with either a NILT or liver biopsy would be those patients
suspected of having liver cirrhosis (F4).
The care pathway reflected in the model is that a positive test result (true positive or false positive)
indicated that the patient would receive monitoring for HCC, varices, ascites and hepatic encephalopathy;
lifestyle advice would also be given. Given a negative test result (true negative or false negative), the
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patient would receive lifestyle advice only, including the recommendation to become abstinent or to
reduce alcohol consumption.
Abstinence rates following diagnosis with liver biopsy
Only one study had been identified regarding abstinence rates following diagnosis, which was a small
sample (n= 96) and had only been published in abstract form (we conducted an updated search on
26 June 2013 and were unable to find a published paper for the study). This study reported that after
diagnosis with liver biopsy, 31% of those with a negative test result for cirrhosis became abstinent,
whereas 62% of those with a positive test result for cirrhosis became abstinent. No specific data were
found on abstinence rates following a NILT.
Probability of developing cirrhosis following diagnosis
There is a probability that patients who continue to drink after diagnosis may develop cirrhosis (false
positive and true negative patients). This was set at 20% following clinical advice.
Quality-adjusted life-years
Quality-adjusted life-year estimates were sourced from a HTA report on HCC screening by Thompson Coon
et al.469 The QALY value reported in the Thompson Coon et al. study for ALD patients with cirrhosis who
undergo annual serum α-fetoprotein with 6-monthly ultrasound scans was used as an estimate for patients
who test true positive and stop drinking. For true-positive patients who continue to drink, QALY value was
based on survival rates for cirrhotic patients who continued to drink derived from a study by Verrill et al.470
For true-negative patients who abstain from drinking, the QALY value was estimated using the average
age from the study by Thompson Coon et al.469 (53 years) and EQ-5D population norms (assuming that
this population would live for a further 20 years). In the absence of further data, it was assumed that the
QALY for false positives who abstain from drinking would be equivalent to that of true negative patients
who abstain. For false-positive patients who continue to drink, the study conservatively assumed the
same QALY; however, it was assumed that the QALY for the proportion of false-negative patients and
true-negative patients who continue to drink and subsequently develop cirrhosis would be the same as
that for true positives who continue to drink.
A QALY value for false-negative patients who abstain from drinking was sourced from the Thompson
Coon et al.469 study. For false-negative patients who continue to drink, the QALY value was set at 40% of
the value of false-negative patients who abstain.
Estimates (where applicable) were adjusted for differing survival rates (abstainers vs. non abstainers) and
for oesophageal bleeds. QALY estimates are detailed in Table 42.
TABLE 42 Quality-adjusted life-year estimates used in model
QALY end points QALY
TP compensated cirrhosis (abstain drinking) 9.679
TP compensated cirrhosis (continue drinking) 4.399
FP compensated cirrhosis (abstain drinking) 11.066
FP compensated cirrhosis (continue drinking) 11.066
TN compensated cirrhosis (abstain drinking) 11.066
TN compensated cirrhosis (continue drinking) 11.066
FN compensated cirrhosis (abstain drinking) 9.359
FN compensated cirrhosis (continue drinking) 3.744
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
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Adverse events and mortality risk
The risk for adverse events (0.72%) and mortality (0.09%) associated with liver biopsy was estimated
following a systematic review.
Liver biopsy adverse events costs and quality-adjusted life-years
A cost of £1000 (reflect hospital stay) and a QALY decrement of 0.2 associated with a serious adverse
effect resulting from liver biopsy applied in the model.
Section 2: amendments to model
Test strategies assessed
We analysed 10 potential testing strategies incorporating the applicable NILTs. The strategies analysed the
use of all tests either alone (biopsy or a NILT) or in combination. We also included a comparator where
all patients receive treatment for cirrhosis (HCC screening) without testing (similar to ‘treat all’ strategies
from the HBV and HCV models).
1. Biopsy all patients.
2. Test all patients with APRI high cut-off and biopsy those in whom cirrhosis is indicated.
3. Test all patients with Fibrotest high cut-off and biopsy those in whom cirrhosis is indicated.
4. Test all patients with Fibrotest low cut-off and biopsy those in whom cirrhosis is indicated.
5. Test all patients with PGAA and biopsy those in whom cirrhosis is indicated.
6. Test all patients with Fibroscan and biopsy those in whom cirrhosis is indicated.
7. Use APRI high cut-off and assume result is definite.
8. Use Fibrotest high cut-off and assume result is definite.
9. Use Fibrotest low cut-off and assume result is definite.
10. Use PGAA and assume result is definite.
11. Use Fibroscan and assume result is definite.
12. Diagnose all patients as having cirrhosis.
Abstinence rates following diagnosis with a non-invasive liver test
As abstinence rates are based on clinical practice and experience, it is plausible to assume that biopsy as
an invasive procedure which may include hospitalisation and the risk of side effects such as fatal bleeding
may serve as a larger warning for patients (patients may be more likely to comply after a positive biopsy
result than after a positive result with a NILT). So, we assumed a lower rate of abstinence for patients who
were tested with a NILT. In the base case, we assumed the rate for abstinence after diagnosis with a NILT
would be 10% lower than the abstinence rates after biopsy. As the abstinence figures after a NILT are not
known with certainty and these figures may potentially have a large impact on the decision tree outcomes,
we undertook a number of sensitivity analyses where we decreased and increased the abstinence values
applicable after diagnosis with a NILT.
The EASL position paper for ALD55 notes that 40% of patients with ALD who have already developed
fibrosis and continue to drink will develop cirrhosis. We received clinical advice on this and in the general
population; the consensus is that 10–30% of patients will develop cirrhosis if they continue to drink.
However, as some persons may not develop fibrosis irrespective of drinking patterns (as developing fibrosis
is genetically determined), the figure may be slightly higher (40%) in those who have developed some
degree of fibrosis, making them more prone to developing cirrhosis. We used the base-case value of 20%
in the main analysis and conducted sensitivity analyses around this parameter.
Costs
We inflated the costs used in the study by Stevenson et al.428 from 2008–9 to 2012 prices using NHS
inflation indices. The costs used in the decision tree are displayed in Table 43.
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The costs had been sourced from a HTA report which looked at the costs associated with screening
persons with ALD for HCC.469 The authors also used the costs for mild and moderate fibrosis health states
for HCV based on the mild HCV trial414 described in Chapter 6 to modify the costs of true-positive
patients progressing to a more severe state (decompensated cirrhosis) if they continued to drink and for
false-positive patients who abstained from further drinking. Estimates for the true-negative end points
were assumed based on clinical advice. The costs of monitoring and treatment of oesophageal bleeding
and the cost of detecting a hepatic encephalopathy were included.
Estimation of probabilities of a non-invasive liver test returning a
true-positive, false-positive, true-negative or false-negative result
The average prevalence of disease (defined as METAVIR score of F4) was taken from the average
prevalence reported in papers included in the meta-analysis (see Chapter 4). We used the sensitivity and
specificity estimates for each NILT (see Chapter 4 for estimates) and the average prevalence estimate
to calculate the probability of each test returning a true-positive, false-positive, true-negative and
false-negative result (see Appendix 7).
Test costs
Costs for APRI and PGAA indirect serum markers were obtained from communication with finance
departments based at the Royal Free Hospital. Costs for patented serum markers (Fibrotest) were sourced
directly from manufacturers and via communication with finance departments based at the Royal Free
Hospital. A test cost for Fibroscan was sourced as per clinical advice; we used the 2011–12 Department of
Health reference costs for an ultrasound with duration of < 20 minutes. The cost of a percutaneous liver
biopsy (see Chapter 5 for further details on choice of liver biopsy) was sourced from published literature428
(see Chapter 5). Test costs including sources are listed in Appendix 9.
Analysis
A PSA was undertaken and we conducted an incremental analysis of the results. A CEAC and CEAF were
constructed. We also carried out univariate sensitivity analyses and conducted two analyses where we
amended the structure of the ALD model. A scatterplot illustrating the position of each testing strategy on
the cost-effectiveness acceptability curve compared with the least costly testing strategy can be found
in Appendix 12.
TABLE 43 Costs of decision tree end points (includes costs of electroencephalograms, and the costs and QALY
implications of screening for varices, providing prophylaxis treatment where appropriate and treating
variceal bleeding)
End point decision tree costs 2012 Cost, £
True positive compensated cirrhosis (abstain drinking) 32,080
True positive compensated cirrhosis (continue drinking) 42,239
False positive compensated cirrhosis (abstain drinking) 26,916
False positive compensated cirrhosis (continue drinking) 26,916
True negative compensated cirrhosis (abstain drinking) 1070
True negative compensated cirrhosis (continue drinking) 1070
False negative compensated cirrhosis (abstain drinking) 27,928
False negative compensated cirrhosis (continue drinking) 38,628
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Sensitivity analyses
Amendments to model inputs
Abstinence rates
We amended the abstinence rates assumed in the model following diagnoses with a NILT. We set the rates
equivalent to those for liver biopsy and then increased the rates in increments of 10% to determine when
the base-case result changed.
Probability of developing cirrhosis
We set the rate to five different values (10%, 30%, 40%, 50% and 60%) to test the impact on results. The
rates chosen reflected the fact that we do not know the exact fibrosis level of patients who test true negative
or false positive, and so this range allows us to test the impact of a change in this parameter on results.
Mortality rates and adverse events
We varied these in the model using a range of lower and upper estimates.
Amendments to model structure
Additional health states
We conducted an analysis where we allowed for progression to HCC and subsequent liver transplant.
This is not included as an option in the Stevenson et al.428 model as they argued that current evidence shows
that it is of borderline cost-effectiveness and would not have an impact on the cost-effectiveness of a NILT.
However, as the NILT may affect the care pathway (including decision to continue drinking which may
indicate further progression to more severe health states), and as ALD is one of the main reasons for liver
transplantation in the UK, we included liver transplant as an option in the care pathway. Furthermore, in the
CELT study of transplantation424 it was found that the larger incremental cost-per-QALY ratio for ALD patients
was in part due to a larger proportion of ALD patients being considered unsuitable for transplantation after
undergoing the assessment process. Since this study was conducted, clear guidelines have been agreed by the
six liver transplant centres within the UK and endorsed by the UK Liver Advisory Group to include careful
assessment of psychosocial and substance use factors for patients with a diagnosis of ALD.471
Cost and QALY estimates were sourced from the CELT study.424 Upon clinical advice, we set the estimate
for the percentage of patients with ALD who have a liver transplant to 4%, to reflect the number of
patients with alcoholic cirrhosis who may potentially develop a tumour while abstinent.
Different starting population-advanced fibrosis (≥ F3)
An additional analysis was undertaken where we used a different section of the data as our starting
population cohort: our base-case population cohort consists of patients who are suspected of having
cirrhosis; the sensitivity analysis analysed the impact of substituting different data, representing patients
who are suspected of having advanced fibrosis (F3), from the meta-analysis.
Results
Base-case results imply that the most cost-effective strategy is to use liver biopsy only to diagnose cirrhosis in
patients with ALD, with an ICER of £822 (Table 44). The strategy producing the highest QALY gain
is where all patients suspected of having cirrhosis receive monitoring; however, this is not the most
cost-effective with an ICER of £70,861, which is above the standard UK cost-effectiveness threshold range.66
We constructed a CEAC (see Appendix 10) and CEAF (Figure 9). The CEAF shows that strategy 2 (liver
biopsy) has the highest probability of being the optimal choice (highest expected net benefit) for threshold
values of £822 and above.
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TABLE 44 Alcoholic liver disease incremental analysis: all strategies compared
Strategy Tests Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Strategy 2 APRI (high cut-off) and liver biopsy 17,415 8.79 – – –
Strategy 7 APRI (high cut-off) 22,463 8.87 – – Dominated
Strategy 10 PGAA 19,061 8.98 – – Dominated
Strategy 11 Fibroscan 20,009 9.02 – – Dominated
Strategy 8 Fibrotest (high cut-off) 19,504 9.03 – – Dominated
Strategy 5 PGAA and liver biopsy 17,613 9.07 198 0.28 701
Strategy 9 Fibrotest (low cut-off) 24,671 9.13 – – Dominated
Strategy 6 Fibroscan and liver biopsy 17,702 9.14 – – Extendedly
dominated
Strategy 3 Fibrotest (high cut-off) and
liver biopsy
17,724 9.17 – – Extendedly
dominated
Strategy 4 Fibrotest (low cut-off) and
liver biopsy
17,801 9.26 – – Extendedly
dominated
Strategy 1 Liver biopsy 17,812 9.31 199 0.24 822
Strategy 12 All patients treated as having
cirrhosis (receive HCC screening)
31,004 9.50 13,193 0.19 70,861
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FIGURE 9 Cost-effectiveness acceptability frontier for ALD.
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The CEAC presented in Appendix 10 shows that strategy 1, liver biopsy, has the highest probability of
being cost-effective (92%) given a cost-effectiveness threshold of £20,000 and this probability falls as the
cost-effectiveness threshold increases (for clarity of illustration, only strategies which have a ≥ 10%
probability of being the optimal strategy are shown in the CEAC).
Sensitivity analysis results
Univariate sensitivity analyses
A number of one-way sensitivity analyses were conducted around parameters in the model for which the
data were assumed or advised by clinical opinion (abstinence rates, probability of developing cirrhosis if
patient continues to drink). Table 45 lists the ranges over which the values were varied and whether or not
this had any impact on the base-case result.
Change in abstinence rate following diagnosis with a non-invasive liver test
(diagnosis of cirrhosis and no cirrhosis)
The base-case values used in the model for abstinence rates after diagnosis with a NILT were 52%
following a diagnosis of cirrhosis and 31% following a diagnosis of no cirrhosis. We conducted a number
of analyses varying these rates (Table 46).
When the abstinence rates after diagnosis with a NILT were set equivalent to the abstinence rates after a
liver biopsy (increase of 10%), the most cost-effective testing option was strategy 4, a combination of
Fibrotest (low cut-off) as an initial test and liver biopsy as a second test to confirm positive diagnoses, with
an ICER of £6366.
However, when we increased the abstinence rates following diagnosis with a NILT by 15% and 20%, this
impacted the results where Fibrotest (high cut-off) became the most cost-effective test with an ICER of
£13,115 and £5896, respectively. This test has the highest sensitivity and specificity (91% and 87%).
TABLE 46 Increase in abstinence rates following NILT
Change in abstinence rate
Rate following
diagnosis:
cirrhosis
Rate following
diagnosis:
no cirrhosis Impact cost-effectiveness
Increase 10% 62% 41% Fibrotest (low cut-off) and liver
biopsy becomes most
cost-effective testing option
Increase 15% 67% 46% Fibrotest (high cut-off) becomes
most cost-effective test
Increase 20% 72% 51% Fibrotest (high cut-off) becomes
most cost-effective test
TABLE 45 Sensitivity analyses, parameters, ranges, result
Parameter
Base-case
value
Extreme values
tested Impact on cost-effectiveness
Probability of developing cirrhosis
(continue drinking FP and TN patients)
20% 10–50% No change
Probability of developing cirrhosis
(continue drinking FP and TN patients)
20% 60% All treated as cirrhotic
(receive HCC screening)
becomes cost-effective option
Mortality rate following liver biopsy 0.09% 0.05–0.20% No change
Adverse event rate following liver biopsy 0.72% 0.05–0.90% No change
FP, false positive; TN, true negative.
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Increase in abstinence rate after diagnosis of no cirrhosis with a
non-invasive liver test
We conducted an analysis where we only increased the probability that patients would become abstinent
after a diagnosis of no cirrhosis (using a NILT), leaving all other base-case values constant. We increased
the base-case value of 31% by 10% and 20%. Increasing the abstinence rate by 10% changed the result
and strategy 4 [Fibrotest (low cut off) with liver biopsy] used as a second test to confirm results became the
most cost-effective with an ICER of £6833. When we increased the abstinence rate by 20%, using strategy
3 [Fibrotest (high cut off) as an initial test and liver biopsy used as a second test to confirm positive results]
became the most cost-effective strategy with an ICER of £4730.
Amendments to model structure
Different starting population: advanced fibrosis (≥ F3)
An analysis where we incorporated a different starting population (F3) did not change the overall result:
liver biopsy remained the most cost-effective testing option. Table 47 displays the results of the analysis.
Additional health states
We allowed for persons with cirrhosis (who remained abstinent within the model) to have a small
probability of undergoing a liver transplant (4%, based on clinical advice). We incorporated cost and QALY
estimates sourced from the CELT study421 specifically for patients with ALD (cost estimate of £11,202 and
QALY value of 0.58); we inflated the historic cost to 2012 prices (£17,741) using NHS inflation indices.
The results are presented in Table 48. Liver biopsy remains the most cost-effective testing option, with an
ICER of £688. However, similar to the base-case analysis, this result is dependent on the abstinence rates
used in the analysis. When we amend the abstinence rate after diagnosis with a NILT so that it became
equivalent to the abstinence rate after diagnosis with a liver biopsy, the results change, so that strategy 4
[Fibrotest (low cut off with liver biopsy to confirm positive results)] becomes the most cost-effective, with
an ICER of £4756.
TABLE 47 Alcoholic liver disease incremental analysis: different starting population (≥ F3)
Strategy Test strategy Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Strategy 3 Forns index (high cut-off)
and liver biopsy
21,135 8.30 – – –
Strategy 8 Forns index (high cut-off) 22,085 8.36 – – Dominated
Strategy 5 YKL-40 and liver biopsy 21,224 8.40 – – Extendedly
dominated
Strategy 10 YKL-40 22,224 8.42 – – Extendedly
dominated
Strategy 9 Fibroscan 23,456 8.62 – – Extendedly
dominated
Strategy 7 CK18 24,646 8.62 – – Extendedly
dominated
Strategy 2 CK18 and liver biopsy 21,486 8.78 351 0.49 722
Strategy 4 Fibroscan and liver biopsy 21,547 8.80 – – Extendedly
dominated
Strategy 1 Liver biopsy 21,652 8.99 166 0.21 800
Strategy 12 All treated as cirrhotic
(HCC screening)
31,963 9.14 10,311 0.15 69,522
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Cost per correct diagnosis analysis
We also constructed a simple probabilistic decision model to assess the cost per correct diagnosis of the
applicable NILTs compared with liver biopsy. As for the decision tree analysis, fibrosis prevalence in
the model was estimated using a section of the meta-analysis equivalent to the proportion of the
population with a test score of ≥ F4, measured using the METAVIR score. Based on the diagnostic accuracy
of each test, the patient was classified as true positive, true negative, false positive or false negative. True
positives and true negatives were considered to be correct diagnoses.
Test costs
We employed the same test costs for the NILTs and liver biopsy as used in the decision tree model.
Analysis
We assumed that liver biopsy as the reference standard had perfect sensitivity and specificity, implying that
biopsy accurately stages liver fibrosis. Using a hypothetical cohort of 1000 ALD patients suspected of
having liver fibrosis, we estimated the incremental cost associated with each test compared with the next
best alternative. Tests which had fewer numbers of true-positive or true-negative outcomes, with a higher
test cost than other tests which had higher correct diagnoses, were ruled out of the analysis (dominated).
We present the results separately for positive and negative diagnoses as the consequences are different for
each. Results are shown in Tables 49 and 50.
Liver biopsy also returns the highest correct number of negative responses (n= 634) (see Table 50);
however, the incremental cost per correct positive diagnosis for using liver biopsy was £13.62, compared
with an incremental cost per correct diagnosis of £0.02 associated with using the next best alternative,
PGAA, as the diagnostic test.
TABLE 48 Alcoholic liver disease incremental analysis: analysis with additional health states added (HCC and
liver transplant)
Strategy Test strategy Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Strategy 2 APRI (high cut-off) and
liver biopsy
17,637 8.80 – – –
Strategy 7 APRI (high cut-off) 22,538 8.88 – – Dominated
Strategy 10 PGAA 19,213 8.99 – – Dominated
Strategy 11 Fibroscan 20,148 9.03 – – Dominated
Strategy 8 Fibrotest (high cut-off) 19,638 9.04 – – Dominated
Strategy 5 PGAA and liver biopsy 17,928 9.09 – – Extendedly
dominated
Strategy 9 Fibrotest (low cut-off) 24,845 9.14 – – Dominated
Strategy 6 Fibroscan and liver biopsy 18,027 9.16 – – Dominated
Strategy 3 Fibrotest (high cut-off) and
liver biopsy
18,055 9.19 – – Dominated
Strategy 4 Fibrotest (low cut-off) and
liver biopsy
18,077 9.28 – – Dominated
Strategy 1 Liver biopsy 18,000 9.33 363 0.53 688
Strategy 12 All treated as cirrhotic
(receive HCC screening)
30,705 9.42 12,705 0.10 133,479
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Results of cost per correct diagnosis analysis
Column 2 in Table 49 shows the number of correct positive diagnoses using a NILT or liver biopsy.
The highest number of correct positive diagnoses is given using a liver biopsy,366 which is estimated from
the disease prevalence from the meta-analysis. Using Fibrotest (low cut-off) returns the next highest
number of true positives.363 The tests are compared incrementally with tests which provide fewer
true-positive results at a higher test cost ruled out (dominated) of the analysis. Liver biopsy returned the
greatest number of correct diagnoses; however, the incremental cost per correct positive diagnosis for
using liver biopsy was £168 compared with an incremental cost per correct diagnosis of £0.18 associated
with using the next best alternative, Fibrotest (low cut-off), as the diagnostic test.
TABLE 49 Results of the cost per correct TP diagnosis
Test
Number of
TPs using NILT Test cost, £
Number of
incremental
correct
diagnoses
Incremental cost
(test only), £
Incremental cost per correct
diagnosis (TP): each test
compared with next best
alternative (£/correct
diagnosis gained)
APRI
(high cut-off)
144 4.05 – – –
PGAA 285 7.69 141 3.64 Extendedly dominated
Fibroscan 315 51.00 – – Dominated
Fibrotest
(high cut-off)
334 43.60 190 39.55 Extendedly dominated
Fibrotest
(low cut-off)
363 43.60 219 39.55 0.18
Liver biopsy 366 956.61 4 593.92 168
TP, true positive.
TABLE 50 Results of the cost per correct TN diagnosis
Test
Number of
TNs using NILT Test cost, £
Number of
incremental
correct
diagnoses
Incremental cost
(test only), £
Incremental cost per correct
diagnosis (TN): each test
compared with next best
alternative (£/correct
diagnosis gained)
Fibrotest F4
(low cut-off)
317 43.60 – – Dominated
APRI F4 (high
cut-off)
392 4.05 – – –
Fibroscan F4 526 51.00 – – Dominated
Fibrotest F4
(high cut-off)
551 43.60 – – Dominated
PGAA F4 564 7.69 172 3.64 0.02
Liver biopsy 634 956.61 70 948.92 13.62
TN, true negative; TP, true positive.
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Discussion
Liver biopsy is the most cost-effective testing option to adopt given our model at the standard UK
cost-effectiveness threshold range. This result is sensitive to assumptions about the abstinence rates after
diagnosis, difference in abstinence between people tested with biopsy and NILT, and rates of progression
to cirrhosis rates in patients who continue to drink. More accurate data on these parameters are needed in
order to reduce uncertainty in these results.
Our results were particularly sensitive to changes in the abstinence rate after diagnosis with a NILT (holding
the rates for liver biopsy constant). When we raise the abstinence rates after diagnosis with a NILT, the test
with the highest sensitivity and specificity becomes the most cost-effective (the summary sensitivity and
specificity would be comparable with liver biopsy).
When we increased the abstinence rate after diagnosis with a NILT by 20%, tests which have high
summary sensitivity and specificities tend to be the most clinically effective: Fibroscan and Fibrotest (low
cut-off) [Fibroscan 86% and 83% and Fibrotest (low cut-off) 100% and 50%]. This implies that when we
increase the abstinence rates following diagnosis with a NILT compared with liver biopsy, tests which have
a similar diagnostic accuracy to liver biopsy tend to be more effective.
Liver biopsy also appears to be the most cost-effective option, even when we amend the modelling
structure to allow for a different patient cohort (F3) or additional health states (liver transplant). However,
this result is also sensitive to changes in the abstinence rates applicable after a NILT; as there are few data
on this, the results are uncertain.
The lack of data available regarding cessation rates after diagnosis with either a NILT or liver biopsy are a
limitation in the study. One is based on a small study, the other on an assumption, and both are key
drivers of the analysis which leave the results very uncertain.
The HTA report by Stevenson et al.428 did not report an incremental analysis. However, they did carry out a
number of threshold analyses where they decreased the abstinence rate and increased it to see at which
point biopsy became cost-effective compared with a test. They found that the lower the abstinence rate
after a NILT, the more likely it is that liver biopsy is cost-effective.
Liver biopsy was also a less costly testing option as we assumed that it had perfect sensitivity and specificity
and could accurately identify false-positive responses from true-negative outcomes. A true-negative
outcome had a lower cost than a false-positive outcome in the model. Any test that returned a high
false-positive result was more costly; for example, using Fibrotest (low cut-off) was more costly and less
effective than using Fibrotest to initially identify patients followed by liver biopsy to confirm diagnosis.
A reduction in all-cause mortality due to abstinence is not captured in the model. This would further
strengthen the robustness of using liver biopsy, if we still assumed higher abstinence rates following a liver
biopsy than following a NILT.
Therefore, despite any mortality or morbidity risks associated with liver biopsy, the increased cost
associated with false positives and the fact that the utility value for these patients was the same as if true
negative (in other words there was no assumed treatment benefit associated with being diagnosed as false
positive in the model) meant that any test which returned a high number of false-positive outcomes would
be the least cost-effective.
The incremental cost of using liver biopsy compared with a NILT is high when we look at the cost per
correct true negative. PGAA, which has the highest specificity, returns the highest number of true
negatives which will be picked up by a NILT. However, for tests with a lower specificity, Fibrotest (low
cut-off), the cost per correct diagnosis (true negative) using a liver biopsy is the cheapest option compared
with using liver biopsy to diagnose true negatives for other tests.
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Chapter 8 Cost-effectiveness analysis:
non-alcoholic fatty liver disease
This chapter details the approach used to conduct an analysis of non-invasive liver tests for use inpatients with NAFLD. The population considered for analysis were persons with NAFLD who were
suspected of having developed NASH with fibrosis or cirrhosis.
Literature search
Cost-effectiveness of non-invasive liver tests in non-alcoholic fatty
liver disease
We conducted a literature review using a modified version of the search strategy used for ALD to locate
published cost-effectiveness studies which had analysed the use of the NILTs in a NAFLD population.
We used the MEDLINE database (via Ovid platform, searched 24 June 2013, all years searched). The search
strategy used is detailed in Appendix 2 and inclusion criteria are listed in Chapter 3. The search returned
14 papers whose titles and abstract were reviewed. No cost-effectiveness studies were found.
Treatment in non-alcoholic fatty liver disease and effectiveness
We identified a position paper on the treatment of NAFLD and NASH published by EASL in 2010472 which
recommends that an initial treatment strategy for patients with NASH would involve treating insulin
resistance and reducing body weight (particularly visceral adiposity). Potential treatment options mentioned
in the guideline include weight loss and physical exercise interventions, insulin-sensitising agents, vitamin E
therapy and antiobesity surgery; however, the guidelines recommend that all pharmacological medications
for treatment of NASH should be considered as experimental. Additionally, treatment and monitoring of
metabolic and cardiovascular comorbidities in patients with NAFLD is recommended by the EASL guidelines.
We searched the reference list of the EASL position paper and the American Association for the Study of
the Liver (AASLD) practice guidelines47 for papers providing evidence of relative treatment effects on the
potential treatment strategies outlined in the guidelines and supplemented this using a general literature
search conducted using Google Scholar (search terms included ‘NAFLD’, ‘NASH’ ‘vitamin E therapy’
and ‘pioglitazone’, searched 26 June 2013). We also sought clinical advice to identify up-to-date,
relevant studies on potential treatments. Using this triple approach, we identified relevant papers on
insulin-sensitising agents,473–475 weight loss and exercise interventions,476,477 behavioural interventions478
and bariatric surgery.479
The EASL position paper472 noted that no studies analysing the impact of glitazones and their effect on the
cessation or decrease in progression of fibrosis/cirrhosis have shown a convincing benefit. We identified a
2010 systematic review and random-effects meta-analysis Rakoski et al.473 of eight published studies480–488
which analysed the use of insulin sensitisers [thiazolidineodiones (glitazones)] and metformin in patients
with NAFLD and/or NASH. The primary outcome of interest for each paper related to histological response
to treatment. When the authors looked at all nine studies together, insulin-sensitising agents showed a
significant improvement in fibrosis; however, a subgroup analysis looking only at studies which
investigated the use of glitazones (six studies) found that glitazones (rosiglitazone, pioglitazone) did not
result in a significant improvement in fibrosis. A sensitivity analysis conducted by the authors excluding
patients with diabetes from the analysis found that, when this subset of patients was removed,
pioglitazone did result in a significant decrease in fibrosis. The study did not, however, provide any
applicable data to use in an economic model, such as the reduced probability of patients progressing to a
more severe NASH state as a result of treatment.
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A 2012 cost–utility study by Mahady et al.475 derived a treatment effect (RR) for histological improvement
with pioglitazone from a 2011 meta-analysis of randomised trials conducted by Mahady et al.489
The authors estimated a RR of 1.40 for pioglitazone versus placebo using three published studies of
randomised trials where pioglitazone was used as add-on therapy to standard lifestyle advice.481–483 However,
the 2012 meta-analysis by Rakoski et al.473 (reviewed above) had also analysed these three studies in their
subgroup meta-analysis of glitazones and found that glitazones did not result in an improvement in fibrosis.
In addition, the 2010 paper by Sanyal et al.,481 which was analysed by Mahady et al.489 in their meta-analysis,
noted that no significant improvement was seen in fibrosis scores as a result of pioglitazone treatment.
Indeed, in their paper, Mahady et al.489 themselves note that the degree of improvements with
thiazoidinediones (TZDs) is modest, estimated at approximately one-quarter of a grade per year for fibrosis.
Rakoski et al.473 also noted that the glitazones have potential serious side effects. This point was
emphasised, too, by the 2012 AASLD Practice Guidelines, which recommend that pioglitazone can be used
to treat steatohepatitis in patients with NASH; however, the long-term safety and efficacy of the drug in
patients with NASH is not yet established.
There are no RCTs published analysing treatment for metabolic conditions and the resulting impact on
fibrosis in patients with NASH.47
The use of metformin was not recommended for use as specific treatment for liver disease in adults with
NASH47 and the EASL position paper472 notes that controlled studies of metformin show no benefit
resulting from this treatment.487,488 Lavine et al.490 conducted a randomised, double-blind, double-dummy,
placebo-controlled clinical trial of 173 patients (aged 8–17 years) with biopsy-confirmed NALFD.490 The
study analysed whether children with NALFD would improve with use of vitamin E or metformin, and
concluded that, compared with a placebo, neither therapy demonstrated significant improvements in
histological features.
The 2012 AASLD guidelines491 recommend that vitamin E (α-tocopherol) administered at daily dose
of 800 IU/day for non-diabetic adults with biopsy-proven NASH may be considered as first-line
pharmacotherapy. The recommendations are partially based on the results of the pioglitazone versus
vitamin E versus placebo for the treatment of nondiabetic patients with non-alcoholic steatohepatitis
(PIVENS) trial,481 which found that although there was an improvement in hepatic steatosis and lobular
inflammation, fibrosis scores were not significantly improved by use of vitamin E. The AASLD guidelines
do not give much detail around the background to this decision; rather, they note that the primary end
point of the PIVENS trial was an improvement in NAS ≥ 2 points, with at least 1-point improvement in
hepatocellular ballooning and 1-point improvement in either the lobular inflammation or the steatosis score,
and no increase in the fibrosis score. It seems that the recommendation was based on the improvement in
liver histology seen during the PIVENS trial (but not necessarily an improvement in the fibrosis score).
The 2012 cost–utility study by Mahady et al.475 also derived a treatment effect (RR) for vitamin E treatment.
This estimate was derived from the PIVENS trial; however, as noted above, the paper for the PIVENS trial481
notes that fibrosis scores were not significantly improved with vitamin E treatment. The RR employed in the
cost–utility study (1.35) indicates that very little benefit results from treatment.
A RCT by Promrat et al.492 assessed the effect of weight loss on NASH and found that weight reduction
achieved through lifestyle interventions (diet and exercise programme and behavioural change) led to
an improvement in steatosis, lobular inflammation and ballooning injury (measured using the NASH
histological activity score); however, there was no significant change in hepatic fibrosis after 1 year of the
study intervention. The study included patients with well-characterised NASH (histologically and clinically),
and used a standardised, protocol-based lifestyle intervention. However, this was a small study (30 persons
completed the study), a post-liver biopsy was carried out for only 90% of the participants and none of the
participants had cirrhosis (16% had bridging fibrosis).492 As the study was conducted for only 48 weeks, it
may not be possible to confirm if lifestyle interventions are effective, as long-term data suggest that only
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15% of participants lose > 10% of their body weight; in addition, adherence to weight-loss programmes
drops after the first few months and most people regain weight.472
Bariatric surgery is indicated to be effective in patients with NASH and fibrosis.479 NICE guidelines for
obesity493 recommend the use of bariatric surgery as a treatment option if patients have a BMI of
≥ 40 kg/m2 or for patients with a BMI between 35 kg/m2 and 40 kg/m2 with other significant disease such
as type 2 diabetes or high blood pressure. The guidelines also recommend this surgery as a first-line
treatment option for adults with a BMI > 50 kg/m2. However, the guidelines do not specifically recommend
bariatric surgery for use in patients with NAFLD. In addition, the recent AASLD guidelines noted that it is
premature to consider bariatric surgery as an established option to specifically treat NASH rather than
obesity in general. A systematic review and meta-analysis by Mummadi et al.479 concluded that fibrosis
appears to improve after surgery-induced weight loss. Another 2008 study by De Freitas et al.494 found
that there is good evidence that bariatric surgery is associated with NAFLD regression in morbidly obese
patients. However, the limitation of these studies is that they are retrospective or prospective studies.
A 2010 Cochrane review495 of bariatric surgery in obese patients with NASH did not locate any RCTs or
quasi-RCTs that evaluated a bariatric procedure compared with another intervention in patients with
NASH, and the authors concluded that this lack of RCT studies meant that they could not assess the
benefits and harms of bariatric surgery as a potential treatment in patients with NASH.
Health-related quality of life in non-alcoholic fatty liver disease patients
The search for papers on treatment effectiveness also identified three studies that contained information
on HRQoL in patients with NAFLD, two of which had reported HRQoL values.
The cost–utility study by Mahady et al.475 could not locate any sources for HRQoL for patients with NASH,
as no prior studies have been conducted. They used utilities from studies based on other causes of liver
disease432,435 and assumed that cirrhosis, decompensated cirrhosis and HCC represent a common pathway
for liver disease and that the decrement in quality of life associated with these conditions is similar
irrespective of the initial cause.
We located two papers which estimated HRQoL values in patients with NASH and NALFD. One was a
study by David et al.496 which assessed HRQoL of patients with diagnosed NAFLD and NASH. Using the
SF-36, they found that patients with NALFD had lower reported scores and greater degrees of physical
limitations than patients with HBV or HCV. They noted that the physical component summary score was
similar to that of patients with HBV in a decompensated cirrhosis health state. Participants were mainly
non-Hispanic white (76%) with a college education (71%), and over half (58%) had an income over
$50,000. HRQoL was lower in the respondents with NASH and the authors also found that scores were
worse for persons with cirrhosis than without cirrhosis. The authors reported the median SF-36 physical
component score by fibrosis level, but insufficient information was provided for the other components
required to enable mapping to the preference-based SF-6D in order to calculate QALYs.
The second was a published study497 which reported HRQoL data for liver disease health states for all
aetiologies including NASH. However, this was based on clinical opinion rather than empirical data
reported by patients. The authors surveyed 18 general practitioners (GPs) and 12 hepatologists (Scotland
and England) using a questionnaire and a Delphi approach. In addition, this report did not detail on what
scale the values were estimated, and so it was not possible to interpret the reported estimates.
Summary
Currently, no pharmacological treatments or surgical interventions are explicitly recommended for use in
patients with NASH by UK guidelines. The main limitation with the current published studies of potential
effective interventions for NALFD/NASH is that none of the studies reviewed collected robust data
on effective treatments for patients with NASH and fibrosis. Some of the recommended treatment
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interventions also include physical exercise and weight-loss programmes; these are also recommended
for the treatment of obesity irrespective of the degree of fibrosis progression, and so it is difficult to
identify the accurate impact on fibrosis regression as any impact may be incidental and may not be
explicitly captured in the programme outcomes.
The lack of published studies with relevant data on treatment options administered specifically for patients
with NASH with fibrosis limited the modelling approach for NASH. As we could not identify robust cost
and QALY estimates or data on treatment effectiveness, we were unable to model the long-term
treatment pathway if diagnosed as true positive, false positive, true negative or false negative and were,
therefore, unable to use the same modelling approach used for the HBV and HCV analyses.
Approach to analysis
We constructed a probabilistic decision model to assess the cost per correct diagnosis of the applicable NILTs
compared with liver biopsy. We also conducted an exploratory analysis to assess the possible implications of
using the NILTs in a primary care setting to inform the referral pathway to tertiary care for patients with NASH.
Cost per correct diagnosis
The systematic review identified data for 35 NILTs for use in NASH (using a section of the meta-analysis
equivalent to the proportion of the population with a METAVIR score of ≥ F3). The number of true-
positive, false-positive, true-negative or false-negative outcomes reported for each NILT was extracted from
the meta-analysis data (see Chapter 4). The average disease prevalence estimated from the meta-analysis
data was 19%. We calculated the probability of each test returning a true-positive, false-positive,
true-negative and false-negative result using the average disease prevalence and sensitivity and specificity
estimates (see Appendix 7).
Five of the tests evaluated in the second stage of the analysis used a combined diagnostic cut-off threshold
(low and high cut-offs) for staging fibrosis; the use of a combined threshold results in a number of
indeterminate responses. We assumed that patients who had an indeterminate response were retested
with a commonly used imaging modality, Fibroscan, based on availability and clinical practice (choice based
on clinical advice). We did not choose patented, direct or indirect tests as several of the tests with a
combined diagnostic cut-off were also in these categories; our clinical advisor advised us that the same
type of test would not be repeated in practice.
Test costs
Costs of imaging modalities were sourced from published Department of Health reference costs.427 Costs
of direct and indirect serum marker were obtained from communication with finance departments based
at the Royal Free Hospital and costs for patented serum markers were sourced directly from manufacturers
and via communication with finance departments based at the Royal Free Hospital (see Appendix 9,
Table 78). The cost of a percutaneous liver biopsy (see Chapter 5 for further details on choice of liver
biopsy) was sourced from published literature.428 Where applicable, costs were inflated to 2012 prices
using NHS inflation indices.67 All NILT test costs are based on incremental costs and exclude the capital
costs of the equipment. Test costs and sources are listed in Appendix 9.
Analysis
We assumed that liver biopsy as the reference standard had perfect sensitivity and specificity, implying that
biopsy accurately diagnoses all healthy and unhealthy patients. Using a hypothetical cohort of 1000
patients with NAFLD and suspected of having liver fibrosis, we estimated the incremental cost associated
with each test compared with the next best alternative. Prevalence was based on mean prevalence data
from the systematic review, which found that 19% of people tested had fibrosis level 3 disease or greater.
Tests which had fewer numbers of true-positive or true-negative outcomes, with a higher test cost than
other tests which had higher correct diagnoses, were ruled out of the analysis (dominated). We present
the results separately for positive and negative diagnoses as the consequences are different for each.
Results are shown in Tables 51 and 52.
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TABLE 51 Results of cost per correct diagnosis (TP)
Test
Number of
TPs using NILT Test cost, £
Number of
incremental
correct
diagnoses
Incremental cost
(test only), £
Incremental cost per correct
diagnosis (TP): each test
compared with next best
alternative (£/correct
diagnosis gained)
NFS TE 15 55.95 – – Dominated
FIB-4
(high cut-off)
71 4.40 – – Dominated
Fibrotest TE 74 94.60 – – Dominated
NFS
(high cut-off)
75 4.95 – – Dominated
APRI 76 4.05 – – Dominated
Fibrotest
(high cut-off)
76 43.60 – – Dominated
AST–ALT
(high cut-off)
88 0.90 – – Dominated
PLT 119 3.50 – – Dominated
Age–PLT
Index
124 3.50 – – Dominated
NFS all 134 20.85 – – Dominated
Hepascore 143 16.24 – – Dominated
AST–ALT
(low cut-off)
149 0.90 – – Dominated
FIB-4 all 149 21.09 – – Dominated
Type
IV collagen
150 20.00 – – Dominated
ELF 151 108.00 – – Dominated
NFS
(low cut-off)
151 4.95 – – Dominated
TE 155 51.00 – – Dominated
NAFIC
(high cut-off)
158 28.17 – – Dominated
Fibrotest all 158 59.31 – – Dominated
FIB-4
(low cut-off)
159 4.40 – – Dominated
BARD 160 0.90 – – –
NFS ELF
(high cut-off)
164 112.95 – – Dominated
Hyaluronic
acid
165 8.00 6 7.10 1.27
NDP 166 21.18 – – Extendedly dominated
Fibrotest
(low cut-off)
169 43.60 – – Dominated
ARFI 170 51.00 – – Dominated
continued
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TABLE 51 Results of cost per correct diagnosis (TP) (continued )
Test
Number of
TPs using NILT Test cost, £
Number of
incremental
correct
diagnoses
Incremental cost
(test only), £
Incremental cost per correct
diagnosis (TP): each test
compared with next best
alternative (£/correct
diagnosis gained)
NFS ELF all 171 114.81 – – Dominated
MR
elastography
172 199.00 – – Dominated
NFS ELF
(low cut-off)
172 112.95 – – Dominated
NAFIC all 180 35.59 – – Dominated
NAFIC
(low cut-off)
181 28.17 16 20.17 1.29
Liver biopsy 189 956.61 8 928.44 112.30
NAFIC, ferritin, fasting insulin, type IV collagen; NDP, NAFLD, diagnostic panel; NFS, non-alcoholic fatty liver disease fibrosis
score; PLT, platelet; TP, true positive.
TABLE 52 Results of cost per correct diagnosis (TN)
Test
Number of
TNs using NILT Test cost, £
Number of
incremental
correct
diagnoses
Incremental cost
(test only), £
Incremental cost per correct
diagnosis (TN): each test
compared with next best
alternative (£/correct
diagnosis gained)
BARD 491 0.90 – – Dominated
NFS
(low cut-off)
535 4.95 – – Dominated
NAFIC
(low cut-off)
545 28.17 – – Dominated
NDP 566 21.18 – – Dominated
AST–ALT
(low cut-off)
568 0.90 – – Dominated
Fibrotest
(low cut-off)
593 43.60 – – Dominated
FIB-4
(low cut-off)
603 4.40 – – Dominated
PLT 617 3.50 – – Dominated
Age–PLT
Index
632 3.50 – – Dominated
NAFIC all 640 35.59 – – Dominated
Type IV
collagen
650 20.00 – – Dominated
NAFIC
(high cut-off)
666 28.17 – – Dominated
Hyaluronic
acid
666 8.00 – – Dominated
APRI 668 4.05 – – Dominated
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Results of cost per correct diagnosis
Cost per correct diagnosis (positive): see Table 51
Column 2 in the table shows the number of correct positive diagnoses using a NILT or liver biopsy. The
highest number of correct diagnoses is given using a liver biopsy (n= 189), and is assumed to be 100%
accurate for all of those tested and which is estimated from the disease prevalence from the meta-analysis.
An indirect serum marker, NAFIC (ferritin, fasting insulin, type IV collagen), using a combined cut-off
threshold or a low cut-off threshold also returns a high number of true positives (n= 180 and n= 181,
respectively). One test, an indirect serum marker, was extendedly dominated, as the incremental cost per
correct diagnosis was higher for this test (£26.65) than for another indirect serum marker, NAFIC with a
low diagnostic cut-off threshold, when compared with the next best alternative, hyaluronic acid. The
incremental cost per correct positive diagnosis for liver biopsy was £112.30, compared with an incremental
cost per correct diagnosis of £1.29 associated with using the next best alternative, NAFIC (low cut-off),
as the diagnostic test.
TABLE 52 Results of cost per correct diagnosis (TN) (continued )
Test
Number of
TNs using NILT Test cost, £
Number of
incremental
correct
diagnoses
Incremental cost
(test only), £
Incremental cost per correct
diagnosis (TN): each test
compared with next best
alternative (£/correct
diagnosis gained)
TE 681 51.00 – – Dominated
Hepascore 682 16.24 – – Dominated
MR
elastography
715 199.00 – – Dominated
ARFI 726 51.00 – – Dominated
ELF 730 108.00 – – Dominated
AST–ALT
(high cut-off)
740 0.90 – – –
FIB-4 all 754 21.09 – – Dominated
NFS ELF
(low cut-off)
778 112.95 – – Dominated
Fibrotest
(high cut-off)
779 43.60 – – Dominated
NFS all 780 20.85 – – Dominated
Fibrotest TE 780 94.60 – – Dominated
Fibrotest all 783 59.31 – – Dominated
FIB-4
(high cut-off)
783 4.40 44 3.50 0.08
NFS
(high cut-off)
786 4.95 3 0.55 0.21
NFS TE 795 55.95 9 51.00 5.53
NFS ELF all 805 114.81 – – Dominated
NFS ELF
(high cut-off)
805 112.95 10 57.00 5.72
Liver biopsy 811 956.61 6 843.66 145.39
NAFIC, ferritin, fasting insulin, type IV collagen; NFS, non-alcoholic fatty liver disease fibrosis score; NPD, NAFLD diagnostic
panel; PLT, platelet; TN, true negative.
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Cost per correct diagnosis (negative): see Table 52
Liver biopsy returns the highest number of correct negative diagnoses (811) estimated from the disease
prevalence from the meta-analysis. The majority of tests were dominated by other tests which had lower
tests costs and returned higher numbers of true-negative results. A combination of NAFLD fibrosis score
(NFS)–ELF test using a combined cut-off threshold returned 805 negative diagnoses at an additional cost
of £5.72 per correct negative diagnosis compared with the next best alternative, NFS combined with
Fibroscan. Although liver biopsy returned the highest amount of negative responses, the cost per correct
negative diagnosis was £145.39 compared with the next best alternative, NFS–ELF (high cut-off). The least
expensive cost per correct diagnosis compared with the next best alternative was FIB-4 (high cut-off)
at £0.08 per correct true-negative response identified.
Exploratory analysis
We conducted an exploratory analysis to assess the possible costs and benefits of using the NILTs in
a primary care setting to inform referral of patients to tertiary care. We constructed a simple decision
model analysing the referral pathway for patients with NAFLD who have suspected fibrosis or cirrhosis.
Given the lack of data available, this analysis can only be considered as exploratory. We estimate the
potential impact of the strategies on the costs of treatment based on the assumptions below. Robust data
were not available to estimate the impact of the alternative strategies on health outcomes; however, we
also present a sensitivity analysis exploring a range of alternative assumptions about possible impacts using
a range of QALY estimates.
Scenarios assessed
Our considered population was a hypothetical cohort of 1000 patients with NAFLD with suspected fibrosis.
Our analysis considered a number of scenarios, which were determined using clinical advice.
1. Immediate referral of all patients having NAFLD (irrespective of fibrosis level) to a tertiary care centre for
testing, treatment and management.
2. At primary care level, test all patients with NAFLD with a NILT. If the Kleiner score is ≥ F3 (advanced
fibrosis), refer patients to tertiary care centre for treatment and management. If the NILT score indicated
low risk for advance fibrosis (Kleiner < F3), treat and manage care in primary care setting.
3. Biopsy all patients, treat and manage all patients with a Kleiner score of ≥ F3 at a tertiary care centre.
Refer those with a Kleiner score of < F3 for treatment and management in primary care.
Strategy 1 was considered to most closely reflect current UK practice. We assumed that scenarios 1 and 2
would incorporate an initial diagnosis with a NILT. Following clinical advice, we modelled the use of an
indirect serum marker test (FIB-4 with a combined diagnostic threshold cut-off). As this test may return
a number of indeterminate results (from the meta-analysis data of the studies for FIB-4 combined, 33%
of the test results would be inconclusive), we assumed that this proportion of patients would receive a
second test with an imaging modality, Fibroscan, to confirm a diagnosis. Using these two tests returned an
outcome where 866 patients were diagnosed as low risk and 134 patients were deemed high risk: true
negative (86%), false negative (1%), true positive (4%) and false positive (9%).
Input parameters
Prevalence of population with fibrosis level of ≥ F3
Following clinical advice we set the average disease prevalence to 5%. We assumed that the sensitivity and
specificity of the tests would be same as observed in the studies included in the systematic review in
this population.
Resource use and cost
We did not identify any published studies in the literature review that provided long-term specific cost data
related to treatment and management of care in patients with NASH and fibrosis. Based on the
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recommended management of NASH (and potential pharmacological or surgical treatment listed in the
EASL guidelines),472 and using clinical advice, we identified resource use items for patients with NASH.
Assumptions regarding resource use
The time frame adopted in the analysis was 5 years and a discount rate of 3.5% was applied.66
High risk (≥ F3) treated in tertiary care
We assumed that this patient group would initially be tested with a NILT, FIB-4 (with inconclusive results
retested with Fibroscan), in either a tertiary care setting (strategy 1) or a primary care setting (strategy 2). Using
strategy 3, we assumed that patients would be tested with a liver biopsy in a primary care setting. Following
clinical advice we assumed that patients with a METAVIR score of ≥ F3 would have two assessments per year
with a consultant hepatologist. Exercise and diet programmes would be initiated and monitored by specialists
(hepatologist, dietitian, physiotherapist and psychologist), with an assessment every 6 months. Treatment
would involve aggressive management of metabolic syndrome components with statins, pioglitazones and
antihypertensives. We modelled that a proportion of this cohort who test true positive (4%) would have a
0.04% probability of progressing to a cirrhotic health state per year.475 Twenty per cent of patients who
progressed to a cirrhotic health state would receive screening for HCC twice per year (using a combination of
ultrasound and monitoring of α-fetoprotein levels). For those patients who progressed to HCC each year, we
allowed for a 30-minute assessment by the hepatologist to feed back results (assuming a full assessment by a
hepatologist would normally last 30 minutes, approximately). For the proportion who did not develop HCC,
we allowed for 30 minutes of a hospital-based nurse’s time to feed back results via letter.
We assumed that 3.5% of the patients who developed HCC would undergo liver transplantation (0.04%
progression rate to HCC health state).475
National Institute for Health and Care Excellence guidance for obesity (CG43) recommends that persons
with a BMI ≥ 40 kg/m2 or with a BMI between 35 kg/m2 and 40 kg/m2 with other significant disease,
who fill the following criteria, may be considered for bariatric surgery:
l individual has a BMI of ≥ 40 kg/m2 OR individual has a BMI between 35 kg/m2 and 40 kg/m2 in addition
to another significant disease (e.g. type 2 diabetes or high blood pressure) that could be improved if
they lost weight
l all appropriate non-surgical measures have been tried but have failed to achieve or maintain adequate,
clinically beneficial weight loss for at least 6 months
l the person has been receiving or will receive intensive management in a specialist obesity service
l the person is generally fit for anaesthesia and surgery
l the person commits to the need for long-term follow-up.
The guidelines also recommend that persons with a BMI > 50 kg/m2 may be recommended for bariatric
surgery as a first-line treatment.493 In the absence of data on the percentage of persons who may be
offered surgery as additional treatment if all other options have failed, we built into our model that a small
proportion of the high-risk cohort will have bariatric surgery. We sourced this proportion using the costing
report for the NICE clinical guidelines for obesity.493 The costing report for the obesity guidelines assumed
that of all adults who are obese nationally, 1% of these would have a BMI of 50 kg/m2, and of those
adults who meet the criteria for bariatric surgery as a first-line intervention, 80% of cases would be
considered appropriate for surgical intervention. The costing report assumed that for those cases in which
bariatric surgery is indicated and appropriate, 100% would choose to have the surgical procedure.
We employed the same assumption as that used by the costing report in or analysis.
Low risk (< F3) treated in tertiary care
We assumed that this patient group would receive an initial test with FIB-4 (with inconclusive results
retested with Fibroscan) in a tertiary care setting (strategy 1). Following clinical advice we assumed that
patients with a METAVIR score of < F3 would receive an initial assessment with a consultant hepatologist
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and thereafter would receive one assessment per year. Exercise and diet programmes would be initiated
and monitored by a hepatologist and 20% of this population cohort would see a dietitian (initial
assessment and once per year thereafter). Treatment would also involve aggressive management of
metabolic syndrome components with statins, pioglitazones and antihypertensives. This patient cohort
would also have annual liver function tests administered by the clinical hepatologist at the yearly
assessment. We assumed that an arbitrary proportion of this group (5%) would have an additional
assessment by the hepatologist to feed back results. The remaining 95% would have results fed back via
letter (we identified the resource use for this as 30 minutes of a hospital-based nurse’s time). This group
would also receive a retest with a NILT to check progression of fibrosis at 5 years. We conservatively
assumed that for the annual liver function tests and the 5-year NILT retest, a hospital-based nurse would
spend 30 minutes’ administration time (non-face-to-face time) for each contact episode organising tests,
sending samples to laboratories for analysis and compiling results.
Low risk (< F3) treated in primary care
We assumed that this patient group either would be tested with a NILT, FIB-4 (with inconclusive results
retested with Fibroscan) in a primary care setting (strategy 2), or would initially be tested with a liver biopsy
in a primary care setting (strategy 3). Following clinical advice we assumed that patients who have a
METAVIR score of < F3 would receive one 30-minute assessment per year with a GP who would advise on
and monitor diet and exercise programmes. As in tertiary care, treatment would also involve aggressive
management of metabolic syndrome components with statins, pioglitazones and antihypertensives.
This patient cohort would also have annual liver function tests (administered by a practice nurse during a
30-minute assessment) and would receive a retest with a NILT to check progression of fibrosis at 5 years.
We conservatively assumed that for the annual liver function tests and the 5-year NILT retest, a nurse based
at a GP practice would spend 30 minutes’ administration time for each contact episode (non-face-to-face
time) organising tests, sending samples to laboratories for analysis and compiling results.
Proportion of patients receiving combination of drugs or drugs alone
(for treatment of metabolic conditions)
Following clinical advice, we modelled that patients could receive more than one drug: pioglitazone,
vitamin E, statins or antihypertensives. The proportion or combination would remain the same if patients
were treated in a tertiary care or a primary care setting. Simvastatin was chosen as the drug of choice for
statins as this is the most commonly prescribed statin.498 Lisinopril was chosen as an antihypernsive drug as
per NICE guidance CG137, which advised that the first-line drug of choice for hypertension should be an
angiotensin-converting enzyme (ACE) inhibitor or an angiotensin ll receptor blocker.499 We assumed that
the drug would be an ACE inhibitor. We sourced the dosage for pioglitazone and vitamin E suspension
(alpha tocopheryl acetate) from the BNF.419 It was assumed in this exploratory analysis that the formulation
of the drugs prescribed would be the cheapest non-proprietary drug available. Estimates of the proportions
taking each type of medication are described in Table 53; estimates were based on clinical opinion.
TABLE 53 Proportion of patients receiving one or combination of drugs for metabolic condition
Drug(s)
Tertiary care and primary care
high risk (≥ F3), %
Tertiary care and primary care
low risk (< F3), %
Statins only 25 40
Statins and pioglitazone 15 10
Statins and vitamin E 20 0
Antihypertensive only 5 20
Antihypertensive and pioglitazone 15 10
Antihypertensive and vitamin E 20 0
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Costs associated with resource use
National published sources of unit cost data were applied to the estimates of resource use: BNF for costs
of medication;419 unit costs of health and social care published by the Personal Social Services Research
Unit (PSSRU) for NHS staff costs;67 and Department of Health reference costs427 for costs of surgical
interventions such as bariatric surgery. The cost of a liver transplant was taken from the CELT study421
described in Chapter 5, using the incremental cost of transplantation for ALD patients from date of
transplant followed up over 2 years. Test costs for FIB-4, Fibroscan and liver biopsy are listed in Appendix 9.
We assumed that test costs would be the same regardless of administration setting (primary or tertiary).
Table 54 provides a list of all identified resource use and associated costs. Where required, costs were
inflated to 2012 prices using NHS inflation indices.67
TABLE 54 Resource use and associated costs applicable in patients with NASH (£ 2011–12)
Resource use Unit cost Lower cost Upper cost Source
Tertiary care staff: first assessment
Consultant hepatologist 216.00 143.00 251.00 Department of Health reference
costs 2011–12 (Code 306)427
Dietitian 91.00 15.00 148.00 Department of Health reference
costs 2011–12 (Code 654)427
Exercise: physiotherapist 49.00 37.00 64.00 Department of Health reference
costs 2011–12 (Code 650)427
Behavioural treatment: psychologist 89.00 66.00 66.00 Department of Health reference
costs 2011–12 (Code 656)427
Tertiary care staff: follow-up assessment
Consultant hepatologist 187.00 98.00 271.00 Department of Health reference
costs 2011–12 (Code 306)427
Dietitian 93.00 16.00 119.00 Department of Health reference
costs 2011–12 (Code 654)427
Exercise: physiotherapist 43.00 24.00 24.00 Department of Health reference
costs 2011–12 (Code 650)427
Behavioural treatment: psychologist 313.00 51.00 204.00 Department of Health reference
costs 2011–12 (Code 656)427
Nurse: hospital based
(hour, non-face-to-face contact)
41.00 35.00 PSSRU 2012 Table 14.367
Primary care staff
GP (per minute patient contact) 3.70 3.10 – PSSRU 2012 Table 10.8B67
Practice nurse
(hour, face-to-face contact)
53.00 45.00 – PSSRU 2012 Table 10.667
Practice nurse
(hour, non-face-to-face contact)
41.00 35.00 – PSSRU 2012 Table 10.667
Medication cost (per year)
Statin (simvastatin) 11.86 – – BNF (accessed 24 June 2013)419
Antihypertensive (lisinopril) 14.47 – – BNF (accessed 24 June 2013)419
Diabetes medication (pioglitazone) 515.5 – – BNF (accessed 24 June 2013)419
Vitamin E 797.60 – – BNF (accessed 24 June 2013)419
continued
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Analysis exploring impact on resource use
We carried out an initial analysis where we estimated a cost per person for each scenario over for a 5-year
period. We discounted the costs and QALYs using the recommended UK discount rate of 3.5%.66 The
costs were based on the resource use identified and included assessment costs, drug costs, screening
costs, surgical costs and test costs. The results have been disaggregated to show the cost of treatment for
those who test low risk (negative test response, true negative or false negative) or high risk (positive test
response, true positive or false positive) for each group. Table 55 presents the results of the cost analysis
for the three scenarios.
Scenario 1 (refer all patients to tertiary care centre) and scenario 2 (refer only those who test ≥ F3 to
tertiary care) result in similar resource use costs per person. The cost for the high-risk scenario is the same
for both groups, as those diagnosed as positive in the primary care setting would be referred to a tertiary
care setting. The cost for the low-risk group differs, with the cost of being treated in a primary care setting
being slightly lower than that of being treated in a tertiary care setting for patients deemed low risk.
TABLE 54 Resource use and associated costs applicable in patients with NASH (£ 2011–12) (continued )
Resource use Unit cost Lower cost Upper cost Source
Test costs
US 51.00 32.00 62.00 Department of Health reference
costs 2011–12 (Code RA23Z)427
Monitoring of α-fetoprotein levels 1.38 – – Royal Free, 8 July 2013,
personal communicationa
Screening for HCC 52.38 – – Assumed to be cost of US and
monitoring of α-fetoprotein
levels
Liver function tests (AST–ALT) 0.90 – – AST, ALT (Royal Free, 8 July
2013, personal communication)a
Surgical interventions – –
Bariatric surgery 6,479 – – NICE guideline CG43:
costing report493
Liver transplant surgery and post care 17,741 – – CELT study424
US, ultrasound.
a See Appendix 9, Table 78.
TABLE 55 Resource costs per scenario (£ 2012)
Year
Scenario 1 Scenario 2 Scenario 3
Cost low
risk
Cost high
risk
Cost
total
Cost low
risk
Cost high
risk
Cost
total
Cost low
risk
Cost high
risk
Cost
total
Year 1 329 218 546 235 218 453 1148 129 1277
Year 2 277 227 504 211 227 438 182 85 267
Year 3 267 220 487 204 220 423 176 82 258
Year 4 258 212 471 197 212 409 170 79 250
Year 5 266 205 471 206 205 411 1000 77 1077
Total 2479 2135 3130
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Allowing for a prevalence rate of 5% means that liver biopsy would accurately diagnose 95% of the
cohort as true negative; in this scenario, fewer patients (n= 50) would be diagnosed and treated as high
risk within a tertiary care centre than in scenario 1 or 2 (n= 134). However, liver biopsy has the most
expensive resource cost per scenario; this was to be expected, as though we allowed for liver biopsy to
have perfect sensitivity and specificity in the analysis, it also had the most expensive test costs (£957).
We conducted a sensitivity analysis where we reduced of liver biopsy to that of Fibroscan and FIB-4
(£55.40) to determine the impact of a change in liver biopsy cost. This changed the results so that liver
biopsy became the least costly scenario (£1482 per person).
The prevalence rate used in the exploratory analysis is 5% (as per clinical advice); if we amended this to
20% (as per systematic review data) the cost per arm would increase (£3170 per person for scenario 1,
£2868 per person for scenario 2 and £4063 per person for scenario 3).
Analysis exploring impact on health outcomes
No data were available to accurately assess the impact of the referral pathway on the health outcomes of
patients. We conducted a further tentative exploratory analysis to assess possible impacts on health
outcomes. We estimated hypothetical QALYs for each test outcome (true negative, false negative, true
positive and false positive) based on assumptions about possible health outcomes in patients with NASH.
We did not identify data on the expected lifetime QALY estimates of people with NAFLD. In the absence of
available data, we assumed illustrative QALY values for patients with NAFLD based on the average lifetime
QALYs of patients with HBV. The expected mean QALYs for each of the four type of diagnosis (true
positive, false positive, true negative, false negative) from the HBeAg-negative model was assumed to
represent the average QALYs for patients with NAFLD and corresponding diagnoses. It is recognised that
the HRQoL and prognoses of patients with NAFLD may be lower in practice; however, data were not
available to include in the analysis.
We assumed that the expected lifetime QALYs of patients diagnosed as true or false positive would be
similar in a primary care setting as for patients diagnosed in tertiary care. A positive diagnosis in primary
care would involve immediate referral to a tertiary centre for further investigation and so would be unlikely
to lead to substantially different health outcomes. A difference in the health outcomes may be more likely
for patients whose test results are negative. We assumed that the estimates of lifetime QALYs for people
with true negative diagnoses treated in a tertiary care centre would be slightly higher than for those
treated in a primary care setting. It is hypothesised that patients treated in tertiary centres may benefit
from additional treatment such as access to behavioural therapists, physiotherapists and advice from
dieticians, even if their disease has not reached a more advanced stage of progression. We hypothesise
that the impact of management in primary care may be greater for patients with false-negative diagnoses,
and that the health outcomes of these patients may be less in primary care than in tertiary care due to less
intensive monitoring. We conducted an illustrative analysis where we assumed that the QALYs gained for
the group of patients treated in primary care would either be 90% or 75% of the QALYs gained of
comparable patients treated in the tertiary care setting (Table 56).
TABLE 56 Range of values for lifetime QALY for TN and FN patients
Diagnostic test outcome
Tertiary care Primary care
Lifetime QALY Varied at 90% Varied at 75%
FN 6.18 5.56 4.64
TN 13.12 11.81 9.84
FN, false negative; TN, true negative.
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Using the assumed range of QALY values, we can estimate the lifetime QALY that may apply for scenarios
1 and 2, assuming that the NILTs used are FIB-4 combined, followed by Fibroscan as a retest for
indeterminate results. The QALY gain for scenario 1 will remain constant at 13.00 as all patients will be
treated within tertiary care. The results are shown in Table 57.
The largest decrease in QALYs for both scenarios 2 and 3 is when we assume that the quality of life is
25% lower in false negative patients and 10% lower in true-negative patients when treated in primary
care as opposed to tertiary care. However, if we assume that true-negative patients have the same QALY
gain regardless of setting but false-negative patients retain a QALY which is 25% less than in tertiary care,
the difference in QALY gain between scenarios 1 and 2 is marginal. This implies that the true-negative
response has a higher impact on the overall QALY gain. This is due to the fact that the testing strategy
used (FIB-4, followed by Fibroscan retest for indeterminate patients) only has a 1% combined probability of
predicting a false-negative result. Tests which have a higher probability of false-negative outcomes and a
lower probability of true-negative outcomes may have different result when the values are varied.
Discussion
The lack of treatments specifically for the treatment of fibrosis progression in people with NAFLD meant
that a different approach to modelling was required. We conducted an incremental cost per case detected
to assess the relative cost-effectiveness of the tests. The results were analysed according to positive and
negative diagnoses as the potential consequences of each are likely to be very different. The analysis of the
incremental cost per correct positive diagnosis found that most of the tests were dominated or extendedly
dominated by liver biopsy; however, hyaluronic acid had an ICER of £1.27 and NAFIC (low cut-off) had an
ICER of £1.29. The ICER for liver biopsy was £112.30, which means that it costs an additional £112.30
to obtain an additional correctly diagnosed positive result compared with the next best alternative. The
analysis of the incremental cost per correct negative diagnosis found that FIB-4 (high cut-off) and NFS
(high cut-off) had ICERs of below £1, the ICERs for NFS ELF was £5.72 and for biopsy was £145.39.
Whether or not the ICERs for the biopsy represent good value for money is difficult to judge as there are
no established cost-effectiveness thresholds for this measure. In addition, they do not take into account
the potential negative impacts of biopsy on morbidity and mortality.
We conducted an exploratory analysis to tentatively assess the potential use of the tests to determine
referral to tertiary care. A lack of data meant that as some of our inputs are arbitrary (frequency of
appointments, exact resource use that would be incurred in primary care including access to specialists
such as dieticians or behavioural therapists), we would expect the results to be sensitive to changes in
assumptions or costs. The fact that they are confirms the need for well-designed long-term studies of
patients with NASH, part of which would include collecting good-quality resource use data for use in
economic models and further analysis.
TABLE 57 Results of exploratory analysis of referral pathways on expected QALYs
Diagnostic test outcome
Expected mean QALYs
Scenario 2 Scenario 3
High impact on FN (75%) and TN (90%) 11.86 11.55
High impact on FN (75%) and low impact on TN (100%) 12.98 12.80
Low impact on FN (90%) and low impact on TN (100%) 12.99 12.80
Low impact on FN (90%) and high impact on TN (90%) 11.87 11.55
FN, false negative; TN, true negative.
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The QALY analysis is based on assumptions as to date there have been no studies that have collected
HRQoL using a comparable measure such as an EQ-5D in patients with NAFLD. The lack of robust QALY
data is also a limitation. In the absence of viable data, we have based the analysis on results for people
with HBV. This assumption may have underestimated the decrement in HRQoL for patients with NASH.
One of the main limitations with regards to modelling NASH is the lack of effectiveness data relating to
the impact of treatment on fibrosis in patients with NASH. Well-designed prospective studies of patients
with NAFLD who are followed for long periods are lacking.472 This lack of data does not allow us to model
the long-term care pathway for NASH patients.
Treatment is often indicated for other conditions (diabetes, obesity, cardiovascular diseases) and, indeed,
most people die earlier from cardiovascular disease-related comorbidities than liver-related disease.500 It is
also hard to separate out why treatment has sometimes been given (e.g. bariatric surgery, liver biopsies are
performed during surgery but surgery is not necessarily carried out for a liver disease-related cause).
Although we did identify a recently published cost–utility analysis for treatment in patients with NASH,
we did not feel that the existing published data of potential treatments and their effect on liver fibrosis in
patients with NASH were of sufficient quality or quantity for use in a detailed economic model. Indeed,
the data derived by Mahady et al.489 indicate that both treatments analysed (pioglitazone and vitamin E)
had only a modest effect on liver fibrosis progression.
Well-designed long-term prospective RCTs are required in patients with NASH to capture the impact
of treatment and its progression on disease, to obtain valid estimates of quality of life and to obtain
good-quality long-term costing estimates for treatment and management of patients with NASH.
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Chapter 9 Cost-effectiveness analysis: cirrhosis
This chapter reports the cost-effectiveness analysis for cirrhosis and contains details of the literaturereview, modelling approach and results. The population of interest are those patients suspected of
having cirrhosis, irrespective of aetiology.
Literature review
Background
Cirrhosis is the end stage of every chronic liver disease. The development of HCC may accelerate the
course of the disease at any stage. Cirrhosis comprises two health states: compensated and
decompensated. Decompensated cirrhosis is defined by the presence of ascites, variceal bleeding,
encephalopathy and/or jaundice. HCC develops at a rate of approximately 3% per year in people
with cirrhosis.501
We searched the NICE guidelines website for national guidance on the management and treatment of
cirrhosis (applicable for all aetiologies). NICE guidelines for cirrhosis are currently in development. We also
searched for recent EASL guidelines for best-practice recommendations for the treatment of cirrhosis.
EASL guidance and position papers for HBV, HCV and ALD37,45 recommend long-term monitoring for HCC
in patients with cirrhosis.
Literature search
A search for relevant literature pertaining to costs and quality-of-life data for cirrhosis was conducted
using the MEDLINE database (via Ovid platform, search date 26 July 2013). To search for literature related
to cost data for cirrhosis we used the search terms ‘cirrhosis’ and ‘costs’ or ‘Costs and Cost Analysis’, and
for literature relating to quality-of-life data we used the search terms ‘cirrhosis’ and ‘Quality of Life’.
The search for cost data returned 413 papers and the search for quality-of-life data returned 739 papers.
We identified four papers that contained relevant data.456,502–504
The study by Thompson Coon et al.456 reported the clinical effectiveness, cost-effectiveness and cost–utility
of surveillance of HCC in patients with cirrhosis, using serum α-fetoprotein testing and/or ultrasound
examination. They allowed for treatment with liver transplantation or resection. The authors456 conducted
an analysis which analysed three aetiologies (ALD, HBV and HCV) separately but also produced a mixed
cohort weighted according to proportions of persons with ALD (57.6%), HBV (7.3%) and HCV (35.1%),
and, using these models, estimated lifetime costs for various HCC surveillance strategies. Thompson Coon
et al.456 concluded that the most cost-effective strategy to adopt for screening for HCC in patients with
cirrhosis (mixed aetiology) was to conduct screening using ultrasound and serum α-fetoprotein testing on a
6-monthly basis.
The 2008 paper identified by Andersson et al.502 looked at a similar screening programme to Thompson
Coon et al.456 within a US setting. They found that semiannual ultrasound surveillance was a cost-effective
strategy that improved outcomes at a reasonable cost. Bolondi et al.503 reported details of an Italian
cost-effectiveness analysis of a programme of monitoring HCC using ultrasound and α-fetoprotein testing.
The analysis was conducted alongside a study in which a cohort of patients with liver cirrhosis (n= 313)
received monitoring and a cohort of similar patients who acted as a control (n= 104). The authors
concluded that the surveillance programme was not a good use of health-care resources.503 Saab et al.504
reported a decision-analytic model to compare the cost-effectiveness of ultrasound, α-fetoprotein with
ultrasound and CT from a US (Medicare) perspective. The authors concluded that ultrasound is the most
cost-effective strategy.
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Of all the studies identified, the analysis by Thompson Coon et al.456 was most relevant to NHS practice;
however, none examined the use of the NILTs to determine which patients enter programmes of
monitoring or screening for HCC. We therefore conducted our own analysis of the cost-effective use of
the NILTs in this setting.
Cost-effectiveness analysis approach
We constructed a decision tree model to estimate the cost-effectiveness of NILTs in diagnosing cirrhosis.
The population were persons who were suspected of having cirrhosis. The analysis adopted a time horizon
of 4 years. The systematic review for NILTs for use in patients with cirrhosis identified 59 applicable tests
(see Chapter 4).
Model structure
The decision tree was based on the recommended management for patients with cirrhosis, which includes
screening for oesophageal varices (and ascites) and HCC. Patients received an initial NILT to diagnose the
presence of cirrhosis. Screening would occur only if the test returned a positive outcome (true positive or
false positive).
Model inputs
Average disease prevalence and test outcome
We estimated the average disease prevalence based on the data from the meta-analysis of the NILTs
(20%). We calculated the probability of each NILT returning a true positive, true negative, false negative or
false positive outcome using the sensitivity and specificity estimates from the meta-analysis data (see
Chapter 4) and the estimated average disease prevalence. The probability of each NILT returning a specific
diagnostic test outcome is listed in Appendix 7.
Screening tests and frequency
Following clinical advice, a large study of a surveillance programme for HCC in cirrhosis patients was
identified.505 This was a RCT analysing screening for HCC (using α-fetoprotein testing and ultrasound
examination every 6 months). Patients were allocated either to screening with an α-fetoprotein test and
ultrasound examination every 6 months or to no screening. The sample size was large (9373 in screening
group and 9443 in control group). The authors found that biannual screening with ultrasound examination
and α-fetoprotein testing was associated with a reduction in mortality (rate ratio 0.63; 95% CI 0.41
to 0.98), compared with no screening. We used this study as the source for effectiveness data related
to screening (as a reduction in HCC mortality of 37%). As our clinical effectiveness data were based on
the combination of the two tests used 6-monthly, we used the same screening strategy in our model.
We sourced costs for the screening tests from national sources,427 and via personal communication with
finance departments at the Royal Free Hospital (see Appendix 9, Table 78). We sourced additional costs of
screening from the study by Thompson Coon et al.456
Mortality from hepatocellular cancer: adjusted for screening and no screening
The study by Zhang et al.505 found that, for patients who were screened for HCC, there was a 37%
reduction in mortality from HCC compared with the non-screened group. We factored this into our model;
we estimated that a diagnostic test outcome of false negative (no screening programme) would have a
QALY value which was 37% lower than a diagnostic test outcome of true positive (screening programme).
Test costs
The cost of the NILTs were sourced from Department of Health reference costs 2011–12,427 personal
communication with finance departments based at the Royal Free Hospital and communication with
manufactures of patented serum markers (see Appendix 9, Table 78). The cost for liver biopsy was sourced
from published literature.428 Where required, costs were inflated to 2012 prices using NHS inflation indices.67
COST-EFFECTIVENESS ANALYSIS: CIRRHOSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
130
Costs and quality-adjusted life-year end points of decision tree
We used the average costs and QALY values over a 4-year period sourced from the model developed for
HBeAg-positive disease. We used this cohort as we sourced the reduction in mortality rate with screening
from the study by Zhang et al.505 who had conducted the RCT in a population with HBV. The time period
was also defined by the Zhang et al.505 study, which recruited patients over a 2-year period and with a
follow-up period of up to 5 years (average time period of follow-up was 3–5 years).
We used the true-positive Markov model for HBeAg-positive as we assumed that patients would receive
usual standard of care (including antiviral agents if applicable) alongside screening or no-screening
programmes. Costs and QALYs values were estimated from the model for a 4-year period. These estimates
also captured the progression through health states (including progression from moderate or cirrhotic
health states to more advanced liver disease states including decompensated cirrhosis). The costs and
QALYs also captured the probability of a patient moving from a compensated cirrhosis health state to a
decompensated cirrhosis health state. The costs and screening for oesophageal varices are included within
the costs and transition probabilities for the compensated cirrhosis health state. This treatment pathway
also captures treatment for HCC with liver transplant, including the post liver transplant state.
We assumed that patients who tested true negative or false positive would incur the costs and QALYs of
patients in a moderate to advanced fibrosis health state (F2–3). As patients who test false positive also
receive screening, we included the additional cost of screening every 6 months with ultrasound
examination and α-fetoprotein testing over a 4-year period in this cost.
We assumed that patients who tested true positive or false negative would incur the costs and QALYs of
patients in a cirrhotic health state (F4). Patients who tested false negative were assumed to not receive
screening, and, therefore, the cost of 6-monthly screening with ultrasound examination and α-fetoprotein
testing was excluded from their 4-year costs.
The cost and QALY end points used in the model are detailed in Table 58.
Analysis
We conducted a probabilistic analysis and compared the results of each non-invasive test and liver biopsy
incrementally to determine the cost-effective testing approach. We also constructed a CEAC and CEAF of
the results.
We conducted a sensitivity analysis where we allowed for an increase of 10% (arbitrary value) to apply to
the QALY value for false positive patients, to reflect the treatment benefit that may apply from receiving
screening (although not necessarily indicated in this patient cohort, there may be some benefit due to
earlier diagnosis of HCC). We also conducted a second sensitivity analysis where we removed the
6-monthly cost of testing with α-fetoprotein.
TABLE 58 Cost and QALY end point decision tree (£ 2012)
Diagnostic test outcome Cost QALY
TP 29,913 1.91
FN 29,703 1.19
TN 23,665 2.25
FP 23,875 2.25
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
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Results
The results of the incremental analysis are listed in Table 59. The results show that the most cost-effective
test to use would be Forns index (serum marker with a sensitivity of 100% and specificity of 74% in
patients with cirrhosis), with an ICER of £1926.
The CEAF (Figure 10) shows that given a cost-effectiveness threshold value of £20,000, Forns index used
alone has a 50% probability of being the optimal test (highest expected net benefit).The CEAC (see
Appendix 10) shows that Forns index has the highest probability of being the most cost-effective test (for
illustrative clarity, only tests which have a ≥ 5% probability of being cost-effective are shown in the CEAC).
A scatterplot illustrating the position of each testing strategy on the cost-effectiveness acceptability curve
compared with the least costly testing strategy can be found in Appendix 12.
TABLE 59 Incremental analysis of NILTs for cirrhosis
Diagnostic test Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
CDS (high cut-off) 24,908 2.082 – – Dominated
Fibrometer (high cut-off) 24,947 2.085 – – Dominated
Fibrosis Index 24,907 2.089 – – –
Hepascore (high cut-off) 24,920 2.090 – – Dominated
Lok’s index (high cut-off) 24,918 2.091 – – Extendedly dominated
FIB-4 (high cut-off) 24,921 2.096 – – Dominated
APRI (high cut-off) 24,920 2.098 – – Extendedly dominated
AST–ALT ratio 24,929 2.105 – – Extendedly dominated
ELF (high cut-off) 25,024 2.108 – – Dominated
BARD 24,935 2.109 – – Extendedly dominated
Fibrotest 24,972 2.122 – – Dominated
GUCI 24,942 2.126 – – Dominated
Forns index (high cut-off) 24,933 2.130 – – Extendedly dominated
APRI (combined cut-off) and Fibroscan 24,942 2.133 – – Dominated
Hepascore (combined cut-off)
and Fibroscan
24,945 2.135 – – Dominated
PIIINP 24,976 2.135 – – Dominated
Fibroindex 24,974 2.136 – – Dominated
Type IV collagen 24,973 2.136 – – Dominated
US SAPI 25,019 2.138 – – Dominated
Fibrotest (high cut-off) 24,967 2.138 – – Dominated
PLT 24,940 2.138 – – Dominated
Fibropaca 25,419 2.139 – – Dominated
Fibrometer 24,976 2.139 – – Dominated
US 24,982 2.139 – – Extendedly dominated
SAFE 25,628 2.140 – – Dominated
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TABLE 59 Incremental analysis of NILTs for cirrhosis (continued )
Diagnostic test Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Fibrotest (combined cut-off)
and Fibroscan
24,979 2.141 – – Dominated
King’s 24,940 2.141 – – Extendedly dominated
MR 25,119 2.141 – – Dominated
MRI 25,118 2.142 – – Dominated
APRI (low cut-off) 24,958 2.143 – – Dominated
PGAA 24,945 2.147 – – Extendedly dominated
Fontana 24,999 2.147 – – Dominated
FIB-4 (combined cut-off) and Fibroscan 24,951 2.148 – – Dominated
APRI 24,973 2.148 – – Dominated
Hepascore (low cut-off) 24,962 2.149 – – Dominated
FIB-4 24,960 2.149 – – Dominated
Hyaluronic acid 24,946 2.150 – – Dominated
Hepascore 24,961 2.151 – – Dominated
FIB-4 (low cut-off) 24,972 2.154 – – Dominated
Lok’s index (low cut-off) 24,982 2.155 – – Dominated
ARFI 25,001 2.155 – – Dominated
PLT–Spleen ratio 24,998 2.157 – – Dominated
ELF (combined cut-off) and Fibroscan 25,059 2.158 – – Dominated
Bordeaux 25,021 2.159 – – Dominated
CEUS 25,046 2.161 – – Dominated
Fibrotest (low cut-off) 25,012 2.161 – – Dominated
Forns index (low cut-off) 25,031 2.161 – – Dominated
Age–Platelet Index 24,971 2.161 – – Dominated
CDS 24,983 2.162 – – Dominated
Fibroscan 24,988 2.162 – – Dominated
Fibrometer (combined cut-off)
and Fibroscan
24,988 2.162 – – Dominated
DW-MRI 25,125 2.162 – – Dominated
CDS (low cut-off) 24,946 2.162 39 0.07 527
ELF (low cut-off) 25,070 2.164 – – Dominated
Forns index (combined cut-off)
and Fibroscan
24,982 2.167 – – Dominated
ELF 25,050 2.168 – – Dominated
Fibrometer (low cut-off) 25,009 2.172 – – Dominated
MR elastography 25,127 2.177 – – Dominated
Forns index 24,975 2.177 29 0.01 1926
CDS, Cirrhosis Discriminant Score; DW-MRI, diffusion-weighted magnetic resonance imaging; PLT, platelet; US, ultrasound.
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Sensitivity analysis
Allowing for a 10% increase to the QALY value for patients who are false positive does change the result
so that using Forns index (low cut-off) becomes the most cost-effective with an ICER of £1106.
A test with a low diagnostic cut-off is more likely to pick up more positive results, as we are increasing the
QALY outcome for patients who are false positive; it is more likely that tests with a low cut-off will have a
higher QALY gain, as evidenced by results (see Appendix 11).
Removing the cost of α-fetoprotein from the analysis did not change the base-case results.
Discussion
The results imply that using an indirect serum marker, Forns index, which has a high sensitivity (100%) and
a specificity of 74%, is the most cost-effective test, although this testing option is sensitive to changes in
assumptions around benefit for those who receive treatment when diagnosed as false positive. It has been
necessary to include several assumptions in order to conduct the analysis. These include that, in the
absence of data on the impact of surveillance on HRQoL, the reduction in mortality from screening would
translate directly into an equivalent reduction in QALYs.
The current analysis only takes a 4-year time horizon. Unfortunately, it was not possible to extrapolate the
data reported in the RCT by Zhang et al. over a longer period.505 If the health outcomes associated with
positive diagnoses were estimated over a longer period, we would expect these to have a greater impact
on the analysis, although this would be tempered by increased costs of surveillance. There is very little
difference in the mid-term outcomes from the tests (cost and QALY values), implying that the difference
between each test given a 4-year horizon is slight; extrapolation to lifetime would give a clearer picture as
it would include the long-term impact of each test (long-term impact based on test diagnoses).
The analysis evaluates screening for HCC using α-fetoprotein testing and ultrasound examination as the
clinical effectiveness data were based on a study which used this screening strategy; however, current practice
may be to use ultrasound examination only. We examined the impact of removing the cost of α-fetoprotein
testing in the sensitivity analysis; however, it may be the case that effectiveness is reduced with the exclusion
of α-fetoprotein testing (likewise, less frequent screening would also reduce the clinical effectiveness).
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FIGURE 10 Cost-effectiveness acceptability frontier for cirrhosis. CDS, Cirrhosis Discriminant Score.
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Chapter 10 Discussion
We have comprehensively reviewed the accuracy and cost-effectiveness of NILTs of fibrosis andcirrhosis. We identified a substantial amount of evidence for the NILTs as a whole (114,071 potential
papers identified, 302 relevant papers), and this is the first study to systematically evaluate and synthesise
this evidence base. The NILTs vary substantially in terms of how they diagnose fibrosis severity, and in their
cost. Some NILTs, such as the AST–ALT ratio, have been available in the NHS for a long time; however,
recently there has been a rapid expansion in the introduction and use of new NILTs, which could put
pressure on NHS resources.
The systematic review identified 41 NILTs for use in HCV, 21 NILTs for use in HBV, seven NILTs for use in
ALD and 28 NILTs for use in NAFLD. Thirty-six NILTs were found for cirrhosis (irrespective of aetiology) and
14 imaging modalities were found that were applicable for all aetiologies. The highest number of studies
identified was for HCV (n= 162). ALD had the lowest number of studies identified (n= 12). Fibroscan was
the NILT assessed in most studies across disease aetiologies: 37 in HCV, 13 in HBV, eight in NAFLD and
six studies in ALD.
Given limited health-care resources, the importance of considering the costs and benefits of competing
interventions is now widely recognised in order to make best use of available resources. The consideration
of cost-effectiveness is just as important for diagnostic tests as it is for treatments; in doing so it is
necessary to consider the health and cost consequences as a result of the test. In relation to this decision
problem, considering a cost per case detected would not give a complete picture as it would not reflect
important differences in the consequences of an incorrect positive test compared with the consequences
of an incorrect negative test. This does create a significant challenge for the cost-effectiveness analysis as
the clinical studies typically focus on the accuracy of the tests rather than on effectiveness and health
outcomes. We have attempted to overcome this challenge through the use of decision-analytic models and
the synthesis of a range of data.
Our analyses have reflected the different causes of fibrosis and cirrhosis. Disease progression, care
pathways and patient characteristics vary substantially between aetiologies; these have been analysed
separately, and different modelling approaches have been required to account for these differences.
For aetiologies HBV and HCV, active treatments are available which could (potentially) be instigated
depending on the presence of a specific level of fibrosis, and there is a reasonable evidence base for these
treatments. In these cases it is possible to reflect the potential consequences of the outcome of the fibrosis
test within the analysis (i.e. the start of treatment or not). The situation for ALD and NAFLD is somewhat
different as most interventions are aimed at behaviour change and would not depend on the outcome of
the test (e.g. a patient presenting with a BMI of 30 kg/m2 would likely be given dietary and exercise advice
regardless of whether the NILT indicates level 1 or 3 fibrosis). There has been investigation of some
pharmacological treatments of fibrosis in these patients, but generally the evidence is considered to be
weak and they have not so far been included in the standard guidelines for treatment (e.g. EASL position
paper for the treatment of patients with NAFLD). In practice, the pathway of care for these patients
diagnosed with significant fibrosis or cirrhosis may include increased monitoring, screening for HCC and
treatment of complications; however, evidence on the effectiveness of these overall packages of care is not
available. The cost-effectiveness analyses of the NILTs in ALD is based on their potential impact on
abstinence rates and draws heavily on a previously published HTA.428 The analysis for NAFLD is limited to
an incremental analysis of the cost per correct positive/negative diagnoses and exploratory analyses around
the cost-effectiveness including longer-term outcomes. The cost-effective testing strategy for each
aetiology is presented in Table 60.
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The results for HCV show that a strategy of treating all those suspected of fibrosis without testing is
cost-effective. For conclusions regarding the population with HBV, the results were less clear. For patients
with HBeAg-negative disease, the conclusion regarding cost-effectiveness depends on the specific
cost-effectiveness threshold employed. In the UK, NICE specifies a cost-effectiveness threshold range of
£20,000–30,000 per additional QALY, below which technologies are usually considered cost-effective and
within which specific additional factors must be considered important. It is unclear which threshold is
appropriate in this circumstance: we note that NICE has previously approved treatment for people with
HBV with an ICER above the £20,000 lower bound;417 however, we also acknowledge that recent research
has suggested that the threshold for the NHS should be lower than that specified by NICE.506
Current NICE guidance for HCV recommends that all patients with mild HCV should receive treatment
with antiviral agents.443 Our analysis reinforces this recommendation; our findings indicate that that
treating all patients irrespective of fibrosis stage without prior testing is the most cost-effective option.
However, recent clinical practice guidelines published by EASL state that all treatment-naive patients with
compensated chronic liver disease related to HCV should receive treatment (if willing).507 The guidelines
also argue that the timing of treatment in patients with minimal or no fibrosis is debatable and could be
deferred pending the development and availability of new treatment (a strategy which should include
regular assessment). One reason to defer would be due to the potential side effects of current triple
therapy (boceprevir and telaprevir). We conducted a sensitivity analysis which incorporated a HRQoL
decrement to represent potential side effects of current treatment; however, this had no effect on the
TABLE 60 Cost-effective testing strategy for each aetiology
Aetiology
Cost-effective test for a threshold
of £20,000 per QALY gained
Cost-effective test for a threshold
of £30,000 per QALY gained
Incremental analysis
HBeAg-positive
Single test GUCI MR elastography
Sequential tests Strategy 2: first NILT, hyaluronic acid;
second NILT, MR elastography
MR elastography used singly
HBeAg-negative
Single and sequential testing No test or treatment Treat all (no prior test)
Hepatitis C
Single test Treat all (no prior test) Treat all (no prior test)
Sequential tests Treat all (no prior test) Treat all (no prior test)
ALD
Liver biopsy Liver biopsy
Cirrhosis
Forns index Forns index
Cost-effective test for a threshold
of £2 per correct diagnosis
Cost-effective test
for a threshold of
£10 per correct
diagnosis
Cost-effective test
for a threshold of
£150 per correct
diagnosis
Cost per correct diagnosis
NAFLD
True positive NAFIC (low cut-off) NAFIC (low cut-off) Liver biopsy
True negative NFS (high cut-off) NFS ELF (high
cut-off)
Liver biopsy
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overall conclusions (see Chapter 6). We also conducted an exploratory analysis to evaluate potential
new antiviral treatment (see Chapter 6), the results of which depended on the increase in treatment
price. With this analysis, if treatment cost was increased by more than approximately £37,500 (with a
corresponding increase in SVR rate: see Chapter 6 for details), the strategy ‘treat all’ was not cost-effective;
however, this analysis was exploratory and not based on actual data. The issue of whether or not
treatment should be deferred until the arrival of new antiviral drugs cannot be answered conclusively given
current data on efficacy and treatment cost.
Current NICE guidelines for HBV374 recommend that antiviral treatment is considered for people with
evidence of fibrosis following a liver biopsy, or following either a biopsy or diagnosis using Fibroscan for
adults aged < 30 years. Our results for HBeAg-positive patients (though highly uncertain: see Chapter 5)
found that the use of a NILT with treatment initiation if the patient tested positive was the most
cost-effective option without the need for biopsy. The analysis focusing on only those tests where the
bivariate model converged found that testing with Fibroscan to assess fibrosis level prior to treatment was
the cost-effective option. This finding applied to all patients in the analysis and not just to young adults
as in the NICE guidance. For HBeAg-negative patients, our findings were somewhat different from the
current NICE guidelines. These found that treatment without prior testing was cost-effective if the upper
bound of the NICE threshold was accepted, and no treatment if the lower cost-effectiveness threshold was
considered to apply. Current EASL clinical practice guidelines for HBV recommend that all patients should
receive treatment if they have HBV DNA levels > 2000 IU/ml and/or serum ALT levels above the ULN for
the laboratory, and results from a liver biopsy or a non-invasive marker showing moderate to severe
necroinflammation and/or fibrosis using a standardised scoring system (e.g. at least grade A2 or stage F2
by METAVIR scoring).45 However, as noted above, our analysis shows that for HBeAg-negative patients,
strategies without prior testing were the most cost-effective options.
The assessment of cost-effectiveness of the NILTs in HCV found that results were driven by the estimates
of treatment effectiveness in this particular group. Treatments for fibrosis in these populations, as for
people with HBV, have marketing authorisations for treatment of fibrosis regardless of METAVIR score,
and patients with only mild fibrosis may benefit from early treatment.443 The absolute benefit in terms of
health outcomes may, however, not be as great as for patients with more severe levels of fibrosis, and the
cost-effectiveness was uncertain. We assessed whether or not using the NILTs to target treatment to those
with more severe fibrosis would be a cost-effective use of resources compared with a strategy of treating
all those people with HBV or HCV and suspected fibrosis. The base-case analysis found that a scenario
where everyone received early treatment was the most effective and cost-effective option, compared with
using NILTs to target treatment for those with more severe fibrosis. However, when we conducted a
sensitivity analysis around the assumption of treatment benefit in patients with mild fibrosis, treating
everyone without a prior diagnostic test stopped being the most cost-effective option when we reduced
treatment benefit by approximately 23%, after which it became cost-effective to use a NILT, MR
elastography, which had high summary sensitivity and specificity in this population (94% and 92%). If the
absolute benefit from treatment is not as high in patients with mild fibrosis as it is for patients with more
advanced fibrosis, then it would be more advisable to target treatment using a NILT to identify those with
advanced disease.
Given that increasingly sedentary lifestyles and changing dietary patterns mean that NAFLD poses a
significant health problem, we strongly recommend that these evidence gaps are addressed. Currently,
fatty liver accounts for 0.1% of all deaths in England (648 deaths annually). Fatty liver is also an underlying
contributory cause for 1801 deaths per year, which is higher than for any other cause of liver disease.
The prevalence of NALFD is also increasing in children, with 10–77% among those who are obese,508
and its presence is associated with progressive liver disease including cirrhosis, which could lead to the
need for liver transplantation. The implications of the increasing extent of NAFLD within the population,
and in particular within the paediatric population, suggest that this will place an ever-increasing burden on
the NHS.
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Long-term prospective studies of target-based interventions are required in this population (both adult and
paediatric) to determine effective treatments to halt the progression of fibrosis and subsequently limit the
encumbrance of this disease on the health-care system.
Additionally, in NAFLD, non-invasive tests differentiate significant fibrosis but not steatohepatitis from
simple steatosis. Whereas simple steatosis is usually benign, steatohepatitis could potentially progress to
end-stage liver disease. Steatohepatitis is not necessarily characterised by fibrosis, meaning that it could
potentially be missed and, therefore, patients and doctors could be falsely reassured. Non-invasive assays
that differentiate steatohepatitis from steatosis are based in apoptosis rather than fibrosis509 and have not
been adequately validated. Subsequent development and validation of such markers is warranted given
the increasing prevalence of NAFLD in the general population. Their assessment was beyond the scope of
this review.
Strengths of analysis
Our meta-analysis of NILTs has been the most detailed and extensive to date, including all described serum
tests and imaging modalities with no language restrictions and using state-of-the-art statistical and
reporting methods. A similar recent study by Chou et al.510 conducted a systematic review evaluating the
diagnostic accuracy of blood tests to identify fibrosis or cirrhosis in patients with HCV infection. However,
this study restricted its analysis to blood tests for fibrosis, searched fewer databases and excluded studies
not in the English language. The study included serum NILTs but did not include imaging modalities such
as Fibroscan in HCV. In addition, the study did not attempt to estimate the cost-effectiveness of these tests
for use in HCV. One of the main strengths of our analysis is that we have analysed the cost-effectiveness
of these tests in both HBV and HCV and we have based this cost-effectiveness on the long-term impact
resulting from a diagnostic test outcome rather than just basing it on the cost of the test itself.
Limitations of analysis
Although the totality of the evidence was substantial for the NILTs, there was considerable variation in
the amount and quality of the evidence for individual tests. A great number of NILTs for specific fibrosis
stages either were assessed in single studies or had results that did not converge using the random-effects
model with correlation between sensitivity and specificity. We assessed the impact of this on the conclusions
from the cost-effectiveness analyses through sensitivity analyses including only those where the most robust
models of test accuracy were possible. This reduced the number of tests analysed for HBV by 20 and for
HCV by 43. The number of tests excluded emphasises how many NILTs had diagnostic accuracy data that
were not robust. When we removed the tests, the results changed for HBeAg-positive model only.
Furthermore, only five of the included studies or 1.6% were of high methodological quality; therefore, all
results are likely to be biased. This implies that further studies with better design are warranted to increase
the robustness of the results.
Finally, cut-offs of NILTs for specific fibrosis stages varied in published studies and were not always
predetermined or sufficiently validated. This is similar to measuring renal function with serum creatinine
but not knowing the exact ULN. Apart from the practical issue of applying the NILTs in clinical practice
with uncertain cut-offs, this resulted in overestimation of diagnostic accuracy of NILTs in the meta-analysis
in all cases where there is a range of cut-offs.
The number of data available varied considerably between aetiologies. For example, for NAFLD we
identified a position paper by EASL472 and a practice guideline by AASLD.47 Current treatment
recommended in both papers included weight-loss programmes and treatment to ameliorate the metabolic
conditions associated with NAFLD. However, we found insufficient evidence around either lifestyle
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interventions or effective pharmacological treatments directed at the liver to prevent fibrosis progression
specifically in patients with NASH.
Uninterpretable and indeterminate results were reported in < 50% of studies; however, they were
infrequent in serum non-invasive tests (<1%) and could be considered negligible. In the case of Fibroscan,
uninterpretable results were prevalent in 8–10% of examinations; this is probably an underestimated
failure rate, as not all studies reported on failures while others included failures in the exclusion criteria.
In a prospective study of over 10,000 Fibroscan examinations, unreliable results were reported in 15.8% of
cases and were associated with obesity, age > 52 years, operator experience and presence of diabetes.511
This significant failure rate is an important caveat in the use of Fibroscan. This NILT was the most
cost-effective option when tests which did not converge (using bivariate model) were excluded from
the analysis for HCV and HBeAg (positive), where the cost-effectiveness threshold was £20,000 and
£30,000, respectively. However, as we did not account for indeterminate Fibroscan results in our
economic analysis, its cost-effectiveness is likely to have been overestimated.
The searches for the systematic review were conducted in April 2012; as the research took place over a
2-year time period, it was not possible to conduct an updated search. This may mean that we have missed
some diagnostic accuracy studies published since April 2012. However, given the robust findings for some
of the aetiologies, for example that the ‘treat all’ strategy remained robust to the majority of sensitivity
analyses for patients with HCV, any additional studies may not have a substantial impact on our analysis.
Currently, most studies report the results for diagnostic test accuracy using a 2 × 2 classification matrix,
which restricts test results to either positive or negative.512 Using these data, we can predict the summary
sensitivity and specificity data required to summarise the diagnostic accuracy for each NILT. We initially
attempted to construct the models for HBV and HCV using a 3 × 3 classification matrix to allow for the
multiple categories of the METAVIR staging system. The restriction of studies reporting in a 2 × 2 format
did not allow us to estimate with precision the proportion of people who tested incorrectly who may have
had a higher or lower degree of disease. For example, if a non-invasive test returns a certain number of
false-positive outcomes, and we used a section of the data which represented a by METAVIR score of F3,
it is not possible from the data provided in the studies to determine the number of persons who actually
have mild (F1) or moderate (F2) fibrosis. Likewise, if we use a F2-by-METAVIR section of the data, although
we can estimate the probability of a test reporting a false-negative result, we do not know the split within
this false-negative result that is applicable to either advanced disease (F3) or cirrhosis (F4).
A 2012 paper by Schuetz et al.513 examined whether a 3 × 2 classification matrix is better than the 2 × 2
classification matrix when assessing diagnostic accuracy. They found that the parameters for diagnostic
accuracy (summary and sensitivity estimates) decrease significantly if a 3 × 2 table is used. As there was a
lack of studies reporting data using a 3 × 2 classification matrices, we used a F2 by METAVIR section of the
data for our HBV and HCV models. Using this meant that we could not model the population cohorts who
are diagnosed as F2 or F3 separately. Although we could identify the prevalence of patients with a
METAVIR score of F4 from the meta-analysis data, we could not with accuracy identify the same for F3 as
the reported data for F3 also included F4 scores (i.e. this section of the data represented diagnostic
accuracy from the study for METAVIR scores which were ≥ F3).
Our findings, though UK based, should be applicable to health systems where the treatment pathway for
patients with liver disease is similar. However, our results may not be generalisable to other settings,
particularly resource-poor countries especially where the finding is to treat all patients irrespective of
disease level.
A transferability issue may also arise over the estimated prevalence used in the analysis. The prevalence
was estimated from the studies found during the systematic review; however, these were conducted in
tertiary care settings, mainly in countries where the populations might be very different from those in
countries with a lower level of health care.
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Liver biopsy, although the reference standard for fibrosis assessment, is not 100% sensitive and specific,
due to sample and intra- and interobserver variability. Moreover, it assesses fibrosis semiquantitatively and
histological scores include both description of fibrosis and architecture. The misclassification rate of liver
biopsy is the source of the myth that non-invasive fibrosis tests cannot achieve a high concordance with
histological stages. However, serum non-invasive fibrosis markers have been developed and calibrated with
direct reference to a set of liver biopsies. Therefore, the perfect serum marker in this case would replicate
the ‘golden’ histological standard and could theoretically reach an AUROC of 1, replicating even the
misclassifications of a liver biopsy. Imaging modalities, such as Fibroscan, that have been developed
independently of liver biopsy, could potentially be affected by the misclassification rate of a liver biopsy.
A potential solution would be to validate NILTs against clinical outcomes; however, this would take time
and would require large cohorts of patients. Another solution would be for non-invasive fibrosis markers,
which assess fibrosis quantitatively, to be ideally developed and validated with reference to a pure
histological quantitative assessment of liver fibrosis. Such histological methods that quantify fibrosis by
measuring liver collagen using digital image analysis have indeed been developed and could be used in
future studies.
DISCUSSION
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Chapter 11 Conclusion
The evidence suggests that, for HCV, treating all patients without prior diagnostic testing is themost cost-effective option. For HBV, the results differed for patients with HBeAg-positive disease
and HBeAg-negative disease. The results suggests that if the upper bound of the standard UK
cost-effectiveness threshold range is accepted for patients with HBeAg-negative disease, a strategy
where all patients are treated regardless of fibrosis level is cost-effective.
For patients with HBeAg-positive disease, at standard UK cost-effectiveness thresholds the results are
highly uncertain, with several test strategies having similar expected outcomes and costs. Based on our
results, using two NILTs sequentially (hyaluronic acid combined with MR elastography using the second
sequential testing strategy outlined in Chapter 2) is most likely to be the optimal strategy at a threshold
of £20,000; however, there is only a 4% probability of this being optimal.
Liver fibrosis and cirrhosis from HBV and HCV are significant health problems worldwide. The findings from
the models may not be transferable to a resource setting where funds are limited and the ability to treat all
patients is not a realistic option.
Abstinence is recommended for patients with ALD. There was a lack of data to allow robust modelling
of the impact of testing on abstinence rates and whether or not these are affected by the degree of
invasiveness of the tests. If abstinence is likely to increase following diagnosis and if it is likely to be higher
following an invasive test, then biopsy is very likely to be cost-effective. If there is no differential impact of
the invasiveness of the test on abstinence, then Fibrotest is likely to be cost-effective (with either a high or
low test threshold depending on the overall impact of fibrosis diagnosis on abstinence rates).
For NAFLD, most interventions are aimed at behavioural change and are not necessarily recommended
specifically to reduce or halt fibrosis progression (e.g. weight-loss programmes for obesity). We located
some studies for pharmacological interventions which had looked at the impact on fibrosis in NASH,
but found that they had not conclusively demonstrated significant impact; this implies that the current
potential pharmacological treatments such as pioglitazones are not effective in patients with NASH
and fibrosis.
Implications for research
Further research could examine if the model is applicable to other settings, particularly resource-poor
settings. Hepatitis is a global health problem and the pathways of care and expected treatment
outcomes are likely to differ between settings. As such, the consequences of a false-negative test and
a false-positive test may have different levels of importance according to locality. The cost-effectiveness
of the non-invasive tests could be evaluated in these specific local settings, taking into account availability
of treatments, local cost data and HRQoL values.
The impact of new therapies on cost-effectiveness (higher costs but fewer side effects and better efficacy)
for HCV also warrant further investigation.
We were limited in our modelling approach as diagnostic studies do not report data using 3 × 2 tables,
which would have allowed us to model the diagnostic test outcomes with precision. Future studies need
to report all outcomes from tests rather than dichotomising into 2 × 2 tables in order to make the results
more applicable for cost-effectiveness studies of diagnostic tests.
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With alcoholic steatohepatitis, as abstinence is recommended at any stage of liver disease, we have
assumed that the diagnosis of fibrosis impacts on abstinence rates and, furthermore, that abstinence may
be further increased through more invasive tests. This was based on weak evidence, and further research
could be conducted to assess the impact of testing on abstinence. It may be the case that interventions
that include monitoring and support may be more effective in patients with lower degrees of fibrosis than
non-invasive tests or biopsy. Further research needs to be conducted in this area.
With NAFLD, the lack of data was a significant limitation to our modelling. Considering the growing
burden of the related complications with this disease on the NHS, long-term prospective studies are
required that collect data on the impact of treatments on patients with NASH and fibrosis, long-term
resource use and associated HRQoL using a comparable measure such as the EQ-5D. Data are also
required on the relative effectiveness of management and treatment in primary care rather than
secondary referrals.
Additionally, NILTs cannot differentiate simple steatosis from steatohepatitis in patients with NAFLD.
Therefore, there is a need to develop reliable non-invasive tests for this, as simple steatosis is usually
non-progressive, whereas steatohepatitis could potentially progress to significant fibrosis and cirrhosis.
High-quality studies with a low risk of bias for NILTs are required to allow for sufficient validation of
specific cut-offs to stage fibrosis in different disease aetiologies. These require the use of predetermined
cut-offs for the NILTs, adequate biopsy samples, selection of consecutive patients with no inappropriate
exclusions and adequate reporting of patient flow and indeterminate results.
The potential use of NILTs to predict liver-related complications rather than to stage fibrosis should be
further explored. This would provide a hard end point and overcome the need for liver biopsy.
CONCLUSION
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Appendix 1 Literature review: diagnostic test
accuracy data
Search strategy
Date of search: April 2012.
1. CT.ti,ab.
2. tomodensitometry.ti,ab.
3. PET.ti,ab.
4. MRI.ti,ab.
5. NMRI.ti,ab.
6. zeugmatogra*.ti,ab.
7. ((computed or computeri?ed or magneti* or proton or “Acoustic Radiation Force Impulse” or ARF)
adj5 (tomogra* or scan or scans or imaging)).ti,ab.
8. Tomography, X-Ray Computed/
9. Magnetic Resonance Imaging/
10. elastography.ti,ab.
11. elastographies.ti,ab.
12. sonoelastography.ti,ab.
13. sonoelastographies.ti,ab.
14. sono-elastography.ti,ab.
15. sono-elastographies.ti,ab.
16. elastogram.ti,ab.
17. elastograms.ti,ab.
18. vibroacoustography.ti,ab.
19. vibroacoustographies.ti,ab.
20. vibro-acoustography.ti,ab.
21. vibro-acoustographies.ti,ab.
22. fibroscan.ti,ab.
23. elastometry.ti,ab.
24. elasticity.ti,ab.
25. “liver stiffness”.ti,ab.
26. elastogra*.ti,ab.
27. echogra*.ti,ab.
28. ultrason*.ti,ab.
29. ultrasound.ti,ab.
30. Ultrasonography/
31. Elasticity Imaging Techniques/
32. Elasticity.ti,ab.
33. ((alanine* or aspartate* or glutamic*) and (transaminase or aminotransferase*)).ti,ab.
34. SGOT.ti,ab.
35. SGPT.ti,ab.
36. AST.ti,ab.
37. ALT.ti,ab.
38. Aspartate Aminotransferases/
39. Alanine Transaminase/
40. platelet.ti,ab.
41. platelets.ti,ab.
42. thrombocyte.ti,ab.
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43. thrombocytes.ti,ab.
44. APRI.ti,ab.
45. Blood Platelets/
46. 46. Biological Markers/
47. ELF.ti,ab.
48. “enhanced liver fibrosis”.ti,ab.
49. Fibrotest.ti,ab.
50. Fibrosure.ti,ab.
51. Fibrometer.ti,ab.
52. FIB4.ti,ab.
53. FIB-4.ti,ab.
54. BARD.ti,ab.
55. Fibrospect.ti,ab.
56. Hepascore.ti,ab.
57. “Hyaluronic acid”.ti,ab.
58. hyaluronate.ti,ab.
59. Hyaluronic Acid/
60. “Forns index”.ti,ab.
61. laminin.ti,ab.
62. Laminin/
63. YKL-40.ti,ab.
64. “YKL 40”.ti,ab.
65. “Type IV collagen”.ti,ab.
66. Collagen Type IV/
67. “Procollagen III N-peptide”.ti,ab.
68. “Lok index”.ti,ab.
69. MP3.ti,ab.
70. MP-3.ti,ab.
71. “Fibrosis probability index”.mp. or “sydney index”.ti,ab.
72. FPI.ti,ab.
73. Fibroindex.ti,ab.
74. “Virahep-C index”.ti,ab.
75. “Virahep C index”.ti,ab.
76. “Göteborg University Cirrhosis Index”.ti,ab.
77. GUCI.ti,ab.
78. SHASTA.ti,ab.
79. Glycocirrhotest.ti,ab.
80. Glycofibrotest.ti,ab.
81. BAAT.ti,ab.
82. “NAFLD fibrosis score”.ti,ab.
83. Cytokeratin-18.ti,ab.
84. “Cytokeratin 18”.ti,ab.
85. M30.ti,ab.
86. M-30.ti,ab.
87. “NASJH test”.ti,ab.
88. “NAFIC score”.ti,ab.
89. PGA.ti,ab.
90. “PGAA index”.ti,ab.
91. “Bonancini score”.ti,ab.
92. “Pohl score”.ti,ab.
93. “Cirrhosis discriminant score”.ti,ab.
94. “Age-platelet index”.ti,ab.
95. TIMP-1.ti,ab.
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96. “tissue inhibitory metalloprotease”.ti,ab.
97. MBT.ti,ab.
98. “C-methacetin breath test”.ti,ab.
99. “Phosphoproteomic biomarker”.ti,ab.
100. “Phosphoproteomic biomarkers”.ti,ab.
101. PICP.ti,ab.
102. PIIINP.ti,ab.
103. PON-I.ti,ab.
104. “paraoxonase I”.ti,ab.
105. MFAP-4.ti,ab.
106. “MFAP 4”.ti,ab.
107. MFAP4.ti,ab.
108. “microfibril associated glycoprotein 4”.ti,ab.
109. or/1-9,27-30,33-39
110. limit 109 to yr=“1988 -Current”
111. or/10-26,30-32,40-108
112. limit 111 to yr=“2001 -Current”
113. 110 or 112
114. cirrhosis.ti,ab.
115. cirrhoses.ti,ab.
116. fibrosis.ti,ab.
117. fibroses.ti,ab.
118. “liver disease”.ti,ab.
119. (hepatitis or hepatic).ti,ab.
120. steatohepatitis.ti,ab.
121. Liver Cirrhosis/
122. Fibrosis/
123. Liver Diseases/
124. Hepatitis/
125. or/114-124
126. 113 and 125
127. exp “sensitivity and specificity”/
128. “reproducibility of results”/
129. diagnos*.ti. or diagnostic.ab.
130. di.fs.
131. sensitivit*.ab.
132. specificit*.ab.
133. (ROC or “receiver operat*”).ab.
134. Area under curve/
135. (“Area under curve” or AUC).ab.
136. (sROC or “optimal cut-off”).ab.
137. (accura* or ((gold* or reference) adj2 standard)).ti,ab.
138. (likelihood adj3 (ratio* or function*)).ab.
139. ((true or false) adj3 (positive* or negative*)).ab.
140. ((positive* or negative* or false or true) adj3 (rate* or predictive)).ti,ab.
141. or/127-140
142. 126 and 141
143. *liver cirrhosis/di
144. *hepatitis/
145. *fibrosis/
146. (liver or hepatitis or hepatic or fibrosis).ab.
147. di.fs.
148. 146 and 147
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149. or/143-145,148
150. 113 and 149
151. 113 and 149
152. 142 or 151
Search narrative
This search strategy has been kept deliberately very broad – utilising only two main search concepts: index
test(s) (concept A) – lines 1–108 – and the disease of interest (concept B)/location of disease of interest
(concept B) – lines 110–120. A methodological filter (concept C) is included but does not act as a filter to
all search results [it is used in parallel: (A AND B AND C) OR (A AND B-focused)].
Potential studies for inclusion were initially identified from published non-Cochrane reviews and
background literature. This generated a reference set of 70 potential (and probable) studies for inclusion
to use to test the search strategy detailed above. The strategy was designed without knowledge of
the 70 potential studies or of the search strategies used to identify the 70 from their original publications.
All 70 studies were identified by the above strategy.
The yield from the above strategy was high. However, due the large number of tests within the scope of
the review, a large yield could not be avoided.
Validation string
(“19196449” or “18448567” or “16823833” or “15685546” or “19013661” or “18673426” or
“18410556” or “18672413” or “16394849” or “16020491” or “17255218” or “18192914” or
“17258346” or “17530363” or “18987556” or “19413672” or “17663420” or “18568136” or
“18637064” or “18818788” or “18930329” or “18705692” or “19261000” or “21904476” or
“17608672” or “18218676” or “19030204” or “19104699” or “18544945” or “19308312” or
“18832522” or “18083083” or “12883497” or “20493576” or “20180868” or “19060630” or
“19013661” or “18672413” or “19758273” or “19171202” or “18339075” or “18285716” or
“18339592” or “19999223” or “18796094” or “18706734” or “18482283” or “18553008” or
“18692034” or “17156890” or “17321634” or “17634962” or “17914968” or “16970597” or
“16538110” or “16487951” or “16863553” or “17032409” or “16118349” or “17032410” or
“16737415” or “16620291” or “16825937” or “16268817” or “16109665” or “15894397” or
“15915455” or “16284529” or “15122779” or “17393509” or “18390575” or “19291784”).ui.)
EMBASE
Date of search: April 2012.
1. exp *Liver Cirrhosis/ or exp *Liver Fibrosis/ or exp *Liver Disease/ or exp *Hepatitis/
2. (liver or hepatic).ti,ab.
3. exp *Liver/
4. 3 or 2
5. (cirrhosis or cirrhoses or fibrosis or fibroses or liver disease or hepatitis or steatohepatitis).ti,ab.
6. 4 and 5
7. 1 or 6
8. (CT or tomodensitometry or MRI or NMRI or zeugmatogra*).ti,ab.
9. ((computed or computerised or computerized or CT or magneti* or MR or NMR or proton) and
(tomogra* or scan or scans or imaging)).ti,ab.
10. exp *computer assisted tomography/
11. exp *nuclear magnetic resonance imaging/
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12. (elastography or elastographies or sonoelastography or sonoelastographies or sono-elastography or
sono-elastographies or elastogram or elastograms or vibroacoustography or vibroacoustographies or
vibro-acoustography or vibro-acoustographies or fibroscan or elastometry or elasticity or liver stiffness
or echogra* or ultrason* or ultrasound).ti,ab.
13. exp *ultrasound/
14. exp *elastography/
15. ((alanine* or aspartate* or glutamic*) and (transaminase or aminotransferase*)).ti,ab.
16. (platelet or platelets or thrombocyte or thrombocytes or APRI or ELF or enhanced liver fibrosis
or Fibrotest or Fibrosure or Fibrometer or FIB4 or FIB-4 or BARD or Fibrospect or Hepascore or
Hyaluronic acid or hyaluronate or Forns index or laminin or YKL-40 or YKL 40 or Type IV collagen or
Procollagen III N-peptide or Lok index or MP3 or MP-3 or Fibrosis probability index or FPI or Fibroindex
or Virahep-C index or Virahep C index or Göteborg University Cirrhosis Index or GUCI or SHASTA or
Glycocirrhotest or Glycofibrotest or BAAT or NAFLD fibrosis score or Cytokeratin-18 or Cytokeratin
18 or M30 or M-30 or NASJH test or NAFIC score or PGA or PGAA index or Bonancini score
or Pohl score or Cirrhosis discriminant score or Age-platelet index or TIMP-1 or tissue inhibitory
metalloprotease or MBT or C-methacetin breath test or Phosphoproteomic biomarker or
Phosphoproteomic biomarkers or PICP or PIIINP or PON-I or paraoxonase I or MFAP-4 or MFAP 4
or MFAP4 or microfibril associated glycoprotein 4).ti,ab.
17. (SGOT or SGPT or AST or ALT).ti,ab.
18. exp *alanine aminotransferase/
19. exp *aspartate aminotransferase/
20. exp *thrombocyte/
21. exp *biological marker/
22. (2001* or 2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or 2009* or 2010* or
2011* or 2012*).em.
23. 12 or 14 or 16 or 20 or 21
24. 22 and 23
25. 8 or 9 or 10 or 11 or 13 or 15 or 17 or 18 or 19
26. limit 25 to yr=“1988 -Current”
27. 24 or 26
28. 7 and 27
Science Citation Index expanded
Date of search: 1988 to April 2012.
#1 TS=(cirrhosis OR cirrhoses OR fibrosis OR fibroses or liver disease or hepatitis or steatohepatitis)
#2 TS=(liver or hepatic)
#3 TS=(CT OR tomodensitometry OR PET OR MRI OR NMRI OR zeugmatogra*)
#4 TS=((Acoustic Radiation Force Impulse or ARFI OR computed OR computerised OR computerized OR CT
OR magneti* OR MR OR NMR OR proton) AND (tomogra* OR scan OR scans OR imaging))
#5 TS=(elastography or elastographies or sonoelastography or sonoelastographies or sono-elastography
or sono-elastographies or elastogram or elastograms or vibroacoustography or vibroacoustographies or
vibro-acoustography or vibro-acoustographies or fibroscan or elastometry or elasticity or liver stiffness
OR echogra* OR ultrason* OR ultrasound)
#6 TS=( (alanine* OR aspartate* OR glutamic*) AND (transaminase OR aminotransferase*))
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#7 TS=(SGOT OR SGPT OR AST OR ALT OR platelet OR platelets OR thrombocyte OR thrombocytes OR
APRI OR ELF OR enhanced liver fibrosis OR Fibrotest OR Fibrosure OR Fibrometer OR FIB4 OR FIB-4 OR
BARD OR Fibrospect OR Hepascore OR Hyaluronic acid OR hyaluronate OR Forns index OR laminin
OR YKL-40 OR YKL 40 OR Type IV collagen OR Procollagen III N-peptide OR Lok index OR MP3 OR MP-3
OR Fibrosis probability index OR FPI OR Fibroindex OR Virahep-C index OR Virahep C index OR Göteborg
University Cirrhosis Index OR GUCI OR SHASTA OR Glycocirrhotest OR Glycofibrotest OR BAAT OR NAFLD
fibrosis score OR Cytokeratin-18 OR Cytokeratin 18 OR M30 OR M-30 OR NASJH test OR NAFIC score OR
PGA OR PGAA index OR Bonancini score OR Pohl score OR Cirrhosis discriminant score OR Age-platelet
index OR TIMP-1 OR tissue inhibitory metalloprotease OR MBT OR C-methacetin breath test OR
Phosphoproteomic biomarker OR Phosphoproteomic biomarkers OR PICP OR PIIINP OR PON-I OR
paraoxonase I OR MFAP-4 OR MFAP 4 OR MFAP4 OR microfibril associated glycoprotein 4)
#8 (#3 OR #4 OR #5 OR #6 OR #7)
#9 (#1 AND #2 AND #8)
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Appendix 2 Literature review: cost-effectiveness
analyses (hepatitis B, hepatitis C, alcoholic liver
disease, non-alcoholic liver disease, cirrhosis)
Hepatitis B
Database, platform: MEDLINE (via Ovid)
Search strategy: Natural History
Date of search: 10 May 2012.
1. *EPIDEMIOLOGY/
2. *INCIDENCE/
3. *PREVALENCE/
4. incidence.ti.
5. prevalence.ti.
6. epidemiol$.ti.
7. (etiolog$ or aetiolog$).ti.
8. or/1-7
9. exp *Hepatitis B/
10. 8 and 9
11. limit 10 to (english language and humans)
12. limit 11 to yr=“2004 -Current”
Search strategy: costs
Date of search: 11 May 2012.
1. exp Hepatitis B/ or Hepatitis B, Chronic/
2. exp Hepatitis B Virus/ or exp Hepatitis B Antibodies/
3. (hbv or hepatitis-B or hepatitis B or HBeAg negative or HBeAg positive or HBsAG).mp.
4. 1 or 2 or 3
5. (pegylat$ adj3interferon$ or peg-ifn or peginterferon$ or pegasys or pegintron or viraferonpeg).mp.
6. (interferon alpha 2a or interferon alfa 2a or interferon alpha 2b or interferon alfa 2b or alpha
interferon or intron$ or viraferon or roferon).mp.
7. exp interferon-alpha/
8. 6 or 7
9. exp Polyethylene Glycols/
10. polyethylene glycol$.mp. or peg$.tw.
11. 9 or 10
12. 8 and 11
13. 5 or 12
14. 13 and 4
15. limit 14 to english language
16. (adefovir dipivoxil or adefovir$ or hepsera).mp.
17. 16 and 4
18. 17
19. limit 18 to english language
20. (tenofovir disoproxil or tenofovir$ or viread).mp.
21. 20 and 4
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22. limit 21 to english language
23. (entecavir or entecavir$ or baraclude).mp.
24. 23 and 4
25. limit 24 to english language
26. exp ECONOMICS/
27. exp ECONOMICS, HOSPITAL/
28. exp ECONOMICS, PHARMACEUTICAL/
29. exp ECONOMICS, NURSING/
30. exp ECONOMICS, DENTAL/
31. exp ECONOMICS, MEDICAL/
32. exp “Costs and Cost Analysis”/
33. Cost-Benefit Analysis/
34. VALUE OF LIFE/
35. exp MODELS, ECONOMIC/
36. exp FEES/ and CHARGES/
37. exp BUDGETS/
38. (economic$ or price$ or pricing or financ$ or fee$ or pharmacoeconomic$ or pharma economic$).tw.
39. (cost$ or costly or costing$ or costed).tw.
40. (cost$ adj2 (benefits$ or utilit$ or minim$ or effective$)).tw.
41. (expenditure$ not energy).tw.
42. (value adj2 (money or monetary)).tw.
43. budget$.tw.
44. (economic adj2 burden).tw.
45. “resource use”.ti,ab.
46. or/26-45
47. news.pt.
48. letter.pt.
49. editorial.pt.
50. comment.pt.
51. or/47-50
52. 46 not 51
53. 52 and 4
54. 52 and 15
55. 52 and 19
56. 52 and 22
57. 52 and 25
58. 53
59. 58 and 54 and 55 and 56 and 57
60. limit 59 to english language
61. limit 60 to yr=“2004 -Current”
Search strategy: quality of life
Date of search: 11 May 2012.
1. value of life/
2. quality adjusted life year/
3. quality adjusted life.ti,ab.
4. (qaly$ or qald$ or qale$ or qtime$).ti,ab.
5. disability adjusted life.ti,ab.
6. daly$.ti,ab.
7. health status indicators/
8. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or
shortform thirty six or short form thirtysix or short form thirty six).ti,ab.
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9. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six or short
form six).ti,ab.
10. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short
form twelve).ti,ab.
11. (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short
form sixteen).ti,ab.
12. (sf20 or sf 20 or short form 20 or shortform or sf twenty or sf twenty or sftwenty or shortform twenty
or short form twenty).ti,ab.
13. (euroqol or euro qol or eq5d or eq 5d).ti,ab.
14. (hql or hqol or h qol or hrqol or hr qol).ti,ab.
15. (hye or hyes).ti,ab.
16. health$ year$ equivalent$.ti,ab.
17. health utilit$.ab.
18. (hui or hui1 or hui2 or hui3).ti,ab.
19. disutil$.ti,ab.
20. rosser.ti,ab.
21. quality of well being.ti,ab.
22. quality of wellbeing.ti,ab.
23. qwb.ti,ab.
24. willingess to pay.ti,ab.
25. standard gamble$.ti,ab.
26. time trade off.ti,ab.
27. time tradeoff.ti,ab.
28. tto.ti,ab.
29. (index adj2 well being).mp.
30. (quality adj2 well being).mp.
31. (health adj3 utilit$ ind$).mp. [mp=title, abstract, original title, name of substance word, subject
heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
32. ((multiattribute$ or multi attribute$) adj3 (health ind$ or theor$ or health state$ or utilit$ or analys$)).mp.
[mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary
concept, rare disease supplementary concept, unique identifier]
33. quality adjusted life year$.mp.
34. (15D or 15 dimension$).mp.
35. (12D or 12 dimension$).mp.
36. rating scale$.mp.
37. linear scal$.mp.
38. linear analog$.mp.
39. visual analog$.mp.
40. (categor$ adj2 scal$).mp.
41. or/1-40
42. (letter or editorial or comment).pt.
43. 41 not 42
44. exp Hepatitis B/ or Hepatitis B, Chronic/
45. exp Hepatitis B Virus/ or exp Hepatitis B Antibodies/
46. (hbv or hepatitis-B or hepatitis B or HBeAg negative or HBeAg positive or HBsAG).mp.
47. 44 or 45 or 46
48. 43 and 47
49. limit 48 to english language
50. limit 49 to yr=”2004 -Current
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Non-alcoholic fatty liver disease
Database, platform: MEDLINE (via Ovid)
Search strategy 1
Date of search: 24 June 2013.
1. (enhanced adj liver adj fibrosis).tw.
2. (elf adj test$).tw.
3. (elf and diagnos$).tw.
4. (elf and (fibros*s or cirrhos*s)).tw.
5. elf.tw.
6. exp liver cirrhosis/ or exp liver diseases/
7. Fatty Liver/di, dh, de, dt, ec [Diagnosis, Diet Therapy, Drug Effects, Drug Therapy, Economics]
8. 6 and 7
9. 5 and 8
10. 1 or 2 or 3 or 4 or 9
11. age-plt index.tw.
12. api index.tw.
13. apri.tw.
14. arfi.tw.
15. astalt.tw.
16. ast-alt.tw.
17. bard.tw.
18. coll4.tw.
19. typeIVcollagen.tw.
20. type IV Collagen.tw.
21. FIB 4.tw.
22. Fibrotest.tw.
23. Hyaluronic Acid.tw.
24. Hepascore.tw.
25. NAFIC.tw.
26. nafic score.tw.
27. ndp.tw.
28. nedaplatin.tw.
29. nfs.tw.
30. nafld fibrosis score.tw.
31. plt.tw.
32. magentic resonance elastography.tw.
33. mre.tw.
34. (transient adj elsatograph$).tw.
35. (elastograph$ and liver).tw.
36. or/11-35
37. exp liver cirrhosis/ or exp liver diseases/
38. Fatty Liver/di, dh, de, dt, ec [Diagnosis, Diet Therapy, Drug Effects, Drug Therapy, Economics]
39. (fibros*s or chirrhos*s).tw.
40. 37 or 38 or 39
41. Biological Markers/
42. (biomarker$ or bio-marker$).tw.
43. (marker$ and (biologic$ or biochemical or serum or direct or indirect)).tw.
44. Algorithms/
45. algorithm$.tw.
46. (composite and blood).tw.
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47. or/41-46
48. 36 and 47
49. Hyaluronic Acid/
50. ((hyaluronic adj acid) or (hyalauronate or hyaluronan)).tw.
51. 49 or 50
52. (procollagen or piinp or p3np or ppcp).tw.
53. ((tissue and inhibitor and metalloproteinase$) or timps).tw.
54. 51 and 52 and 53
55. 52 or 53 or 54
56. 36 and 55
57. Alpha-Macroglobulins/
58. ((alpha and macroglobulin$) or (alpha adj 2m)).tw.
59. 57 or 58
60. ((apolipoprotein$ adj a 1) or apoa 1).tw.
61. Haptoglobins/
62. haptoglobin$.tw.
63. 61 or 62
64. (bilrubin$ or hematoidin$).tw.
65. (gamma adj glutamyl adj transpeptidase$).tw.
66. (gamma adj glutamyltransferase$).tw.
67. 64 or 65 or 66
68. 59 and 60 and 63 and 64 and 67
69. 59 or 60 or 63 or 64 or 67
70. 36 and 69
71. (alanine adj (aminotransferase$ or aminotransaminase$)).tw.
72. (serum adj glutamic adj oxaloacetic adj transaminase$).tw.
73. sgpt.tw.
74. 71 or 72 or 73
75. (asparate adj (aminotransferase$ or aminotransaminase$)).tw.
76. (serum adj glutamic adj oxaloacetic adj transaminase$).tw.
77. sgot.tw.
78. 75 or 76 or 77
79. 59 and 60 and 63 and 64 and 67 and 74 and 78
80. 59 or 60 or 63 or 64 or 67 or 74 or 78
81. 36 and 80
82. exp “Sensitivity and Specificity”/
83. sensitivity.tw.
84. specificity.tw.
85. ((pre-test or pretest) adj probability).tw.
86. post-test probability.tw.
87. predictive value$.tw.
88. likelihood ratio$.tw.
89. or/82-88
90. 48 and 89
91. 56 and 89
92. 70 and 91
93. 81 and 89
94. 90 or 91 or 92 or 93
95. iqur.tw.
96. biopredictive.tw.
97. echosens.tw.
98. 95 or 96 or 97
99. 10 or 36 or 54 or 68 or 79 or 94 or 98
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100. exp “Costs and Cost Analysis”/
101. Economics/
102. exp Economics, Hospital/
103. exp Economics, Medical/
104. Economics, Nursing/
105. exp models,economic/
106. Economics, Pharamceutical/
107. exp “Fees and Charges”/
108. exp Budgets/
109. budget$.tw.
110. ec.fs.
111. cost$.ti.
112. (cost$ adj2 (effective$ or utilit$ or benefit$or minimi$)).ab.
113. (economic$ or pharmaceconomic$ or pharmaco-economic$).ti.
114. (price$ or pricing$).tw.
115. (financial or finance or finances or financed).tw.
116. (fee or fees).tw.
117. (value adj2 (money or monetary)).tw.
118. quality-adjusted life years/
119. (qaly or qalys).af.
120. (quality adjusted life year or quality adjusted life years).af.
121. 101 or 120
122. 99 and 121
123. Liver Cirrhosis/ or Middle Aged/ or Aged/ or Liver Diseases, Alcoholic/ or Hepatitis/ or Fatty Liver/ or
Adult/ or Liver Diseases/ or non alcoholic liver disease.mp. or Liver/
124. 122 and 123
Search strategy 2
Date of search: 26 July 2013.
1. cost effectiveness.mp. or Cost-Benefit Analysis/
2. Hepatitis/ or Fatty Liver/ or non alcoholic steatohepatitis.mp. or Liver/
3. 1 and 2
Alcoholic liver disease
Database, platform: MEDLINE (via Ovid)
Search strategy
Date of search: 21 June 2013.
1. (enhanced adj liver adj fibrosis).tw.
2. (elf adj tests$).tw.
3. (elf and diagnos$).tw.
4. (elf and (fibros* or cirrhos*s)).tw.
5. elf.tw.
6. exp liver cirrhosis/ or exp liver diseases, alcoholic/
7. 5 and 6
8. 1 or 2 or 3 or 4 or 7
9. Cytokeratin-18.tw.
10. Forns.tw.
11. Fibroscan.tw.
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12. YKL-40.tw.
13. (transient adj elastograph$).tw.
14. (elastograph$ and liver).tw.
15. or/9-14
16. exp liver cirrhosis/ or exp liver diseases, alcoholic/
17. (fibros* or cirrhos*s).tw.
18. 16 or 17
19. Biological Markers/
20. (biomarker$ or bio-markers$).tw.
21. (marker$ and (biologic$ or biochemical or serum or direct or indirect)).tw.
22. Algorithms/
23. algorithm$.tw.
24. (composite and blood).tw.
25. or/19-24
26. 18 and 25
27. Hyaluronic Acid/
28. ((hyaluronic adj acid) or (hyaluronate or hyaluronan)).tw.
29. 27 or 28
30. (procollagen or piinp or p3np or ppcp).tw.
31. ((tissue and inhibitor and metalloproteinase$) or timps).tw.
32. 29 and 30 and 31
33. 30 or 31 or 32
34. 18 or 33
35. Alpha-Macroglobulins/
36. ((apha and macroglobulin$) or (alpha adj 2m)).tw.
37. 35 or 36
38. ((apolipoprotein$ adj a 1) or apoa 1).tw.
39. Haptoglobins/
40. haptoglobin$.tw.
41. 39 or 40
42. (bilirubin$ or hematoidin$).tw.
43. (gamma adj glutamyl adj transpeptidase$).tw.
44. (gamma adj glutamyltransferase$).tw.
45. ((gamma adj gt) or ggt or ggtp).tw.
46. 43 or 44 or 45
47. 37 and 38 and 41 and 42 and 46
48. 37 or 38 or 41 or 42 or 46
49. 18 and 48
50. (alanine adj (aminotransferase$ or aminotransaminase$)).tw.
51. (serum adj glutamic adj pyruvic adj transaminase$).tw.
52. sgpt.tw.
53. 50 or 51 or 52
54. (aspartate adj (aminotransferase$ or aminotransaminase$)).tw.
55. (serum adj glutamic adj oxaloacetic adj transaminase$).tw.
56. sgot.tw.
57. 54 or 55 or 56
58. 37 and 38 and 41 and 42 and 46 and 53 and 57
59. 37 or 38 or 41 or 42 or 46 or 53 or 57
60. 18 and 59
61. exp “Sensitivity and Specificity”/
62. sensitivity.tw.
63. specificity.tw.
64. ((pre-test or pretest) adj probability).tw.
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65. post-test probability.tw.
66. predictive value$.tw.
67. likelihood ratio$.tw.
68. or/61-67
69. 26 and 68
70. 34 and 68
71. 49 and 68
72. 60 and 68
73. 69 or 70 or 71 or 72
74. iqur.tw.
75. biopredictive.tw.
76. echosens.tw.
77. 74 or 75 or 76
78. 7 or 15 or 32 or 47 or 58 or 73 or 77
79. exp “Costs and Cost Analysis”/
80. Economics/
81. exp Economics, Hospital/
82. exp Economics, Medical/
83. Economics, Nursing/
84. exp models, economic/
85. Economoics, Pharmaceutical/
86. exp “Fees and Charges”/
87. exp Budgets/
88. budget$.tw.
89. ec.fs.
90. cost$.ti.
91. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimi$)).ab.
92. (economic$ or pharmacoeconomic$ or pharmaco-economic$).ti.
93. (prices$ or pricing$).tw.
94. (financial or finance or finances or financed).tw.
95. (fee or fees).tw.
96. (value adj2 (money or monetary)).tw.
97. quality-adjusted life years/
98. (qaly or qalys).af.
99. (quality adjusted life year or quality adjusted life years).af.
100. or/79-99
101. 78 and 100
102. limit 101 to english language
Hepatitis C
Database, platform: MEDLINE (via Ovid)
Natural history
Search strategy
Date of search: 1 December 2012.
1. *EPIDEMIOLOGY/
2. *INCIDENCE/
3. *PREVALENCE/
4. incidence.ti.
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5. prevalence.ti.
6. epidemiol$.ti.
7. (etiolog$ or aetiolog$).ti.
8. or/1-7
9. exp *Hepatitis C/
10. 8 and 9
11. limit 10 to (human and english language)
12. limit 11 to yr=“2004 -Current”
Costs
Search strategy
Date of search: 1 December 2012.
1. exp Hepatitis C/ or Hepatitsi C, Chronic.mp. [mp=title, abstract, original title, name of substance word,
subject heading word, keyword heading word, protocol supplementary concept, rare disease
supplementary concept, unique identifier]
2. exp Hepatitis C Virus/ or exp Hepatitis C Antibodies/
3. (hcv or hepatitis-C or heptatitis C).mp.
4. 1 or 2 or 3
5. ((pegylat$ adj3 interferon$) or peg-ifn or peginterferon$ or peg-interferon$ or pegasys or pegintron
or viraferonpeg).mp.
6. (interferon alpha 2a or interferon alfa 2a or interferon alpha 2b or interferon alfa 2b or alpha
interferon or intron$ or viraferon or roferon).mp.
7. exp interferon-alpha/
8. 6 or 7
9. exp Polyethylene Glycols/
10. polyethylene glycol$.mp. or peg$.tw.
11. 9 or 10
12. 8 and 11
13. 5 or 12
14. 4 and 13
15. limit 14 to english language
16. (Ribavirin or ribavirin$ or copegus or rebetol).mp.
17. 4 and 16
18. 17
19. limit 18 to english language
20. (Telaprevir or telaprevir$ or incivo).mp.
21. 4 and 20
22. limit 21 to english language
23. (Boceprevir or Boceprevir$ or victrelis).mp.
24. 4 and 23
25. limit 24 to english language
26. exp ECONOMICS/
27. exp ECONOMICS, HOSPITAL/
28. exp ECONOMICS, PHARMACEUTICAL/
29. exp ECONOMICS, NURSING/
30. exp ECONOMICS, DENTAL/
31. exp ECONOMICS, MEDICAL/
32. exp “Costs and Cost Analysis”/
33. Cost-Benefit Analysis/
34. VALUE OF LIFE/
35. exp MODELS, ECONOMIC/
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36. exp FEES/ and CHARGES/
37. exp BUDGETS/
38. (economics$ or price$ or pricing or fianc$ or fee$ or pharamacoenomics$ or pharma economics$).tw.
39. (cost$ or costly or costing$ or costed).tw.
40. (cost$ adj2 (benefit$ or utilit$ or minim$ or effective$)).tw.
41. (expenditure$ not energy).tw.
42. (value adj (money or monetary)).tw.
43. budget$.tw.
44. (economic adj2 burden).tw.
45. “resource use”.ti,ab.
46. or/26-45
47. news.pt.
48. editorial.pt.
49. comment.pt.
50. letter.pt.
51. or/47-50
52. 46 not 51
53. 52 and 4
54. 52 and 15
55. 52 and 19
56. 52 and 23
57. 52 and 25
58. 53 and 54 and 55 and 56 and 57
59. limit 58 to english language
Quality of life
Search strategy
Date of search: 1 December 2012.
1. value of life/
2. quality adjusted life year/
3. quality adjusted life.ti,ab.
4. (qaly$ or qald$ or qale$ or qtime$).ti,ab.
5. disability adjusted life.ti,ab.
6. daly$.ti,ab.
7. health status indicators/
8. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or
shortform thirty six or short form thirtysix or short form thirty six).ti,ab.
9. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six or short
form six).ti,ab.
10. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short
form twelve).ti,ab.
11. (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short
form sixteen).ti,ab.
12. (sf20 or sf 20 or short form 20 or shortform or sf twenty or sf twenty or sftwenty or shortform twenty
or short form twenty).ti,ab.
13. (euroqol or euro qol or eq5d or eq 5d).ti,ab.
14. (hql or hqol or h qol or hrqol or hr qol).ti,ab.
15. (hye or hyes).ti,ab.
16. health$ year$ equivalent$.ti,ab.
17. health utilit$.ab.
18. (hui or hui1 or hui2 or hui3).ti,ab.
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19. disutil$.ti,ab.
20. rosser.ti,ab.
21. quality of well being.ti,ab.
22. quality of wellbeing.ti,ab.
23. qwb.ti,ab.
24. willingess to pay.ti,ab.
25. standard gamble$.ti,ab.
26. time trade off.ti,ab.
27. time tradeoff.ti,ab.
28. tto.ti,ab.
29. (index adj2 well being).mp.
30. (quality adj2 well being).mp.
31. (health adj3 utilit$ ind$).mp. [mp=title, abstract, original title, name of substance word, subject
heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
32. ((multiattribute$ or multi attribute$) adj3 (health ind$ or theor$ or health state$ or utilit$ or analys$)).mp.
[mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary
concept, rare disease supplementary concept, unique identifier]
33. quality adjusted life year$.mp.
34. (15D or 15 dimension$).mp.
35. (12D or 12 dimension$).mp.
36. rating scale$.mp.
37. linear scal$.mp.
38. linear analog$.mp.
39. visual analog$.mp.
40. (categor$ adj2 scal$).mp.
41. or/1-40
42. (letter or editorial or comment).pt.
43. 41 not 42
44. exp Hepatitis C/ or Hepatitis C, Chronic/
45. exp Hepatitis B Virus/ or exp Hepatitis B Antibodies/
46. (hbv or hepatitis-C or hepatitis C).mp.
47. 44 or 45 or 46
48. 43 and 47
49. limit 48 to english language
Cirrhosis
Platform: MEDLINE (via Ovid)
Date of search: 26 July 2013.
Search strategy
Costs
1. cirrhosis.mp.
2. costs.mp. or “Costs and Cost Analysis”/
3. 1 and 2
4. limit 3 to english language
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Quality of life
1. cirrhosis.mp.
2. quality of life.mp. or “Quality of Life”/
3. 1 and 4
4. limit 5 to english language
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Appendix 3 Results: meta-analysis data
TABLE 61 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage of ≥ F1 in patients with
chronic HCV
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Indirect serum non-invasive tests
King’s 1 24.3 0.80 (0.74 to 0.85) 0.67 (0.30 to 0.90) Single study
Direct serum non-invasive serum tests
Hyaluronic
acid
1 16 0.36 (0.28 to 0.45) 0.92 (0.87 to 0.95) Single study
Commercial non-invasive serum tests
FibrospectII 1 42 0.86 (0.49 to 0.97) 0.69 (0.50 to 0.83) Single study
Imaging modalities
ARFI 3 1.04–1.19 0.71 (0.65 to 0.77) 0.86 (0.70 to 0.94) Fixed-effect model for
sensitivity and random-effects
model for specificity without
correlation
Fibroscan 8 4.5–8.8 0.85 (0.75 to 0.91) 0.87 (0.75 to 0.91) Random-effects model for
sensitivity and specificity
without correlation
TABLE 62 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage of ≥ F3 in patients with
chronic HCV
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Indirect non-invasive serum tests
APRI
(low cut-off)
18 0.5–1.0 0.84 (0.82 to 0.86) 0.56 (0.44 to 0.68) Fixed-effect model for sensitivity
and random-effects model for
specificity without correlation
APRI
(high cut-off)
15 1.5–2.0 0.53 (0.43 to 0.62) 0.86 (0.79 to 0.91) Bivariate random-effects model
with correlation between
sensitivity and specificity
CDS 2 8 0.54 (0.43 to 0.65) 0.74 (0.66 to 0.81) Fixed-effects model for
sensitivity and specificity
without correlation
FIB-4
(low cut-off)
11 1.45 0.80 (0.72 to 0.86) 0.64 (0.56 to 0.72) Bivariate random-effects model
with correlation between
sensitivity and specificity
FIB-4
(high cut-off)
11 3.25 0.37 (0.28 to 0.46) 0.94 (0.90 to 0.97) Bivariate random-effects model
with correlation between
sensitivity and specificity
Forns index
(low cut-off)
1 4.2 0.92 (0.81 to 0.97) 0.34 (0.26 to 0.43) Single study
Forns index
(high cut-off)
1 6.9 0.55 (0.41 to 0.68) 0.87 (0.80 to 0.92) Single study
continued
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TABLE 62 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage of ≥ F3 in patients with
chronic HCV (continued )
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
FibroQ 1 1.6 0.86 (0.78 to 0.91) 0.44 (0.35 to 0.52) Single study
GUCI 1 0.26 0.58 (0.39 to 0.76) 0.73 (0.58 to 0.84) Single study
King’s 1 24.3 0.74 (0.59 to 0.85) 0.90 (0.84 to 0.94) Single study
Lok’s index
(low cut-off)
2 0.2 0.90 (0.85 to 0.95) 0.33 (0.27 to 0.39) Fixed-effects model for
sensitivity and specificity
without correlation
Lok’s index
(high cut-off)
2 0.5–0.58 0.50 (0.40 to 0.59) 0.84 (0.77 to 0.89) Fixed-effects model for
sensitivity and specificity
without correlation
NIHCED 1 6 0.72 (0.65 to 0.78) 0.75 (0.67 to 0.81) Single study
Platelets 2 140–150 0.53 (0.43 to 0.99) 0.88 (0.47 to 0.98) Random-effects model for
sensitivity and fixed-effect
model for specificity without
correlation
Pohl index 3 Positive 0.15 (0.04 to 0.42) 0.98 (0.96 to 0.99) Random-effects model for
sensitivity and fixed-effect
model for specificity without
correlation
Direct serum non-invasive serum tests
13C-caffeine
breath test
1 0.021 0.75 (0.63 to 0.85) 0.79 (0.64 to 0.89) Single study
Hyaluronic
acid
4 20–85 0.79 (0.52 to 0.93) 0.72 (0.65 to 0.78) Random-effects model for
sensitivity and fixed-effect
model for specificity without
correlation
Hyaluronic
acid (low
cut-off)
1 48 0.77 (0.50 to 0.92) 1.00 (0.98 to 1.00) Single study
Hyaluronic
acid (high
cut-off)
1 160 0.22 (0.13 to 0.37) 1.00 (0.98 to 1.00) Single study
Hepascore 7 0.5–0.83 0.81 (0.71 to 0.87) 0.76 (0.68 to 0.83) Bivariate random-effects model
with correlation between
sensitivity and specificity
Hepascore
(low cut-off)
2 0.49 0.81 (0.41 to 0.96) 0.75 (0.18 to 0.98) Fixed-effect model for sensitivity
and random-effects model for
specificity without correlation
Hepascore
(high cut-off)
2 0.84–0.90 0.48 (0.40 to 0.56) 0.93 (0.90 to 0.95) Fixed-effects model for
sensitivity and specificity
without correlation
PIIINP 2 8–9.1 0.71 (0.58 to 0.81) 0.63 (0.54 to 0.71) Fixed-effects model for
sensitivity and specificity
without correlation
PIIINP/MMP1
index
1 0.3 0.86 (0.71 to 0.94) 0.74 (0.67 to 0.80) Single study
Type IV
collagen
1 130 0.67 (0.53 to 0.78) 0.76 (0.60 to 0.87) Single study
YKL-40 1 100 0.82 (0.70 to 0.90) 0.57 (0.49 to 0.65) Single study
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TABLE 62 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage of ≥ F3 in patients with
chronic HCV (continued )
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Commercial non-invasive serum tests
ELF
(low cut-off)
1 9.59 0.85 (0.77 to 0.90) 0.63 (0.57 to 0.70) Single study
ELF
(high cut-off)
1 10.22 0.70 (0.61 to 0.78) 0.85 (0.80 to 0.89) Single study
Fibroindex 1 1.35 0.52 (0.33 to 0.70) 0.92 (0.75 to 0.98) Single study
Fibrometer 2 0.63–0.67 0.84 (0.77 to 0.89) 0.78 (0.75 to 0.81) Fixed-effects model for
sensitivity and specificity
without correlation
FibrospectII 1 0.5 0.85 (0.72 to 0.92) 0.72 (0.62 to 0.80) Single study
Fibrotest 9 0.32–0.67 0.73 (0.56 to 0.85) 0.69 (0.55 to 0.80) Bivariate random-effects model
with correlation between
sensitivity and specificity
Fibrotest
(low cut-off)
2 0.22 0.85 (0.44 to 0.98) 0.58 (0.54 to 0.99) Fixed-effect model for sensitivity
and random-effects model for
specificity without correlation
Fibrotest
(high cut-off)
2 0.59–0.63 0.69 (0.59 to 0.74) 0.84 (0.81 to 0.87) Fixed-effects model for
sensitivity and specificity
without correlation
Imaging modalities
ARFI 4 1.49–2.11 0.85 (0.69 to 0.94) 0.89 (0.72 to 0.97) Random-effects model for
sensitivity and specificity
without correlation
Real-time
elastography
1 3.25 0.86 (0.72 to 0.93) 0.96 (0.82 to 0.99) Single study
Fibroscan 19 8.6–15.4 0.88 (0.82 to 0.92) 0.90 (0.85 to 0.93) Bivariate random-effects model
with correlation between
sensitivity and specificity
CDS, Cirrhosis Discriminant Score; MMP-1, matrix metalloproteinase-1; NIHCED, non-invasive hepatitis C-related
early detection.
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TABLE 63 Diagnostic accuracy of non-invasive tests for detection of ≥ F1 in patients with chronic HBV
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Indirect non-invasive serum tests
APRI
(low cut-off)
1 0.4 0.70 (0.59 to 0.78) 0.83 (0.68 to 0.92) Single study
APRI
(high cut-off)
1 1.5 0.37 (0.26 to 0.50) 0.82 (0.73 to 0.89) Single study
CDS 1 4 0.28 (0.19 to 0.41) 0.90 (0.80 to 0.95) Single study
Lok’s index 1 0.87 0.48 (0.36 to 0.61) 0.90 (0.80 to 0.95) Single study
Direct serum non-invasive tests
CTGF 1 125.6 0.61 (0.49 to 0.71) 0.71 (0.47 to 0.87) Single study
Commercial non-invasive serum tests
Fibrotest 1 – 0.72 (0.57 to 0.83) 0.64 (0.49 to 0.76) Single study
Imaging modalities
Real-time
elastography
1 – 0.87 (0.76 to 0.94) 0.85 (0.64 to 0.95) Single study
Fibroscan 2 6.1 0.69 (0.53 to 0.82) 0.62 (0.39 to 0.80) Fixed-effects model for
sensitivity and specificity
without correlation
CDS, Cirrhosis Discriminant Score.
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TABLE 64 Diagnostic accuracy of non-invasive tests for detection of ≥ F3 in patients with chronic HBV
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Indirect non-invasive serum tests
FIB-4
(low cut-off)
2 0.67–1.00 0.89 (0.84 to 0.93) 0.76 (0.69 to 0.81) Fixed-effects model for
sensitivity and specificity
without correlation
FIB-4
(high cut-off)
1 2.65 0.38 (0.33 to 0.44) 0.98 (0.96 to 0.99) Single study
Forns index
(low cut-off)
2 5.2 0.99 (0.85 to 1.00) 0.20 (0.12 to 0.32) Fixed-effects model for
sensitivity and specificity
without correlation
Forns index
(high cut-off)
2 8.4 0.32 (0.20 to 0.46) 0.92 (0.83 to 0.97) Fixed-effects model for
sensitivity and specificity
without correlation
Hui index 2 0.15 0.88 (0.76 to 0.94) 0.51 (0.37 to 0.65) Fixed-effects model for
sensitivity and specificity
without correlation
Direct serum non-invasive tests
13C-caffeine
breath test
1 1.49 1.00 (0.76 to 1.00) 0.72 (0.56 to 0.84) Single study
CTGF 1 141 0.69 (0.44 to 0.86) 0.85 (0.75 to 0.92) Single study
Commercial non-invasive serum tests
Fibrotest 3 0.31–0.42 0.49 (0.01 to 0.99) 0.71 (0.53 to 0.84) Random-effects model for
sensitivity and fixed-effect
model for specificity without
correlation
Imaging modalities
Real-time
elastography
1 80.7 0.73 (0.54 to 0.86) 0.76 (0.62 to 0.85) Single study
Fibroscan 13 7.3–10.7 0.69 (0.58 to 0.78) 0.84 (0.79 to 0.89) Bivariate random-effects model
with correlation between
sensitivity and specificity
CTGF, connective tissue growth factor.
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TABLE 65 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage of ≥ F1 in patients with
non-alcoholic steatohepatitis
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Indirect non-invasive serum tests
APRI 1 0.5 0.05 (0.01 to 0.17) 0.97 (0.87 to 0.99) Single study
NAFLD fibrosis
score (low cut-off)
3 –0.1657 to
–1.456
0.82 (0.77 to 0.87) 0.48 (0.40 to 0.56) Bivariate random-effects
model with correlation
between sensitivity and
specificity
NAFLD fibrosis
score (high cut-off)
2 0.676 0.29 (0.22 to 0.36) 0.92 (0.85 to 0.96) Bivariate random-effects
model with correlation
between sensitivity and
specificity
Direct serum non-invasive serum tests
Hyaluronic acid 1 24.6 0.82 (0.52 to 0.95) 0.68 (0.46 to 0.85) Single study
Laminin 1 282 0.82 (0.52 to 0.95) 0.89 (0.69 to 0.97) Single study
NAFLD diagnostic
panel
1 0.42 0.61 (0.46 to 0.75) 0.72 (0.57 to 0.84) Single study
Type IV collagen 1 145 0.64 (0.35 to 0.85) 0.89 (0.69 to 0.97) Single study
Commercial non-invasive serum tests
ELF 1 9.8 0.61 (0.52 to 0.69) 0.80 (0.70 to 0.87) Single study
Imaging modalities
Real-time
elastography
1 102 0.79 (0.65 to 0.88) 0.90 (0.60 to 0.98) Single study
Fibroscan 3 5.3–5.9 0.87 (0.81 to 0.92) 0.76 (0.57 to 0.88) Bivariate random-effects
model with correlation
between sensitivity and
specificity
Combination of non-invasive test algorithms
NAFLD fibrosis
score and ELF
(low cut-off)
1 0.92 (0.86 to 0.96) 0.52 (0.41 to 0.63) Single study
NAFLD fibrosis
score and ELF
(high cut-off)
1 0.60 (0.51 to 0.69) 0.91 (0.83 to 0.96) Single study
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TABLE 66 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage of ≥ F2 in patients with
non-alcoholic steatohepatitis
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Indirect non-invasive serum tests
APRI 2 0.43–0.5 0.69 (0.21 to 0.95) 0.82 (0.07 to 0.97) Fixed-effect model
for sensitivity and
random-effects model
for specificity without
correlation
BARD 1 2 0.44 (0.35 to 0.54) 0.70 (0.62 to 0.77) Single study
FIB-4 1 1.45 0.55 (0.45 to 0.64) 0.87 (0.81 to 0.92) Single study
NAFLD fibrosis
score (low cut-off)
4 –1.455 0.79 (0.56 to 0.92) 0.65 (0.46 to 0.80) Bivariate random-effects
model with correlation
between sensitivity and
specificity
NAFLD fibrosis
score (high cut-off)
5 0.676 0.29 (0.07 to 0.68) 0.95 (0.87 to 0.98) Bivariate random-effects
model with correlation
between sensitivity and
specificity
Direct serum non-invasive serum tests
Hepascore 1 0.44 0.51 (0.41 to 0.60) 0.88 (0.82 to 0.93) Single study
Hyaluronic acid 1 218 0.78 (0.45 to 0.94) 0.89 (0.67 to 0.97) Single study
NAFIC
(low cut-off)
1 0 0.95 (0.91 to 0.98) 0.33 (0.29 to 0.37) Single study
NAFIC
(high cut-off)
1 2 0.84 (0.77 to 0.89) 0.75 (0.71 to 0.78) Single study
Commercial non-invasive serum tests
ELF 1 9.9 0.70 (0.59 to 0.79) 0.80 (0.72 to 0.86) Single study
Fibrometer 1 0.490 0.78 (0.67 to 0.87) 0.96 (0.92 to 0.98) Single study
FibrospectII 1 20 1.00 (0.95 to 1.00) 0.42 (0.32 to 0.52) Single study
Fibrotest
(low cut-off)
3 0.30–0.34 0.70 (0.56 to 0.81) 0.75 (0.70 to 0.80) Bivariate random-effects
model with correlation
between sensitivity and
specificity
Fibrotest
(high cut-off)
2 0.7 0.15 (0.03 to 0.90) 0.98 (0.90 to 0.99) Random-effects model
for sensitivity and
fixed-effect model for
specificity without
correlation
continued
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TABLE 66 Diagnostic accuracy of non-invasive tests for detection of fibrosis stage of ≥ F2 in patients with
non-alcoholic steatohepatitis (continued )
Test
Number of
studies Cut-off
Summary sensitivity
(95% CI)
Summary specificity
(95% CI) Statistics
Imaging modalities
Real-time
elastography
1 94 0.84 (0.65 to 0.94) 1.00 (0.87 to 1.00) Single study
Fibroscan 7 6.8–10.0 0.79 (0.72 to 0.85) 0.76 (0.71 to 0.80) Random-effects model
for sensitivity and
fixed-effect model
for specificity without
correlation – the studies
were clustered; fixed
effects model for both
sensitivity and specificity
did not alter the mean
but altered the CI by
about 2%
Combination of non-invasive test algorithms
NAFLD fibrosis
score and ELF
(low cut-off)
1 0.90 (0.81 to 0.95) 0.86 (0.78 to 0.91) Single study
NAFLD fibrosis
score and ELF
(high cut-off)
1 0.79 (0.69 to 0.87) 0.91 (0.85 to 0.95) Single study
NAFLD fibrosis
score and
Fibroscan
1 0.65 (0.51 to 0.76) 0.64 (0.56 to 0.71) Single study
Fibrotest and
Fibroscan
1 0.71 (0.57 to 0.81) 0.76 (0.68 to 0.82) Single study
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Appendix 4 Diagnostic test accuracy of
non-invasive fibrosis tests in individual studies
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Appendix 5 Forest plots
This appendix presents forest plots of sensitivity and specificity of non-invasive tests across all fibrosisstages in patients with chronic HBV, chronic HCV, NAFLD and ALD. Plots are presented when there are
data available from at least two studies. Studies are represented by their reference number in the report.
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FIGURE 11 Alcoholic liver disease: APRI F2 (high cut-off) – sensitivity.
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FIGURE 12 Alcoholic liver disease: APRI F2 (high cut-off) – specificity.
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FIGURE 13 Alcoholic liver disease: APRI F2 (low cut-off) – sensitivity.
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FIGURE 14 Alcoholic liver disease: APRI F2 (low cut-off) – specificity.
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FIGURE 15 Alcoholic liver disease: TE F3 – sensitivity.
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FIGURE 16 Alcoholic liver disease: TE F3 – specificity.
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FIGURE 17 Alcoholic liver disease: TE F4 – sensitivity.
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FIGURE 18 Alcoholic liver disease: TE F4 – specificity.
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FIGURE 19 Hepatitis B: APRI F2 (high cut-off) – sensitivity.
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FIGURE 20 Hepatitis B: APRI F2 (high cut-off) – specificity.
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FIGURE 21 Hepatitis B: APRI F2 (low cut-off) – sensitivity.
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FIGURE 22 Hepatitis B: APRI F2 (low cut-off) – specificity.
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FIGURE 23 Hepatitis B: FIB-4 F2 (low cut-off) – sensitivity.
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FIGURE 24 Hepatitis B: FIB-4 F2 (low cut-off) – specificity.
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FIGURE 25 Hepatitis B: Fibrotest F2 – sensitivity.
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FIGURE 26 Hepatitis B: Fibrotest F2 – specificity.
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FIGURE 27 Hepatitis B: TE F2 – sensitivity.
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FIGURE 28 Hepatitis B: TE F2 – specificity.
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Sensitivity
FIGURE 29 Hepatitis B: FIB-4 F3 (low cut-off) – sensitivity.
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FIGURE 30 Hepatitis B: FIB-4 F3 (low cut-off) – specificity.
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FIGURE 31 Hepatitis B: Fibrotest F3 – sensitivity.
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FIGURE 32 Hepatitis B: Fibrotest F3 – specificity.
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FIGURE 33 Hepatitis B: Forns index F3 (high cut-off) – sensitivity. Val, validation cohort.
(266)-test
(266)-val
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
Specificity
FIGURE 34 Hepatitis B: Forns index F3 (high cut-off) – specificity. Val, validation cohort.
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FIGURE 35 Hepatitis B: Forns index F3 (low cut-off) – sensitivity. Val, validation cohort.
(266)-val
(266)-val
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
Specificity
FIGURE 36 Hepatitis B: Forns index F3 (low cut-off) – specificity. Val, validation cohort.
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FIGURE 37 Hepatitis B: Hui index F3 – sensitivity. Val, validation cohort.
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FIGURE 38 Hepatitis B: Hui index F3 – specificity. Val, validation cohort.
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FIGURE 39 Hepatitis B: TE F3 – sensitivity. Tx, treatment; val, validation cohort.
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FIGURE 40 Hepatitis B: TE F3 – specificity. Tx, treatment; val, validation cohort.
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Sensitivity
FIGURE 41 Hepatitis B: AST–ALT ratio F4 – sensitivity.
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FIGURE 42 Hepatitis B: AST–ALT F4 – specificity.
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FIGURE 43 Hepatitis B: APRI F4 (high cut-off) – sensitivity.
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FIGURE 44 Hepatitis B: APRI F4 (high cut-off) – specificity.
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FIGURE 45 Hepatitis B: APRI F4 (low cut-off) – sensitivity.
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FIGURE 46 Hepatitis B: APRI F4 (low cut-off) – specificity.
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FIGURE 47 Hepatitis B: FIB-4 F4 (low cut-off) – sensitivity.
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FIGURE 48 Hepatitis B: FIB-4 F4 (low cut-off) – specificity.
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Sensitivity
FIGURE 49 Hepatitis B: Fibrotest F4 – sensitivity.
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FIGURE 50 Hepatitis B: Fibrotest F4 – specificity.
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FIGURE 51 Hepatitis B: TE F4 – sensitivity.
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FIGURE 52 Hepatitis B: TE F4 – specificity.
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FIGURE 53 Hepatitis C: TE F1 – sensitivity.
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FIGURE 54 Hepatitis C: TE F1 – specificity.
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FIGURE 55 Hepatitis C: APRI F2 (high cut-off) – sensitivity. Pros, prospective; val, validation cohort.
DOI: 10.3310/hta19090 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 9
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Crossan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
287
(195)-pros
(195)-pros
(89)
(220)
(72)
(97)
(94)
(91)
(81)
(79)
(74)
(73)
(31)
(24)-val
(210)
(187)
(182)
(158)
(157)
(156)
(154)
(153)
(151)
(150)
(143)
(131)
(126)
(123)
(103)
(100)
(146)
(140)
(209)
(218)-val
(218)-test
(24)-test
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
Specificity
FIGURE 56 Hepatitis C: APRI F2 (high cut-off) – specificity. Pros, prospective; val, validation cohort.
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FIGURE 57 Hepatitis C: APRI F2 (low cut-off) – sensitivity. Pros, prospective; retr, retrospective;
val, validation cohort.
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FIGURE 58 Hepatitis C: APRI F2 (low cut-off) – specificity. Pros, prospective; retr, retrospective;
val, validation cohort.
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FIGURE 59 Hepatitis C: AST–ALT (F2) – sensitivity. EALT, elevated ALT; NALT, normal ALT.
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FIGURE 60 Hepatitis C: AST–ALT (F2) – specificity. EALT, elevated ALT; NALT, normal ALT.
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Sensitivity
FIGURE 61 Hepatitis C: FIB-4 F2 (high cut-off) – sensitivity. Tot, total; val, validation cohort.
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FIGURE 62 Hepatitis C: FIB-4 F2 (high cut-off) – specificity. Tot, total; val, validation cohort.
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FIGURE 63 Hepatitis C: FIB-4 F2 (low cut-off) – sensitivity. Tot, total; val, validation cohort.
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FIGURE 64 Hepatitis C: FIB-4 F2 (low cut-off) – specificity. Tot, total; val, validation cohort.
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Sensitivity
FIGURE 65 Hepatitis C: Fibroindex F2 (high cut-off) – sensitivity. EALT, elevated ALT; NALT, normal ALT;
test, derivation cohort; val, validation cohort.
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FIGURE 66 Hepatitis C: Fibroindex F2 (high cut-off) – specificity. EALT, elevated ALT; NALT, normal ALT; test,
derivation cohort; val, validation cohort.
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Sensitivity
FIGURE 67 Hepatitis C: Fibroindex F2 (low cut-off) – sensitivity. EALT, elevated ALT; NALT, normal ALT;
test, derivation cohort; val, validation cohort.
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FIGURE 68 Hepatitis C: Fibroindex F2 (low cut-off) – specificity. EALT, elevated ALT; NALT, normal ALT;
test, derivation cohort; val, validation cohort.
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FIGURE 69 Hepatitis C: Fibrometer F2 – sensitivity.
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FIGURE 70 Hepatitis C: Fibrometer F2 – specificity.
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FIGURE 71 Hepatitis C: FibroSpect II F2 – sensitivity.
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FIGURE 72 Hepatitis C: FibroSpect II F2 – specificity.
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FIGURE 73 Hepatitis C: Forns index F2 (high cut-off) – sensitivity. EALT, elevated ALT; NALT, normal ALT;
test, derivation cohort; val, validation cohort.
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FIGURE 74 Hepatitis C: Forns index F2 (high cut-off) – specificity. EALT, elevated ALT; NALT, normal ALT;
test, derivation cohort; val, validation cohort.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
298
(156)
(194)
(186)-EALT
(186)-NALT
(144)
(146)
(157)
(158)
(154)
(126)
(100)
(115)-val
(115)-test
(31)
(91)
(81)
(24)-val
(24)-test
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
Sensitivity
FIGURE 75 Hepatitis C: Forns index F2 (low cut-off) – sensitivity. EALT, elevated ALT; NALT, normal ALT;
test, derivation cohort; val, validation cohort.
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FIGURE 76 Hepatitis C: Forns index F2 (low cut-off) – specificity. EALT, elevated ALT; NALT, normal ALT;
test, derivation cohort; val, validation cohort.
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Sensitivity
FIGURE 77 Hepatitis C: Fibrotest F2 – sensitivity. EALT, elevated ALT; NALT, normal ALT.
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FIGURE 78 Hepatitis C: Fibrotest F2 – specificity. EALT, elevated ALT; NALT, normal ALT;
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FIGURE 79 Hepatitis C: Fibrotest F2 (high cut-off) – sensitivity.
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FIGURE 80 Hepatitis C: Fibrotest F2 (high cut-off) – specificity.
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Sensitivity
FIGURE 81 Hepatitis C: Fibrotest F2 (low cut-off) – sensitivity.
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FIGURE 82 Hepatitis C: Fibrotest F2 (low cut-off) – specificity.
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Sensitivity
FIGURE 83 Hepatitis C: GUCI F2 – sensitivity.
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FIGURE 84 Hepatitis C: GUCI F2 – specificity.
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Sensitivity
FIGURE 85 Hepatitis C: hyaluronic acid F2 – sensitivity.
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FIGURE 86 Hepatitis C: hyaluronic acid F2 – specificity.
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Sensitivity
FIGURE 87 Hepatitis C: Hepascore F2 – sensitivity.
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FIGURE 88 Hepatitis C: Hepascore F2 – specificity.
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Sensitivity
FIGURE 89 Hepatitis C: Lok’s index F2 – sensitivity.
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Specificity
FIGURE 90 Hepatitis C: Lok’s index F2 – specificity.
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Sensitivity
FIGURE 91 Hepatitis C: platelet–spleen F2 – sensitivity.
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Specificity
FIGURE 92 Hepatitis C: platelet–spleen F2 – specificity.
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Sensitivity
FIGURE 93 Hepatitis C: platelet F2 – sensitivity.
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Specificity
FIGURE 94 Hepatitis C: platelet F2 – specificity.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
308
(100)
(102)
(105)
(106)
(116)
(119)
(130)
(137)
(141)
(141)
(148)
(155)
(153)
(159)
(161)
(164)
(170)
(201)
(223)
(29)
(75)
(87)
(86)
(76)
(99)
(95)
(98)
(88)
(200)
(194)
(199)
(110)
(211)
(172)
(224)
(28)
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
Sensitivity
FIGURE 95 Hepatitis C: Fibroscan F2 – sensitivity.
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Specificity
FIGURE 96 Hepatitis C: Fibroscan F2 – specificity.
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Sensitivity
FIGURE 97 Hepatitis C: type IV collagen F2 – sensitivity.
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FIGURE 98 Hepatitis C: type IV collagen F2 – specificity.
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Sensitivity
FIGURE 99 Hepatitis C: APRI F3 (high cut-off) – sensitivity. Pros, prospective; retr, retrospective.
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FIGURE 100 Hepatitis C: APRI F3 (high cut-off) – specificity. Pros, prospective; retr, retrospective.
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FIGURE 101 Hepatitis C: APRI F3 (low cut-off) – sensitivity. Pros, prospective; retr, retrospective.
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Specificity
FIGURE 102 Hepatitis C: APRI F3 (low cut-off) – specificity. Pros, prospective; retr, retrospective.
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Sensitivity
FIGURE 103 Hepatitis C: FIB-4 F3 (high cut-off) – sensitivity. Tot, total; val, validation cohort.
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FIGURE 104 Hepatitis C: FIB-4 F3 (high cut-off) – specificity. Tot, total; val, validation cohort.
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FIGURE 105 Hepatitis C: FIB-4 F3 (low cut-off) – sensitivity. Tot, total; val, validation cohort.
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Specificity
FIGURE 106 Hepatitis C: FIB-4 F3 (low cut-off) – specificity. Tot, total; val, validation cohort.
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FIGURE 107 Hepatitis C: Fibrotest F3 – sensitivity.
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FIGURE 108 Hepatitis C: Fibrotest F3 – specificity.
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FIGURE 109 Hepatitis C: hyaluronic acid F3 – sensitivity.
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Specificity
FIGURE 110 Hepatitis C: hyaluronic acid F3 – specificity.
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Sensitivity
FIGURE 111 Hepatitis C: Hepascore F3 – sensitivity.
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FIGURE 112 Hepatitis C: Hepascore F3 – specificity.
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FIGURE 113 Hepatitis C: 13C-caffeine breath test F4 – sensitivity.
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FIGURE 114 Hepatitis C: 13C-caffeine breath test F4 – specificity.
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FIGURE 115 Hepatitis C: APRI F4 (high cut-off) – sensitivity.
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FIGURE 116 Hepatitis C: APRI F4 (high cut-off) – specificity.
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FIGURE 117 Hepatitis C: APRI F4 (low cut-off) – sensitivity.
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FIGURE 118 Hepatitis C: APRI F4 (low cut-off) – specificity.
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FIGURE 119 Hepatitis C: AST–ALT ratio F4 – sensitivity.
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FIGURE 120 Hepatitis C: AST–ALT ratio F4 – specificity.
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FIGURE 121 Hepatitis C: FIB-4 F4 (high cut-off) – sensitivity.
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FIGURE 122 Hepatitis C: FIB-4 F4 (high cut-off) – specificity.
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FIGURE 123 Hepatitis C: FIB-4 F4 (low cut-off) – sensitivity.
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FIGURE 124 Hepatitis C: FIB-4 F4 (low cut-off) – specificity.
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FIGURE 125 Hepatitis C: Fibrometer F4 – sensitivity.
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FIGURE 126 Hepatitis C: Fibrometer F4 – specificity.
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FIGURE 127 Hepatitis C: Fibrotest F4 – sensitivity.
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FIGURE 128 Hepatitis C: Fibrotest F4 – specificity.
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FIGURE 129 Hepatitis C: GUCI F4 – sensitivity.
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FIGURE 130 Hepatitis C: GUCI F4 – specificity.
DOI: 10.3310/hta19090 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 9
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Crossan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
329
(125)
(135)
(129)-val
(163)
(168)
(180)
(221)
0.00
Sensitivity
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
FIGURE 131 Hepatitis C: hyaluronic acid F4 – sensitivity.
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FIGURE 132 Hepatitis C: hyaluronic acid F4 – specificity.
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FIGURE 133 Hepatitis C: Hepascore F4 – sensitivity. Val, validation cohort.
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FIGURE 134 Hepatitis C: Hepascore F4 – specificity. Val, validation cohort.
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FIGURE 135 Hepatitis C: platelet F4 – sensitivity.
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FIGURE 136 Hepatitis C: platelet F4 – specificity.
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FIGURE 137 Hepatitis C: TE F4 – sensitivity.
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FIGURE 138 Hepatitis C: TE F4 – specificity.
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FIGURE 139 Non-alcoholic fatty liver disease: NFS F1 (high cut-off) – sensitivity.
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FIGURE 140 Non-alcoholic fatty liver disease: NFS F1 (high cut-off) – specificity.
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FIGURE 141 Non-alcoholic fatty liver disease: NFS F1 (low cut-off) – sensitivity.
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FIGURE 142 Non-alcoholic fatty liver disease: NFS F1 (low cut-off) – specificity.
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FIGURE 143 Non-alcoholic fatty liver disease: TE F1 – sensitivity.
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FIGURE 144 Non-alcoholic fatty liver disease: TE F1 – specificity.
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Sensitivity
FIGURE 145 Non-alcoholic fatty liver disease: APRI F2 – sensitivity.
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FIGURE 146 Non-alcoholic fatty liver disease: APRI F2 – specificity.
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FIGURE 147 Non-alcoholic fatty liver disease: Fibrotest F2 (high cut-off) – sensitivity. Val, validation cohort.
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FIGURE 148 Non-alcoholic fatty liver disease: Fibrotest F2 (high cut-off) – specificity. Val, validation cohort.
DOI: 10.3310/hta19090 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 9
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Crossan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
339
(284)
(314)-val
(314)-test
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
Sensitivity
FIGURE 149 Non-alcoholic fatty liver disease: Fibrotest F2 (low cut-off) – sensitivity. Val, validation cohort.
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Specificity
FIGURE 150 Non-alcoholic fatty liver disease: Fibrotest F2 (low cut-off) – specificity. Val, validation cohort.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
340
(287)
(290)
(311)
(322)
(320)
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
Sensitivity
FIGURE 151 Non-alcoholic fatty liver disease: NFS F2 (high cut-off) – sensitivity.
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FIGURE 152 Non-alcoholic fatty liver disease: NFS F2 (high cut-off) – specificity.
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Sensitivity
FIGURE 153 Non-alcoholic fatty liver disease: NFS F2 (low cut-off) – sensitivity.
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Specificity
FIGURE 154 Non-alcoholic fatty liver disease: NFS F2 (low cut-off) – specificity.
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Sensitivity
FIGURE 155 Non-alcoholic fatty liver disease: TE F2 – sensitivity.
(329)
(326)
(308)
(296)
(119)
(294)
(288)
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
Specificity
FIGURE 156 Non-alcoholic fatty liver disease: TE F2 – specificity.
DOI: 10.3310/hta19090 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 9
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Crossan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
343
(319)
(327)
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
(301)
Sensitivity
FIGURE 157 Non-alcoholic fatty liver disease: APRI F3 – sensitivity.
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FIGURE 158 Non-alcoholic fatty liver disease: APRI F3 – specificity.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
344
(284)
(291)
(300)
(301)
(312)
(315)
(319)
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
Sensitivity
FIGURE 159 Non-alcoholic fatty liver disease: BARD F3 – sensitivity.
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FIGURE 160 Non-alcoholic fatty liver disease: BARD F3 – specificity.
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Sensitivity
FIGURE 161 Non-alcoholic fatty liver disease: FIB-4 F3 (high cut-off) – sensitivity.
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FIGURE 162 Non-alcoholic fatty liver disease: FIB-4 F3 (high cut-off) – specificity.
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FIGURE 163 Non-alcoholic fatty liver disease: FIB-4 F3 (low cut-off) – sensitivity.
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FIGURE 164 Non-alcoholic fatty liver disease: FIB-4 F3 (low cut-off) – specificity.
DOI: 10.3310/hta19090 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 9
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Crossan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
347
(165)
(292)
(316)
(321)
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
Sensitivity
FIGURE 165 Non-alcoholic fatty liver disease: hyaluronic acid F3 – sensitivity.
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FIGURE 166 Non-alcoholic fatty liver disease: hyaluronic acid F3 – specificity.
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Sensitivity
FIGURE 167 Non-alcoholic fatty liver disease: NFS F3 (high cut-off) – sensitivity. Val, validation cohort.
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FIGURE 168 Non-alcoholic fatty liver disease: NFS F3 (high cut-off) – specificity. Val, validation cohort.
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FIGURE 169 Non-alcoholic fatty liver disease: NFS F3 (low cut-off) – sensitivity. Val, validation cohort.
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FIGURE 170 Non-alcoholic fatty liver disease: NFS F3 (low cut-off) – specificity. Val, validation cohort.
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FIGURE 171 Non-alcoholic fatty liver disease: TE F3 – sensitivity.
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FIGURE 172 Non-alcoholic fatty liver disease: TE F3 – specificity.
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FIGURE 173 Non-alcoholic fatty liver disease: APRI F4 – sensitivity.
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FIGURE 174 Non-alcoholic fatty liver disease: APRI F4 – specificity.
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FIGURE 175 Non-alcoholic fatty liver disease: platelet F4 – sensitivity.
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FIGURE 176 Non-alcoholic fatty liver disease: platelet F4 – specificity.
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FIGURE 177 Non-alcoholic fatty liver disease: TE F4 – sensitivity.
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FIGURE 178 Non-alcoholic fatty liver disease: TE F4 – specificity.
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FIGURE 179 Radiology: MR elastography F2 – sensitivity.
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FIGURE 180 Radiology: MR elastography F2 – specificity.
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FIGURE 181 Radiology: ultrasound F2 – sensitivity.
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FIGURE 182 Radiology: ultrasound F2 – specificity.
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FIGURE 183 Radiology: ultrasound SAPI F2 – sensitivity.
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FIGURE 184 Radiology: ultrasound SAPI F2 – specificity.
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Sensitivity
FIGURE 185 Radiology: MR elastography F3 – sensitivity.
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FIGURE 186 Radiology: MR elastography F3 – specificity.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
358
(167)
(93)
(336)
(330)
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
Sensitivity
FIGURE 187 Radiology: ultrasound F3 – sensitivity.
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FIGURE 188 Radiology: ultrasound F3 – specificity.
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FIGURE 189 Radiology: MR elastography F4 – sensitivity.
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FIGURE 190 Radiology: MR elastography F4 – specificity.
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FIGURE 191 Radiology: ultrasound F4 – sensitivity.
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FIGURE 192 Radiology: ultrasound F4 – specificity.
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Appendix 6 Summary receiver operating
characteristic curves
This appendix presents SROC curves of non-invasive tests across different disease aetiologies and fibrosisstages. We included only non-invasive tests that had available results from at least four studies with
convergence by METADAS. The dot represents the relative sensitivity or specificity and the line represents
the 95% CIs.
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FIGURE 193 APRI (high cut-off) in diagnosing ≥ F2 in patients with chronic HBV.
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FIGURE 194 APRI (low cut-off) in diagnosing ≥ F2 in patients with chronic HBV.
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FIGURE 195 FIB-4 (low cut-off) in diagnosing ≥ F2 in patients with chronic HBV.
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FIGURE 196 Fibrotest in diagnosing ≥ F2 in patients with chronic HBV.
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FIGURE 197 Transient elastography (Fibroscan) in diagnosing ≥ F2 in patients with chronic HBV.
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FIGURE 198 Transient elastography (Fibroscan) in diagnosing ≥ F3 in patients with chronic HBV.
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0
Specificity
Se
n
si
ti
vi
ty
FIGURE 199 Transient elastography (Fibroscan) in diagnosing F4 in patients with chronic HBV.
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FIGURE 200 APRI (high cut-off) in diagnosing ≥ F2 in patients with chronic HCV.
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FIGURE 201 APRI (low cut-off) in diagnosing ≥ F2 in patients with chronic HCV.
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FIGURE 202 FIB-4 (high cut-off) in diagnosing ≥ F2 in patients with chronic HCV.
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FIGURE 203 Lok’s index in diagnosing ≥ F2 in patients with chronic HCV.
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FIGURE 204 Forns index (high cut-off) diagnosing ≥ F2 in patients with chronic HCV.
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FIGURE 205 Forns index (low cut-off) in diagnosing ≥ F2 in patients with chronic HCV.
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FIGURE 206 Fibrometer in diagnosing ≥ F2 in patients with chronic HCV.
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FIGURE 207 Fibrotest in diagnosing ≥ F2 in patients with chronic HCV.
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FIGURE 208 Fibrotest (high cut-off) in diagnosing ≥ F2 in patients with chronic HCV.
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FIGURE 209 Hyaluronic acid in diagnosing ≥ F2 in patients with chronic HCV.
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FIGURE 210 Hepascore in diagnosing ≥ F2 in patients with chronic HCV.
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FIGURE 211 Platelet count in diagnosing ≥ F2 in patients with chronic HCV.
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FIGURE 212 Transient elastography (Fibroscan) in diagnosing ≥ F2 in patients with chronic HCV.
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FIGURE 213 Hepascore in diagnosing ≥ F3 in patients with chronic HCV.
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FIGURE 214 FIB-4 (high cut-off) in diagnosing ≥ F3 in patients with chronic HCV.
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FIGURE 215 FIB-4 (low cut-off) in diagnosing ≥ F3 in patients with chronic HCV.
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FIGURE 216 APRI (high cut-off) in diagnosing ≥ F3 in patients with chronic HCV.
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FIGURE 217 Fibrotest in diagnosing ≥ F3 in patients with chronic HCV.
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FIGURE 218 Transient elastography (Fibroscan) in diagnosing ≥ F3 in patients with chronic HCV.
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FIGURE 219 APRI (high cut-off) in diagnosing F4 in patients with chronic HCV.
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FIGURE 220 APRI (low cut-off) in diagnosing F4 in patients with chronic HCV.
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FIGURE 221 AST–ALT ratio in diagnosing F4 in patients with chronic HCV.
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FIGURE 222 Platelet count in diagnosing F4 in patients with chronic HCV.
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FIGURE 223 Hyaluronic acid in diagnosing F4 in patients with chronic HCV.
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FIGURE 224 Fibrotest in diagnosing F4 in patients with chronic HCV.
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FIGURE 225 Hepascore in diagnosing F4 in patients with chronic HCV.
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FIGURE 226 Transient elastography (Fibroscan) in diagnosing F4 in patients with chronic HCV.
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FIGURE 227 Non-alcoholic fatty liver disease fibrosis score (low cut-off) in diagnosing ≥ F2 in patients with NASH.
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FIGURE 228 Non-alcoholic fatty liver disease fibrosis score (high cut-off) in diagnosing ≥ F2 in patients with NASH.
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FIGURE 229 Non-alcoholic fatty liver disease fibrosis score (low cut-off) in diagnosing ≥ F3 in patients with NASH.
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FIGURE 230 Non-alcoholic fatty liver disease fibrosis score (high cut-off) in diagnosing ≥ F3 in patients with NASH.
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FIGURE 231 BARD score in diagnosing ≥ F3 in patients with NASH.
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FIGURE 232 Magnetic resonance elastography in diagnosing ≥ F3 in patients irrespective of liver disease aetiology.
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FIGURE 233 Ultrasound in diagnosing ≥ F3 in patients irrespective of liver disease aetiology.
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FIGURE 234 Ultrasound in diagnosing F4 in patients irrespective of liver disease aetiology.
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Appendix 7 Probability of non-invasive liver tests
returning true-positive, false-negative, true-negative
or false-positive results
TABLE 72 Hepatitis C: outcome of diagnostic tests (% TP, FN, TN and FP results; average prevalence 53%)
(≥ F2 by METAVIR)
Test TP, % FN, % TN, % FP, %
Summary
sensitivity
Summary
specificity
Age–Platelet Index 33 20 38 10 0.58 0.70
AST–ALT 23 29 33 14 0.44 0.71
APRI 40 12 38 9 0.77 0.81
APRI (high cut-off) 21 32 44 4 0.39 0.92
APRI (low cut-off) 43 10 27 20 0.82 0.57
ARFI 42 11 42 5 0.79 0.89
CT 37 16 30 17 0.70 0.64
Bordeaux algorithm 46 6 42 5 0.88 0.89
CDS 38 13 23 24 0.66 0.49
ELF 44 9 33 14 0.84 0.70
ELF (high cut-off) 25 28 43 5 0.47 0.90
ELF (low cut-off) 47 5 25 23 0.90 0.52
EOB-MRI 34 19 38 10 0.64 0.79
FIB-4 18 35 41 6 0.34 0.86
FIB-4 (high cut-off) 31 22 35 12 0.59 0.74
FIB-4 (low cut-off) 47 6 20 28 0.89 0.42
Fibrosis Index 38 15 40 7 0.71 0.84
Fibroindex (high cut-off) 13 40 46 1 0.24 0.98
Fibroindex (low cut-off) 44 9 27 20 0.83 0.57
Fibrometer 42 11 34 14 0.79 0.73
Fibropaca algorithm 45 8 43 5 0.85 0.90
FibroQ 41 12 31 16 0.78 0.66
FibroSpect 41 11 33 14 0.78 0.71
Forns index 16 37 18 29 0.30 0.39
Forns index (high cut-off) 18 35 45 2 0.35 0.96
Forns index (low cut-off) 46 7 19 28 0.88 0.40
Fibrosis Probability Index (high cut-off) 22 30 45 2 0.42 0.95
Fibrosis Probability Index (low cut-off) 48 5 21 26 0.91 0.45
Fibrotest 36 17 34 13 0.68 0.72
Fibrotest (high cut-off) 30 23 14 7 0.57 0.85
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TABLE 72 Hepatitis C: outcome of diagnostic tests (% TP, FN, TN and FP results; average prevalence 53%)
(≥ F2 by METAVIR) (continued )
Test TP, % FN, % TN, % FP, %
Summary
sensitivity
Summary
specificity
Fibrotest (low cut-off) 48 5 20 28 0.91 0.41
GUCI 34 18 37 10 0.65 0.79
Hyaluronic acid 39 13 36 12 0.75 0.75
Hyaluronic acid (high cut-off) 13 41 43 4 0.23 0.92
Hyaluronic acid (low cut-off) 36 17 29 18 0.67 0.62
Hepascore 37 14 34 13 0.73 0.73
Hepascore (high cut-off) 17 35 44 4 0.33 0.92
King’s 44 8 33 14 0.84 0.70
King’s (high cut-off) 31 22 37 10 0.58 0.79
King’s (low cut-off) 33 20 38 9 0.62 0.81
Lok’s index 35 17 26 21 0.67 0.55
MP3 43 9 35 13 0.85 0.73
MR 45 8 43 4 0.85 0.90
PIINP/MMP-1 index 38 18 40 7 0.65 0.85
PIINP 41 12 36 11 0.78 0.76
PLT 26 26 42 5 0.50 0.89
PLT–Spleen 46 6 5 13 0.88 0.73
Pohl Index 3 50 47 1 0.06 0.99
Fibroscan 42 11 39 8 0.79 0.83
Type IV collagen 46 6 35 13 0.88 0.73
YKL-40 (high cut-off) 18 35 38 9 0.33 0.80
YKL-40 (low cut-off) 42 11 16 32 0.80 0.33
US 18 34 40 7 0.35 0.86
US SAPI 39 14 37 10 0.74 0.79
US SAPI (high cut-off) 32 20 45 2 0.61 0.96
US SAPI (low cut-off) 50 3 19 29 0.94 0.39
CEUS 46 6 35 13 0.88 0.73
DW-MRI 41 11 37 10 0.78 0.78
MR elastography 50 3 43 4 0.94 0.92
APRI (combined cut-off) 40 13 41 7 0.75 0.86
ELF (combined cut-off) 43 9 40 8 0.82 0.84
FIB-4 (combined cut-off) 44 9 35 14 0.83 0.73
Fibroindex (combined cut-off) 30 22 45 2 0.58 0.95
Fibrospect (combined cut-off) 53 0 47 0 1.00 1.00
Forns (combined cut-off) 39 14 43 4 0.74 0.91
Fibrotest (combined cut-off) 47 7 35 12 0.87 0.74
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
376
TABLE 72 Hepatitis C: outcome of diagnostic tests (% TP, FN, TN and FP results; average prevalence 53%)
(≥ F2 by METAVIR) (continued )
Test TP, % FN, % TN, % FP, %
Summary
sensitivity
Summary
specificity
Hyaluronic acid (combined cut-off) 34 19 34 13 0.64 0.72
Hepascore (combined cut-off) 22 31 43 4 0.42 0.91
YKL-40 (combined cut-off) 33 20 29 18 0.63 0.62
Leroy algorithm 47 5 46 1 0.90 0.98
SAFE algorithm 53 0 38 9 1.00 0.81
CDS, Cirrhosis Discriminant Score; CEUS, contrast-enhanced ultrasound; DW-MRI, diffusion-weighted magnetic resonance
imaging; EOB-MRI, (gadolinium-ethoxybenzyl-diethylenetriamine-penta-acetic-acid) enhanced magnetic resonance imaging;
FN, false negative; FP, false positive; MMP-1, matrix metalloproteinase-1; MP3, metalloproteinase-3; PLT, platelet;
TN, true negative; TP, true positive; US, ultrasound.
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TABLE 73 Hepatitis B: outcome of diagnostic tests (% TP, FN, TN and FP results; average prevalence 54%)
(≥ F2 by METAVIR)
Test TP, % FN, % TN, % FP, %
Summary
sensitivity
Summary
specificity
AAR 31 23 27 19 0.57 0.59
APGA 9 45 8 38 0.17 0.98
Age-Platelet Index 4 51 28 17 0.07 0.62
APRI (combined cut-off) 39 15 41 4 0.73 0.91
APRI (high cut-off) 20 34 43 3 0.37 0.93
APRI (low cut-off) 43 11 30 16 0.80 0.65
ARFI 38 16 31 15 0.71 0.67
FIB-4 (combined cut-off) 9 46 45 1 0.16 0.98
FIB-4 (high cut-off) 5 49 45 1 0.09 0.99
FIB-4 (low cut-off) 37 17 33 12 0.68 0.73
Fibrotest 36 18 37 9 0.66 0.80
Forns (combined cut-off) 14 40 46 0 0.26 1.00
Forns index (high cut-off) 8 46 46 0 0.15 1.00
Forns index (low cut-off) 31 23 35 10 0.58 0.77
GUCI 36 18 44 1 0.67 0.97
Hyaluronic acid 46 9 38 8 0.84 0.83
Hepascore 43 12 34 12 0.79 0.74
Hui index 27 27 42 4 0.50 0.91
PAPAS 39 15 36 10 0.73 0.78
Fibroscan 38 16 38 7 0.71 0.84
US 19 35 39 7 0.35 0.86
CEUS 48 6 33 12 0.88 0.73
DW-MRI 42 12 36 10 0.78 0.78
MR elastography 51 3 42 4 0.94 0.92
US SAPI 40 14 36 10 0.74 0.79
US SAPI (high cut-off) 33 21 44 2 0.61 0.96
US SAPI (low cut-off) 51 3 18 28 0.94 0.39
CT 38 16 29 17 0.70 0.64
AAR, AST–ALT ratio; APGA, AST, platelet count, GGT, α-fetoprotein; CEUS, contrast-enhanced ultrasound;
DW-MRI, diffusion-weighted magnetic resonance imaging; FN, false negative; FP, false positive; PAPAS, age, ALP,
α-fetoprotein, AST; TN, true negative; TP, true positive; US, ultrasound.
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TABLE 74 Alcoholic liver disease: outcome of diagnostic tests (% TP, FN, TN and FP results; average prevalence
37%) (≥ F4 by METAVIR)
Test TP, % FN, % TN, % FP, % Summary sensitivity Summary specificity
APRI (high cut-off) 15 24 22 39 0.40 0.62
Fibrotest (high cut-off) 33 8 3 55 0.91 0.87
Fibrotest (low cut-off) 36 2 0 32 1.00 0.50
29 7 8 56 0.78 0.89
Fibroscan 32 11 5 53 0.86 0.83
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
DOI: 10.3310/hta19090 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 9
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Crossan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
379
TABLE 75 Non-alcoholic fatty liver disease: outcome of diagnostic tests (% TP, FN, TN and FP results; average
prevalence 19%) (≥ F3 by Kleiner)
Test TP, % FN, % TN, % FP, %
Summary
sensitivity
Summary
specificity
Age–Platelet Index 14 7 61 17 0.66 0.78
APRI 9 13 65 14 0.40 0.82
ARFI 20 2 70 8 0.90 0.90
AST–ALT (high cut off) 10 12 71 7 0.46 0.91
AST–ALT (low cut-off) 17 5 55 23 0.79 0.70
Bard 18 3 48 31 0.84 0.61
Type IV collagen 17 4 63 16 0.79 0.80
ELF 17 4 70 8 0.80 0.90
FIB-4 (high cut-off) 8 13 76 3 0.98 0.97
FIB-4 (low cut-off) 18 3 58 20 0.84 0.74
Fibrotest (high cut-off) 9 13 75 3 0.40 0.96
Fibrotest (low cut-off) 19 3 57 21 0.88 0.73
Fibrotest: Fibroscan 9 13 75 3 0.39 0.96
Hyaluronic acid 19 3 64 13 0.88 0.82
Hepascore 16 5 66 12 0.75 0.84
NAFIC (high cut-off) 18 4 64 14 0.84 0.82
NAFIC (low cut-off) 21 1 53 26 0.96 0.67
NDP: advanced fibrosis 19 3 55 24 0.88 0.70
NFS ELF (high cut-off) 19 3 78 1 0.86 0.99
NFS ELF (low cut-off) 14 7 75 3 0.91 0.96
NFS (high cut-off) 9 13 76 2 0.40 0.97
NFS (low cut-off) 17 4 52 27 0.80 0.66
NFS Fibroscan 2 20 77 1 0.08 0.98
PLT 14 8 60 19 0.63 0.76
Fibroscan (TE) 18 4 66 13 0.82 0.84
MR elastography 20 2 69 9 0.91 0.88
FIB-4 combined cut-off (inconclusive
results retested with Fibroscan)
17 5 73 5 0.79 0.93
NFS (combined cut-off) (inconclusive
results retested with Fibroscan)
15 6 75 3 0.71 0.96
NAFIC (combined cut-off) (inconclusive
results retested with Fibroscan)
21 1 62 16 0.95 0.79
NFS ELF (combined cut-off) (inconclusive
results retested with Fibroscan)
20 2 78 1 0.90 0.99
Fibrotest (combined cut-off) (inconclusive
results retested with Fibroscan)
18 4 76 3 0.83 0.87
FN, false negative; FP, false positive; NDP, NAFLD diagnostic panel; PLT, platelet; TN, true negative; TP, true positive.
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TABLE 76 Cirrhosis: outcome of diagnostic tests (% TP, FN, TN and FP results; average prevalence 20%)
Test TP, % FP, % FN, % TN, %
Summary
sensitivity
Summary
specificity
Age–Platelet Index 18 22 2 59 0.88 0.73
APRI 16 24 4 56 0.79 0.70
APRI (combined cut-off) 13 7 7 73 0.64 0.91
APRI (high cut-off) 9 6 11 74 0.45 0.93
APRI (low cut-off) 15 17 5 63 0.75 0.78
ARFI 17 18 3 62 0.84 0.87
AST–ALT ratio 10 10 10 70 0.49 0.87
BARD 10 13 10 67 0.52 0.84
Bordeaux 17 4 3 76 0.87 0.95
CDS 18 26 2 54 0.88 0.67
CDS (high cut-off) 7 1 13 79 0.33 1.00
CDS (low cut-off) 18 8 2 72 0.89 0.90
ELF 19 17 1 63 0.93 0.79
ELF (combined cut-off) 17 13 3 67 0.84 0.84
ELF (high cut-off) 10 8 10 72 0.52 0.90
ELF (low cut-off) 18 38 2 42 0.90 0.53
Fibrosis Index (FI) 8 1 12 79 0.38 1.00
FIB-4 16 18 4 62 0.80 0.78
FIB-4 (combined cut-off) 15 6 5 74 0.75 0.93
FIB-4 (high cut-off) 8 6 12 74 0.42 0.92
FIB-4 (low cut-off) 17 23 3 57 0.84 0.71
Fibroindex 14 7 6 73 0.70 0.91
Fibrometer 14 10 6 70 0.72 0.88
Fibrometer (combined cut-off) 18 2 2 78 0.89 0.97
Fibrometer (high cut-off) 7 2 13 78 0.39 0.98
Fibrometer (low cut-off) 19 23 1 57 0.96 0.71
Fibropaca 15 2 5 78 0.73 0.97
Fontana 16 27 4 53 0.79 0.66
Forns index 20 21 0 59 1.00 0.74
Forns index (combined cut-off) 19 20 1 60 0.97 0.75
Forns index (high cut-off) 13 7 7 73 0.67 0.91
Forns index (low cut-off) 18 50 2 30 0.88 0.37
Fibrotest 12 11 8 70 0.61 0.87
Fibrotest (combined cut-off) 14 4 6 76 0.70 0.95
Fibrotest (high cut-off) 15 5 5 75 0.73 0.94
Fibrotest (low cut-off) 18 28 2 52 0.89 0.65
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TABLE 76 Cirrhosis: outcome of diagnostic tests (% TP, FN, TN and FP results; average
prevalence 20%) (continued )
Test TP, % FP, % FN, % TN, %
Summary
sensitivity
Summary
specificity
GUCI 13 11 7 69 0.64 0.86
Hyaluronic acid 16 9 4 71 0.81 0.88
Hepascore 16 13 4 67 0.82 0.84
Hepascore (combined cut-off) 13 1 7 79 0.66 0.99
Hepascore (high cut-off) 8 1 12 79 0.39 0.99
Hepascore (low cut-off) 16 14 4 66 0.80 0.83
King’s 15 8 5 72 0.74 0.90
Lok’s index (high cut-off) 8 4 12 76 0.40 0.95
Lok’s index (low cut-off) 17 27 3 53 0.84 0.66
MR 15 22 5 58 0.75 0.72
PGAA 16 9 4 71 0.78 0.89
PIIINP 14 17 6 63 0.70 0.79
PLT 14 10 6 70 0.72 0.88
PLT–Spleen 17 14 3 66 0.85 0.82
SAFE 15 6 5 74 0.74 0.93
Fibroscan 18 9 2 71 0.89 0.89
Type IV collagen 14 20 6 61 0.71 0.76
CEUS 17 10 3 70 0.84 0.88
DW-MRI 18 22 2 58 0.88 0.73
MR elastography 20 5 0 75 1.00 0.93
MRI 15 16 5 64 0.75 0.80
US 15 9 5 70 0.73 0.88
US SAPI 15 26 6 54 0.73 0.67
CDS, Cirrhosis Discriminant Score; CEUS, contrast-enhanced ultrasound; DW-MRI, diffusion-weighted magnetic resonance
imaging; FN, false negative; FP, false positive; PLT, platelet; TN, true negative; TP, true positive; US, ultrasound.
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Appendix 8 Probabilistic sensitivity analysis
parameters
TABLE 77 Probabilistic sensitivity analysis parameters
Parameter
Base-case
value
Standard
error Distribution
HBV health-state costs (£ 2012)
Mild fibrosis 185 36 Gamma
Moderate fibrosis 959 102
Compensated cirrhosis 1521 309
Decompensated cirrhosis 36,194 9967
HCC 36,194 9967.190
Liver transplant 64,122 5886
Post liver transplant 16,321 7933
HBV utilities
Mild fibrosis 0.77 0.035 Gamma
Moderate fibrosis 0.66 0.018
Compensated cirrhosis 0.55 0.032
Decompensated cirrhosis 0.57 0.076
HCC 0.57 0.076
Liver transplant 0.73 0.016
Post liver transplant 0.78 0.064
HCV health-state costs (£ 2012)
Mild fibrosis 185 36 Gamma
Moderate fibrosis 959 102
Compensated cirrhosis 1521 309
Decompensated cirrhosis 38,871 9410
HCC 38,871 9410
Liver transplant 69,174 7055
Post liver transplant 4356 862
HCV utilities
Mild fibrosis 0.77 0.035 Beta
Moderate fibrosis 0.66 0.018
Compensated cirrhosis 0.55 0.032
Decompensated cirrhosis 0.49 0.056
HCC 0.49 0.056
Liver transplant 0.51 0.053
Post liver transplant 0.52 0.061
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TABLE 77 Probabilistic sensitivity analysis parameters (continued )
Parameter
Base-case
value
Standard
error Distribution
During treatment: mild fibrosis 0.65 0.03
During treatment: moderate fibrosis 0.55 0.018
During treatment: cirrhosis 0.44 0.032
Following successful treatment: mild treatment 0.82 0.04
Following successful treatment: moderate treatment 0.71 0.05
Following successful treatment: compensated cirrhosis 0.60 0.04
ALD
Probability cirrhosis if continue to drink 20% 0.02 Beta
Abstinence rate after diagnosis of no cirrhosis with
liver biopsy
41% 0.041
Abstinence rate after diagnosis of cirrhosis with liver biopsy 62% 0.0612
Abstinence rate after diagnosis of no cirrhosis with a NILT 31% 0.031
Abstinence rate after diagnosis of cirrhosis with a NILT 52% 0.052
Probability adverse event after liver biopsy 0.72% 0.00072
Mortality risk after liver biopsy 0.09% 0.00009
Cirrhosis
Reduction in mortality with HCC screening 37% 0.037 Beta
HBV and HCV
Transition probabilities and all-cause mortality rate Dirichlet
All aetiologies
Summary sensitivity and specificity estimates Beta
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Appendix 9 Unit costs of non-invasive liver tests
and liver biopsy
TABLE 78 Unit costs of NILTs and liver biopsy (2012–13)
Test Unit cost, £ Source
AAR 0.90 Royal Free, 12 December 2012, personal communication
AP (age–PLT ratio)
(API?)
3.50 Royal Free, 12 December 2012, personal communication
APGA 4.95 Royal Free, 22 January 2013, personal communication
APRI 4.05 Royal Free, 12 December 2012, personal communication
ARFI 51.00 As per personal communication Royal Free: costed at same cost as Fibroscan
AST–ALT ratio (AAR) 0.90 Royal Free, 12 December 2012, personal communication
BARD 0.90 Royal Free, 29 May 2013, personal communication
Bordeaux 94.60 Costed as combination strategy (Fibrotest and Fibroscan)
CDS 7.19 Royal Free, 30 January 2013, personal communication
CEUS 113.70 Department of Health reference costs 2011–12427 (US > 20 minutes) plus
contrast (SonoVue) cost: £48.70 (Royal Free personal communication)
CT 105.00 Department of Health reference costs 2011–12427 (CT with contrast pre and
post scan): Diagnostic Imaging Outpatients
DW-MRI 199.00 Cost as per MRI with contrast (as per personal communication, Royal Free,
4 December 2012)
ELF 108.00 Wiktoria Jonasson, Royal Free, 9 May 2012, personal communication: cost of
ELF is £90+VAT
EOB-MRI 199.00 Cost as per MRI with contrast (as per Royal Free)
FIB-4 4.40 Royal Free, 12 December 2012, personal communication
Fibroindex 48.00 Royal Free, 14 January 2013, personal communication
Fibrometer 44.00 Anne Laure Gilles, BioLiveScale, 22 May 2012, personal communication: quoted
approximate price €50 (converted to UK cost using OECD indices)
Fibropaca-algorithm 509.89 Tests: APRI, Forns index, liver biopsy, Fibrotest: proportion calculated using
Sebastiani et al.31
FibroQ 7.19 Royal Free, 30 January 2013, personal communication
Fibroscan (TE) 51.00 Department of Health Reference Costs 2011–12:427 US < 20 minutes.
From Diagnostic Imaging, Outpatients (DIAGIM-OP) code RA23Z. As per
advice from Royal Free
Fibrosis Index (FI) 4.40 Royal Free, 12 December 2012, personal communication
Fibrospect 35.34 Royal Free, 14 January 2013, personal communication
Fibrotest 43.60 Jean Marie Castille, Directeur General (Biopredictive), 31 May 2012, personal
communication: converted to GBP Sterling (OECD PPP and exchange rates data:
rate 0.871929)
Fontana F4 31.50 Royal Free, 24 July 2013, personal communication
Forns index 4.26 Royal Free, 22 January 2013, personal communication
FPI high 8.58 Royal Free, 22 January 2013, personal communication
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TABLE 78 Unit costs of NILTs and liver biopsy (2012–13) (continued )
Test Unit cost, £ Source
FPI low 8.58 Royal Free, 22 January 2013, personal communication
Fibrotest Fibroscan 94.60 Costed as Fibrotest and Fibroscan
GUCI 6.84 Royal Free, 22 January 2013, personal communication
Hyaluronic acid 8.00 Royal Free, 22 January 2013, personal communication
Hepascore 16.24 Royal Free, 22 January 2013, personal communication
Hui index 4.60 Royal Free, 22 January 2013, personal communication
King’s 6.84 Royal Free, 22 January 2013, personal communication
Leroy algorithm 724.74 Tests: APRI, liver biopsy, Fibrotest: proportion calculated using Sebastiani et al.31
Liver Biopsy 956.61 Stevenson et al.428
Lok’s index (HALT-C) 7.19 Royal Free, 30 January 2013, personal communication
MP3 20.00 Royal Free, 30 January 2013, personal communication
MR elastography 199.00 Department of Health Reference Costs 2011–12:427 Diagnostic Imaging
Outpatients, MRI one area pre and post contrast (code RA23Z)
MRI 199.00 Cost as per MRI with contrast (as per Royal Free)
NAFIC 28.17 Royal Free, 29 May 2013, personal communication
NDP 21.18 Royal Free, 29 May 2013, personal communication
NFS high 4.95 Royal Free, 29 May 2013, personal communication
NFS ELF 112.95 Royal Free, 29 May 2013, personal communication
NFS TE 55.95 Sum of NFS and Fibroscan (TE)
PAPAS 5.15 Royal Free, 22 January 2013, personal communication
PGAA 9.07 Royal Free, 24 July 2013, personal communication
PIIINP/MMP-1 index 48.00 Royal Free, 14 January 2013, personal communication
PIINP 28.00 Royal Free, 12 December 2012, personal communication
PLT 3.50 Royal Free, 29 May 2013, personal communication
PLT–Spleen (SPRI) 54.50 Royal Free, 4 December 2012, personal communication
Pohl Index 4.40 Royal Free, 30 January 2013, personal communication
SAFE 743.22 Tests: APRI, liver biopsy, Fibrotest: proportion calculated using Sebastiani
et al.31,187
TE 51.00 Department of Health Reference Costs 2011–12:427 US < 20 minutes [from
Diagnostic Imaging, Outpatients (DIAGIM-OP) code RA23Z as advised by
Royal Free]
Type IV collagen 20.00 Royal Free, 30 January 2013, personal communication
US 51.00 Department of Health Reference Costs 2011–12:427 US < 20 minutes [from
Diagnostic Imaging, Outpatients (DIAGIM-OP) code RA23Z]
US SAPI 65.00 Department of Health Reference Costs 2011–12:427 US > 20 minutes
YKL-40 20.00 Royal Free, 8 February 2013, personal communication
AAR, AST–ALT ratio; APGA, AST, platelet count, GGT, α-fetoprotein; API, Age-Platelet Index; CDS, Cirrhosis Discriminant
Score; CEUS, contrast-enhanced ultrasound; DW-MRI, diffusion-weighted magnetic resonance imaging; EOB-MRI,
(gadolinium-ethoxybenzyl-diethylenetriamine-penta-acetic-acid) enhanced magnetic resonance imaging; FPI, Fibrosis
Probability Index; HALT-C, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis; MMP-1, matrix metalloproteinase-1;
MP3, metalloproteinase-3; NDP, NAFLD diagnostic panel; OECD, Organisation for Economic Co-operation and
Development; PAPAS, age, ALP, α-fetoprotein, AST; PLT, platelet; US, ultrasound; VAT, value-added tax.
The costs of non-invasive tests were sourced through our clinical collaborators (authors on the report) who sourced these
from the biochemistry department and the finance department at the Royal Free Hospital.
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Appendix 10 Cost-effectiveness acceptability
curves
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FIGURE 235 Cost-effectiveness acceptability curve for HBeAg-positive. HA, hyaluronic acid; MRE, MR elastography.
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FIGURE 236 Cost-effectiveness acceptability curve for HBeAg-negative. HA, hyaluronic acid; MRE, MR elastography.
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FIGURE 238 Cost-effectiveness acceptability curve for ALD.
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FIGURE 239 Cost-effectiveness acceptability curve for cirrhosis. HA, hyaluronic acid.
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Appendix 11 Sensitivity analysis
Results of sensitivity analyses: for clarity and presentation, all testing strategies which were ‘dominated’or ‘extendedly dominated’ are excluded from the tables.
Sensitivity analyses tables for hepatitis B
HBeAg-positive
TABLE 79 HBeAg-positive: sensitivity analysis of tests where bivariate model converged (only)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,831 9.64 – – –
APRI (high
cut-off)
75,210 11.45 37,380 1.81 20,673
Fibroscan 79,000 11.61 3790 0.16 23,345
Treat all 101,484 12.18 22,484 0.57 39,747
TABLE 80 HBeAg-positive: sensitivity analysis using minimum disease prevalence
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 29,410 12.23 – – –
GUCI 57,054 13.73 27,644 1.50 18,486
MR elastography 60,233 13.81 3179 0.09 37,348
Treat all 99,263 14.76 39,030 0.95 41,177
TABLE 81 HBeAg-positive: sensitivity analysis using maximum disease prevalence
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 49,392 6.30 – – –
FIB-4 (high
cut-off)
108,296 9.59 58,904 3.30 17,871
TABLE 82 HBeAg-positive: sensitivity analysis using 25th quartile value
Test strategy Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
No treat 34,436 10.709 – – –
GUCI 67,387 12.432 32,951 1.72 19,121
MR elastography 70,256 12.520 2869 0.09 32,618
Hyaluronic acid 72,298 12.570 2042 0.05 40,722
Treat all 100,896 13.264 28,598 0.69 41,229
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TABLE 83 HBeAg-positive: sensitivity analysis using 75th quartile value
Test strategy Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
No treat 41,192 8.68 – – –
Forns index (high cut-off) 79,060 10.45 37,868 1.77 21,387
Treat all 103,038 11.35 23,978 0.90 26,718
TABLE 84 HBeAg-positive: sensitivity analysis assuming no treatment benefit for patients who are incorrectly
treated while in a mild health state
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
No treat 37,831 9.64 – – –
GUCI 74,924 11.50 37,093 1.86 19,934
MR elastography 77,610 11.59 2686 0.08 32,200
Treat all 102,064 11.63 24,454 0.04 550,668
TABLE 85 HBeAg-positive: sensitivity analysis using alternative utility values
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 38,109 9.58 – – –
GUCI 75,108 11.48 36,999 1.90 19,476
MR elastography 77,641 11.57 2533 0.10 26,589
US SAPI (low cut-off) 91,418 11.91 13,777 0.34 41,083
Treat all 101,954 12.15 10,535 0.25 42,996
US, ultrasound.
TABLE 86 HBeAg-positive: sensitivity analysis no disutility associated with liver biopsy
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,831 9.64 – – –
GUCI 74,925 11.52 37,095 1.88 19,733
MR elastography 77,585 11.64 2660 0.11 23,449
Treat all 101,484 12.18 23,899 0.54 44,019
TABLE 87 HBeAg-positive: sensitivity analysis assuming larger disutility associated with liver biopsy
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,831 9.64 – – –
GUCI 74,918 11.52 37,087 1.88 19,727
MR elastography 77,594 11.64 2676 0.11 23,846
Treat all 101,484 12.18 23,890 0.54 43,922
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TABLE 88 HBeAg-positive: sensitivity analysis on health state costs (decompensated cirrhosis and HCC)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 19,248 9.64 – – –
GUCI 56,277 11.52 37,029 1.88 19,694
MR elastography 59,473 11.66 3196 0.14 22,918
Treat all 84,468 12.24 24,994 0.58 43,095
TABLE 89 HBeAg-positive: sensitivity analysis – retest cost set to APRI (all costs set to APRI)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
No treat 37,831 9.64 – – –
GUCI 74,915 11.52 37,084 1.88 19,725
MR elastography 77,013 11.64 2098 0.12 17,810
Treat all 101,484 12.18 24,471 0.54 45,456
TABLE 90 HBeAg-positive: sensitivity analysis on sensitivity and specificity of retest [set to APRI (low cut-off)]
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,831 9.64 – – –
MR elastography 95,175 12.02 57,345 2.38 24,077
Treat all 101,484 12.18 6309 0.15 40,836
TABLE 91 HBeAg-positive: sensitivity analysis on sensitivity and specificity of retest (set to Fibrotest)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,831 9.64 – – –
MR elastography 90,312 11.94 52,481 2.29 22,868
Treat all 101,484 12.18 11,172 0.24 46,317
TABLE 92 HBeAg-positive: sensitivity analysis on sensitivity and specificity of retest (set to Fibroscan)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,831 9.64 – – –
MR elastography 91,679 11.97 53,848 2.32 23,182
Treat all 101,484 12.18 9805 0.21 45,952
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TABLE 93 HBeAg-positive: sensitivity analysis on selection of tests for second stage of analysis (sequential testing)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,831 9.64 – – –
(S2) Hyaluronic acid
and US SAPI (high cut-off)
75,246 11.52 37,414 1.88 19,903
(S2) Hyaluronic acid
and US SAPI (low cut-off)
77,560 11.62 2315 0.09 24,883
Hyaluronic acid 79,005 11.66 1444 0.04 34,084
Treat all 101,484 12.18 22,480 0.52 43,150
S2, strategy 2; US, ultrasound.
TABLE 94 HBeAg-positive: sensitivity analysis on length of successful response rate to treatment with
peginterferon (reduced to 15 years – and reintroduces risk of progression to more severe health states)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,831 9.64 – – –
GUCI 75,271 11.52 37,440 1.88 19,928
MR elastography 77,930 11.64 2659 0.12 22,601
Treat all 101,484 12.18 23,554 0.54 43,636
HBeAg-negative
TABLE 95 HBeAg-negative: sensitivity analysis of tests where bivariate model converged (only)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,579 8.83 – – –
Treat all 96,525 10.92 58,947 2.09 28,137
TABLE 96 HBeAg-negative: sensitivity analysis using minimum disease prevalence
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 28,696 11.23 – – –
Treat all 120,532 15.24 91,836 4.02 22,871
TABLE 97 HBeAg-negative: sensitivity analysis using the maximum disease prevalence
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 49,584 5.68 – – –
MR elastography 96,726 7.87 47,142 2.18 21,581
US SAPI (low cut-off) 99,174 7.93 2448 0.07 36,897
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TABLE 98 HBeAg-negative: sensitivity analysis using 25th quartile value
Test strategy Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
No treat 33,514 9.837 – – –
Treat all 94,495 11.842 60,981 2.01 30,413
TABLE 99 HBeAg-negative: sensitivity analysis using 75th quartile value
Test strategy Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
No treat 40,908 7.927 – – –
Treat all 97,007 9.971 56,099 2.04 27,447
TABLE 100 HBeAg-negative: sensitivity analysis – all retest costs set to cost of APRI
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
No treat 37,579 8.83 – – –
Treat all 96,525 10.92 58,947 2.09 28,137
TABLE 101 HBeAg-negative: sensitivity analysis assuming no treatment benefit for patients who are incorrectly
treated while in a mild health state
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,579 8.83 – – –
MR elastography 71,699 9.87 34,120 1.04 32,694
Treat all 95,989 10.32 24,290 0.45 53,660
TABLE 102 HBeAg-negative: sensitivity analysis to utility values
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,589 8.76 – – –
Treat all 96,314 10.82 58,724 2.05 28,603
TABLE 103 HBeAg-negative: sensitivity analysis assuming no disutility associated with liver biopsy
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no none 37,579 8.83 – – –
Treat all 96,525 10.92 58,947 2.09 28,137
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TABLE 104 HBeAg-negative: sensitivity analysis of greater disutility associated with liver biopsy (increased to 0.3)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,579 8.83 – – –
Treat all 96,525 10.92 58,947 2.09 28,137
TABLE 105 HBeAg-negative: sensitivity analysis on health state costs (decompensated cirrhosis and HCC)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 18,894 8.83 – – –
Treat all 77,894 10.90 59,000 2.07 28,456
TABLE 106 HBeAg-negative: sensitivity analysis to amend sensitivity and specificity of retest [set to APRI (low
cut-off)]
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,579 8.83 – – –
MR elastography 89,722 10.72 52,144 1.90 27,476
Treat all 96,525 10.92 6803 0.20 34,501
TABLE 107 HBeAg-negative: sensitivity analysis to amend sensitivity and specificity of retest (set to Fibrotest)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,579 8.83 – – –
MR elastography 86,285 10.64 48,706 1.82 26,831
Treat all 96,525 10.92 10,241 0.28 36,615
TABLE 108 HBeAg-negative: sensitivity analysis to amend sensitivity and specificity of retest (set to Fibroscan)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 37,579 8.83 – – –
MR elastography 85,041 10.63 47,462 1.81 26,260
Treat all 96,525 10.92 11,484 0.29 39,934
TABLE 109 HBeAg-negative: sensitivity analysis to amend selection of tests for second stage of analysis
(sequential testing)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
No treat 37,579 8.83 – – –
Treat all 96,525 10.92 58,947 2.09 28,137
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TABLE 110 HBeAg-negative: sensitivity analysis to reduce length of successful response rate to treatment with
peginterferon (reduced to 15 years – and reintroduces risk of progression to more severe health states)
Test Cost £ QALY Incremental cost, £ Incremental QALY ICER £
Treat no one 37,579 8.83 – – –
Treat all 96,525 10.92 58,947 2.09 28,137
TABLE 111 HBeAg-negative: sensitivity analysis to amend sex distribution and starting age changed to reflect
HBeAg-positive model
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 38,737 9.26 – – –
GUCI 73,824 10.78 35,088 1.52 23,065
MR elastography 76,631 10.89 2807 0.11 25,547
US SAPI (low cut of) 90,200 11.17 13,569 0.28 48,775
Treat all 99,905 11.36 9705 0.20 49,720
US, ultrasound.
Sensitivity analysis tables for hepatitis C
TABLE 112 Hepatitis C: sensitivity analysis of tests where bivariate model converged (only)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Forns index (high cut-off) 47,426 14.119 – – –
Fibroscan 47,448 14.278 22 0.16 141
Treat all 51,241 14.732 3793 0.45 8370
TABLE 113 Hepatitis C: sensitivity analysis using minimum disease prevalence
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Pohl 29,537 15.26 – – –
US SAPI (high cut off) 29,638 15.33 100 0.07 1424
MR elastography 29,974 15.39 337 0.06 5939
CEUS 30,269 15.42 294 0.03 9149
Treat all 38,159 16.18 7890 0.75 10,457
CEUS, contrast-enhanced ultrasound; US, ultrasound.
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TABLE 114 Hepatitis C: sensitivity analysis using maximum disease prevalence
Test strategy Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
(S4) Type IV collagen and
MR elastography
70,627 12.40 – – –
MR elastography 70,710 12.42 84 0.02 3893
Treat all 72,058 12.64 1348 0.22 6155
S4, strategy 4.
TABLE 115 Hepatitis C: sensitivity analysis utility values set equal to Shepherd et al.392
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 47,212 19.52 – – –
Treat all 51,488 19.92 4276 0 10,813
TABLE 116 Hepatitis C: sensitivity analysis increasing utility values by 0.1
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 47,138 16.34 – – –
Type IV collagen 47,792 16.41 654 0.08 8615
Treat all 51,369 16.80 3577 0.39 9181
TABLE 117 Hepatitis C: sensitivity analysis allowing for small risk of progression to decompensated cirrhosis and
HCC after SVR in compensated cirrhosis health state
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 49,455 14.16 – – –
Treat all 53,211 14.57 3757 0.41 9112
TABLE 118 Hepatitis C: sensitivity analysis with specific SVR rates for mild, moderate and cirrhotic health states
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 49,668 14.12 – – –
Treat all 52,924 14.62 3256 0.50 6517
TABLE 119 Hepatitis C: sensitivity analysis to change test and retest costs [all set as a NILT (APRI serum marker)]
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 46,603 14.26 – – –
Treat all 51,241 14.73 4638 0.47 9938
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TABLE 120 Hepatitis C: sensitivity analysis setting sensitivity and specificity of retest to APRI
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat all 51,241 14.73 – – –
TABLE 121 Hepatitis C: sensitivity analysis setting sensitivity and specificity of retest to Fibrotest
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat all 51,241 14.73 – – –
TABLE 122 Hepatitis C: sensitivity analysis setting sensitivity and specificity of retest to Fibroscan
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat all 51,241 14.73 – – –
TABLE 123 Hepatitis C: sensitivity analysis on selection of tests for second-stage analysis (most effective and least
costly tests)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
(S4) PIINP/MMP and
MR elastography
46,772 14.19 – – –
MR elastography 46,891 14.27 119 0.08 1452
Treat all 51,241 14.73 4350 0.46 9516
MM, matrix metalloproteinase; S4, strategy 4.
Hepatitis C: sensitivity analysis of genotype distribution used in analysis
TABLE 124 Hepatitis C: sensitivity analysis of genotype distribution used in analysis
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 43,423 14.33 – – –
Treat all 46,182 14.76 1898 0.44 4352
TABLE 125 Hepatitis C: sensitivity analysis assuming no disutility for liver biopsy applied
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 46,851 14.27 – – –
Treat all 51,241 14.73 4391 0.46 9468
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TABLE 126 Hepatitis C: sensitivity analysis increasing disutility for liver biopsy to 0.3
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 46,875 14.27 – – –
Treat all 51,241 14.73 4366 0.457 9546
TABLE 127 Hepatitis C: sensitivity analysis of disutility associated with adverse events from telaprevir
and boceprevir
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 47,117 14.26 – – –
Type IV collagen 47,752 14.33 635 0.07 8824
Treat all 51,350 14.70 3598 0.37 9704
TABLE 128 Hepatitis C: reduction in effectiveness of treatment (decreasing SVR rate by 80%)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
US SAPI (high cut-off) 47,259.70 14.16 – – –
MR elastography 47,281.65 14.22 22 0.07 336
US, ultrasound
TABLE 129 Reduction in effectiveness of treatment (decreasing SVR rate by 70%)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 47,283 14.23 – – –
TABLE 130 Hepatitis C: reduction in effectiveness of treatment (decreasing SVR rate by 60%)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 47,142 14.23 – – –
Treat all 55,028 14.24 7886 0.011 723,503
TABLE 131 Hepatitis C: reduction in effectiveness of treatment (decreasing SVR rate by 50%)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 47,158 14.24 – – –
Treat all 54,153 14.32 6995 0.08 83,697
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TABLE 132 Reduction in effectiveness of treatment (measured using SVR rate by 40%)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 47,125 14.25 – – –
Treat all 53,800 14.40 6675 0.15 45,877
TABLE 133 Hepatitis C: reduction in effectiveness of treatment (decreasing SVR rate by 30%)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 47,071 14.26 – – –
US SAPI (low cut-off) 50,623 14.38 3552 0.12 28,435
Treat all 53,193 14.47 2571 0.09 29,740
US, ultrasound.
TABLE 134 Hepatitis C: reduction in effectiveness of treatment (decreasing SVR rate by 20%)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 46,951 14.26 – – –
Treat all 52,545 14.56 5594 0.30 18,830
TABLE 135 Reduction in effectiveness of treatment (decreasing SVR rate by 10%)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 46,902 14.27 – – –
Treat all 51,241 14.73 4339 0.462 9384
TABLE 136 Hepatitis C: sensitivity analysis increasing effectiveness of treatment (increase in SVR rate)
and price (£20,000)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
MR elastography 43,631 14.71 – – –
TE 44,188 14.72 557 0.01 56,413
Treat all 49,207 15.27 5576 0.56 10,009
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TABLE 137 Hepatitis C: sensitivity analysis increasing effectiveness of treatment (increase in SVR rate)
and price (£40,000)
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Treat no one 54,940 12.46 – – –
Pohl 55,973 14.46 1033 2.00 517
US SAPI (high cut-off) 56,931 14.62 314 0.07 6083
MR elastography 57,913 14.73 982 0.11 9189
Treat all 69,108 15.26 11,195 0.53 21,174
US, ultrasound.
Sensitivity analyses tables for alcoholic liver disease
TABLE 138 Alcoholic liver disease sensitivity analysis: probability of progressing to cirrhosis if continue to drink
with diagnosis of no cirrhosis (probability set to 10%)
Strategy Tests Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Strategy 2 APRI (high cut-off) and liver biopsy 15,787 9.06 – – –
Strategy 5 PGAA and liver biopsy 15,908 9.35 122 0.29 416
Strategy 3 Fibrotest (high cut-off) and
liver biopsy
16,016 9.46 108 0.10 1041
Strategy 4 Fibrotest (low cut-off) and
liver biopsy
16,187 9.53 171 0.08 2271
Strategy 1 Liver biopsy 16,321 9.56 134 0.03 5199
Strategy 12 All patients treated as having
cirrhosis (receive HCC screening)
30,574 9.65 14,253 0.10 146,491
TABLE 139 Alcoholic liver disease sensitivity analysis: probability of progressing to cirrhosis if continue to drink
with diagnosis of no cirrhosis (probability set to 30%)
Strategy Tests Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Strategy 2 APRI (high cut-off) and liver biopsy 19,199 8.52 – – –
Strategy 1 Liver biopsy 19,409 9.08 210 0.56 377
Strategy 12 All patients treated as having
cirrhosis (receive HCC screening)
31,377 9.35 11,967 0.27 44,302
TABLE 140 Alcoholic liver disease sensitivity analysis: probability of progressing to cirrhosis if continue to drink
with diagnosis of no cirrhosis (probability set to 40%)
Strategy Tests Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Strategy 1 Liver biopsy 20,971 8.82 – – –
Strategy 12 All patients treated as having
cirrhosis (receive HCC screening)
31,672 9.20 10,701 0.37 28,747
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
402
TABLE 141 Alcoholic liver disease sensitivity analysis: probability of progressing to cirrhosis if continue to drink
with diagnosis of no cirrhosis (probability set to 50%)
Strategy Tests Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Strategy 1 Liver biopsy 22,352 8.58 – – –
Strategy 12 All patients treated as having
cirrhosis (receive HCC screening)
31,944 9.04 9591 0.46 20,835
TABLE 142 Alcoholic liver disease sensitivity analysis: probability of progressing to cirrhosis if continue to drink
with diagnosis of no cirrhosis (probability set to 60%)
Strategy Tests Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Strategy 1 Liver biopsy 24,107 8.31 – – –
Strategy 12 All patients treated as having
cirrhosis (receive HCC screening)
32,461 8.85 8355 0.55 15,232
TABLE 143 Alcoholic liver disease sensitivity analysis: adverse events (associated with liver biopsy) decreased to
0.05% from 0.72%
Strategy Tests Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Strategy 2 APRI (high cut-off) and liver biopsy 17,480 8.80 – – –
Strategy 5 PGAA and liver biopsy 17,703 9.08 223 0.28 795
Strategy 1 Liver biopsy 17,913 9.32 209 0.24 854
Strategy 12 All patients treated as having
cirrhosis (receive HCC screening)
30,984 9.51 13,071 0.18 71,616
TABLE 144 Alcoholic liver disease sensitivity analysis: adverse events (associated with liver biopsy) increased from
0.72% to 0.90%
Strategy Tests Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Strategy 2 APRI (high cut-off) and liver biopsy 17,486 8.79 – – –
Strategy 5 PGAA and liver biopsy 17,674 9.06 188 0.27 693
Strategy 1 Liver biopsy only 17,882 9.29 208 0.24 884
Strategy 12 All treated as having cirrhosis 30,954 9.48 13,072 0.19 69,697
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TABLE 145 Alcoholic liver disease sensitivity analysis: mortality rate (associated with liver biopsy) reduced to 0.05%
Strategy Tests Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Strategy 2 APRI (high cut-off) and liver biopsy 17,480 8.80 – – –
Strategy 5 PGAA and liver biopsy 17,703 9.08 223 0.28 795
Strategy 1 Liver biopsy 17,913 9.32 209 0.24 854
Strategy 12 All patients treated as having
cirrhosis (receive HCC screening)
30,984 9.51 13,071 0.18 71,616
TABLE 146 Alcoholic liver disease sensitivity analysis: mortality rate (associated with liver biopsy) increased
to 0.20%
Strategy Tests Cost, £ QALY
Incremental
cost, £
Incremental
QALY ICER, £
Strategy 2 APRI (high cut-off) and liver biopsy 17,488 8.78 – – –
Strategy 1 Liver biopsy 17,840 9.29 169 0.23 721
Strategy 12 All patients treated as having
cirrhosis (receive HCC screening)
30,973 9.49 13,133 0.20 65,679
Cirrhosis sensitivity analysis
TABLE 147 Cirrhosis sensitivity analysis: increased benefit for patients diagnosed as false positive who receive
screening for HCC
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Fibrosis Index 24,908 2.09 – – –
CDS (low cut-off) 24,946 2.18 39 0.09 439
Forns index 24,974 2.22 28 0.04 653
Forns index (low cut-off) 25,032 2.27 58 0.05 1106
CDS, Cirrhosis Discriminant Score.
TABLE 148 Cirrhosis sensitivity analysis: screening cost for α-fetoprotein testing removed from analysis
Test Cost, £ QALY Incremental cost, £ Incremental QALY ICER, £
Fibrosis Index 24,908 2.09 – – –
CDS (low cut-off) 24,946 2.16 38 0.07 526
Forns index 24,974 2.18 28 0.01 1884
CDS, Cirrhosis Discriminant Score.
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Appendix 12 Scatterplots of cost-effectiveness
analysis results
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FIGURE 240 Scatterplot of results: HBeAg (negative) – first stage of the analysis (all tests strategies compared with
‘treat no one’). US, ultrasound.
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FIGURE 241 Scatterplot of results: HBeAg (negative) – second stage of the analysis (all tests strategies compared
with ‘treat no one’). HA, hyaluronic acid; MRE, MR elastography; S1, strategy 1.
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FIGURE 242 Scatterplot of results: HCV – first stage of the analysis (all tests strategies compared with
‘treat no one’). MRE, MR elastography; US, ultrasound.
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FIGURE 243 Scatterplot of results: HCV – second stage of the analysis (all tests strategies compared with
‘treat no one’). HA, hyaluronic acid; MRE, MR elastography; S1, strategy 1.
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FIGURE 244 Scatterplot of results: ALD (all test strategies compared with least costly test strategy).
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FIGURE 245 Scatterplot of results: cirrhosis (all tests strategies compared with least costly test strategy).
CDS, Cirrhosis Discriminant Score; US, ultrasound.
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Appendix 13 Reporting patient and public
involvement
Patient representatives were not present in the steering committee meetings, as these were dedicated totechnical discussions around meta-analysis and disease-modelling data and assumptions.
Upon completion of our study, the British Liver Trust, which is the leading liver charity in the UK, was
contacted in order to arrange the presentation and dissemination of the findings of our study in patients
and their representatives.
There were no slots available in their latest meeting; however, these will be presented in a future meeting.
We further collaborated with Research Media and produced a flyer, which explains in simplified language
our research on non-invasive tests, their effectiveness and their cost-effectiveness. This will be published
online in the British Liver Trust website and also in International Innovation, which is considered one of the
leading global dissemination resources (www.research-europe.com/index.php/digital_magazine/). Fifty hard
copies of this publication will be sent to key stakeholders.
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